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Abstract 
The research contained in this thesis concerns two distinctly separate approaches to 
the design of novel drugs that can be used to treat cancer. 
The disruption of the p53-Mdm2 interaction is an attractive therapeutic strategy for 
activating p53 tumour supressor activity in tumours expressing wild type p53. One 
such strategy for the disruption of the P53-Mdm2 interaction is the design of low 
molecular weight ligands that bind at the p53-Mdm2 interface. The molecular 
docking programme LIDAEUS has identified a sulfonamide scaffold that has the 
potential to bind at the p53-Mdm2 interface. Adopting a high-throughput, 
combinatorial chemistry approach, a number of sulfonamides and amides have been 
synthesized and screened in vitro for their ability to disrupt the p53-Mdm2 
interaction. 
Cyclin dependent kinases (CDKs) are important in cell cycle regulation as they 
control the transition between the four primary phases. The association of a cyclin 
dependent kinase with a cyclin subunit, and subsequent phosphorylation of the 
complex formed, is essential for CDK activity. Therefore, the design of ATP 
antagonists that inhibit the activity of CDKs is an attractive strategy for the treatment 
of proliferative disorders. Using microwave assisted organic synthesis, a high-
throughput synthetic sequence has been developed to afford a series of 6-anilino-4-
aryl-pyrimidines (I) that have been subsequently screened in vitro against a panel of 
kinases. Several of these compounds have been shown to be low micromolar 
inhibitors of the CDK2/cyclin E complex. 
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1 	An introduction to the p53-Mdm2 interaction 
1.1 	The cell cycle 
In eukaryotic cells, the process of DNA replication and cell division follows a series 
of coordinated events known as a cell cycle. The cell cycle is composed of five 
distinct stages, as illustrated in Figure 1.1. 
Figure 1.1: The cell cycle. 
In each cell cycle, the chromosomes of the cell are replicated once in what is termed 
the synthesis phase (S-phase) and segregated, to create two genetically identical 
daughter cells during mitosis (M-phase). The interval between mitosis and synthesis 
is called the G1  gap phase, and the interval between synthesis and mitosis is called 
the G2  gap phase. Both gap phases are periods of cell growth and reorganisation, 
during which, various mRNAs and proteins are synthesized that are required for 
either DNA synthesis or mitosis. When a cell is in any phase of the cell cycle other 
than mitosis, it is often said to be in interphase. Cells can leave the cell cycle, either 
temporarily or permanently, exiting the cycle at G1 and entering the G0 phase, during 
which period the cell is often called 'quiescent'. G0 cells can carry out their functions 
within the organism until they die. However, with proper stimulation, some G0 cells 
can reenter into the cell cycle at the late G1 stage and proceed onto new rounds of 
1 
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alternating S phase and mitosis. Crucially, cancer cells cannot enter G0 and therefore 
repeat the cell cycle indefinitely.' 
The cell cycle is controlled by at least two mechanisms. The first mechanism of 
control involves a highly regulated kinase family called the cyclins.2 Activation of a 
transiently expressed cyclin through association with a second protein subunit, a 
cyclin-dependant kinase (CDK), generates a complex with unique substrate 
specificity. Regulatory phosphorylation and dephosphorylation fine-tune the activity 
of the CDK-cyclin complex, allowing the progression of the cell through well-
delineated transitions between cell cycle stages.3 The cyclins and cyclin-dependent 
kinases are the subject of discussion in Chapter 3. 
A second regulatory mechanism in the cell cycle involves cell cycle checkpoints that 
monitor completion of critical events such as DNA replication and chromosome 
segregation.4 The primary cell cycle checkpoint is the restriction point at the G,-S 
phase transition after which, the cell is generally committed to a further round of 
DNA replication and division. There is also a checkpoint at the G2-M phase 
transition, which prevents cells with incompletely replicated or damaged DNA from 
entering mitosis.5 The activation of these checkpoints causes a delay in cell cycle 
progression, thus averting the danger of mutation. 
1.2 Oncogenes and tumour supressors 
Human cancer can be defined as a disease that is characterized by deregulation of the 
cell cycle and increased genetic instability.6 Two classes of genes, oncogenes and 
tumour supressors, play crucial roles in the development and progression of cancer. 
A proto-oncogene is a gene whose products function in signal transduction pathways 
that promote cell proliferation. The activation of proto-oncogenes, through genetic 
mutation, can promote or allow the uncontrolled growth of cancer.7 Genetic 
mutations of oncogenes can be inherited or caused by an environmental exposure to 
carcinogens. A tumour suppressor is a gene whose function is to inhibit cell growth 
or proliferation. This can be achieved through cell cycle arrest and induction of 
2 
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apoptosis. Although inactivation of both copies of a tumour suppressor gene is 
required for loss of function, mutation, inactivation or deletion of part or all of one 
allele of a tumour suppressor gene predisposes that individual to increased risk of 
tumour development because only one mutational event is required to prevent 
synthesis of any functional gene product.3  Activation of proto-oncogenes that 
promote cell proliferation, and inactivation of tumour suppressor genes that inhibit 
cell proliferation leads to tumour formation, growth and progression. 
This chapter will focus on the tumour suppressor gene p53; discussing its role in the 
cell cycle, highlighting its structure and provide an introduction to current strategies 
which target p53 with the aim of providing effective cancer therapy. 
1.3 	p53  and the cell cycle 
1.3.1 The role of p53 
The p53 protein was first identified as a cellular protein that could be 
immunoprecipitated with the simian virus 40 (SV40) large T-antigen.8 The human 
p53 tumour suppressor gene encodes a 393 amino acid nuclear phosphoprotein that 
acts as a tetrameric sequence-specific DNA-binding protein that regulates the 
transcription of a number of genes involved in cell cycle arrest or apoptosis.9 Wild 
type p53 (wt-p53) is present at low concentrations in normal cells, but, in response to 
cellular stress, such as DNA damage'° or hypoxia,11 p53 accumulates in the nucleus 
of cells where it is active. 12  The activation of p53 can lead to various responses, 
depending on the nature of the stress and the cell type, with a common aim to prevent 
damaged cells from proliferating and passing mutations on to the next generation. 
13 
The p53 protein can halt the progression of the cell cycle in both the G,/S and G2 
checkpoints. 
3 
1.3.2 p53  regulation of the G1/S checkpoint 
Cell cycle progression is halted at the G1/S checkpoint in response to DNA damage. 
After exposure of cells containing wild-type p53 to genotoxic agents, p53 is activated 
and transcriptionally upregulates the CDK inhibitor p2 i.'4 p21 can inhibit the 
binding of either cyclin and CDK subunits or the activated cyclin-CDK complexes 
that mediate G1  phase progression, resulting in pRB hypophosphorylation. In its 
hypophosphorylated state, pRB binds to E217 to inhibit S phase entry. Once 
hyperphosphorylated, pRB releases E2F that results in the activation of genes 
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Figure 1.2: Regulation of the G,/S checkpoint. 
1.3.3 p53  regulation of the G2JM checkpoint 
During S and G2  phases, cells accumulate the cyclin B 1 -Cdc2 complex in an inactive 
form due to inhibitory phosphorylations by Weel and Myti kinases. Cdc25c 
phosphatase mediates the conversion of Cdc2 from an inactive to an active form and, 
in doing so, stimulates mitosis. In response to genotoxic stress, the Chki and Chk2 
kinases are activated and phosphorylate Cdc25c. 
16  This phosphorylation promotes 
the interaction of Cdc25c with 14-3-3 adaptor proteins and inhibits the ability of 
Cdc25c to activate the cyclin B1-Cdc2 complex, resulting in cell cycle arrest at the 
rd 
G2/M checkpoint. Furthermore, in response to genotoxic stress, activated Chkl and 
Chk2 also phosphorylate p53, resulting in stabilization and activation of the 
protein. 17 In turn, p53 activation upregulates the 14-3-3cy protein that causes G2 arrest 
via sequestration of Cdc25c in the cytoplasm and G2/M arrest due to inhibition of 
Cdc2 activity. 18 The transcription of p21 is also upregulated by p53.'4 P21 binds to 
cyclin-Cdk complexes to reduce the level of phosphorylation of pRB. 
Hypophosphorylated pRB sequesters E2F, and, in doing so, prevents E2F from 
mediating the biosynthesis of cyclin B 1 and Cdc2 (Figure 1.3).' 
Chkl/2 
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Figure 1.3: Regulation of the G2/M checkpoint. 
1.3.4 p53 and cancer 
Most human cancers have a defect in the p53 pathway. Indeed, it has been reported 
that p53 is inactivated by mutations and other genomic alterations in about one half 
of all human cancer cases.19 These genomic alterations include, for example, 
mutational inactivation of upstream activating enzymes of p53, or amplification of 
cellular or viral oncogenes responsible for the inhibition of the activity of p53.2° 
Cells that lack functional p53 can accumulate mutations that favour the development 
of cancer as they are unable to respond appropriately to stress. In vivo studies in mice 
5 
- 	- 
have shown that inactivation of the Trp53 gene, which encodes p53, has no effect on 
the development of the mouse but renders it more prone to tumours, with death 
occurring in all cases within 10 months. 21  It has been shown that tumour derived p53 
mutants are defective in DNA binding 22  and cannot function as a transcription 
factor.23  
1.3.5 The structure of p53 
The p53 protein can be divided into a number of domains, including the N-terminal 
transactivation domain; 24  the core DNA-binding domain; 25  a tetramerisation domain 
that facilitates sequence specific DNA binding; 26  and the C-terminal domain that is 
involved in regulation of the sequence-specific DNA-binding function. 27  The crystal 
structure of p53, resolved by Pavletich,28 is shown in Figure 1.4. 
Figure 1.4: The crystal structure of a p53-DNA complex (PDB code 1TSR).28  
Several in vivo phosphorylation sites have been mapped to the N- and C- termini of 
the p53 protein. A number of residues located in the core DNA-binding domain, 
31 
namely Arg175, G1y245, Arg248, Arg249, Arg273 and Arg282, are often mutated in 
human turnours.28 These mutations destroy p53's sequence-specific DNA-binding 
activity, suggesting that this function is critical for tumour supression. A schematic 
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Figure 1.5: A schematic of the structure of p53.29 
1.4 Mdm2 
An important step in tumourgenesis is the targeting and inactivation of p53 by a 
number of viral oncogenes. The gene encoding Mdm2 (murine double-minute) was 
first identified on a mouse double minute chromosome. 30  Later, Mdm2 was 
rediscovered as a p53 binding protein in several transformed rat fibroblast cell lines 
overexpressing a mutant p53 protein. 3' The Hdm2 gene, the human homologue of 
Mdm2, encodes a 491-amino acid polypeptide that contains several functional 
domains, namely, a N-terminus which contains the p53 binding site and a DNA-
dependent protein kinase (DNA-PK) phosphorylation site which can affect binding 
to p53;32 an acidic domain; a zinc-binding domain; and a ring-finger domain at its C-
terminus that can mediate protein-protein and protein-DNA interactions (Figure 
1 .6).29  Hdm2 has been shown to be overexpressed in a number of human tumours, 
particularly sarcomas.33  
7 
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Figure 1.6: A schematic of the structure of Mdm2.29 
1.5 	Strategies to restore the tumour supressor activity of mutant 
p53  
Restoring the tumour suppressor activity of mutant p53 can be achieved in a number 
of ways. Gene therapy with wt-p53 has been evaluated in both clinical and 
preclinical models. 34  Another strategy is the pharmacological rescue of mutant p53 
function, although this strategy requires various approaches owing to the number of 
different mutations of the p53 gene. Studies have identified a number of second-site 
mutations in p53 that can suppress natural deactivating mutations, 35  and one 
approach would be to mimic these suppressor mutations with small-molecule 
pharmaceutical agents. A third strategy involves the mimicking of downstream p53-
dependent gene products, such as p2 1,14  to replace the tumour suppressor function of 
p53. Indeed, it has been reported that short peptides derived form the N- and C-
terminal domains of p21 inhibit pRB phosphorylation and induce G1IS growth arrest 
when introduced into cells through conjugation with a membrane-penetrating 
peptide. 36 
16 	Strategies to increase the tumour supressor function of wild 
type p53 
Strategies for activating the transcriptional activity of wild type p53, and in doing so 
its tumour supressor function, include inhibition of the nuclear export of p53; 
inhibition of Mdm2 ubiquitin ligase activity; and disruption of the Mdm2-p53 
interaction. 37 
8 
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1.6.1 The p53-Mdm2 interaction 
The binding site for Mdm2 on p53 has been mapped to a small region in the N-
terminus of p53 38 The binding of Mdm2 to p53, interferes with p53's transcriptional 
activity as it conceals the DNA-binding domain of the p53 protein. 
39  Studies have 
shown that the interaction between p53 and Mdm2 forms an autoregulatory negative 
feedback loop, keeping the activity of p53 and levels of Mdm2 in a cell in balance. In 
healthy cells, wt-p53 stimulates the synthesis of Mdm2 which, in turn, through its 
binding to p53, inhibits the transcriptional activity and growth-supressing activity of 
p53.4°  Mdm2 also contains a signal sequence that is similar to the nuclear export 
signal of various viral proteins. 4 ' After binding to p53, Mdm2 induces its nuclear 
export to the cytoplasm, thereby inhibiting the ability of p53 as a transcription 
factor. 42  Mdm2 is an ubiquitin ligase43 and studies have shown that the binding of 
Mdm2 to p53, targets p53 for ubiquitin mediated degradation. 44  In tumour cells, 
accumulation of mutant p53 is a result of its inability to activate Mdm2 transcription. 
Furthermore, Mdm2 is unable to bind to mutant p53, and consequently there is no 
Mdm2-mediated p53 degradation. 45 
Although, embryos of Mdm2 gene-knockout mice die early during gestation, it has 
been shown that death is prevented by additional deletion of Trp53, which encodes 
p53, signifying the importance of Mdm2 in the down-regulation of the activity of 
p53.46 Mdm2 overexpression has been shown to block p53-mediated cell cycle arrest 
and apoptosis.47 The activation of p53 tumour suppressor activity therefore depends 
on its association with Mdm2, and several activation pathways have been reported. 
For example, p53's association with Mdm2 is prevented by the phosphorylation of 
several different p53 residues (Ser15, Thr18 or Ser20) that is induced by DNA 
damage .48 Alternatively, Mdm2-mediated degradation of p53 can be prevented by 
the expression of ARF, which can be stimulated by the activation of oncogenes such 
as c-MYC or RAS .49  Mdm2 has also been shown to interact physically and 
functionally with several other regulators of the cell cycle, such as pRb, E2F1 and 
p10750 and TAF250/CCG1.5' 
(hupfc?1  
The disruption of the Hdm2-p53 interaction is therefore an attractive therapeutic 
strategy for activating p53 tumour supressor activity in tumours expressing wild type 
p53. Two different approaches have so far been reported; the design of Mdm2 
antisense oligodeoxynucleotides, which knock down the expression of Mdm2 and, in 
doing so, stabilize p53; and the design of low-molecular-weight ligands that bind at 
the p53-Mdm2 interface, and, in doing so, prevent their association. 
1.7 	Properties of the p53-Mdm2 complex 
There have been many studies on the characterisation of the p53-Mdm2 interface. In 
a yeast two-hybrid screen, the Mdm2-binding domain of p53 was identified on the 
amino-terminus from residues 1-41 and the p53-binding domain of Mdm2 was 
identified at the amino terminus from residues 1-118. Similarly, 
immunoprecipitation experiments identified residues 1-52, on p53, and 19-102, on 
Mdm2, as being at the p53-Mdm2 interface. 52  The six residue sequence 18TFSDLW23  
was identified as being the minimal Mdm2-binding site on the p53 protein using 
synthetic peptides, 38  and the importance of residues Leul4, Phel9, Leu22 and Trp23 
in the binding of p53 to Mdm2 was confirmed following mutation studies. Leu22 and 
Trp23 have been shown to be responsible for transactivation.53  
1.7.1 The Mdm2 cleft 
The region that corresponds to residues 13 - 119 of Xenopus laevis Mmd2 and 
residues 17-125 of Hdm2 have been crystallized in complex with a peptide that 
corresponds to residues 15-29 of p53.54 The Mdm2 N-terminal domain has been 
shown to contain two structurally similar portions, 45 and 38 amino acids long. The 
repeat structure consists of a 13  strand, an a helix, a P strand, a longer a helix and a (3 
strand as illustrated in Figure 1.7. 
10 
Figure 1.7: The Mdm2 N-terminal domain. 
The two longer helices of the repeat and the first two 13  strands form a small globular 
structure, similar to a twisted trough, containing a hydrophobic cleft, the bottom of 
which is formed by the two shorter helices (ctl and al').  The cleft is capped at each 
end with a pair of three stranded 13  sheets, one of which contains the amino and 
carboxylic termini of the polypeptide (Figure 1.8). The cleft is about 25 A long, 10 A 
wide near the surface, but narrows towards the bottom, which is up to 10 A deep. 
The cleft is lined with 14 hydrophobic and aromatic amino acids, namely Met50, 
Leu54, Leu57, Gly58, Ile61 and Met62 from the ct2 helix; Tyr67, His73, Va175, 
Phe91 and Va193 from the 13-strands 133, 131' and 132'; and His96, 11e99 and TyrlOO 








Figure 1.8: Three approximately orthogonal views of the p53-Mdm2 complex. The 
Mdm2 amino terminal domain is shown in cyan, whereas the p53 peptide is coloured 
yellow. The NI-12- and COOH- termini of p53 and Mdm2 are labeled N and C 
respectively. (A) The floor of the Mdm2 cleft in the plane of the figure. (B) The 
complex rotated approximately 900  about the horizontal axis of (A). (C) The 
complex rotated approximately 90° about the vertical axis of (B), looking down the 
helix of p53. Also shown are Phel9, Trp23 and Leu26 of p53, which insert deep into 
the Mdm2 cleft .54 
1.7.2 The p53 binding domain 
It was shown that P53 529 binds to the hydrophobic cleft that is present at the surface 
of Mdm2. Residues 18 to 26 of p53 were reported to form an amphipathic a helix, 
initiated by a network of hydrogen bonds formed by residues Thri 8 and Asp2 1, with 
12 
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one 310helical hydrogen bond at its C-terminal. Thrl8 has also been reported to be 
particularly important in the regulation of the p53-Mdm2 interaction by 
phosphorylation.48 The triad of key amino acid residues; Phel9, Trp23 and Leu26; 
make sequential Van der Waals contacts and have extended side-chain 
conformations inserting deeply into the Mdm2 cleft.54 Consequently these three 
residues contribute to a large extent to the binding energy of the p53 peptide.55 These 
three residues have been reported to be involved in transactivation, supporting the 
hypothesis that Mdm2 inactivates p53 by restricting access to its transactivation 
domain. The aromatic side chains of Phe 19 and Trp23 have been shown to stack face 
to face in a staggered arrangement (Figure 1.9). The two charged amino acids of the 
helix; Asp2l and Lys24; are within salt bridge distance. Immediately after the a 
helix is Pro-27, which is likely to contribute to its termination. NMR studies have 
shown that the p53 protein is loosely folded in solution, 56  suggesting that the a helix 
is stabilized by Mdm2 binding. The a helix is readily digested by proteases in the 
absence of Mdm2, in particular by cleavage at Trp23.57 
13 
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Figure 1.9: (A) Surface representation of the Mdm2 binding cleft, coloured grey. 
The p53 amino acids that interact with this surface are shown in yellow, and are 
labeled. (B) A cross section of the Mdm2-p53 interface showing that the residues 
Phel9, Trp23 and Leu26 pf p53 fit tightly in the Mdm2 pocket. The Mdm2 surface is 
represented as a blue wire mesh and p53 residues 18 - 27 are in space filling 
representation. 54 
The peptide-protein interface relies primarily on Van der Waals contacts between the 
hydrophobic and aromatic amino acids that line the Mdm2 cleft and p53. The p53 a- 
14 
helix makes its primary Van der Waals contacts along about three-quarters the length 
of the cleft over a portion that resembles a wide deep pocket. Where the cleft is 
narrower and shallower, it has little hydrophobic character and there are only a few 
Van der Waals contacts in this region, primarily involving the Phe 19 side chain of 
p53. Van der Waals contacts are made between Phel9 and the residues G1y58 and 
11e61 on Mdm2. These two residues on Mdm2 are also involved in Van der Waals 
contacts to Trp23 on p53. Additional Van der Waals contacts occur between Leu22 
and the side of the Mdm2 cleft. Only two intermolecular hydrogen bonds have been 
identified at the p53-Mdm2 interface, these being between the p53 Trp23 indole 
group and the Mdm2 Leu54 backbone carbonyl deep inside the cleft, and between 
the Phe 19 backbone amide of p53 and the G1n72 side chain of Mdm2 at the entrance 
of the cleft. Preservation of one or both of these hydrogen bonds should obviously be 
a key feature in the design of low molecular weight inhibitors to ensure sufficient 
affinity. 54  The p53-Mdm2 interaction is illustrated in more detail in Figure 1.10. 
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Figure 1.10: The p53-Mdm2 interaction in more detail. (A) The Mdm2 cleft is 
coloured blue, with Mdm2 amino acid residues at the interface coloured cyan. The 
amphipathic 11 helix of p53 is coloured pink, with residues at the Mdm2-p53 
interface coloured yellow. Blue and red spheres represent nitrogen and oxygen atoms 
respectively. For simplicity, only the p53 amino acids are labeled. The two 
intermolecular hydrogen bonds at the interface are shown as red dotted lines. (B) The 
interface rotated 900  about the vertical axis of (A). The Mdm2 112 helix is below the 
plane of the figure, its 13 sheet is above the plane, and p53 is between the two. Only 





The small size of the p53-Mdm2 interface and the combined molecular mass of the 
sidechains of Phel9, Trp23 and Leu26 of around 300 Da makes the design of low 
molecular weight molecules that can inhibit the Mdm2-p53 interaction a very 
attractive strategy. This would stabilize the p53 protein and lead to a direct 
pharmaceutical activation of the p53 tumour supressor response in cells expressing 
wild type p53. 
1.8 Current research into the inhibition of the p53-Mdm2 
interaction 
A number of groups have examined the feasibility of the p53-Mdm2 model. Lane et 
al. have shown that p53 accumulation and activation are induced by the expression 
of a modified thioredoxin containing a peptidic homologue of p53 on its surface. 58 
The induction of activity of p53 in some tumour cells by the same peptidic 
homologue of p53 fused to the glutathione S-transferase protein (GST) has also been 
reported .59 Furthermore, it has been shown that inhibition of the p53-Mdm2 
interaction, through microinjection of normal human fibroblasts with 3G5 antibody 
(directed against the p53-binding domain of Mdm2), induces expression of p53 
responsive genes. 60 However, it has also been reported that inhibition of the p53 - 
Mdm2 interaction prevents the normal cell proliferation. 6 1  This raises the issue of 
toxicity of inhibitors of the p53-Mdm2 interaction to healthy tissue. 
It has been reported that three synthetic peptides derived from wild-type p53 
(p5312-20, p5317-26 and p5312-26),  and coupled to the leader sequence of the 
antennapedia protein, are toxic to various p53-null tumour cell lines in addition to 
cell lines that express wild-type or mutant p53, but are not toxic to normal cells. The 
induction of apoptosis via a p53-independent mechanism was suggested as no p53-
apoptotic markers, such as Bax and p21, were identified after treatment with the 
peptides. It was postulated that the common sequence Glu-Thr-Phe-Ser, contained in 
each of the three peptides, was attributable for the observed cytotoxicity.62 
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1.9 	Other members of the p53 and Mdm2 families 
Recently, two p53-related genes, p63 and p73, were identified. The primary sequence 
of p53 has a similarity of 62% with p63 and 69% with p73. Although structurally 
similar to p53, each of these two genes has distinct physiological function. 63  There is 
evidence to suggest that p53 is involved more with tumour suppression whereas p73 
and p63 are more important during development and differentiation respectively. 64 
One Mdm2 related gene, MdmX, has been identified .65 The primary sequence of 
Mdm2 has a 37% similarity with MdmX. 
The homology between p53, Mdm2 and their respective family members suggest that 
cross association may be a possibility. Indeed, MdmX has been reported to bind to 
P53, p6365 and p73.66 Mdm2 has also been reported to associate with p6367 and 
p73.66 Also, inhibitors of the p53-Mdm2 interaction have been demonstrated to 
disrupt the p53-MdmX interaction. 68  This presents the challenge of the design of 
selective inhibitors that specifically only disrupts one of these interactions. 
1.10 The design of inhibitors of the p53-Mdm2 interaction 
The short sequence of contiguous amino acids on p53, shown to be essential for 
Mdm2 binding, allow the design of small peptidic inhibitors which would mimic the 
interaction of p53. However, the significant Van der Waals character of the Mdm2-
p53 interaction differentiates it from most other known protein-peptide interactions 
in which there are extensive hydrogen bonding contacts. In these complexes, a 
significant proportion of the buried surface is polar, whereas in the Mdm2-p53 
complex the majority of the buried surface, amounting to some 1498 A2 of surface 
area, is hydrophobic. Indeed, as approximately 70% of the interfacial atoms are non-
polar, a key feature of inhibitors of the p53-Mdm2 interaction would be the presence 
of lipophilic groups, which, although having a negative effect on the oral 
bioavailability of the inhibitors, may provide a favourable entropic contribution to 
the binding energy upon interaction with Mdm2. 13  However, it is important to 
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conserve the key hydrogen bond in the p53-Mdm2 complex, that between Trp23 on 
p53 and Leu54 on Mdm2, in order to ensure sufficient affinity of the inhibitors. 
1.10.1 Peptidic Mdm2 inhibitors and peptidomimetics 
The identification of the minimal Mdm2 binding site on p53 as a contiguous six-
residue sequence ('8TFSDLW23) induced the design of small peptides to inhibit the 
p53-Mdm2 interaction. Initial studies on the hexapeptide p5318-23  indicated it had 
little affinity. 58  Further studies, involving the screening of phage-displayed peptide 
libraries allowed the identification of more potent peptides, including the 1 2mer 
peptide (Table 1.1, 2) that was 28-fold more potent in vitro than the corresponding 
p53 wild-type peptide (Table 1.1, 1). Truncation studies on the 1 2mer peptide, 1, 
revealed that its size could be reduced to eight residues whilst retaining micromolar 
affinity (Table 1. 1, 3)69 
To further increase the potency of peptide 3, the residues Asp2l and G1y25 were 
substituted with the non-natural amino acids a-amino isobutyric acid (AIB) and 1-
amino-cyclopropanecarboxylic acid (AC3C) to favour the pre-organisation of a 
helical structure of the peptide in solution, thereby hoping to mimic that observed in 
the p53-Mdm2 crystal structure reported by Kussie et al.54 These modifications 
resulted in a> 4-fold increase in potency of peptide 3 (Table 1. 1, 4)69 
To enhance the affinity of peptide 4, and in doing so provide a positive enthalpic 
contribution to the peptide's binding to Mdm2, two modifications were made. The 
residue corresponding to Tyr22 on p53 was replaced with phosphonomethyl-
phenylalanine (PMP) to favour the formation of a salt bridge with the Lys94 residue 
of Mdm2. Also, the residue corresponding to Trp23 on p53 was replaced with 6-
chloro-tryptophan, with the aim being to fill a small hydrophobic cavity left 
unoccupied by wild-type p53 in the Mdm2 cleft. The result of these modifications 
was to increase the affinity of peptide 4440-fold (Table 1. 1, 6).69 
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Cmpd Structure IC50 QM) 
1 Ac-Gln-Glu-Thr-Phe '9-Ser-Asp-Leu-Trp23-Lys-Leu-Leu26-Asn-NH2 8.7 
2 Ac-Met-Pro-Arg-Phe'9-Met-Asp-Tyr-Trp23-GIu-Gly-Leu26-Asn-NH2 0.3 
3 Ac-Phe '9-Met-Asp-Tyr-Trp23-Glu-GIy-Leu26-Asn-NH2 8.9 
4 Ac-Phe '9-Met-AIB-Tyr-Trp23-Glu-AC3C-Leu26-Asn-NH2 2.2 
5 Ac-Phe '9-Met-AIB-PMP-Trp23-Glu-AC3C-Leu26-Asn-NH2 0.3 
6 Ac-Phe '9-Met-AIB-Tyr-6CITrp23-Glu-AC3 C-Leu26-Asn-NH2 0.005 
Table 1.1: Peptidic inhibitors of the p53-Mdm2 interaction; IC50 values shown 
represent inhibition of wild type p53 binding to GST-Hdm2. 
1.10.2 Non-peptidic small-molecule Mdm2 inhibitors 
There has been very little reported to date on non-peptidic or natural inhibitors of the 
p53-Mdm2 interaction. The discovery and structure determination of chiorofusin, 7, 
a fungal metabolite that antagonizes the p53-Mdm2 interaction has been reported.70 
Chlorofusin has been shown to have an 1050 of 4.6jiM in an enzyme-linked 
immunosorbent assay (ELISA). However, it is not known whether chlorofusin binds 
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Recently, Zhao et al. have reported on the initial evaluation of non-peptidic small-
molecule Mdm2 inhibitors selected from a virtual screen based on the p53-Mdm2 
complex structure. 71 The advantages associated with non-peptidic small molecules 
are that they generally have higher cell permeability than peptides and can also be 
synthesized more cost effectively by chemical methods. In this study, of the 23 
synthetic small molecules and nine intermediate products evaluated, five showed 
affinity with Hdm2 and were shown to affect the viability of several tumour cells 
lines that express wt-p53. More importantly, one of these compounds, syc-7, 8, was 





A number of chalcones (1,3-diphenyl-2-propene-1-ones) have been reported to 
inhibit the p53-Mdm2 interaction in vitro on ELISA and gel-shift assays. NMR 
studies have indicated that these compounds, exemplified by the chalcone B-i, 9, 
interact with the p53 Trp23 binding pocket subsite on the Mdm2 protein and, 
therefore, do not fully occupy the p53 binding cleft of Hdm2, which is perhaps 
reflected in their low potency of between 50 pM and 250 tM.72 
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Significantly and more recently, a series of small-molecule antagonists of Mdm2 
have been reported based around a cis-imidazoline scaffold .73 These antagonists, 
named 'Nutlins' and exemplified by Nutlin-2, 10, have been shown to bind to Mdm2 
in the p53 binding pocket, leading to p53 accumulation, through decreased 
degradation of the protein, and subsequent cell cycle arrest and apoptosis in tumour 
cells expressing wt-p53. The IC50 value of 10, representing the inhibition of wild 
type p53 binding to Hdm2, was determined to be 0.14 tM. 
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Furthermore, it was shown that the Nutlin 10 mimics the interaction of the p53 
peptide to a high degree with the imidazoline scaffold successfully replacing the 
helical backbone of p53, as illustrated by Figure 1.11. 
Figure 1.11: An overlay of Nutlin-2 with the peptide side chains of Phel9, Trp23 
and Leu26 of p53. For the inhibitor atoms are coloured as follows: C, white; N, blue; 
0, red; Br, brown. For the protein atoms are coloured C, green; N, blue, 0, red.73  
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The crystal structure of the Hdm2-Nutlin2 complex was solved (Figure 1. 12)  that 
revealed one bromophenyl moiety of the ligand extending deeply into the pocket 
normally occupied by Trp23, one bromophenyl moiety occupying the Leu26 pocket, 
and the ethyl ether moiety directed towards the Phe 19 pocket. 
Figure 1.12: Nutlin-2 located in the p53 binding pocket of Mdm2. The surface of the 
protein has been coloured as follows: Buried regions, green; Exposed portions, red. 
The inhibitor is coloured: C, white, N, blue; 0, red; Br, brown. 73 
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2 	The development of novel inhibitors of the p53-Mdm2 
interaction 
2.1 	An introduction to structure based ligand design 
2.1.1 An overview of structure based design 
This chapter concerns the design and synthesis of high affinity ligands that disrupt the 
p53-Mdm2 interaction. By way of introduction, certain aspects of ligand design within 
the drug discovery process have been discussed. 
For binding to occur between a drug and receptor, both must have a complementary 
shape and charge distribution to achieve the required negative interaction energy. A 
small increase in binding energy can lead to an almost tenfold increase in potency, as 
shown by Equation 2.1, which relates the binding energy (AG) to the binding constant, 
K. The binding energy of a ligand can be influenced by various factors including 
molecular shape, electrostatic interactions, Van der Waals (hydrophobic) interactions 
and hydrogen bonding. 75 
AG = -RTInK 
	
(Equation 2.1) 
A combination of these factors is considered in the rational design of a ligand for a 
particular receptor site. Molecular modelling software enables the factors that contribute 
to the binding energy of a ligand to be evaluated, and, through the calculation of these 
factors at many points around the surface of a receptor, a picture of the binding site can 
be generated showing where particular atoms will bind most strongly. Subsequently, a 
ligand can be built and docked in the binding site and visualized using modelling 
software, providing an effective tool for the synthetic chemist. 
24 
Thus, structure based design is an iterative process of computational design, synthesis, 
screening, testing, structure elucidation and data analysis illustrated by Figure 2.1. 3D 
structures can be used for the design of de novo ligands, if the structure of a protein, or 
protein-ligand complexes are known which may involve the screening of 3D databases 
of small molecules for predicted binding to a known protein target (computational 
virtual screening). Molecular modelling also enables the optimization of existing leads 
for affinity and selectivity, by examining the effect of modifications or extension to the 
ligand in the binding site. 
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Figure 2.1: An overview of the structure based design of ligands. 
2.1.2 Protein-ligand interactions 
The contribution of non-bonded protein-ligand interactions to binding affinity is difficult 
to quantify. However, several structure-activity relationship studies have shown that 
enhanced binding affinity is frequently observed by enlargement of the lipophilic contact 
Ll 
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surface of the ligand by addition of a lipophilic substituent, capable of forming 
hydrophobic interactions with the protein surface. Conform ati onal ly constrained ligands 
often bind more strongly than flexible ligands because the binding of a ligand to a 
protein results in a loss of entropy due to freezing of internal degrees of freedom. 
Furthermore, additional hydrogen bonds between polar groups may improve selectivity 
and make the ligand more water soluble, although this may not necessarily improve 
binding affinity. One further contribution to the enhancement of the binding affinity of a 
ligand to a protein can be achieved through the displacement of water molecules at the 
binding site. If the ligand forms more hydrogen bonds than the number of water 
molecules released, strong binding can be achieved.76 
2.2 	Project background - lead discovery 
For the current work, no crystal structure existed for a small ligand bound to the Mdm2 
cleft. However much was known about the structure of p53 and Mdm2 .54 At the Institute 
of Cell and Molecular Biology at Edinburgh University, Paul Taylor used the docking 
programme LIDAEUS, developed by himself, to generate the ligand template for the 
current work. Using the available structural information about the p53-Mdm2 complex, 
the LIDAEUS programme screened the 46,000 membered Maybridge compound library 
for small molecules able to bind to the hydrophobic cleft of Mdm2. To achieve this, the 
LIDAEUS programme calculates the interaction energy between a "probe atom" and the 
protein on a 3D grid of site points around the protein active site. In the calculation, 
carbon and oxygen atoms are used as probe atoms, with favoured hydrophilic 
interactions mapped out by the carbon atoms, to generate areas of low energy in the 
protein active site. A negative template of the active site of the target protein can then 
be generated, by turning the areas of low energy into site points. The template obtained 
contains information on the geometrical and chemical properties of putative ligands and 
the data can then be used to search the Maybridge Fine Chemicals database to select the 
best-fitting ligand for the site points. The list of commercially available compounds 
obtained is subjected to a second selection process on the basis of molecular weight and 
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hydrophobicity. The most hydrophobic ligands with molecular weight less than 500 are 
chosen, since smaller, hydrophobic ligands can more easily penetrate the crystal to reach 
the binding site. 
The LIDAEUS hits were further visualised by Campbell McInnes at Cyclacel Ltd., 
resulting in the selection of 78 compounds for purchase and their subsequent screening 
using in vitro Mdm2 competitive binding assays developed by Cyclacel Ltd. From this 
screen, two sulfonate esters, KM05076, 11, (IC50 = 106 tM) and KM05658, 12, (IC50 
95 .tM), were both identified as being novel inhibitors of the p53-HdM2 binding 
interaction in a fluorescein-labelled peptide fluorescence polarisation (FP) assay and 
also were active in an immobilised biotin-peptide assay, with 1050's of 12 tM and 13 
tM respectively. Furthermore, the benzothiazole N-oxides CD03683, 13, and CD09069, 
14, were shown to be active in the immobilised biotin-peptide assay, with respective 
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Two hit expansion libraries were purchased from the Maybridge and Chembridge 
commercial compound database based on the two substructures of these 4 hits (Figure 
2.2). 





Figure 2.2: Substructures forming the basis of a hit expansion library for inhibitors of 
the p53-Mdm2 interaction. 
Of the 191 compounds purchased with Substructure 1, 27 compounds were active in the 
primary screen using the FP p53-Mdm2 competitive binding assay, resulting in >50% 
inhibition of p53-Mdm2 binding at 500 jiM concentration. Of these 27 ligands, IC50 
values were determined for 16 compounds in a secondary screen using the FP p53-
Mdm2 competitive binding assay. Of the 174 compounds purchased with substructure 2, 
there were no hits in the primary screen. 
Early structure activity relationship studies deducible from the 191 membered hit 
expansion library of substructure 1 were limited. Of this library, a subset of 172 
members had thiophene functionality, and activity in the primary screen was confined to 
this group. All 65 members that contained an unsubstituted thiophene moiety were 
shown to be inactive in the primary screen. There were five 5-chloro-4-nitro-thiophene-
2-sulfonamide analogues in the expansion library and, in the secondary screening assay, 
the IC50 values of each were shown to be in the range of 107 - 181 jiM. A further 4 
ligands from a subset of 24 5-halo-thiophene-2-sulfonamides or sulfonate esters were 
shown to exhibit activity in the secondary screen. Those ligands with the greatest 
activity in the hit expansion library, as determined by the secondary screen, were shown 
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to be 2-sulfonyl-3-chloro-5-trifluoromethyl-pyridine analogues exemplified by KM5576, 
15, and KM5582, 16, with IC50 values of 123 iM and 69 jiM respectively. 
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2.3 	Initial expansion libraries 
Given the activity of sulfonamides 15 and 16 in the FP p53-Mdm2 competitive binding 
assay, it was desirable to screen further compounds that contained this pharmacophore in 
order to generate and gather more structure-activity relationship (SAR) data and also to 
discover analogues with improved binding. The initial aim of this project was to 
investigate this pharmacophore with an expansion library of N-substituted sulfonamides, 
synthesized using solution phase combinatorial techniques. From an early molecular 
modelling study of an N-alkylated sulfonamide ligand, 17, docked in the binding site of 
Mdm2 (Figure 2.3), undertaken by scientists at Cyclacel Ltd., it was envisaged that the 
introduction of a third substituent off the sulfonamide nitrogen atom had the potential to 
generate new contacts with the Leu26 pocket in the receptor binding site. Furthermore, 
this would address whether a hydrogen bond donor at this site was essential for ligand 
activity. The initial modelling studies also suggested that the thiophene moiety was 
placed in the Phel9-binding pocket of Mdm2, with the aromatic group of the ligand 
probing deep into the Trp23 pocket. Following the synthesis of novel libraries of 
sulfonamides and favourable first round screening in the FP assay, those ligands found 




Figure 2.3: An early modelling study of 17 docked in the p53-binding site of Mdm2 
undertaken by Cyclacel Ltd. 
2.3.1 Strategies for the synthesis of N-substituted sulfonamides. 
An obvious disconnection of the template exhibited by 15 and 16 was the sulfonamide 
linker to obtain the sulfonyl chloride and aniline synthons. A library of N-substituted 
sulfonamides could be generated by initial coupling of a sulfonyl chloride with an 
amine, followed by N-alkylation, which could be achieved through a number of 
strategies such as direct alkylation with an alkyl halide or using the Tsunoda 
modification of the Mitsunobu reaction.77 Owing to the commercial availability of a 
large number of sulfonyl chlorides, anilines, primary alcohols and alkyl halides, this 
strategy had the potential to produce diverse sets of combinatorial libraries fairly rapidly, 
without resorting to the synthesis of building blocks. 
2.3.2 The Tsunoda modification of the Mitsunobu reaction. 
Sulfonamides are relatively weak acids and require activation via conversion to their 
conjugate base before they can react with alkyl halides. The alkylation of both amides 
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also be achieved through the Mitsunobu reaction 79,80  in which an amide or imide is 
treated with equimolar amounts of an alcohol in the presence of triphenyiphosphine and 
diethyl azodicarboxylate at room temperature, as illustrated in Scheme 2.1. As reviewed 
by Mitsunobu, the reaction proceeds via formation of a zwittionic P-N adduct, 18, which 
is protonated in the presence of an acidic component, 19, to form an alkoxyphosphonium 
salt, 20, and the reduced hydrazine by-product, 21. Finally, the deprotonated acidic 
component reacts with the alkoxyphosphonium salt in an SN2 manner to provide the 
alkylated acidic species, 22, and triphenylphosphine oxide. 
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Scheme 2.1: Mechanism of the Mitsunobu N-alkylation reaction. 
A number of factors are crucial to the success of the Mitsunobu reaction, namely the pKa 
of the acidic component, 81 19, which needs to be acidic enough to protonate the 
zwittionic adduct, 18. However, the deprotonated acidic species must be less 
nucleophilic than the alcohol in order to prevent a competing reaction with the 
phosphonium salt, which would prevent formation of the alkoxyphosphonium 
intermediate, 21. It has been reported that the maximum pKa of the acidic component for 
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the reaction to proceed is approximately 11 - 13 and much lower yields are obtained 
with acidic components with PKa'S 13 - 14.82 
Tsunoda et al. have reported a number of modifications to the Mitsunobu system namely 
replacement of DEAD with either of the more basic, and thereby activating, diazo 
compounds N, N, N', N'-tetramethylazo-dicarboxamide (TMAD, 23) or 1,1'-
(azodicarbonyl)-dipiperidine (ADDP, 24), both of which are commercially available, 
and replacement of triphenylphosphine with the less bulky, more nucleophilic, 
tributyiphosphine, that has the effect of localizing the positive charge exclusively on the 
phosphorus atom facilitating activation of the alcohol and attack of the deprotonated 





2.3.3 N-Alkylation of sulfonamides 
Initial efforts were focussed on the synthesis of sulfonamide 26 following a previously 
reported method by Arcoria et al. 83  Treatment of a methanolic solution of aniline with 2-
thienyl sulfonyl chloride, 25, followed by stirring the solution at room temperature for 
24 hours afforded the sulfonamide 26, in 75% yield (Scheme 2.2). 
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Scheme 2.2: Reagents and conditions: aniline, methanol, room temperature, 24h. 
N-Methylation of 26, following the protocol developed by Tsunoda et al.77 using 
TMAD, TBP and methanol, using benzene as solvent and under an atmosphere of 
nitrogen and at 0 °C, afforded 27 in 30% yield (Scheme 2.3). 
26 	 27 
Scheme 2.3: Reagents and conditions: methanol, TMAD, TBP, benzene, room 
temperature, 24h. 
Using the Tsunoda protocol, subsequent N-alkylation of 26, using either ethanol, n-
butanol, benzyl alcohol or allyl alcohol respectively, and conducted at room temperature 
afforded 28, (49%), 29, (45%), 30, (35%) and 31, (66%). It was postulated that the lower 
yield obtained from the N-benzylation reaction was attributable to increasing steric 
demands at the SN2  reaction site. The isolated yields of 28 - 31 were lower than 
expected and at this stage it was considered that the reaction temperature could have an 
effect on the outcome of the reaction, although this was not investigated. 
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2.3.4 The attempted synthesis of 2-sulfonyl-3-chloro-5-trifluoromethyl-pyridine 
analogues 
Given the initial success of the Tsunoda N-alkylation reaction, the N-alkylation of the 
commercially available KM5576, 15, and KM5582, 16, was attempted using allyl 
alcohol and following the protocol used for the synthesis of 31. However, after 24 hours, 
analysis of both reaction mixtures by TLC revealed no reaction had taken place. 
Similarly, there was no evidence of N-allylation after addition of a further 1 .5 
equivalents of allyl alcohol and allowing each reaction mixture to stir at room 
temperature for a further 66 hours. Both reactions were repeated using 'fresh' TMAD, 
although, again, this resulted in the recovery of either 15 or 16. In instances where no N-
alkylated product was isolated, Tsunoda had reported the isolation of the oxadiazole, 34, 
through rearrangement of the zwittionic P-N adduct, 32, via the pathway illustrated in 
Scheme 2.4. However the oxadiazole, 34, was not isolated in the above study. 
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Scheme 2.4: Proposed formation of oxadiazole, 34, in the Tsunoda modification of the 
Mitsunobu alkylation reaction.77 
Although Tsunoda et al. had shown that TMAD was more versatile in the Mitsunobu 
reaction than ADDP when used in conjunction with tributyiphosphine in benzene, it was 
decided to investigate the allylation of 15 and 16 using ADDP for completeness. In both 
cases, no evidence of the N-allylated 15 and 16 species was identified upon work up. 
A short study was undertaken varying the reaction solvent from benzene. The N-
allylation of 26 was carried out using either THF, toluene and, again, benzene. Apart 
from the N-alkylation performed in THF, which afforded 31 in 44% yield, each reaction 
resulted in the recovery of 26 with no N-allylated species detected by TLC. Results from 
this study highlighted the capricious nature of the reaction and not only pointed to the 
reaction solvent having an effect on the outcome of the reaction, but also questioned its 
reproducibility using the current protocol. 
In order to address the synthesis of N-alkylated 15 and 16 analogues, another strategy 
had to be found. It was thought that the coupling of 5-chloro-thiophene-2-sulfonyl 
chloride, 35, with either the 4-trifluoromethyl or 4-methoxy substituted aniline to yield 
the sulfonamide 36 or 37 could then be followed by N-allylation, under Tsunoda 
conditions, to afford 38 or 39. Subsequent nucleophilic displacement of the 5-chloro 
functionality with the commercially available 3-chloro-5-(trifluoromethyl)-pyridine-2-
thiol, 40, to yield the thioether, 41, adopting similar conditions to those reported by 
Barnish et al.84 for the synthesis of 5-(arylthio)- and 5-(arylsulfonyl)-thiophene-2- 
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sulfonamides from 5-bromo-thiophene-2-sulfonamide, would then be followed by 
oxidation of the thioether to afford the sulfone, 42 (Scheme 2.5). 
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Scheme 2.5: Reagents and conditions: a) 4-substituted aniline, DIPEA, THF, room 
temperature, 24 h. b) allyl alcohol, TMAD, TBP, benzene, room temperature, 4, days. c) 
NaOH (aq.), DMF. d) H202, AcOH, 100 °C, 1 h. 
The synthesis of sulfonamide 37 using DIPEA (1.0 eq.) to activate the sulfonyl chloride, 
proceeded in quantitative yields. However, adopting a similar procedure for the 
synthesis of 36, the bis-sulfonamide 43 (Scheme 2.6) was isolated in 23% yield and the 
sulfonamide 36 was not identified. This result was unexpected as it was envisaged that 
the electron withdrawing effect of the sulfonyl group would decrease the nucleophilicity 
of the sulfonamide nitrogen compared with that of the aniline. However, formation of 
the bis-sulfone species, 43, suggests a greater reactivity of the sulfonamide compared 
with that of the aniline. 
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Scheme 2.6: Proposed mechanism for the formation of bis-sulfonamide species 43. 
N-A!lylation of sulfonamide 37 afforded 39 in 92% yield. Nucleophilic displacement of 
the 5-chioro functionality with the commercially available 3-chloro-5-(trifluoromethyl)-
pyridine-2-thiol, 40, was unsuccessful, resulting in the recovery of 39. It was postulated 
that conversion of the chioro group to either a bromo- or iodinated species would 
activate 39 for reaction. However, as the halogen exchange reaction has not been 
reported for chiorothiophenes, it would be necessary to resynthesize the N-alky!ated 
sulfonamide from 5-bromo-thiophene-2-sulfonyl chloride. 
An alternative strategy (Scheme 2.7) was the conversion of sulfonamide 39 to the a-
lithio species, 45, and subsequent reaction with the sulfonyl chloride, 44, to afford 42. It 
was envisaged that 44 could be prepared directly from the thiol, 41, following a method 
reported by Park et al.85 However, two attempts to synthesize the sulfonyl chloride 44 
were not successful and afforded a complex mixture of products. Clearly this strategy 
required further work and ultimately it would only yield one ligand, 42, for screening in 
the p53-Mdm2 competitive binding assay. It was therefore decided that the best strategy 
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would be to synthesize a number of combinatorial libraries containing novel 
sulfonamides that could be submitted for screening in the p53-Mdm2 competitive 
binding assay. In turn this would generate a valuable SAR picture of the Mdm2 binding 
cleft with regards to sulfonamide ligands. 
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Scheme 2.7: Alternative strategy for the synthesis of 2-sulfonyl-3-chloro-5-
trifluoromethyl-pyridine analogues. Reagents and conditions: a) S0202, KNO3, DCM 
(anhydrous), room temperature, 24 h. b) BuLi, Et20, -78 °C, 30 mins. c) 44, room 
temperature, 2 days. 
Sulfonamides 37, 39 and 43 were submitted for screening in the FP p53-Mdm2 
competitive binding assay, the TC50 values determined for these sulfonamides are 
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presented in Table 2.1. Details of each assay are given in Section 5.2. A discussion of 
the biological assay results is presented in Section 2.10. 
Compound No IC50 j.tM IC, 0 PM 
37 338 >50() 
39 >500 407 
43 1 56 >500 
Table 2.1: IC50 values (tM) determined in FP assay 1 (blue) and 2 (red) for 
sulfonamides 37, 39 and 43. 
2.4 	Combinatorial synthesis of sulfonamide libraries 
2.4.1 Equipment 
Figure 2.4 is a representation of the robotic equipment available at Edinburgh University 
for parallel array preparation, synthesis, purification and analysis of combinatorial 
libraries. After the time-consuming installation and training on each piece of equipment 
had been completed, the aim was to prepare a small library of sulfonamide analogues in 
order to become familiar with the operation of each system, and to illustrate the 
application of the full range of equipment to the synthesis of combinatorial libraries in 
the ligand design process. 
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Figure 2.4 Parallel Array Synthesis and Analysis 
The first step in library preparation was development of a synthetic route to the desired 
sulfonamide analogues. In order to minimise the possibility of the formation of the bis-
sulfonamide species that had been reported using the protocol adopted for the synthesis 
of sulfonamide 36, and also to make the sulfonamide condensation reaction more suited 
to an automated approach by dispensing with the requirement of a separate addition of 
base to each reaction vessel, it was decided to investigate whether the sulfonamide 
coupling would proceed using pyridine as the reaction solvent, rather than using THF 
and small volumes of NN-diisopropylethylamine. Indeed, this was found to be the case, 
with the sulfonamide 36 being synthesized in good yield, with no evidence of the his-
sulfonamide side reaction (Scheme 2.8). Consequently, this protocol was adopted for the 
synthesis of pilot sulfonamide Library U. 
The choice of an appropriate solvent is often crucial to the success of an automated 
synthesis of an array of compounds, formed using common building blocks, as it is an 
important requirement to be able to dispense all of the required reagents as solutions, in 
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order to minimize manual input. Furthermore, a problem associated with the poor 
solubility of a reagent could not only manifest itself in inadequate transferral of that 
reagent to a number of reaction vessels, resulting in poor yields, but could potentially 
block the cannula of the Bodhan Neptune TM-MB Automated Workstation causing 
termination of the automated synthesis. 
a) 	Ifl9H 
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Scheme 2.8: Reagents and conditions: a) 4-trifluoromethyl-aniline, pyridine, room 
temperature, 24 h. 
The NeptuneTM is capable of tare weighing vials and dispensing solvent to prepare 
solutions of known concentration, when the compound molecular weights and required 
solution volumes have been entered. Thus, although the accurate weights and volumes 
are calculated by the computer, all solid reagents must be weighed out approximately by 
hand. Considering that a 48-membered library would commonly consist of a 6 x 8 array 
of building blocks, only 14 stock solutions would be required. Therefore it was decided 
to prepare these manually rather than with the Neptune TM. The Neptune TM would then be 
used to dispense a fixed volume of each stock solution to designated reaction vessels 
contained in a MiniBlockTM. 
The next challenge proved to be adaptation of the chosen synthetic route to make it 
suitable for automation. Using MiniBlockTM technology, it was neither possible nor 
desirable to perform each sulfonamide synthesis on a 2.8 mmole scale, as for 
sulfonamide 36. Furthermore, there was an economic factor associated with some of the 
commercially available sulfonyl chloride building blocks. It was hoped to synthesize ca. 
50 mg of each sulfonamide, not only to provide ample quantities of ligand for screening 
at Cyclacel Ltd., but also to provide enough material for full characterization. 
Anticipating a 70% yield for each reaction in the pilot library, a reaction scale of 0.15 
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mmole was set, based on a 50 mg scale of the 4,5-dibromo-thiophene-2-sulfonyl 
chloride building block. 
Prior to purification of the library, each reaction mixture had to undergo an acidic wash 
and an extraction into organic solvent to remove excess pyridine from the reaction 
mixture. It was anticipated that the Myriad® Allex liquid-liquid extraction system could 
be used for this purpose. The Allex is capable of separating a two-phase system 
(aqueous and organic layers) by sensing the change in dielectric constant at the 
meniscus. It can then be programmed to transfer either the top or bottom layer to a 
different reaction vessel, with separation just above or just below the meniscus 
depending on the layer required. Two-phase systems can also be mixed before 
separation, through aspiration of the mixture. 
Clearly, there was also an issue associated with the scale of each reaction when 
addressing the subject of parallel purification. Too high a concentration of a sample in a 
given solution had the potential to overload a column and give poor separation. 
Although this could be addressed by multiple injections of the sample, this was not 
considered attractive, as it would lengthen the time required to purify a library. 
Equipment available in the laboratory suitable for parallel, automated purification 
consisted of the Biotage Quad3TM,  the Biotage Parallex FlexTM  and the Waters ZMD 
4000 LCMS system. 
Potentially, the Quad3TM  can purify up to 12 compounds, at a scale of around 0.250 g, in 
around 30 minutes, using normal-phase flash chromatography techniques. It is limited to 
elution using an isocratic solvent system, unless additional solvent systems are prepared 
and loaded onto the system manually. Owing to the need to monitor the purification by 
thin layer chromatography and to combine and then concentrate desired fractions in 
vacuo, its maximum output is, however, probably limited to 24 compounds per day. It 
was thought that the quantities of sulfonamides synthesized in each library would be at 
the lower end of the scale with respect to the purification range of this machine. 
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One further option was to use the Biotage Parallex Flex TM  reverse phase 1-IPLC. 
Potentially, the F!exTM  has the capacity to purify up to 0.250 g of injected sample on a 
Supercosil ABZ+Plus reverse-phase column, of dimension 25 cm x 21.2 mm, particle 
size 12 gM, although, in practice following subsequent work on CDK inhibitor 
programme as discussed in Chapter 4, this was found to be around 0.050 g. The 
threshold for collection of a peak in the chromatogram can be lowered, allowing ligands 
present in small concentrations to be collected. Samples may be queued to allow for 
sequential automated purification. The main disadvantage to using this system was that 
it was envisaged that a considerable amount of time would have to be spent developing 
reverse-phase purification methods. 
Perhaps the most attractive option was the use of an automated mass directed 
purification system, such as the Waters ZMD 4000 reverse-phase LCMS system. This 
equipment has the potential of sequentially purifying compounds in concentrations up to 
50 mg ml, with typical methods of around 20 minutes duration and maximum injection 
volumes of I mL. Although a commitment of time would be required to develop 
reverse-phase purification methods on this system, the use of the ZMD would provide 
identification of the sulfonamides by ESI-MS and furthermore to give a reasonable 
indication of the reaction progress, including reagents remaining and product formation. 
2.4.2 Pilot sulfonamide library Li and early SAR 
The sulfonamide combinatorial chemistry programme was initiated with a test library of 
12 sulfonamides (Table 2.2) consisting of 2-sufonyl chloride building blocks dropped 
from a proposed initial 'full-scale' (48 member) library, and 6 anilines. The rationale 
for the design of both this library was based on the review of the 191-membered hit 
expansion library based on the sulfonamide and sulfonate ester template. From this hit 
expansion library, both thiophene and aniline part of those ligands shown as being active 
in either the FP or ELISA assay were identified and considered separately for inclusion 
within the combinatorial library. 
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For the pilot library Li two sulfonyl chlorides were selected, both of which contained a 
5-halo substituent at the thiophene ring. Of the 10 ligands containing these building 
blocks in the initial hit expansion library, 2 were shown to have IC50 values <500 VtM in 
the FP assay. Notably, of the 6 anilines selected as building blocks for library Li, 3,5-
bis-trifluoromethylaniline had been represented by 2 ligands in the hit expansion library, 
both of which were active in the FP assay. Of the 6 anilines selected, only 3,5-
dichloroaniline had not been represented in the initial hit expansion library, its inclusion 
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Table 2.2: Library U. Compound numbers are given in bold, together with percentage 
yields. 1050's (p.M) in the FP assay are given in blue (FP assay 1) and red (FP assay 2). 
Library Li was synthesized on the Neptune TM  adopting the protocol used for the 
synthesis of 36, on a 0.15 mmole scale. Stock solutions of each reagent were prepared in 
20 ml reagent vials, 2 containing a 0.15M concentration of either 4,5-dibromo- or 5-
chloro-thiophene-2-sulfonyl chloride in pyridine, and 6 containing a 0.16M 
concentration of the selected substituted aniline in pyridine. The reagents were 
dispensed into a MiniBlockTM  (the MiniBlock consists of 48 fitted tubes, each 
reversibly sealed at the narrow tube end by a pinching mechanism, and encased in an 
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insulated block which may be heated or cooled) that was shaken at room temperature for 
a period of 24 hours. The reactions were carried out in 2.0 mL total volume of solution. 
The first problem encountered in performing the library synthesis was in the transferral 
of the reaction mixtures from the MiniBlockTM  to the test tubes used on the Allex 
system, owing to the limited compatibility of the volume and format of reagent vessels 
used in the MiniBlockTM  and Allex systems. Although MiniBlock tubes can be drained 
into the commercially available 48-we!l microtitre plates, which are compatible with the 
Allex, these plates have a well volume of 5 ml and the Allex requires at least 2 mL of 
solvent in each layer to facilitate accurate separation. This meant that the solutions 
contained in the MiniBlock would first have to be transferred to larger test tubes on the 
Allex. To each test tube would then be added a solution of HC! (3 mL), followed by a 
1:1 mixture of Et20: EtOAc (3 mL), the mixture would then be aspirated and the organic 
layers transferred to a separate test tube, to which brine (3 mL) would be added. 
Following the aspiration of this second mixture, the organic layer (approximately 3 mL) 
would finally be transferred to a 48-well microtitre plate for solvent concentration using 
the Christ evaporation system. Even using these larger volumes of solvent, problems 
were encountered during the separation steps, with approximately 0.5 mL of organic 
solvent not being transferred to either the second test tube or the 48-well microtitre plate. 
However, increasing the volume of solvent used in each liquid-liquid extraction step 
would be counterproductive as each sample had to be contained in a format suitable for 
parallel sample concentration using the Christ system. Another problem encountered 
when using the Allex system was that, following aspiration, some mixtures had a 
tendency to emulsify. Although, in some instances, this could be addressed by 
programming a number of wait cycles between the aspirate and dispense steps, the 
problem could not be completely solved and, in some instances, resulted in no detection 
of a liquid-liquid interface and consequently the organic solutions were not transferred 
to the 48-well microtitre plate for concentration. In these cases manual separation 
techniques had to be employed. 
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Further problems were encountered during purification of library Li. Sulfonamides 46 
and 47 were used as test samples for mass directed purification on the ZMD 4000. 
Unfortunately, the molecular ions of these two sulfonamides were not detected and 
consequently, despite further attempts to identify the molecular ions of these species by 
ESI-MS, it was decided to undertake the remaining purifications on the Flex TM HPLC 
system. It is postulated that failure to detect the molecular ions of these species may 
have been attributable to the presence of the pyridinium ion in the samples. 
Library Li yielded 6 sulfonamides for screening with failures resulting from 2 
compounds lost at the purification stage (46 and 47), 3 failed reactions (48, 53 and 57) 
and I compound, 51, cross-contaminated. Yields were disappointingly low, with only 
trace amounts of sulfonamide being isolated and identified by ES1-MS. It was thought 
that the low yields obtained were mostly attributable to problems encountered with the 
use of the Allex. Of the 6 compounds isolated and subsequently submitted for screening, 
4 displayed <500 jiM activity in the FP assay (with 56 (88 jiM) acting as a control and 
previously tested as KMO 1046 (199 jiM) in the screening of the hit expansion library). 
Significantly, both 50 and 56 were shown have good activity in the FP assay, and 
perhaps suggested a favourable interaction between the 3,5-trifluoromethylanilino 
moiety and the Mdm2 protein. Sulfonamide 49, exhibiting a 3,5-dichloroanilino moiety 
was also shown to have good activity in the FP assay, with an IC50 value of 194 jiM. 
Both 49 and 50 containing the 4,5-dibromothiophene moiety were active in the FP assay. 
2.4.3 Library L2. 
A 48-membered library, as shown in Tables 2.3.1 and 2.3.2, followed library Li. Again, 
library L2 was selected based on review of the hit expansion library screened by 
Cyclacel Ltd. A decision was made not to include the 5-chloro-4-nitro-thiophene-2-
sulfonyl chloride building block in the combinatorial library for a number of reasons, 
despite the favourable activity of analogues containing this functionality screened from 
the hit expansion library. Firstly, scientists at Cyclacel Ltd. had found that the reactivity 
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of the 5-chioro- substituent to nucleophilic substitution was high, owing to the electron 
withdrawing effect of the adjacent 4-nitro- group. Consequently, reaction of the 5-
chloro-4-nitro-thiophene-2-sulfonyl chloride with an aniline often afforded either the 5-
anilino-4-nitro-thiophene sulfonic acid or the 5-anilino-4-nitro-thiophene-2-sul fan ilide 
upon work up. Secondly, scientists at Cyclacel were focussing on the synthesis of further 
5-chloro-4-nitro thiophene analogues and it was felt that the main objective of the 
combinatorial programme was to identify novel ligands. To address this issue, 4-oxazol-
2-yl-benzenesulfonyl chloride and 3-nitrobenzene-sulfonyl chloride were included as 
building blocks for library L2 to increase its diversity; to investigate whether the 
thiophene ring could be replaced by a benzene moiety; and to probe for additional non-
covalent interaction in the Mdm2 binding cleft. Also, 5-benzenesulfonyl-thiophene-2-
sulfonyl chloride was included as a building block to investigate whether sulfonamides 
containing this moiety would have similar activity to the 2-sulfonyl-3-chloro-5-
trifluoromethyl-pyridine analogues, exemplified by 15 and 16. Of the 8 anilines selected 
for inclusion within the library, 3 contained a substitution pattern that had not been 
screened in the hit expansion library. The unsubstituted aniline was selected to 
investigate whether functionality off the anilino ring was required for activity. 4-
Methylaniline was selected to examine the effect of an electron-donating group in the 
anilino ring. 2,4-Dichloroaniline was selected for comparison with the 3,5-
dichioroaniline analogues to gain insight into a preferred substitution pattern on the 
anilino ring. 
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Table 2.3.1: Library L2. Compound numbers are shown in bold, with percentage yields 
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Table 2.3.2: Library L2. Compound numbers are shown in bold, with percentage yields 
given. 1050's (jiM) in the FP assay are given in blue (FP assay 1) and red (FP assay 2). 
Owing to the poor yields of sulfonamides obtained for library Li, the synthetic protocol 
was adjusted, with the scale of each reaction being increased from 0.15 mmole to 0.20 
mmole. However, similar problems to those reported for library Li were still 
encountered when performing the automated work-up of the library, despite having 
inserted additional wait cycles into the work-up programme. 
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It was still envisaged to purify the library members using the ZMD and therefore 16 
reactions (90 - 105) were used as test samples for mass directed purification. 
Unfortunately, for each sample the molecular ion of the sulfonamide was not detected 
and the majority of the samples were dispensed to waste. Consequently, a further 16 
membered library was planned to resynthesize samples 90 - 105 lost at the purification 
stage. Where some residual crude mixture had been recovered and for subsequent library 
members 58 - 89, the sample was dissolved in methanol (1 mL) and injected directly 
onto the Biotage Parallex FIexTM  HPLC. 
Despite these difficulties library L2 afforded 30 novel sulfonamides for screening, with 
failures resulting from 13 compounds being lost at the purification stage on the ZMD 
and 5 failed reactions where only the sulfonic acid was identified by ESI-MS. Again, the 
isolated yields of sulfonamides recovered from the HPLC was extremely low compared 
to those sulfonamide condensations synthesized and purified by conventional 
techniques. To address this, an attempt was made to resynthesize library Li using 
triethylamine as opposed to pyridine as a reaction solvent. However, this was not 
successful as it was found that in the majority of cases, activation of the sulfonyl 
chloride with triethylamine precipitated the species out of solution, rendering automated 
transfer impossible. 
A small 2 x 2 array was undertaken using the 5-bromo-thiophene- and 3-nitrobenzene-
sulfonyl chlorides and 3,5-dichloro- and 2,4-dichloro- anilines. The reactions were 
performed at 0.20 mmole scale using DCM as the reaction solvent. A solution of DIPEA 
(2.0 eq.) in DCM was added to each reaction vessel and the mixtures allowed to stir for 
64 hours at room temperature. NMR and ESI-MS analysis of the unpurified reaction 
mixtures failed to identify the presence of the sulfonamide products. 
The protocol adopted for the synthesis of library L2 was slightly modified for the 
resynthesis of sulfonamides 90 - 105 (Table 2.3.2). Prior to the liquid-liquid extraction 
step on the Allex, the samples were transferred from MiniBlock to a 48-well microtitre 
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plate and concentrated in vacuo on the Christ system in order to remove excess pyridine. 
Rather than using a 1:1 mixture of EtOAc:Et20, solely EtOAc was used for extraction. 
An additional aqueous wash was performed on each sample prior to washing each with 
brine. More significantly, a decision was made to purify each reaction manually, using 
small scale, normal phase column chromatography techniques. In doing so, it was 
expected that the added attention to each individual purification would result in a higher 
recovery of isolated sulfonamide. Indeed, for most reactions this was found to be the 
case, with isolated yields from the reactions purified manually ranging from 2 - 30 %, 
with an average yield of 16 % for the 16 reactions, compared to I - 10%, with an 
average yield of 2%, for the reactions from library L2, purified using automated 
purification techniques. However, isolated yields were clearly still significantly lower 
than those anticipated based on the manual synthesis of 36 (71 %) and clearly further 
work was required on developing the existing protocol. Furthermore, although manual 
purification of sulfonamides 90 - 105 had resulted in an overall increase in isolated 
yields, it would not be practical to adopt this approach if larger combinatorial libraries 
were required to be synthesized nor if throughput was an issue. 
The biological assay results obtained from library L2 are presented in Tables 2.3.1 and 
2.3.2 and are discussed in detail in Subsection 2.9. However, some general trends were 
immediately observed from the data. Those sulfonamides containing either a 3,5-
dichloro- or 3,5-bis-trifluoromethyl- substitution pattern on the anilino aromatic ring 
generally had good activity in the FP assay, demonstrated by ligands 64 and 70 with IC50 
values of 159 tM and 246 LM respectively. Furthermore, assay results indicated that the 
thiophene ring could be replaced by an aromatic ring and afford compounds with some 
activity. 
2.4.4 Library L3 
To address the resynthesis of 2 sulfonamides, 50 and 56, to provide additional ligand for 
further in vitro screening, library L3 (Table 2.4) was planned. Additionally, this library 
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aimed to investigate a small number of sulfonamides made from 4-ch loro-3 -nitro-
benzene sulfonyl chloride. Only 2 ligands, 106 and 107, had been screened prior to the 
generation of this library that contained the 4-chloro-3-nitro-benzene moiety. Both 106 
and 107 exhibited moderate activity in the FP assay, with IC53 values of 192 iM and 
232 jiM respectively. It was postulated that the 4-chloro-3-nitro-benzene moiety could 
interact with Mdm2 in a similar manner to the 5-chloro-4-nitro-thiophene moiety. 
Finally, the benzoyl chloride building block was included to investigate whether an 
amide linker could replace the sulfonamide linker. Of the anilines chosen for inclusion 
within the library, both the 3,5-bis-trifluoromethyl-aniline and 3-trifluoromethyl-aniline 
moieties had been present in hits from the initial hit expansion library; the 3-chioro-
benzene moiety had been present in the form of an active sulfonate ester from the hit 
expansion library; and the 3,4-dichlorobenzene moiety had been present in the form of 
an inactive sulfonate ester in the hit expansion library. 
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Table 2.4: Library U. Compound numbers are shown in bold, with percentage yields 
given. 1050's (tM) in the FP assay are given in blue (FP assay 1) and red (FP assay 2). 
Adopting identical protocol to that used for the resynthesis of sulfonamides 90 - 105, 
library L3 yielded 15 compounds for screening, with I failed reaction. A minimal 
amount of 56 was isolated (2%) owing to the majority of the sample being transferred to 
waste during the liquid-liquid extraction stage. Otherwise, yields of isolated 
sulfonamides were in the range 3 - 38%, with an average yield of 15%. 
FP assay results obtained from library L3 suggested that the amide linker was not 
tolerated in the Mdm2 binding pocket. However, given the IC50 value obtained for 114 
of 129 1iM, it was decided that a more suitable comparison could be made by adding 4-
chloro-3-nitro- substitution pattern to the benzene carbonyl chloride. The novel ligands 
112 and 113, both containing the 4,5-dibromothiophene moiety, were shown to be active 
in the FP assay, with IC50 values of 199 j.tM and 160 jtM respectively. 
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2.4.5 Library L4 
A further sulfonamide library, Library L4 (Tables 2.5.1 and 2.5.2), was planned to 
explore a number of novel sulfonyl chloride building blocks that had been made 
available from Maybridge. 4,5 -dibromo-thiophene-2-sulfonyl chloride was included as 
this building block had exhibited activity in the form of ligand 50. The anilines selected 
for this library included the 3,5-bis-trifluoromethyl-, 4-trifluoromethyl- and 4-chloro-
substitution patterns, featured in ligands from library L2, that had been shown to have 
good activity in the FP assay. It was decided to investigate whether an additional Cl-I2 
spacer would be tolerated between the sulfonamide linker and the aromatic ring, and to 
address this issue, 3 ,5-bis-trifluoromethyl-benzylamine, 4-trifluoromethyl-benzylamine 
and 4-chloro-benzylamine were selected for inclusion within the library. Furthermore, to 
continue the investigation of whether an additional interaction could be found between 
the ligand and the Leu26 pocket, both (R)- and (S)- enantiomers of 1-(4-chlorophenyl)-
ethylamine were included as building blocks. 
The protocol adopted for the synthesis of library L4 was based on that established for 
the manual synthesis of sulfonamides shown in Table 2.7, detailed in 2.6.1, with only 
one equivalent of pyridine, in a solution of DCM, being added to each reaction vessel. 
The library was synthesized on the Neptune and the scale of each reaction increased 
from 0.20 mmole to 0.40 mmole. Owing to mechanical downtime of the Allex, each 
work-up was to be performed manually, again using the protocol adopted for the 
sulfonamides shown in Table 2.7. It was envisaged that Library L4 would be purified 
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Table 2.5.1: Library L4. 1050 values determined for each ligand in the (new) FP assay 
are shown in red. 
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CI 4% 29% 5% 
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147 155 162 
Cl 7% 2% 16% 
I-12N 9)) 50)) 5)))) 
148 156 163 
Cl 5% 8% 18% 
H2N 50)) 5)9) 50)) 
149 157 
164 Cl 13% 3% 
H2N 500 -50)) Reaction Failed 
CF3 
150 158 50 
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N f? 
28% 29% 2% 
165 265 02 
IF IA 
CF3 
/ \ 151 159 165 44% 33% 33% 
H2N 50)) 500 50)) 
CF  
152 160 46 
CF3 8% 8% 38% 
- 329 5)9) 163 
153 161 166 
/—
- 	
CF3 32% 19% 13% 
H2N 59)) 50)) 5)))) 
Table 2.5.2: Library U. 1050 values (.xM) determined for each ligand in FP assay 2 are 
shown in red. 
Library L4 afforded 36 sulfonamides for screening, 35 of which were novel. 8 reactions 
failed owing to poor solubility of the building block containing the benzoylaminomethyl 
moiety that resulted in minimal transferral of the reagent to the reaction vessels. Isolated 
yields were in the range 2% - 44%, with an average yield of 16%, comparable to that of 
15% for library U. 
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Assay results obtained from members of Library L4 indicated that an additional CH2 
spacer between the sulfonamide functionality and the aromatic ring was not tolerated in 
the Mdm2 binding cleft, demonstrated by 150 (IC50 165 p.M) and 151 (1050 >500 !iM). 
Furthermore, the activity of sulfonamides 126, 134 and 150, with IC50 values in the FP 
assay of 106 pM, 193 tM and 165 j.xM respectively, suggested that the benzothiazole 
and benzothiadiazole ring systems could potentially replace the thiophene ring. The 
significance of the biological data is discussed in detail in Section 2.10. 
2.5 	Exploratory solid phase work 
To attempt to optimize the synthesis of sulfonamide libraries, whilst still retaining a 
high-throughput approach, some exploratory work was undertaken focussing on the use 
of 'catch and release' resins. The applicability of polymer supported DMAP as a catch 
and release resin of acid chlorides and sulfonyl chlorides to synthesize a variety of acyl 
and sulfonyl derivatives, including esters, amides and sulfonamides, has been reported .86 
The electrophilic acyl or sulfonyl chloride can be reacted with PS-DMAP, 167, to form 
an N-substituted pyridinium salt, 168, which can then be reacted with various 
nucleophiles such as alcohols, amines and thiols, without the requirement of a tertiary 
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Scheme 2.9: The use of PS-DMAP as a catch and release resin. 
The perceived advantage of using a catch and release strategy was that by using the 
nucleophile as the limiting reagent, the product could be isolated in high purity by 
filtration, with the excess electrophile remaining bound to the resin. This strategy would 
not only remove the problematic liquid-liquid extraction steps on the Allex but also 
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eradicate the need for purification of each sample by HPLC or normal phase column 
chromatography. In turn, an increase in throughput was expected. One disadvantage to 
using the catch and release strategy was that the scale of each reaction would be required 
to be decreased owing to the small volume of the reaction vessels used by the MiniBlock 
(3 mL) and the relatively low loading of the resin (0.35 mmole g1). Also, the resin 
would have to be washed prior to addition of the nucleophile to remove excess unbound 
sulfonyl chloride. 
Seven trial reactions were undertaken using this strategy. Typically, the resin (1.0 eq.) 
was mixed with a solution of the sulfonyl chloride (1.5 eq.) in anhydrous DCM and 
allowed to stir at room temperature for 2 hours. After thorough washing of the resin with 
DCM to remove excess sulfonyl chloride, a solution of the aniline (0.7 eq.) in the chosen 
reaction solvent was added. The mixture was allowed to stir at room temperature for a 
period of 1-3 days before being filtered, washed with DCM and the filtrate and washings 
concentrated in vacuo. Analysis of the residue by TLC and ESI-MS revealed, in the 
majority of cases, little sulfonamide, with the unreacted aniline being detected in all 
cases. Preliminary results from this study (Table 2.6) suggested that either the sulfonyl 
chlorides were not being successfully loaded onto the resin or failure of the anilines to 
react with the bound sulfone owing to the poor nucleophilicity of the aniline species. 
This question could have been addressed by collection and concentration of the resin 
washings after the loading of the sulfonyl chloride. However, with only I sulfonamide 
being recovered in from 6 reactions, in low yield and after purification by column 
chromatography, the catch and release protocol in its current form was deemed not as 
successful as the methodology developed for libraries L2 and L3 and, consequently, it 




















171 172 173 
H2N—[\j—F 
- Aniline isolated 23% Aniline isolated 
Table 2.6: Exploratory reactions examining a catch and release strategy using PS-
DMAP, 167. Compound numbers are shown in bold, with the isolated yield of 172 
shown. Shaded boxes represent those reactions not undertaken. 
2.6 	Synthesis of N-alkylated sulfonamides 
2.6.1 Manual scale up of sulfonamide synthesis to allow second-generation library 
Given that a number of sulfonamides synthesized in libraries Li - L4 had been shown to 
be active in the FP assay, it was decided to resynthesize a number of these (Table 2.7) on 
a larger scale, ranging from 1.9-3.1 mmole, and, in doing so, not only satisfy a demand 
for further in vitro screening but also to allow the synthesis of a second generation 
library of N-alkylated sulfonamides. To facilitate work-up and purification of the 
ligands, it was decided to use a stoichiometric amount of pyridine in the synthesis, rather 
than an excess. The isolated yields obtained for each sulfonamide synthesis shown in 
Table 2.7 were encouraging and significantly better than those obtained using the same 
method utilizing the combinatorial equipment for the synthesis of library L4, although it 
should be noted that library L4 was performed on a 0.4 mmole scale. 
Choi—l ei 2 
Br 02N 
ClS2 SoCi2 Br Cl -tj- SOC 2 BrsSOCl2 s 
83 56 50 
89% 81% 97% 
CF, 
88 52 46 114 H2N 
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-- H2N— F 86% 
Table 2.7: Manual resynthesis of a selection of sulfonamides active in the FP assay. 
Compound numbers are shown in bold, with percentage yields of isolated sulfonamides 
given. Shaded boxes represent those reactions not undertaken. 
2.6.2 N-Alkylation of sulfonamides 
Screening results of two ligands synthesized by Shudong Wang at Cyclacel Ltd., 
CY12258 (IC50 42 riM, FP assay 1), 176, and CYC12263 (IC50 15 tM, FP assay 1), 177, 
suggested that N-alkylation of the sulfonamide moiety resulted in an increase in potency 
of thiophene sulfonamides in vitro. 
02N 
CI 	 N1I 
176 
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CI ~S~-N —a 
01 
177 
This observation was supported by screening data obtained from the FP assay for several 
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Furthermore, a modelling study undertaken by Mark Thomas at Cyclacel Ltd., which 
built on earlier work detailed in Chapter 2.3, had suggested that potentially an N-alkyl-
or N-benzyl- substituent could fill the Leu26 binding pocket of Mdm2. 
With the aim of generating a small library of N-alkylated 56 analogues, 3 reactions were 
undertaken to evaluate the applicability of the Tsunoda reaction performed under 
perceived optimal conditions based on unpublished work undertaken by Mascio within 
the group. In each case the N-a!kylated sulfonamides 180, 181 and 182 were not 
isolated, and only unreacted 56 was recovered. Clearly this reaction did not lend itself 
well to library synthesis in its current form, and consequently, other methods of N-














Selective synthesis of N-alkylanilines via direct alkylation with excess aniline in the 
presence of an alkyl halide is often problematic due to the difficulty in preventing the 
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formation of the corresponding N-N-dialkylaniline and the quaternary ammonium salt. 
One convenient method for the synthesis of a secondary amine is via reductive 
amination of an aniline, 183, with an aldehyde, 184, using the Borch reduction. 
17  The 
reductive animation can be regarded as proceeding via a hemiaminal intermediate, 185, 
that can undergo conversion to an imine, 186, followed by reduction, using NaBl-I3CN, 
187, to the N-alkylated anilino moiety, 188. Again, overalkylation is often a problem 
associated with this reaction. It was expected that subsequent reaction of the N-alkylated 
anilino species, 188, with a sulfonyl chloride, 189, would afford the N-alkylated 
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Scheme 2.10: Reductive amination and subsequent condensation to afford a 
sulfonamide. 
The perceived advantage associated with this strategy was that, by fixing the sulfonyl 
chloride species and varying the aldehyde, a diverse 1-dimensional library could be 
generated, based on an existing mono-substituted sulfonamide that had shown good 
activity in the FP assay. The library would therefore directly examine the effect of N-
alkylation. However, this strategy would require the generation of two novel libraries as 
opposed to only the one - one of secondary amines, which were not likely to be useful 
for screening purposes, and one of N-alkylated sulfonamides. Also, the perceived 
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difficulty of purification of secondary amines and inherent stability issues associated 
with this species was potentially a challenge. 
Given that a number of sulfonamides had been isolated in good yield (Table 2.7) a 
convenient strategy to generate a library of N-alkylated sulfonamides would be by SN2 
alkylation of the sulfonamide with an alkyl halide. Table 2.8 shows those reactions 
undertaken. Typically, for each alkylation, the alkyl halide (5.0 eq.) was added to a 
stirring solution of the sulfonamide (1.0 eq.) in acetone and sufficient triethylamine was 
added to make the reaction mixture basic. For alkylation 192 the reaction mixture was 
allowed to stir at room temperature for 24 hours. For alkylation 196 the reaction mixture 
was subjected to microwave irradiation at 150 °C for 5 minutes. Other alkylations shown 
in Table 2.8 were performed under microwave irradiation at 60 °C for 10 minutes. The 
isolated yields of N-alkylated sulfonamides obtained, following manual purification 
using normal phase column chromatography, were generally moderate. In those 
reactions where the N-alkylated sulfonamide was not isolated this was attributable to 
poor separation, in the case of the methylation reactions, or in the instance of isobutyl 
iodide, steric demands. 
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210 217 224 
- CF3 
Not Isolated Not Isolated Not Isolated 
0 H 
Table 2.8: N-alkylated sulfonamides synthesized. Compound numbers are in bold, with 
percentage yields given. Shaded boxes represent reactions not undertaken. 1050 (jiM) 
values as determined in FP assay I are shown in red. 
As a result of this chemistry, 24 novel ligands were submitted for screening in the FP 
assay, although, disappointingly, all were shown to have >500 jiM activity. Following 
further investigation, it was postulated that the absence of the 4-nitro- group on the 
thiophene ring removes the potential for the formation of a hydrogen bond to the side 
chain of Gln59, and consequently the thiophene sulfonamide may adopt a different 
binding mode than that modelled for the 5-chloro-4-nitro-thiophene series. 
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2.7 	Replacement of the sulfonamide linker 
Using molecular docking, Mark Thomas at Cyclacel Ltd. investigated the replacement of 
the sulfonamide linker with an amide linker in the context of nine 5-chloro-4-nitro-
thiophene sulfonamides and concluded that all molecules examined had the potential to 
dock in a similar manner to that observed in the sulfonamide series. Consequently it was 
decided that it would be useful to prepare a library of amides that could be screened in 
the FP p53-Mdm2 competitive binding assay. 
Amides synthesized are shown in Tables 2.9.1 and 2.9.2. A key feature of the aromatic 
amides shown in Table 2.9.1 is the 3-nitro- functionality. It was hoped that the 4-chloro-
3-nitro- substitution pattern would either mimic the 5-chloro-4-nitro- substitution pattern 
in the thiophene analogues or afford amides of comparable activity to the sulfonamides 
114 - 117 synthesized in library L3. Furthermore the 4-methyl-3-nitro- substitution 
pattern had been investigated in the sulfonamide series and was present in a number of 
ligands shown to be active in the FP assay. 
Amides shown in Table 2.9.2 contain heterocyclic functionality. Of the 5 acid chloride 
building blocks selected, 4 contained a thiophene ring. The 5-chloro-4-nitro-, 4-nitro-
and 5-nitro- substitution patterns were selected on the basis of demonstrated activity 
exhibited by ligands synthesized by chemists at Cyclacel Ltd. for the sulfonamide series. 
Benzo[b]thiophene-2-carbonyl chloride was selected for inclusion within the array as a 
result of the IC50 value obtained for ligand 134 in the sulfonamide series. Only 9 ligands 
containing a furan ring had been screened in the hit expansion library, and, although all 
9 were shown to be inactive in the FP assay, it was considered worthwhile to include 5-
(4-chloro-phenyl)-2-methyl-furan-3-carbonyl chloride as a building block for the array 
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Table 2.9.1: Aromatic amides synthesized. Percentage yields are given. Figures in red 
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Table 2.9.2: Heterocyclic amides synthesized. Percentage yields are given. Figures in 
red indicate the concentration (tM) at which the amide precipitated out of the FP assay. 
68 
P 2 	 RuIi,\ c L)iL//.ssin I 
A number of the acid chloride starting materials required to be synthesized, owing to 
their lack of commercial availability. Nitration of the commercially available 5-chioro-
thiophene-2-carboxylic acid, 290, using procedure reported by Fu et al. 88 afforded the 
mono-nitrated thiophene, 291, exclusively in moderate yield (36%). It is postulated that 
the 3-position is deactivated to nitration owing to the presence of the 2-carboxyl group. 
Conversion of 291 to the carbonyl chloride, 292, was achieved using oxalyl chloride and 
a catalytic amount of DMF (Scheme 2.11). 292 was used directly, without purification, 
for the synthesis of 254 - 259. 
02N 	 02N 
C1 	
'OH 	a) 	ci 3OH 	
b) 	 ci 
0 	 0 	 0 
290 	 291 	 292 
Scheme 2.11: Reagents and conditions: a) HNO3, HOAc, Ac20, room temperature, 24 
h. b) (COC1)2, DMF, DCM, room temperature, 24 h. 
Nitration of the commercially available thiophene-2-carboxylic acid afforded a mixture 
of 5-nitro- and 4-nitro-thiophene-2-carboxylic acids that was converted to the respective 
isomeric mixture of carbonyl chlorides without purification. It was planned to isolate 
both isomers following reaction of the mixture of carbonyl chlorides with a selection of 
anilines, (Table 2.9.2, 274 - 277) and, in doing so, provide 2 novel amides per anilino 
coupling, for screening in the FP assay. However, owing to the suspension of the p53-
Mdm2 inhibitor programme, these purifications were not performed. 
5-Nitro-thiophene-2-carboxylic acid 294 was synthesized by treating the commercially 
available 5-nitro-thiophene-2-carbaldehyde, 293, with silver oxide, according to protocol 
reported by Satonaka89 (Scheme 2.12). The acid 294 was converted to the carbonyl 
chloride 295, which was used, without isolation, for amide couplings 278 - 289. 
me 
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293 	 294 
Scheme 2.12: Reagents and conditions: a) NaOH, AgNO3, H20, room temperature, 2 h. 
The general procedure used for the synthesis of amides 225 - 238 involved the addition 
of the substituted benzoy! chloride (1.1 eq) to a solution of the aniline (1.0 eq.) in 
anhydrous DCM. The reaction mixture was subjected to microwave irradiation at 110 °C 
for 5 minutes, before being extracted into EtOAc; washed with water, dried over 
anhydrous Na2SO4 and concentrated in vacuo to afford the amide in good purity. 
One further method investigated for the synthesis of amides was based on work reported 
by Booth that employs the use of polymer-bound quenching reagents for high-
throughput parallel purification.90 Owing to its simplicity and efficiency, this 
methodology enables the rapid, parallel purification of crude reaction products obtained 
via solution phase synthesis and is therefore an attractive alternative to solid-phase 
organic synthesis in the application of combinatorial chemistry. The modified procedure, 
used for the synthesis of amides 239 - 289, involved reacting an excess of a substituted 
benzoyl chloride (1.2 eq.) with an aniline (1.0 eq.) in anhydrous DCM, in the presence 
of resin bound morpholine. Following stirring overnight at room temperature, the 
reaction was then quenched by the addition of tris-(2-aminoethyl)amine resin. After a 
period of 4 hours, the resin was filtered and washed with DCM, the filtrate being 
collected and concentrated in vacuo to afford the amide in excellent purity. 
Recently, Perreux et al. reported the synthesis of amides via pyrolysis of the salts 
obtained by mixing neat primary amines and carboxylic acids under solvent free 
conditions and under microwave irradiation. 91  Although the reported yields were low 
when reacting either aniline or 4-methoxyaniline with benzoic acid, this was considered 
an attractive strategy owing to the wide commercial availability of benzoic acid 
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analogues. Three exploratory reactions were undertaken using 4-nitro-benzoic acid and 
either 3,5-bis-trifluoromethyl-, 295, 4-trifluoromethyl-, 296, or 4-chloro-aniline 297, of 
which only 296 was successful, affording 4-nitro-N-(4-trifluoromethy!-phenyl)-
benzamide in 15% yield (Scheme 2.13). Although this one result was encouraging, this 
strategy was not pursued as it was apparent that time would have to be spent optimizing 









Scheme 2.13: Reagents and Conditions: a) Substituted aniline, solvent free, microwave 
irradiation, 160 °C, 15 mins. 
Amides 225 - 289 were submitted for screening in the FP p53-Mdm2 competitive 
binding assay. Unfortunately all amides screened suffered from poor solubility in the 
assay, and consequently, IC50 values for each of the ligands could not be determined. 
This result was extremely disappointing and, owing to the subsequent suspension of the 
p53-Mdm2 programme, time did not permit the modification of the assay conditions. 
2.8 Reversed amides and sulfonamides 
Intriguingly, the effect of reversal of the sulfonamide or amide linker on the binding of a 
ligand to Mdm2 had not been addressed. Biological assay data had been collected for 
only one example of a pair of sulfonamides, namely sulfonamides 114 and CYC-
0043560, 298, which had IC50 values of 128 tM and 153 ltM respectively, in the FP 
p53-Mdm2 competitive binding assay. This suggested that the reversal of the 
sulfonamide linker was tolerated in the p53-binding pocket of Mdm2 for aromatic 
sulfonamides. Therefore, it was desirable to see if a similar modification could be made 
in the thiophene sulfonamide series. 
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Using protocol reported by Galvez et al. ,92 reaction of the acid, 291, with 
diphenylphosphorylazide, 299, would afford the azide, 300, that would undergo the 
Curtius rearrangement 93  to afford the isocyanate, 301. Using tert-butanol as the reaction 
solvent would afford the carbamate, 302 (Scheme 2.14). It was envisaged that 
subsequent deprotection of 302 and reaction with a benzoyl or benzene sulfonyl chloride 
would afford an amide or sulfonamide respectively. 
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OH 
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C"4/S \ NHBOC 
302 
Scheme 2.14: Reagents and conditions: tert-butanol, triethylamine, reflux, 20 h. 
Unfortunately, the reaction between 291 and 299 afforded a brown oil that was 
polymeric in character. Subsequent ESI-MS analysis of this oil did not reveal the 
isotopic distribution pattern expected for chloro- containing molecules. Therefore, it was 
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postulated that incomplete reaction of the isocyanate, 301, with tert-butanol lead to the 
formation of the carbaminic acid, 303, upon aqueous work up which immediately 
underwent decarboxylation to afford the amine, 304 (Scheme 2.15). Subsequent 
nucleophilic displacement of the 5-chioro group by the amine, 304, may have taken 
place affording a polymeric material. Subsequently, however, the suspension of the p53-
Mdm2 programme prohibited further investigation. 
02N 	 02N 	 02N 
C = 0 	
H20 
C 	N 	 CI NAOH 	 CI NH2 
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301 	 303 	 304 
Scheme 2.15 
2.9 Discussion of biological data 
Analysis of the biological assay data obtained for those ligands screened in the FP assay 
has enabled an understanding of the SAR of these ligands. Firstly, the majority of 
sulfonamides with activity <100 jtM in the FP assay are 5-chloro-4-nitro-thiophenes, 
illustrated by CYCI2100, 305 (IC50 26 tM). In this series, the 4-nitro group was 
considered essential to activity, interacting with the sidechain amino group of the G1n59 
residue of Mdm2. Removal of the 4-nitro group to afford 54 resulted in a decrease in 
potency (IC50 319 jiM). Similarly, the 5-nitro analogue CYC43275, 306, exhibited a 
decrease in potency in the FP assay (IC50 430 tM). Removal of the 5-chloro group to 
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N-methylation of 5-chloro-4-nitro-thiophene sulfonamides has been shown to lead to an 
increase in potency, exemplified by CYC 12262, 308, (1050 20 !LM) and CYC12441, 309, 
(IC50 7 jtM). However, it has been shown that thiophene sulfonamides not containing 
this substitution pattern have their activity removed following N-methylation, 
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Similarly, the activity of CYC12258 (IC50 42 jIM), 176, was enhanced following N-
benzylation, illustrated by CYC12444 (1050 15 LM), 178, whereas the activity of 50 
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(1050 163 tM) was supressed, illustrated by 202 (1050 >500 tM). Clearly, the effect of a 
hydrogen bond acceptor on the 4-position of the thiophene ring is crucial for direction of 
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The insertion of a CH2 spacer between the sulfonamide group and the aromatic ring 
results in a slight increase in potency in the 5-chloro-4-nitro-thiophene series, 
exemplified by CYC 12262 (IC50 20 tM), 308, and CYC 12429 (IC50 11 tM), 310, but 
again removes activity in thiophene sulfonamides that do not exhibit this substitution 
pattern, illustrated by 50 (IC50 163 j.tM) and 166 (1050 >500 tM). 
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Research at Cyclacel Ltd. has shown that the half-life of CYC12I00, 305, in whole 
mouse blood at 37°C was less than 30 minutes. Analysis of LC/MS spectra obtained 
from plasma samples identified a degradation product with overall mass 2 Da less than 
the parent compound. LC/MS analysis of 5-chloro-4-nitro-thiophene sulfonamides in 
0.05% glutathione, 311, showed that these compounds degraded very quickly under 
these conditions and confirmed the formation of a degradant, postulated to be species 
312 (Scheme 2.16). Furthermore, both the in vitro activity and cytotoxicity of 305 in the 
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presence of 0.05% glutathione were significantly reduced. However, chloro-/bromo- and 
chloro substituted thiophenes and aromatic sulfonamides, including one substituted with 
both a chloro and a nitro group, were stable at the conditions used (0.05% glutathione at 




























The role of the 5-chloro group with regards to the activity of the ligand is not clear. 
Replacement of the chloro group with thioacetate has been shown to be tolerated, 
illustrated by CYC43751, 313 (IC50 16 tM). However, the 5-ethyl analogue, 
CYC43572, 314, (1050 237 jtM) was shown to be less potent than the corresponding 
unsubstituted sulfonamide 307. 
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Replacement of the 5-chloro-4-nitro-thiophene moiety has been shown to significantly 
reduce the activity of the sulfonamide in the FP assay. Aromatic sulfonamides 
CYC12203 (1050 192 riM), 315, CYC16745 (IC50 119 tiM), 316, and 114 (IC50 129 
tM), each containing a 4-chloro-3-nitro substitution pattern have been shown to exhibit 
moderate activity. Similarly, CYC43547, 317, has exhibited moderate activity in the FP 























Furthermore, the benzothiophenes 126 (IC50 106 1.iM) and 134 (IC50 193 tM) and the 
benzothiadiazole 150 (1050 165 riM) have moderate inhibitory activity of the p53-Mdm2 















Unfortunately, crystalization studies of l-Idm2 (17-125) and Hdm2 (1-118), undertaken 
by lain McNae at the Institute of Cell and Molecular Biology at Edinburgh University, 
have not been successful to date. However, analysis by Paul Barlow of NMR data 
collected for several chloro/nitro containing sulfonamides in complex with Mdm2 has 
shown that the amino acid residues shifts generated by NMR are not inconsistent with 
the binding mode predicted by molecular docking experiments undertaken by Thomas 
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Figure 2.5: The thiophene sulfonamide 178 docked in the Mdm2 binding cleft. 
78 
A~~,,cep.Ats.- 








Figure 2.6: The aromatic sulfonamide 114 docked in the Mdm2 binding cleft. 
The generation of novel ligands for the inhibition of the p53-Mdm2 interaction was 
suspended to allow the focus of research into the development of novel inhibitors of the 
CDK family of enzymes, discussed in Chapters 3 and 4. NMR and crystalization studies 
of Mdm2 in complex with sulfonamide ligands are ongoing, to allow for the resumption 
of synthetic chemistry once further structural evidence and rationale for Mdm2 
inhibition by current leads is obtained. 
2.10 Conclusions and Future work 
A number of aromatic and thiophene sulfonamides have been shown to be moderate to 
potent inhibitors of the p53-Mdm2 interaction in vitro. The most active sulfonamides in 
the series, containing a 5-chloro-4-nitro-thiophene moiety, have been shown to suffer 
from poor stability in whole mouse blood. Other thiophene and aromatic sulfonamides 
not containing a chioro/nitro substitution have been shown to be stable in whole blood, 
although exhibit only moderate inhibitory activity of the p53-Mdm2 interaction with 
IC50 values >100 M. Although molecular modelling and NMR studies of several 
sulfonamides in complex with Mdm2 have shown that in the majority of cases, the 3 
p53-binding pockets in the Mdm2 cleft are not fully occupied by the sulfonamide 
ligands, the determination of a crystal structure of a sulfonamide bound to Mdm2 is of 
paramount importance to the advancement of this programme. A solid foundation for 
structure-based ligand design would enable the further investigation into the replacement 
of the thiophene ring; replacement of the 5-chloro substituent to improve ligand stability 
in whole blood; and N-benzylation of sulfonamide ligands containing a nitro group 
which can hydrogen bond to the side chain amino group of G1n59. 
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3 	Cyclin dependent kinases 
3.1 Introduction 
Protein kinases have become attractive targets for low-molecular weight therapeutic 
agents to treat cancers as they have been shown to be important regulators of 
intracellular signal transduction pathways. 94  Abnormalities in, and deregulation of, these 
signaling pathways have been identified in the majority of cancers. The development of 
selective protein kinase inhibitors is therefore an attractive and promising approach for 
the treatment of proliferative disorders. 95  The following discussion will introduce the 
reader to protein kinases, specifically focusing on the cyclin dependent kinases (CDK5), 
and highlight strategies taken to target these proteins with a view to improving cancer 
treatment. Particular attention will be made to reviewing the efforts made to discover 
potent and selective small molecular weight inhibitors of the CDKs. 
3.2 	Protein kinases 
3.2.1 An introduction to protein kinases 
As a result of the Human Genome Project, in excess of 800 protein kinases and 130 
protein phosphatases are thought to be present in the human genome.96 Both of these 
enzyme classes can be subdivided into three categories based upon their catalytic 
specificity; those specific for Ser/Thr; those specific for Tyr; and those specific for both 
Ser/Thr and Tyr. 
Mutations that lead to activated kinase activity;94 deregulation of kinase activity by 
activation of oncogenes97 or loss of tumour suppressor functions; 98  or deregulation of 
kinase activity by over-expression99 have all been shown to play a role in the 
development and maintenance of human malignancies. 
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There are a number of approaches available to generate protein kinase inhibitors. One 
approach is to design low molecular weight peptidic compounds capable of interfering 
with either ligand or protein substrate binding. This bisubstrate inhibitor approach has to 
date proven difficult and little progress has been made in transforming these peptides 
into cell-permeable peptidomimetics.100 Another approach is to generate allosteric 
inhibitors, although this approach has been met with little success.101 The most 
successful strategy to date has been to target the catalytic site of kinases to generate 
antagonists of ATP, 318. Recently, this strategy has been aided by progress made in the 
crystallization of protein kinases, with a significant number of crystal structures of 
protein kinases complexed with ATP site directed inhibitors. However, the synthesis of 
low molecular weight protein kinase inhibitors that display both selectivity and 
specificity for a target protein kinase is a considerable challenge as each cell will have a 
complement of between 50 and 100 different protein kinases. 95 
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3.2.2 Similarities of the ATP binding site amongst protein kinases 
The ATP binding site is highly conserved among the protein kinases and contains a 
number of key features, two of which, an adenine region and a hydrophobic pocket, have 
been exploited to achieve selectivity in a number of protein kinase inhibitors. The 
adenine region of the ATP binding site is hydrophobic in character and contains two key 
hydrogen bonds formed between the N-i and N-6 amino groups of the adenine ring and 
the backbone NH and carbonyl of the adenine anchoring hinge region of the protein 
kinase. The hinge region also contains a number of backbone carbonyls that can serve as 
hydrogen bonds acceptors for some inhibitors. The selectivity of most protein kinase 
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inhibitors is achieved through exploitation of the hydrophobic pocket region in the ATP-
binding site of the kinase. Other distinct regions in the ATP-binding site are the sugar 
region, a region that is hydrophilic in the majority of protein kinases, and a phosphate 
binding region that appears to contribute little in terms of binding affinity. The ATP-
binding site also contains a hydrophobic channel which opens to solvent, and, as it is not 
occupied by ATP, could be exploited to achieve further binding affinity. 95 
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Figure 3.1: Schematic showing the ATP binding site of protein kinases. ATP is in red. 
sugi, Hypi, and Hyci are residues lining the sugar region (Sug), hydrophobic pocket 
(Hyp), and hydrophobic channel (1-luc), respectively. Hin, hinge region. 95 
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3.3 	The cyclin dependent kinases 
3.3.1 Introduction 
Cyclin dependent kinases (CDKs) are of paramount importance in cell cycle regulation 
as they control the transition between the four primary phases.' 
02  Cyclin dependent 
kinases are low molecular weight serine-threonine kinases, between 34-40 Wa, that 
constitute a catalytic subunit and require association to a regulatory subunit, a cyclin, to 
be activated. Cyclins are synthesized and destroyed during the cell cycle, during which 
their levels of expression fluctuate. For example, cyclins A and B accumulate during the 
S and late G2  phase and undergo proteolysis during mitosis, whereas cyclins C, D, and E 
function mainly during the G1 phase and the G1-S transition, before undergoing ubiquitin 
mediated degradation. In contrast, CDK expression remains relatively constant during 
the cell cycle. 
To date, at least 9 CDKs and 15 cyclins have been identified, although the relationship 
between some cyclins, namely cyclins F, G and I, and the CDKs is still to be 
characterized. (Figure 3.1). There are also several CDK-related kinases, recognized by 
their sequence homology to known CDKs, with no identified cyclin partner. CDKs 
positively regulate the cell cycle by catalyzing the transfer of phosphate from ATP to 
specific protein substrates. 
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Figure 3.1: Schematic showing the known relationships between the CDKs and the 
cyclins. 
The principal function of the cell cycle is to bring about the duplication of DNA and to 
distribute this DNA to newly divided daughter cells. Specific CDKIcyclin complexes are 
known to operate in distinct phases of the cell cycle as illustrated by Figure 3.2.'° For 
example, CDK4/cyclin D and CDK6/cyclin D are responsible for progression of the cell 
through the G1 phase and the G1 - to 5- phase transition by phosphorylation and 
inactivation of the retinoblastoma phosphoprotein, Rb. 
104  As a consequence of Rb 
phosphorylation, the phosphorylated Rb (pRb) is unable to bind and inactivate the 
transcription factor E217 1, which leads to the transactivation of E217-dependent genes and 
progression to S phase. 105  CDK2/cyclin E is required for progression from G1 to 5, 
CDK2/cyclin A is required for progression through the S phase and CDKI/cyclin B 
(also known as Cdc2/cyclin B) is required for the transition through G2 to M.'°6 
Deregulation of CDKs and their activators or inhibitors are frequently observed in 
cancers. CDKs are therefore attractive targets for anticancer therapy. 
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Figure 3.2: Cell cycle regulatory components determined to be altered in human 
cancers. 103 
In additional to playing a role in the regulation of the cell cycle, CDKs have also been 
reported to have additional functionality. Some members of the CDK family, known as 
CDK-activating kinases or CAKs, play a regulatory role in controlling the activity of 
cell cycle CDKs by phosphorylation of critical serine and threonine residues needed for 
activity. 108 More recently, several other cellular functions of CDKs have been identified. 
CDKs have been reported to be involved in apoptosis (CDK2, CDK5), in neuronal 
functions (CDK5), in transcription (CDK7, CDK8, CDK9) and in differentiation 
(CDK4, CDK5, CDK9).'°9 
3.3.2 Regulation of CDK activity 
Monomeric CDK is inactive, its activation being dependent on a two-step process 
namely association with a cyclin subunit' 10 and subsequent phosphorylation of the 
CDKIcyclin complex by the CDK-activating kinase (CAK)." This two-step activation 
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process is illustrated in Figure 3.3. Association of the CDK to the cyclin imparts partial 
activity to the complex, although this activity is increased 100-fold following 
phosphorylation."2 
Cyclin 	 CAK 
Inactive 	Partially active 	Fully Active 
INK4 	 KIP 
Inhibitors Inhibitors 
Figure 3.3: Regulation of CDKs and CDK/cyclin complexes. 
A family of small inhibitory proteins called cycl in -dependent kinase inhibitors (CKIs) 
have been shown to regulate CDKs and CDK!cyclin complexes. There are two families 
of CKIs; the INK4 family, whose members are p15INK4B 16INK4A 18INK4C and 
p19INK4;ll3 and the kinase inhibitor protein (CIP/KIP) family, whose members are 
p21'', p27 K1P1 and p57 KIP214 The INK4 family inhibits the CDK4ICyclin D and 
CDK6/Cyclin D complexes by binding directly with the CDK and preventing its 
association and subsequent activation, causing cells to accumulate in the late G, phase. 
The INK4 family can also bind to the CDKlcyclin complex.' 3 The CIP/KIP family has a 
broader CDK preference, regulating the complexes CDK2/cyclin E, CDK2/cyclin A and 
CDK 1/cyclin B by binding directly to the CDKlcyclin complex.' 4 
3.3.3 Activation of CDKs 
Structural studies of the CDKs have revealed the catalytic centre includes a core of 
approximately 300 amino acid residues that possesses a high degree of homology 
between the different members of this protein kinase family. 115  The majority of crystal 
structures of CDK/inhibitor complexes studied to date focus on the monomeric, 
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inactivated form of CDK2. The N-terminal domain of CDK2 consists of five anti-
parallel n-strands that form a f3-sheet, and one helix. The C-terminal domain of CDK2 is 
larger and predominantly a-helical. A flexible hinge links these two domains and the 
deep cleft formed by the classic bi-lobal kinase fold contains the ATP-binding site.'16 
CDK2 contains two unique regions that regulate its activity. Firstly, CDK2 contains an 
cc-helix located in its N-terminal domain that has a unique PSTAIRE sequence found 
only in cyclin-dependent kinases. Secondly, CDK2 contains a regulatory loop known as 
the 'T-loop', consisting of residues 150-165, that blocks access of the polypeptide 
substrate to the ATP-binding site. The structure of monomeric CDK2 in ribbon 
representation is shown in Figure 3.4. 
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Figure 3.4: The structure of monomeric CDK2 shown in ribbon representation. The N 
terminal domains (residues I - 86) are shown in blue with the exception of the glycine-
rich loop (residues 11 - 24) coloured magenta, the hinge region (residues 81-84) 
coloured orange and the C-helix (PSTAIRE helix, residues 46 —55) coloured yellow. 
The C-terminal domain is coloured red, with the activation segment (residues 145 - 172) 
that contains the T loop highlighted in green (PDB code - I HCL). 
Upon cyclin binding, the cyclin forms contacts to both lobes of the CDK, with key 
interfacial contacts being made with the C-helix, which contains the PSTAIRE 
sequence. Cyclin binding causes the C-helix to swing in towards the ATP-binding site, a 
key conformational change that facilitates coordination of the cc-phosphate of ATP for 
phosphotransfer, directed partially by the residue G1u5 1, contained in the PSTAIRE 
helix. The residues Lys33 and Asp145 together with a magnesium ion are also involved 
in the phosphorylation step.117 Another consequence of cyclin binding is the movement 
of the T loop away from the entrance of the ATP-binding cleft, an event which also 
exposes the phosphorylation site on the T loop (Thr 160). Subsequent phosphorylation of 
89 
ThrI 60 invokes an additional conformational change of the T loop, with the phosphate 
group coordinating to three arginine side-chains, one from the N-terminal domain, one 
from the C-terminal domain and one from the T loop of the CDK. In turn, the arginine 
residues hydrogen bond to other CDK and cyclin groups, and in doing so stabilize the 
CDKIcyclin complex. 112 
3.3.4 The CDK2/ATP complex 
The X-ray crystal structure of a CDK2/ATP complex has been reported and reveals a 
number of key interactions between the kinase and the ligand, providing a solid 
foundation for further structure-based design of low molecular weight, ATP-competitive 




Figure 3.5: Crystal structure of ATP bound to CDK2 (PDB Code IHCK). ATP is 
coloured as follows; C grey, N light blue, 0 red, P orange. Mg2 is coloured green. 
CDK2 is coloured as follows; the hinge region (residues 81-84) is coloured dark blue; 
the ribose/phosphate binding region (residues 11 - 18) and residues Lys33 and Asp 145, 
which form a salt bridge, are coloured magenta; residues IlelO, Ala31 and Leu134, that 
dictate the width of the ATP binding cleft, are coloured yellow; and Phe80 is coloured 
cyan. 
all 
Hydrogen bonds have been identified between Leu83 and N-I of ATP, between Glu81 
and N(6)H2 and between Asp86 and 0(2')H, and the phosphate chain of ATP interacts 
with the pocket at Lys33, Asn132, Asp 145, Lys 129, ThrI4 and Wat558.118 A schematic 
of these key interaction is illustrated in Figure 3.6. 
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Figure 3.6: Schematic showing interactions between ATP and CDK2 at the ATP-
binding site. 118 
3.3.5 CDK2 ATP antagonist binding modes 
There have been a number of reports in the literature of X-ray crystal structures of small 
molecule inhibitors complexed with monomeric CDK2. The majority of these show 
inhibitors bound at the site occupied by the adenine ring in the CDK2/ATP complex. 
This site resembles a narrow cleft, formed between the N- and C- terminal domains of 
CDK2, the width of which is determined by the hydrophobic side chains of Ile 10, Val 18, 
Ala3 I and Leu 134. A n—strand, containing the residues Phe80, Glu8 1, Leu83 and His84, 
forms the boundary wall of the cleft and links the N- and C- terminal domains. In all 
cases, the backbone amide groups of Glu8 I and Leu83 make key hydrogen bond 
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interactions with the inhibitors, although two distinct hydrogen bonding patterns have 
been observed; one where the NH of Leu83 and the carbonyl of Glu8 I act as a donor-
acceptor pair for a complimentary hydrogen bond donor and acceptor on the inhibitor 
with an additional interaction between the carbonyl of Leu83 and a CH on the inhibitor; 
and one where the NH and carbonyl of Leu83 acts as a donor and acceptor to a 
complimentary acceptor and donor pair on the inhibitor, with an additional interaction 
between an aromatic proton on the ligand and the carbonyl of G1u8 I. The former 
binding mode has been observed in CDK2 complexes with ATP,' 9 flavopiridol,12° 319, 
and the 4-heteroaryl-2-amino-pyrimidines CYCI, 320, and CYC2,12 ' 321, whereas the 
latter binding mode has been observed for purvalanol B,'22 322, roscovitine,'23 323, and 
0L567, 324.124 
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3.3.6 The validity of using structure based design to target monomeric CDK2 
Activation of CDK2 has two main effects on the ATP-binding site. Firstly it causes a 
rotation of the N- and C- terminal domains by approximately 5° about the hinge region 
and a slight widening of the ATP cleft. Secondly, as a result of the movement of the C-
helix and subsequent reorganization of the residues involved in coordination to ATP, the 
phosphate-binding site is reshaped, the ATP cleft is deepened and an additional pocket is 
formed. 125 These conformational changes raise the question of the validity of using 
monomeric CDK2 to design inhibitors of the active kinase and, indeed, to interpret the 
structure-activity relationships of inhibitors arising from biological assays on the active 
complex. Indeed, a recent analysis of the binding of the inhibitor indirubin-5-sulfonate, 
325, to both active and inactive forms of CDK2 revealed that on activation, the 
interactions between the inhibitor and the kinase at the ribose site were considerably 
altered owing to movements of the glycine loop, suggesting that the accuracy of 
monomeric CDK2 as a inhibitor design template is restricted to the adenine binding site 







Figure 3.7: Active site detail of CDK2 in complex with indirubin-5-sulphonate, 325, 
coloured by structural displacement between monomeric and binary complexes. The 
structures were superimposed on the basis of the inhibitor. Atoms are coloured from 
blue (displacement <0.5 A) through yellow to red (displacement> 2.5 A). 
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3.4 	A review of ATP-competitive CDK inhibitors 
3.4.1 Introduction 
All CDK inhibitors identified so far share a common mechanism of action, acting at the 
ATP-binding pocket of the kinase and, in doing so, competing with ATP for binding. 
CDK inhibitors display antiproliferative properties, terminating the cell cycle in G1 and 
G2/M phases depending on the conditions and cell type. This section attempts to provide 
an overview of the key pharmacophores that have been reported to inhibit the CDKs. 
Where possible, attention is drawn to crystal structures of the inhibitor/CDK complex 
and key protein-ligand interactions are exemplified in the text. Next generation 
inhibitors based around the particular scaffold, where reported in the literature, are 
discussed, and a current understanding of the structure activity relationship of the 
pharmacophore is presented together with key features of the inhibitors selectivity 
profile. 
3.4.2 Staurosporine and analogues 
The natural product staurosporine, 326, isolated from Streptomyces staurosporeus, is an 
ATP-competitive inhibitor of a numbers of CDKs.'27 Staurosporine exhibits an 1050 of 7 
nM against CDK2/cyclin A'28 and 3-10 tM against CDK4/cyclin 13,129 but also inhibits 
PKC and cAPK. The crystal structure of staurosporine bound to CDK2 (Figure 3.8) 
revealed a similar hydrogen-bonding pattern to that observed in the CDK2/ATP 
complex, namely a hydrogen bond donor interaction to the oxygen of G1u8 1 and a 
hydrogen bond acceptor interaction to the nitrogen of Leu83. Additional hydrogen bonds 
were reported between the methylamino group of staurosporine and the carbonyls of 






Figure 3.8: Staurosporine bound to CDK2 (PDB code IAQI). 
The hydroxystaurosporine analogue UCN-01, 327, has been reported as a non-specific 
kinase inhibitor against PKC, CDKI and CDK2 and is currently undergoing clinical 
trials. 131 
327 
A series of indolo[6,7-a]pyrrolo[3,4-c]carbazoles, as illustrated by the scaffold shown in 
Figure 3.9, have been reported as potent, nanomolar inhibitors of CDK2 and CDK4.132 It 
was shown that the C- il position, and to a lesser extent C-12, tolerated the greatest 
diversity of substituents in terms of CDK inhibition although those inhibitors 
incorporating an aminoalkyl sidechain at C-12 exhibited the highest selectivity and 
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activity in the series with 1050's against CDK4/cyclin Dl < 69 nM. Scaffolds bearing 
aminoethanol at C-12 generally showed the greatest inhibition of CDK2. These 
inhibitors have been shown to induce strong GI arrest in two human cell lines and to 





Figure 3.9: The indolo[6,7-a]pyrrolo[3,4-c]carbazole scaffold. 
3.4.3 Flavonoids 
Quercetin, 328, a naturally occurring flavonoid, has been reported as a relatively weak 
CDK inhibitor that exhibits antiproliferative effects at the G0/G1 interface of the cell 
cycle. 133  Another flavonoid, flavopiridol, 319, has also been reported as an effective 
CDK inhibitor and is the most advanced in terms of clinical development.' 31 In vitro, 
flavopiridol has been shown to be a relatively non-selective kinase inhibitor, exhibiting 






The crystal structure of desch!oroflavopiridol (Figure 3.10) cocrystallized with CDK2 
has been reported which revealed the core hydrogen bonds between 0(5)H and G1u8 1, 
and between 0(4) and Leu83.137 In addition to these two interactions, key hydrogen 
bonds were identified between 0(3) of the hydroxypiperidine moiety and the residues 
Lys33 and Wat384, and between 0(3)H and N(1 1)H of the hydroxypiperidine moiety 
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Figure 3.10: Schematic showing interactions between CDK2 and deschloroflavopiridol. 
Flavopiridol analogues, thio- and oxoflavopiridols, 329 and 330, that contain a sulfur or 
oxygen between a piperidylchromone ring and a hydrophobic side chain, have been 
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reported as selective CDKI inhibitors with potencies of 110 and 130 nM respectively.' 
20 
Flavopiridol analogues 329 and 330 exhibit selectivity over CDK2 by approximately 20-
fold and 50-150-fold over CDK4. Analogues with hydrophilic side chains, such as 
pyrimidine or aniline, were shown to cause a severe reduction in CDK inhibitory 
activity. X-ray crystal studies of ligand-protein complexes formed between flavopiridol 
or thioflavopiridol and CDK2, together with a comparison of the sequences of CDKI, 
CDK2 and CDK4, revealed the basis for CDKI selectivity in these compounds. The 
CDKI selectivity of thioflavopiridol compared to flavopiridol was attributed to a relative 
decrease in CDK2 binding resulting from a less-than-optimal interaction between the 
chlorophenyl ring and IlelO, a residue conserved in CDKI, CDK2 and CDK4. A 
compensating interaction was reported between the chlorophenyl ring and Lys89 in the 
thioflavopiridol-CDK2 complex. Lys89 is common to both CDKI and CDK2 but not to 
CDK4. In CDKI, sequence differences near Lys89 (Met85 in CDKI versus G1n85 in 
CDK2) increase the hydrophobic nature of this region and alter packing preferences, and 










3.4.4 Paullones and analogues 
Zaharevitz et al. reported the identification of 9-bromo-7, I 2-dihydro-indolo[3,2-
d][1]benzazepin-6(511)-one, kenpaullone, 331, through analysis of the National Cancer 
Institute Human Tumor Cell Line Anti-Cancer Drug Screen data using the COMPARE 
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algorithm '38  to detect similarities in the pattern of compound activity to flavopiridol. 
Kenpaullone is a potent inhibitor of CDKI/cyclin B (IC50, 400 nm) and also shows some 
activity against CDK2/cyclin A (1050, 680 nm), CDK2/cyclin E (IC50, 7.5 jiM), and 
CDK5Ip25 (1050, 850 nm). Significantly, kenpaullone has little activity against CDK4. 
Molecular modeling studies have suggested that kenpaullone can bind in the ATP-
binding site of CDK2, with similar binding interactions to those observed in other CDK2 
inhibitors, namely hydrogen bonds to both the backbone and carbonyl amide of Leu83 
and positioning of ring atoms between the Leu134 and IlelO hydrophobic sidechains. 
Furthermore it was shown that analogues of kenpaullone, notably 1 0-bromopaullone, 
332, were reported to lead to a reduction in kinase specificity inhibiting various protein 
kinases including CDKs, several protein kinase C isozymes and casein kinase 2. 
139 
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A further study, focusing on derivatives of kenpaullone provided useful information 
concerning the structure-activity relationship of this new class of pharmacophore against 
CDK1/cyclin B. Electron withdrawing substituents at the 9-position were shown to be 
favourable. A 9-trifluormethyl substituent was found to give comparable activity to the 
9-bromo substituent of kenpaullone (IC50 400 nM), whereas a substantial increase in 
potency was observed following replacement of the 9-bromo substituent with 9-cyano 
(IC50 24 nM) or 9-nitro (1050 35 nM). With the exception of a 2,3-dimethoxy 
substitution on the paullone basic scaffold, substitutions at the 2-, 3-, 4-, and 11-
positions were not well-tolerated and led to decreased CDKI inhibition. Evaluation of 
the paullone derivatives in a cancer cell line screening showed, surprisingly, that the 
antiproliferative activity of the compounds was not directly related to CDKI inhibition. 
Me 
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Indeed, the 9-cyano paullone displayed no in vitro antitumour activity, despite having an 
1050 of 24 nM against CDK1. The 9-nitropaullone, alsterpaullone, 333, exhibited 
excellent in vitro antitumour in addition to greater activity against CDK1 than both 
flavopiridol and roscovitine and was therefore selected for preclinical development. 
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Further work on the paullone series of CDK inhibitors has shown that 2-substitution of 
the paullone scaffold with a 2-cyanoethyl substituent, 334, significantly enhanced 
CDK1/cyclin B inhibition and in vitro antiproliferative activity. Molecular modeling 
indicated that 2-substitution of the paullone scaffold with carbon chains containing polar 
terminal groups resulted in partial occupancy of the access channel of the ATP binding 
site, forming favourable interactions with solvent molecules or amino acid side chains in 
the vicinity of the ATP binding site. 14' However, data collected on the paullone series of 
inhibitors shows that cellular activity does not parallel CDK activity, suggesting 
alternative mechanisms for cellular antiproliferative effects for some of the 
compounds. 140 
A later study revealed that paullones act as potent inhibitors of glycogen synthase 
kinase-3L3(GSK-313). 	4 - 80 11 LI in addition to the neuronal CDK5Ip25 (1050 20 - 
200 nM).142 Both GSK-313 and CDK5 are responsible for hyperphosphorylation of the 
microtubule-binding protein tau, a feature observed in the brains of patients with many 
pathological conditions, including Alzheimer's disease, Down's syndrome and Pick's 
disease. 143  It was shown that alsterpaullone acts by competing with ATP for binding to 
GSK-3. The binding of alsterpaullone to GSK-313 inhibits the phosphorylation of tau in 
vivo at sites that are typically phosphorylated by tau in Alzheimer's disease. Although 
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results obtained from a screen of some 50 paullones against GSK-313, CDKI and CDK5 
indicate that GSK-313 appears to be more sensitive to paullones than CDKs, there exists 
the potential to develop paullone derivatives selective for either GSK-313 or CDKs. 
Indeed, from the screen, it was shown that CDK5 activity appears to be very sensitive to 
substitution at the 12-position of the paullone ring, as exemplified by the ligand 335, 
whose IC50 values against GSK3, CDKI and CDK5 were shown to be 0.4 tM, 6.2 j.iM 




The purine derivative olomoucine, 336, has been developed as a selective inhibitor of 
both CDKI and CDK2.144 In addition to two key hydrogen bonds between N-7 and NH 
of Leu83, and between N-6 and the carbonyl of Leu83, it was shown that an additional 
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A novel purine derivative, (R)-roscovitine, 323, was identified as a selective, orally 
bioavailable CDK2 inhibitor that targets the ATP-binding site. 
123  (R)-Roscovitine has 
1050's of 80 nM, 390 nM, 1.1 pM and 12 pM against CDK2, CDK7, CDKI and CDK4 
respectively and has been shown to induce apoptotic cell death from all phases of the 
cell cycle. (R)-Roscovitine is currently in Phase II clinical trials. 
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Whilst olomoucine lacked the potency required of a suitable drug candidate, with an 
IC50 against CDK2 of 4.5 tM, it has been a useful tool for further structure-based 
design. Adopting a combinatorial approach, other work on the olomoucine scaffold, 
involving amination at the 2- and 6-positions and Mitsunobu alkylation at N-9, has 
afforded several diverse libraries of compounds that have been used to examine the 
effects of a range of substituents on the purine ring. 122  A number of benzylamine and 
aniline substituents at the 6-position were reported to lead to significant improvements 
in CDK2 binding compared to olomoucine. At the 2-position, amino alcohols derived 
from alanine, valine and isoleucine were shown to improve binding affinity by up to 6.5-
fold relative to the hydroxyethyl substituent of olomoucine. Purines with small alkyl or 
hydroxyalkyl substituents at N-9 were shown to be more potent CDK2 inhibitors than 
those purines with larger substituents at this position. X-ray studies have revealed that 
substituents at the N-9 position of the purine ring occupy a small hydrophobic pocket 
formed by the side chains Val18, Ala3l, Phe80, Leu134 and A1a144. This pocket is 
unoccupied in the CDK2/ATP complex and, in other kinases, is much larger owing to a 
smaller residue at its entrance. Consequently, this feature has been exploited by many 
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other purine-based inhibitors to achieve selectivity. 145  This study resulted in the 
identification of the CDK2 inhibitor purvalanol B, 322, which has an 1050 of 6 nM 
against the CDK2/cyclin A complex, a 100-fold increase over olomoucine. Significantly, 
purvalanol B has an 1050 against CDK4/cyclin Dl of >10,000 nM.'22 X-ray studies have 
shown that purvalanol B has a similar binding mode to olomoucine in the ATP-binding 
site of CDK2, although exhibits improved packing interactions resulting from the tight 
packing of the 3-chloroanilino group at N-6 of the purine ring of the inhibitor against the 
side chains of IlelO and Phe82, with additional stabilization coming from polar 
interactions between the chloro group and the side chain of Asp86 and between the 
carboxy aniline group and the amino portion of the Lys89 side chain, which notably is a 
threonine residue in CDK4. The increased binding affinity of purvalanol B compared to 
olomoucine may also result from steric constraints imposed by the purine and the 
chlorinated aniline ring systems that limit the number of conformations of purvalanol B 
compared to olomoucine. Furthermore, the region occupied by the substituent at N-6 of 
the purine ring is empty in the CDK2-ATP complex, an observation that may account 
for the higher binding affinity and selectivity of purvalanol B and olomoucine compared 
to ATP. 
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Similar increases in potency against CDK2 compared to olomoucine have been observed 
for other 2,6,9-trisubsitituted purine systems, illustrated by CGP 74514, 337, which has 
been shown to have an 1050 against CDK2 of 9 nM.'46 
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The 2,6,9-trisubstituted purine derivative H717 (Figure 3.11), has been shown to adopt a 
slightly different binding mode in complex with CDK2 than that observed for 
olomoucine and purvalanol, as illustrated in Figure 3.11. It was shown that the 
orientation of the C2-p-diaminocyclohexyl portion of the inhibitor generated two novel 
interactions generated by the amino group, namely a salt bridge to Asp145-061 and a 
hydrogen bond with Asn132-01. Interestingly, this charged amino group was shown to 
be in close proximity to the Mg 2+  ion that binds to the phosphates and to Asp 145 of 
CDK2 in the CDK2/ATP complex. The retention of this ionic interaction may contribute 
favourably to the binding affinity of H717 with CDK2. The N-9 cyclopentyl ring was 
shown to fully occupy a space formed predominantly by the residues Phe80, Val] 8 and 
Va164, a region only partially occupied in the complexes formed between CDK2 and the 
homologous inhibitor olomoucine. H717 was shown to have selectivity for CDKs 1 and 
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Figure 3.11: Schematic showing the polar interactions between the inhibitor H717 and 
CDK2 with distances given in A. Only interactions up to 4.0 A are shown. Contacts to 
CDK side chain atoms are indicated by lines to the respective box boundaries, whereas 
interactions to main chain atoms are shown as lines to the specified atoms. 147 
Other CDK inhibitors based around a purine scaffold have been described in the 
literature. These include isopentenyladenine,123 338, bohemine,'48 339, CVT 313,149 340, 
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Recently, a series of 2,6,8,9-tetrasubstituted purines have been reported as novel CDKI 
inhibitors, exemplified by 341.151  This research built on the work undertaken on the 
roscovitine pharmacophore and extended it further by introducing a novel modification 
at the C-8 position of the purine ring. A screen of this series of tetrasubstituted purines 
against CDK1 revealed that introduction of a C-8 substituent lowered the CDK1 
inhibitory activity of roscovitine, an observation that was later confirmed by molecular 
modeling studies which revealed some degree of steric repulsion between the C-8 
substituents and the fairly rigid hinge region at the 'back' of the ATP-binding site. 
341 
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3.4.6 Quinoxalines 
Several pyrazolo[3,4-b]quinoxalines, exemplified by 342, have been reported to be sub-
micromolar inhibitors of CDKI/cyclin B. These pyrazolo[3,4-b]quinoxalines are 
structurally similar to some purine inhibitors reported, such as roscovitine and 
olomoucine and, although the synthesis of further analogues is required to explore the 
kinase selectivity of this class of inhibitors, it has been shown that even minor 
modifications at the 6- and 7-positions, such as the introduction of a methyl group, leads 
to a significant reduction in kinase inhibition. 152 
6 a N N' 
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3.4.7 Oxindoles 
The oxindole 343 has been reported as a modestly potent CDK inhibitor, with some 
selectivity towards CDK4/cyclin D (1050 4.9 jtM).153 A slight modification of the 
oxindole scaffold, incorporating a pyridine ring, afforded compounds, illustrated by 344, 
with submicromolar activity against CDK2, although, in some cases, CDK selectivity 
was not achieved. It was shown that a number of substitutions at the 5-position of the 
pyridine ring were tolerated, in addition to alkyl- or aryl-substitution on the pendant aryl 
ring. 154 
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Two classes of compounds, IH-indole-2,3-dione 3-phenylhydrazones and 3-
(anilinomethylene)- 1,3 -dihydro-2H-indol-2-ones, based on the oxindole scaffold, have 
been reported that are low nanomolar ATP-competitive inhibitors of both CDK2 and 
CDK1, with approximately 10-fold selectivity for CDK2. 155  Analysis of X-ray crystal 
structures of CDK2lligand 345 complex (Figure 3.12) revealed two hydrogen bonds 
analogous to hydrogen bonds between ATP and CDK2, namely between the amide NH 
of the inhibitor and the backbone carbonyl of G1u8 1 and between the amide carbonyl 
oxygen with the backbone NH of Leu83. Replacement of the hydrazone linker in the 
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Figure 3.12: The 1H-indole-2,3-dione 3-phenyihydrazone inhibitor 345 bound to 
CDK2 The binding cavity is illustrated with a dot surface. Hydrogen bonds between the 
inhibitor and CDK2 are shown as yellow lines. Atoms are coloured as follows: C, green; 
H, light blue; N, dark blue; 0, red; S, yellow; Br, purple. 155 
Further structure based design focused on variation of the substituents off the oxindole 
ring. It was shown that 4-substitution with small lipophilic groups, such as ethyl, 
isopropyl and isobutyl, afforded potent CDK2 inhibitors with IC50 values in the range 1 
- 8 nM, the enhancement in affinity attributable to the 4-susbstituent occupying a 
relatively hydrophobic region of the protein formed by the residues Val 18 and Leu 134. 
Substitution at the 5-position with a hydrogen bond acceptor, such as a carboxylic ester, 
was shown to enhance inhibitor affinity by the hydrogen bonding to the side chain of 
Lys33 and/or the backbone NH of Asp145. Disubstitution at the 4- and 5-positions 
afforded highly potent inhibitors, exemplified by 346, particularly in the case of 
compounds with 4,5-fused heterocycles with a hydrogen bond acceptor at the 5-position 
and hydrophobic character at the 4-position. It was hoped that variation of the 
substituent at the 6-position would probe CDK2 selectivity as the substituent would be 
ME 
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projected towards the small Phe80 pocket. However, although no measurable inhibition 
was reported for compounds containing larger substituents at the 6-position, such as ten-
butyl and phenoxy, only a moderate enhancement of binding affinity was observed for 
those inhibitors containing smaller substituents such as ethyl, isopropyl and 
hydroxymethyl. Substitution at the 7-position was shown to decrease inhibitor activity 
owing to unfavourable steric interactions between the substituent and the side chain of 
Phe8O.155 
NH 





Recently a novel series of indenopyrazole-based ATP competitive CDK inhibitors have 
been disclosed, which display remarkable selectivity for CDK4 over CDK2. Using the 
crystal structure of CDK2/cyclin A as a starting point, a homology model of the 
CDK4/cyclin D complex was constructed and the indenopyrazole, 347, with IC50 values 
of 460 nM and 510 nM against CDK4 and CDK2 respectively, was docked in the ATP 
binding pocket of the enzyme (Figure 3.13). Several observations were made that 
supported the SAR observed in this series of inhibitors. Firstly, the key interactions seen 
between the inhibitor and the kinase were similar to those reported in the X-ray crystal 
structure of olomucine bound to CDK2, namely the pyrazole NH interacting with the 
backbone carbonyl of Va196 (Leu83 in CDK2), and the adjacent pyrazole nitrogen 
acting as a hydrogen bond acceptor from the backbone NH of Va196. Additionally, 
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another key interaction was observed between the 5-substituted acetamide carbonyl and 
the side chain amino group of Lys35. Indeed, those inhibitors in the series that did not 
possess a hydrogen bond acceptor at the 5-position were reported to suffer from a 
significant decrease in potency against both CDK2 and CDK4. Although no significant 
interactions were observed between the indeno ring carbonyl and the kinase, it was 
suggested that the indeno ring carbonyl allowed the formation of an intramolecular 
hydrogen bond with the adjacent amide NH and, in doing so, aligned the acetamide 
group for more favourable interaction with the kinase. 
0 
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Figure 3.13: Molecular model of 347 docked to the ATP binding pocket of a CDK4/Dl 
homology model. Protein carbons are coloured light green and inhibitor carbons yellow. 
Further increases in activity against CDKs 2 and 4 were achieved through the 
preparation of a number of glycinamide analogues of 347, which revealed that 
substitution at the cc-carbon with a six-membered saturated ring containing an additional 
nitrogen at the 4-position afforded compounds, such as the inhibitor 348 (IC50 125 nM 
CDK4; 12 nM CDK2), which were some 10-fold more potent. Branching a to the amide 
carbonyl was not tolerated, but replacing the a-carbon with an sp2 hybridized nitrogen 
111 
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introduced an additional hydrogen bond donating element into the molecule, which, in 
conjunction with further substitution at the nitrogen, generated a series of 
urealsemicarbazide analogues. Crucially it was reported that those inhibitors containing 
the semicarbazide moiety displayed a 10-fold increase in activity against CDK4 when 
compared to their corresponding glycinamide analogues, as the inhibitor 349 
demonstrates (1050 9nM CDK4; 12 nM CDK2). It was suggested that the improved 
activity of the semicarbazide series, compared to the glycinamide series, is attributable 
to the interaction of the semicarbazide NH with the side chain carbonyl of Asp 156. The 
improved selectivity of the semicarbazide series against CDK4 could not be explained 
by molecular modeling, as Asp156 is conserved in both CDK2 and CDK4, and further 
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A further study by Yue and co-workers focused on the effects of substitution at the C3 
of the indeno[1,2-c]pyrazol-4-one core with alkyls heterocycles and substituted phenyls 
and concluded, following analysis of a crystal structure of the CDK2/ligand 350 
complex (Figure 3.14), that substituents at C3 were positioned towards the exterior of 
the kinase and partially exposed to solvent. It was suggested that bulkier groups that fill 
the binding pocket and maximize Van der Waals interactions could be less exposed to 
solvent than linear alkyl or large hydrophobic groups and therefore exhibit increased 
binding with the protein. In general, heterocycles at C3, particularly a thienyl moiety, 
gave the most potent analogues.' 57 
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Figure 3.14: The inhibitor 350 bound to CDK2. Protein carbons are coloured green and 
inhibitor carbons white.' 57 
Tang et al. have reported the synthesis of a novel series of anilinopyrazoles based on 
351 that have been shown to be about 100-fold more potent as inhibitors of CDK2 than 
other kinases. An essential feature of this series of anilinopyrazoles was shown to be a 
para-sulfonamide on the 3-anilino moiety, which was shown to hydrogen bond with 
Asp86, and a small hydrophilic substituent at 3' of the bromophenyl ring which is 
projected towards a cavity formed by Lys33.158 
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3.4.9 Pyrimidines 
A number of phenylaminopyrimidines (PAPs) have been identified as potent inhibitors 
of various protein kinases, including CDK1 and CDK2. The PAP, COP 60474, 352, has 
been shown to bind to the hinged region of CDK2, forming two hydrogen bonds 
between the pyrimidine N-i and the amide-NH of Leu83 and between the anilino 
nitrogen and the carbonyl group of Leu83 .146 
The identification of a series of guanines and pyrimidines that acted as ATP competitive 
inhibitors of CDK1/cyclin BI and CDK2/cyclin A3 has been reported. 
159  An X-ray 
crystal structure of the inhibitor 06-cyclohexylmethyguanine (NU2058), 353, bound to 
CDK2 (Figure 3.15) revealed three key hydrogen bonds between the inhibitor and the 
protein, these being between NH-9 and Glu8l, N-3 and Leu83 and 2-NH2 and Leu83. 
NU2058 was shown to have an IC50 value of 5 tM against CDK1 and 12 iM against 
CDK2. This novel hydrogen-bonding pattern was also observed in the crystal structure 
of the inhibitor NU6027, 354, and CDK2. NU6027 was shown to have an IC50 value of 
2.5 jtM against CDK1 and 1.3 tM against CDK2. 159  Crystal structures of four additional 
guanidines based around this template bound to monomeric CDK2 were reported which 
revealed that optimum binding with the kinase was achieved with moderately sized non-
polar alkyl or cycloalkyl 06  substituents packing against a hydrophobic region of the 
glycine loop, centered on Val 18. In this study, no compound was identified that was 
markedly more potent or selective than the initial lead compound 353, which led to the 
conclusion that exploitation of the ribose binding pocket for the development of potent 
114 
and selective CDK2 inhibitors would be difficult owing to its hydrated nature and high 
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Figure 3.15: Overlay of the CDK2/olomoucine structure with that of the CDK2/353 
complex in the vicinities of the inhibitor binding sites. Olomoucine carbon atoms are 
coloured yellow and 353 carbon atoms are coloured green. Conserved hydrogen bonds 
between the CDK2 backbone, at residues G1u8 land Leu83, and NU2058 are shown as 
thin lines. Only CDK2 residues Phe80 to Leu83 in the CDK2/NU2058 complex are 
included for clarity. 159 
An extension to this work reports on the structure-based design of a series of 04
cyclohexylmethyl-5-nitroso-6-am inopyrimidines containing a range of 2-arylamino 
substituents that are potent inhibitors of both CDKI and CDK2.16' 2-
Arylaminopyrimdines with a sulfonamide or carboxamide group at the 4'-position were 
shown to be potent inhibitors of CDK2 with nanomolar potency. A crystal structure of 
the 4'-carboxamide derivative, 355, in complex with Thr160 CDK2/cyclin A (Figure 
3.15) revealed 4 hydrogen bonds between the inhibitor and CDK2. In addition to 
hydrogen bonds formed between the amino group at the 6-position of the pyrimidine 
ring and the carbonyl of Glu8l; between N-I of the pyrimidine ring and the amide 
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backbone of Leu83; and between the anilino nitrogen at the 2-position of the pyrimidine 
ring and the carbonyl of Leu83; a further interaction between the carboxamide group and 
Asp86 was suggested (Figure 3.16).b61 
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Figure 3.16: Interaction of 355 with active site of phospho-Thrl6O CDK2/cyclin A. 
The identification of a series of 3,7 disubstituted pyrazolo[4,3-d]pyrimidines as novel 
inhibitors of CDK1/cyclin B has been reported. 162  In contrast to C-2, C-6, and N-9 
trisubstituted purine inhibitors, such as olomoucine, the pyrazolo[4,3-d]pyrimidines, 
illustrated by 356, demonstrate a comparable inhibitory effect against CDK1 with only 
two substituents off the central ring. Focusing on a variety of amines at the 7-position of 
the ring, a series of pyrazolo[4,3-djpyrimidines was synthesized and screened against 
CDKI/cyclin B together with their 6,9-disubstituted purine analogues. It was shown that 
members of the pyrimidine series were approximately 2-10 times more potent as 
inhibitors ofCDKI than the respective 6,9-di substituted purines. 
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356 
A class of compounds, based on the pyrido[2,3-d]pyrimidin-7-one moiety, have been 
described that exhibit modest selectivity for CDK4.163 The most potent of these 
inhibitors, 357, has an 1050 of 4 nM, compared with an IC50 of 25 LM for ATP. X-ray 
crystallographic analysis of an analogous inhibitor, 358, bound to CDK2 (Figure 3.17) 
indicated that the ligand occupied the ATP binding site, and kinetic studies indicated 
that the binding was competitive. Again, the key features of this phamacophore are the 
aromatic amine at the C-2 position that generates a hydrogen bond from the anilino NH 
to the carbonyl of Leu83 in CDK2 (Val-96 in CDK4), and the pyrimidine N-3 nitrogen, 
which forms a hydrogen bond to the NH of Leu83. The electronic properties of the 
aromatic amine were shown to have a significant effect on the potency of the compound, 
with electron poor anilines being generally less potent than the initial lead. Mixed results 
were observed with electron rich anilines and amine-substituted anilines were generally 
more potent than oxy- or halo-substituted anilines. Substitution at the N-8 position of the 
ring was shown to allow occupancy of a fairly large and predominantly hydrophobic 
region on the binding site. Consequently, alkyl groups were reported to be preferred to 










Figure 3.17: Crystal structure of the inhibitor 358 bound to CDK2.163 
A potent series of inhibitors based around the imidazof 1 ,2-a}pyridine template has been 
reported. 164 Analysis of a crystal structure of the imidazo[1,2-a]pyridine 359 bound with 
inactivated, monomeric CDK2 revealed three key hydrogen-bonding interactions. Two 
hydrogen bonds were observed between the pyrimidine N-i and Leu83 backbone NH, 
and the 2-amido NH and Leu83 backbone carbonyl oxygen atom and are consistent with 
the accepted kinase-purine mimetic pharmacophore and were also observed in a 
bisanilinopyrimidine/CDK2 complex. A third, previously unreported, hydrogen bond 
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Figure 3.18: Crystal structure of CDK2 complexed with the imidazo[1,2-a]pyridine 
inhibitor 359.164  
It was shown that a para-suiphonamoyl substituted aniline 360, at the 2-position of the 
pyrimidine ring, not only improved potency against both CDK2 and CDK4, attributable 
to the generation of hydrogen bonds with the Asp86 backbone NH and with its 
carbocylic side chain, but also highly improved selectivity for CDK2, presumably as a 















Figure 3.19: Crystal structure of CDK2 complexed with the inhibitor 360•1M 
More recently, 2-phenylamino-4-thiazolopyrimidines have been identified as potent in 
vitro and in vivo CDK2 inhibitors.' 65 This series of ligands, exemplified by 361 which is 
the most potent CDK2 inhibitor reported to date with an IC50 <1 nM, forms the basis of 







Notably, the introduction of an aromatic substituent to the amino group of ligand CYC2, 
321, has been shown to result in a different binding mode between the ligand 362 and 
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Figure 3.20: H-bonding interactions of ATP, 318, and ligands 321 and 362 with the 
backbone of CDK2 residues G1u81 and Leu83. 
Furthermore, the application of computational methods to this series of 2-phenylamino-
4-thiazolopyrimidines has enabled the derivation of a structural basis for specific, high-
affinity binding of inhibitors to the CDK4 active site.' 
66  It was postulated that 
appropriate incorporation of an ionizable function into a CDK2 inhibitor results in a 
more favourable binding to CDK4, owing to a favourable interaction between the ATP 
cleft of CDK4 (Asp99, Glu 144), whereas the inhibitor is repulsed from the active site of 
CDK2 owing to the presence of Lys89. 
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Lastly, and of particular significance to the discussion presented in Chapter 4, a series of 
4,6-bis-anilino pyrimidines'67 and 2,4-bis-anilino pyrimidines'68 have been reported as 
inhibitors of CDK4. Given demonstrated activity in the 4,6-bis-anilino series'67 it was 
postulated that the pyrimidine 5H (Figure 3.21) could be crucial to activity as it would 
contribute to the twisting of the aniline rings out of the plane of the pyrimidine in the 
bioactive conformation. However, crystal structures obtained of members of both series 
of ligands bound to CDK2 indicated that both series adopted the same binding mode that 
was consistent with the accepted kinase purine-mimetic pharmacophore, namely the 
pyrimidine N-I acting as a hydrogen bond acceptor and the 6-aniline NH acting as a 
hydrogen bond donor with the amide NH and amide carbonyl oxygen of Leu83 
respectively. However, it was reported that the tilt in the B ring (Figure 3.21) with 
respect to the pyrimidine varied substantially between different enzyme/inhibitor 
complex structures both within and between the two series. Furthermore, it was shown 
that the 2,4-disubstituted pyrimidine series was generally more potent than the 
equivalent 4,6-series, with improvements in IC50 values against CDK2 and CDK4 




Figure 3.21: General scaffold for reported 4,6-bis-anilino pyrimidine inhibitors of 
CDK4. 
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4 	The development of novel inhibitors of cyclin dependent 
kinases 
4.1 Introduction 
Research carried out at Cyclacel Ltd. has provided a solid foundation for the 
development of a number of novel series of inhibitors of cyclin dependent kinases. The 
CYC-202 programme, focusing on the purine analogue (R)-roscovitine, 323, has entered 






Cyclacel Ltd. have also developed a second generation family of CDK2 inhibitors based 
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The general synthetic route to 2anilino-4-heteroaryl-pyrimidines is shown in Scheme 
4.1. Reaction of an N-substituted alkyithiourea, 364, with 3-chloro-2,4-pentanediOfle 365 
affords the thiazole 366 which is subsequently refluxed in N-N-dimethylformamide 
dimethylacetal to yield the enaminone 367. Cyclisation of the enaminone 367 with a 
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Scheme 4.1: Reagents and conditions: a) methanol, pyridine; b) N,N-
dimethylformamide dimethyl acetal, 120 °C; c) 1-1NO3, cyanamide (aq.), 100°C, reflux, 
24 h; d) NaOH, 2-methoxyethanol, 125 °C. 
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The X-ray crystal structure of the inhibitor 363 bound to CDK2 has been solved by 
McNae and is shown in Figure 4.1 .121 
2 
Figure 4.1: The X-ray crystal structure of the inhibitor CYC4223, 363, bound to CDK2. 
The two positions of the nitro group are distinguished from each other by one of the 
rings being coloured green. Key hydrogen-bonding interactions between the inhibitor 
and the protein are shown as red broken lines. Carbon atoms are coloured black and 
green; nitrogen blue; sulfur yellow; and oxygen red. CDK2 residues are labeled (PDB 
Code IPXO). 
Notably, the crystal structure of the CDK2/ligand 363 complex showed that Ni of the 
pyrimidine ring acts as a hydrogen-bond acceptor and interacts with the backbone NH of 
Leu83, and the aniliho-NH of the inhibitor acts as a hydrogen-bond donor and interacts 
with the carbonyl of Leu83. There was some ambiguity in the electron density of the 
anilino moiety of 363 that suggested the aromatic ring of the aniline could adopt one of 
two different binding modes. The nitrogen of the nitrophenyl group was shown to form 
weak but favourable electrostatic interactions to Asp86 and a close contact with the 
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backbone carbonyl of Gin 131. In the alternative conformation, the nitro group was 
shown to be weakly hydrogen-bonded to the side chain of Lys89. The nitrogen of the 
thiazole ring was shown to be within hydrogen-bonding distance to the carboxylic acid 
of Asp145. The primary amino group at the 2-position of the thiazole ring was shown to 
interact with the side chains of Asp145 and Asn132.12 ' Significantly, the nitrogen at the 
3-position of the pyrimidine ring did not appear to be involved in any binding 
interactions with the protein. This observation raised the question of whether the 
pyrimidine ring could be substituted with other aromatic ring systems, such as a pyridine 
or a pyrazine, whilst still retaining CDK inhibitory activity. Modifications to the central 
ring system would also have a subtle effect on the PKa of the hydrogen-bond acceptor at 
N-I, deemed to be essential for CDK binding, and, as such, would merit further 
investigation. 
A further challenge of CDK inhibitors targeting the ATP binding pocket is achieving 
selectivity between the protein kinases. Consequently, CDK inhibitors synthesized are 
routinely screened against other protein kinases, for example glycogen synthase kinase 
(GSK-3). A recent study 169  argues that selectivity between GSK-33 and CDK2 may be 
achieved through exploitation of one of the main structural differences between the two 
kinases, namely the residues Phe80 in CDK2 and Leu 132 in GSK-3p. In the context of 
the CDK2 inhibitor 363, it has been shown that the thiazol-4-yl methyl group is directed 
towards the Phe80 phenyl ring in CDK2. 165  It is postulated that this favourable 
hydrophobic interaction in not present in the GSK-33l1igand 363 complex (Figure 
4.2).' ° Substitution studies at the 4-position of the thiazole ring may give rise to 363 
analogues with increased selectivity. 
126 
Figure 4.2: Comparison of the ATP-binding pockets in CDK2 and GSK-313. The 
residues involved in direct interactions between CDK2 and ATP are shown in green, 
whereas the corresponding residues in GSK-30 are shown in orange. The CDK2 binding 
modes of the inhibitor CYC-4223 are shown in CPK colouring (PDB Code lI-ICK and 
1 IO9).' °  
To date there are no examples in the literature of CDK inhibitors based around a 
pyrimidine scaffold that contains a 4-aryl substituent. Furthermore, the replacement of 
the pyrimidine scaffold present in the 2-anilino-4-(thiazol-5-yl)-pyrimidine with a 4,6-
disubstituted pyrimidine warranted further investigation. Therefore, the primary aim of 
the research discussed in this chapter was to develop a number of novel CDK inhibitors 
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4.2 	Synthetic strategy 
Ultimately, as it was desirable to generate a large number of inhibitors based around the 
4-aryl-6-anilino-pyrimidine template that contained some functional diversity, it was 
perceived that the synthetic route selected would need to be simple, efficient and 
amenable to combinatorial chemistry. Alternatively, it was envisaged that if microwave-
assisted organic synthesis could be utilized to shorten reaction times, the automated 
serial synthesis of ligands would be possible. 
Retrosynthetic analysis of the 4-aryl-6-anilino-pyrimidine template revealed that the 
simplest synthetic strategy would be to leave the central pyrimidine ring intact and to 
make two disconnections, a carbon-carbon disconnection at C-4 and a carbon-nitrogen 
disconnection at C-6, thereby rendering the template into three synthons, each of which 
could contain some structural diversity. It was envisaged that the Suzuki reaction could 
be employed to couple a substituted phenylboronic acid to the commercially available 
4,6-dichloropyrimidine. Similarly, nucleophilic substitution of an aniline with the 
chloropyrimidine could be used to generate the carbon-nitrogen bond at C-6 (Scheme 
4.2). 
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Scheme 4.2: Retrosynthetic analysis of the 4-aryl -6-an ilino-pyri mid ine template 371. 
4.2.1 The Suzuki Reaction 
The Suzuki reaction 171  is only one of the reactions available to the synthetic organic 
chemist that enables the synthesis of new carbon-carbon bonds. Other methods include 
the Stille,'72 Negishi,'73 Heck, 174  Kumada,'75 Sonogashira'76 and Hiyama reactions. '77 
The generally accepted reaction mechanism for the Suzuki reaction is shown in Scheme 
4.3. Oxidative addition of an aryl, alkenyl or alkynyl halide, 372, with a palladium (0) 
complex, 373, affords a palladium (II) species, 374. Activation of an organoboron 
compound, usually a boronic acid, by reaction with a base, to afford 375 and subsequent 
reaction with the palladium (II) species results in transmetallation to afford a palladium 
(II) species, 376, that undergoes reductive elimination to yield the coupling product, 
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Scheme 4.3: The general catalytic cycle for the Suzuki reaction. 
A wide range of palladium (0) catalysts can be used for the cross-coupling reaction, such 
as Pd(dba)2 or, more commonly, Pd(PPh3)4 although PdC12(PPh3)2 or Pd(OAc)2 plus 
PPh3 or other phosphine ligands can be used as they are readily reduced to the active 
palladium (0) complexes. 171 
Often, the rate-limiting step of the Suzuki reaction is the oxidative addition of the halide 
or triflate to the palladium (0) complex, 373, with the relative reactivity decreasing in 
the order of I > OTf> Br >> Cl.178 Although there are many literature examples of 
palladium catalyzed cross-coupling reactions involving the use of aryl bromides and 
iodides, it is only recently that examples of palladium-catalyzed cross-coupling reactions 
involving organic chlorides have been reported. The bond dissociation energy of Ph-Cl 
(96 kcal mol) is significantly higher than that of the Ph-Br (81 kcal moF') and Ph-I (65 
kcal mo1) bonds, reflecting the relative strength of the C-Cl bond. 179  Certain aryl 
chlorides, in particular electron-poor aryl chlorides that are activated towards oxidative 
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addition, have been shown to be suitable substrates for the Suzuki cross-coupling 
reaction. Furthermore, the successful use of the Suzuki reaction has been reported for 
other chloro-substituted nitrogen heterocycles including pyridines, pyrazines, 
pyridazines, triazines, quinolines, isoquinolines, quinazolines and purines.180  
The choice of phosphine ligand is often of paramount importance to the success of the 
Suzuki coupling of activated aryl chlorides. Shen reported that palladium complexes that 
include a bulky, electron-rich trialkylphosphine were effective at catalyzing the cross-
couplings of activated aryl chlorides and proposed that the electron-richness of the 
ligand might aid the oxidative addition of the Ar-Cl bond to the palladium (0) centre 
and, furthermore, steric crowding of the ligand around the palladium centre may favour 
its dissociation to afford an active monophosphine palladium catalyst. 181 
The decision to employ the Suzuki reaction for the formation of the carbon-carbon bond 
at C-4 of the pyrimidine ring was made based on the commercial availability of 4,6-
dichioropyrimidine and a relatively large number of aryl-boronic acids, which could be 
used to develop an understanding of the SAR based around the 4-aryl-pyrimidine 
pharmacophore. It was envisaged that a study of various substitutions off the 4-aryl 
substituent would probe the region around the Asp] 45 and Phe80 residues of CDK2 and, 
following the subsequent screening of ligands against a panel of kinases, provide an 
insight into the selectivity preferences between the CDK family and GSK-
33. Furthermore, the stability of boronic acids to heat, air and moisture as well as their 
non-toxic nature warranted the use of this strategy over other cross-coupling methods. 
The electron deficient nature of the pyrimidine ring makes this system far more reactive 
to Suzuki couplings compared to analogous benzenoid halides. Gronowitz et al. reported 
the coupling of 2,4-dichloropyrimidine with 2-thienylboronic acid and showed that the 
reaction selectively took place at the 4-position of the pyrimidine ring, as opposed to the 
more electron-rich 2-position (Scheme 4.4). 112 
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Scheme 4.4: Reagents and conditions: a) Pd(PPh3)4 (3 %), Na2CO3 (aq.), DME, reflux. 
More recent examples of the Suzuki coupling of 2,4-dichioropyrimidine that show 
selectivity at the 4-position as opposed to the 2-position have been reported by Jiang et 
al. 183  and Gong et al. 184 Schomaker et al. have reported the Suzuki cross-coupling 
reaction between 2,4-dibromopyrimidine and phenylboronic acid, 185  isolating both the 2-
bromo-4-phenyl-pyrimidine and 2,4-diphenylpyrimidine in 58% and 22% yield 
respectively. An analogous coupling, using 4,6-dibromopyrimidine afforded both 6-
bromo-4-phenyl-pyrimidine and 4,6-diphenylpyrimidine in respective yields of 56% and 
23%. The palladium catalyzed cross-coupling of 4,6-dichloro-2-methyl-5-
nitropyrimidine with o-(trifluoromethyl)-phenylboronic acid to afford the 4-aryl-
substituted pyrimidine as the major product has been reported by Cocuzza et al. 116 
4.2.2 Microwave assisted organic synthesis 
In the electromagnetic spectrum, the microwave radiation region is located between 
infrared radiation and radio waves, with microwaves having wavelengths ranging from 
1mm - lm. The use of microwaves to heat materials is not a novel concept, dating back 
some 50 years. In chemistry, studies using microwave technology have been undertaken 
since the late 1970s, initially within the field of inorganic chemistry, and, during the 
mid-1980s, within organic chemistry. Although microwave chemistry has been slow to 
develop, hampered primarily because of its lack of reproducibility and controllability, 
recently, it is evident from the increasing number of publications in the field that there 
has been renewed interest in the technology. This interest has emerged as a result of the 
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recent influx of availability of commercial microwave equipment, the development of 
novel solvent-free techniques, and as a reaction to increasing pressure in the 
pharmaceutical industry to seek shorter reaction times to aid in the synthesis of a greater 
number of novel chemical entities. 
Microwave dielectric heating has a number of advantages over traditional heating 
techniques, such as oil baths and heating jackets. Firstly, the microwave radiation heats 
only the reactants and solvents, and not the reaction vessel itself. Secondly, the use of 
correctly designed single mode cavity microwave reactors ensures the uniform heating 
of samples, unlike traditional heating techniques, where local hot spots or temperature 
gradients can sometimes develop. One further advantage gained by the use of 
microwave technology in chemistry is that it is possible to heat reactions to a 
temperature far greater than the conventional boiling point of the reaction solvent used, 
as reaction mixtures are heated in sealed tubes which, when heated, act as pressurized 
systems. 1 8 
The main advantage of using microwave assisted organic synthesis is the shorter 
reaction times. The rate of reaction can be described by the Arrhenius equation 
(Equation 4.1). 
k = A e -AG/RT 
	
(Equation 4.1) 
The pre-exponential factor, A, describes molecular mobility and is related to the 
frequency of vibrations of the molecules at the reaction interface. Microwaves induce an 
increase in molecular vibrations, and it has been proposed that this can affect the pre-
exponential factor, in turn, leading to an increase in rate of reaction, k.188 It has also been 
proposed that microwave irradiation can affect alter the exponential factor by affecting 
the free energy of activation. 189 
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Recently, microwave technology has been successfully applied to many different aspects 
of synthetic organic chemistry including heterocyclic synthesis,' 90  solvent free 
reactions,' 91  phase transfer catalysis, 192  cycloaddition reactions, 193  and transition metal 
catalyzed processes. 194  Kappe and co-workers have extended the application of 
microwave-assisted chemistry to parallel synthesis using reactors with suitable 
multimode microwave cavities.195 Furthermore, it has been shown that high-speed serial 
microwave-assisted organic synthesis can offer an attractive alternative to parallel 
synthesis using conventional combinatorial chemistry apparatus. 196 
4.3 	Results and discussion 
4.3.1 Initial Strategy 
Exploratory research in the group by Causton'97 had shown that a number of substituted 
aryl boronic acids could be selectively coupled to the 4-position of the commercially 
available 2,4-dichloropyrimidine, 378, under Suzuki conditions using microwave 
assisted organic synthesis. Optimized reactions conditions were determined to be the 
irradiation of a solution of 2,4-dichloropyrimidine in MeCN/H20 with a stoichiometric 
amount of the aryl boronic acid, 379, at 110°C for 10 minutes in the presence of 
Pd(OAc)2 and Cs2CO3. Furthermore, Causton had demonstrated that the reaction 
mixture containing the mono-substituted Suzuki intermediate, 380, could then undergo 
subsequent coupling with an aniline, 381, under acidic conditions, to afford a range of 2-
anilino-4-aryl-pyrimidines, 382, (Scheme 4.5). 197  This strategy was very attractive, 
allowing the high-throughput synthesis of novel CDK inhibitors, from commercially 
available building blocks, with only one purification step required at the end of the 
synthetic sequence. Research was still ongoing in this area upon the initiation of the 
chemistry discussed in the remainder of this chapter. 
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378 	379 	 380 	 382 
Scheme 4.5: Reagents and conditions: a) Pd(OAc)2, Cs2CO3 (3 eq.), MeCN/H20, 
twave, 110 °C, 15 mm. b) HC1 (2M), jlwave, 110 °C, 5 mm. 
Initially, it was envisaged that the synthetic route developed in the group by Causton to 
afford 2-anilino-4-aryl-pyrimidines could be employed to synthesize 6-aryl-4-anilino 
analogues. Prior to obtaining Causton's method, 3 trial two-step reactions were 
undertaken, illustrated in Scheme 4.6. Reaction of 2,4-dichloropyrimidine with either 4-
chloro-, 4-methyl- or 3, 5-bis-trifluoromethyl-aniline under basic conditions afforded 
anilino-pyrimidines 384 - 386, identified by ESI-MS. Analysis of the mass spectra of 
385 and 386 also confirmed the presence of the bis-anilino pyrimidine. Subsequent 
palladium catalyzed cross-coupling of 384 - 386 with phenylboronic acid afforded the 
4-aryl-6-anilino-pyrimidines 387 - 389 in very low yields. Analysis of the mass 
spectrum of 387 also revealed the presence of triphenyiphosphine oxide. However, it 
was encouraging that in just two steps, each consisting of very short reaction times, and 
with only one final purification step, two novel ligands, 388 and 389, had been 
synthesized which could be subsequently screened against the CDKs. 
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C1 	 C1 
a) b)
C1 	 N 	 N N'C 
384 R 1 = 4-Cl 387 R1 4-Cl 
383 	 385 R' = 4-CH3  388 R' = 4-CH3  
386 R' = 3,5-CF3  389 R' = 3,5-CF3  
Scheme 4.6: Reagents and conditions. a) R'-Substituted aniline, NaOH (2M), twave, 
110 °C, 5 mm. b) Phenylboronic acid, Pd(OAc)2 (5%), PPh3 (10%), Cs2CO3 (3 eq.), 
THFjtwave, 110°C, 15mins. 
It was postulated that the poor yields of 387 - 389 were attributable to formation of the 
bis-anilino species and consequently it was decided to reverse the steps, i.e.to perform 
the Suzuki coupling initially, followed by the amination reaction for subsequent 
syntheses of ligands. Recently, Qing et al. have reported that treatment of 4,6-
dichioropyrimidine with two equivalents of boronic acids under Suzuki coupling 
conditions resulted in the formation of 4,6-di substituted pyrimidines in high yield with 
no evidence of the homo-coupling of the boronic acid. 198  However, it has been shown 
that the trichioropyrimidine 390 can couple with phenylboronic acid under Suzuki 
conditions to afford 2,4-dichloro-6-phenylpyrimidine, 391, in excellent yield (Scheme 
4.7). 185  Therefore, it was envisaged that the treatment of 383 with one equivalent of 
boronic acid would afford the primarily the mono-substituted pyrimidine as the greater 
electron-richness of the 4-aryl-6-chloropyrimidine compared with that of the 4,6-
dichloropyrimidine would prevent the bis-Suzuki coupling from taking place. 
Furthermore, given Causton's success employing a Suzuki coupling and subsequent 
anilino coupling in the 2,4-dichloropyrimidine series, it seemed prudent to adopt this 














Scheme 4.7: Reagents and conditions: Phenylboronic acid (1 eq.), Pd(OAc)2, PPh3, 
glyme/H20, Na2CO3, reflux, 18 h.'85 
The Suzuki coupling between 4,6-dichioropyrimidine and 3-nitrophenyl boronic acid 
using the protocol developed by Causton for the 2,4-dichioropyrimidine series (Table 
4.1) was adopted, and ran in triplicate on a 4.0 mmole scale. Following the Suzuki 
coupling step, the reaction mixture was apportioned into three aliquots and to each 
aliquot was added an aniline followed by HCl (2M, 4.0 eq.). Each sample was sealed 
and irradiated in the microwave at 110 °C for 5 minutes. From each reaction vessel, 1 
mL organic solvent was taken and injected directly onto the Flex TM  (1 mL is the 
maximum injection volume on this system). Following purification, a sample was taken 
from each well corresponding to a discrete peak on the chromatogram and analysed by 
ESI-MS. Appropriate wells, corresponding to peaks shown to represent product, were 
combined and concentrated in vacuo to afford the 4-(3-nitrophenyl)-6-anilino 
pyrimidines 392 - 400. Of the 9 samples injected, only four pyrimidines, 392, 393, 395 
and 396 were recovered, and in approximately 1% yield. However, a further 4 
pyrimidines, 394, and 398 - 400, were identified by ESI-MS, although their mass spectra 
indicated the presence of other species. Only one ligand, 397, was not detected by ESI-
MS. Although it was planned to perform multiple injections onto the FlexTM  for each of 
the remaining reaction mixtures 392 - 400, given that the isolated yields of each ligand 
from the first injection was low, it was considered more worthwhile to pursue the 
synthesis of further libraries, with the aim of improving the reaction conditions. 
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Table 4.1: Reagents and conditions: a) 3-nitrophenylboronic acid, Pd(OA02, Cs2CO3 (3 
eq.), MeCN/I-120, p.wave, 110 °C, 15 mm. b) R1 -Substituted aniline, HC1 (2M), pwave, 
110°C, 5mm. 
Causton had found that using p-toluenesulfonic acid to catalyse the nucleophilic 
aromatic substitution of the unreacted chioro moiety of the 2,4-substituted pyrimidine 
led to increased yields for the two-step reaction sequence. Consequently this was 
explored in the 4,6-di substituted pyrimidine series, with a 5 x 5 array of boronic acids 
and amines. The scale of the Suzuki reaction was increased from 4.0 to 6.7 mmole to 
allow for the generation of sufficient 4-aryl-6-chloropyrimidine to be subsequently 
reacted in 5 amine coupling reactions. Unfortunately, this strategy was found to be less 
successful than using HCI for the anilino-coupling step, resulting in the recovery of only 
one ligand, 401 (Scheme 4.8). For the majority of these reactions, HPLC analysis 
revealed the presence of unreacted amine and 4-aryl-6-chloro-pyrimidine among other 
species. 
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Scheme 4.8: Reagents and conditions: a) 2,5-difluoro-phenyl boron ic acid, Pd(OAc)2 
(5%), PPh3 (10%), Cs2CO3 (1.5 eq.), MeCN, jLwave, 130 °C, 15 mins. b) Aniline, p-
toluenesulfonic acid (2 eq.), twave, 110°C, 5 mins. 
It was postulated that the low recovery of ligand 401 could be attributable to poor 
solubility of Cs2CO3, hindering transmetallation in the Suzuki coupling step. Therefore 
the concentration of the Suzuki coupling step was reduced from 1.34 M, as used for the 
synthesis of 401, to 0.22 M. A 3 x 2 array was synthesized to afford the ligands 402 - 
407 (Table 4.2). Following Suzuki coupling, a sample of each reaction mixture was 
analysed by ESI-MS and the presence of 4-aryl-6-chloropyrimidine was confirmed. 
Evidence of bis-Suzuki coupled pyrimidine was found in the mass spectrum of 4-(2,5-
difluorophenyl)-6-chloropyrimidine. Anilino couplings were performed using HCI (4 
eq.). 
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402 - 407 
No. R' R2 
402 2,5-F 3,5-CF3 
403 2,5-F 4-CF3 
404 2-OCH, 5-F 3,5-CF;  
405 2-OCH3, 5-F 4-CF3 
406 3-CF-3 3,5-CF3 
407 3-CF3 4-CF3 
Table 4.2: Reagents and conditions: a) R'-substituted-phenyl boronic acid, Pd(OA02 
(5%), PPh3 (10%), Cs2CO3 (1.5 eq.), MeCN, twave, 130 °C, 15 mins. b) R2-Substituted 
aniline, HC! (4.0 eq.), [wave, 110 °C, 5 mins. 
Again the quantity of product recovered from each reaction was low, with the estimated 
recovery of each ligand in the range 1 - 4 %, based on the injection volume of each 
sample compared to the total reaction volume. Clearly this was not satisfactory. 
However, each of the pyrimidines 402 - 407 had been isolated, purified and identified 
by ESI-MS, and were subsequently submitted for screening. 
The protocol used for the synthesis of pyrimidines 402 - 407 was adopted for the 
synthesis of pyrimidines 408 - 423 (Table 4.3). Again, these pyrimidines contained 
either a 3,5-bis-trifluoromethyl- or 4-trifluoromethyl-anilino moiety at C-6 of the 
pyrimidine ring. It was hoped that by fixing the C-6 substituent some insight could be 
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following subsequent screening of each ligand. The isolated yields of 408 — 423 whilst 
still low, were generally an improvement over those obtained for 402 — 407. 
	








383 	 408 - 423 
No. R' R2 % Yield 
408 4-F 3,5-CF3  8 
409 3,5-CH3  3,5-CF3  23 
410 4-CF3 3,5-CF3  10 
411 2-NO2 3,5-CF3  1 
412 4-OH 3,5-CF3  3 
413 4-OCH3 3,5-CF3  6 
414 3-NH2 3,5-CF3  
415 4-F 4-CF3 9 
416 2-Br 4-CF3 7 
417 3,5-CH3 4-CF3 18 
418 4-CF3  4-CF3  7 
419 2-NO2 4-CF3  2 
420 4-OH 4-CF3  8 
421 4-OCH3  4-CF3 15 
422 3-NH2 4-CF3  1 
423 	1 
thiophene-5- 
carbaldehyde 4-CF3  2 
Table 4.3: Reagents and conditions: a) R'-substituted-phenylboronic acid, Pd(OAc)2 
(5%), PPh3 (10%), Cs2CO3 (1.5 eq.), MeCN, iwave, 130 °C, 15 mins. b) R2-substituted 
aniline, HCI (4.0 eq.), twave, 110 °C, S mins. Note: For the synthesis of ligand 423, 5-
formyl-thiophene-2-boronic acid was used for (a). 
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Work continued on the synthesis of further pyrimidines for screening against CDK2, 
whilst modifying reactions conditions for both the Suzuki cross-coupling and the anilino 
substitution reaction. Unfortunately, however, results were inconsistent, depending not 
only on the conditions applied but also both the boronic acid and the aniline used. Other 
bases were investigated for the Suzuki coupling step including Na2CO3, K2CO3, KOBut 
and TBAB but no real improvements were made on the outcome of the two-step 
sequence. Similarly, several Suzuki couplings were performed using Pd(OAc)2 in the 
absence of triphenylphosphine; Pd(OAc)2 in the presence of tri-o-tolylphosphine; and 
Pd(PPh3)4 alone, however, again, consistently good results for the two-step synthetic 
sequence were not attainable. Reactions were also performed in alternative solvent 
systems, including THF, dioxane and glyme, as it has been reported that the solvent 
system used in the Suzuki coupling step can affect the selectivity of the cross-
coupling. 185  Those pyrimidines synthesised are presented in Table 4.4. 
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No. R' R2 % Yield 
424 3-NO2 4-OH 15 
425 3-(CH)4-4 4-OH 2 
393 3-NO2 4-Cl 31 
426 3-(CH)4-4 4-NO2 33 
427 3-NHCOCH3 3,5-OCH3 6 
428 3-NO2 3-OH 15 
429 3-OH 3-OH 32 
430 2,5-F 3-OH, 4-OCH3 9 
431 2,5-F 3,4-OCH3 29 
432 2,5-F 3-OH 63 
433 2,5-F 4-OH 22 
434 3-NT-I2 3,5-OCH3 16 
435 2,5-F 3,5-OCH3 20 
436 3-OH H 31 
437 3-OH 3-NO2 15 
438 3-OH 3-F 13 
439 2,5-CH3 3-CH20H 4 
440 2,5-CH3 3-F 8 
Table 4.4: 4-aryl-6-anilino-pyrimidines synthesized from 4,6-dichioropyrimidine via 
Suzuki cross-coupling and subsequent nucleophilic substitution by an aniline. 
ESI-MS analysis of products obtained from several two-step synthetic sequences 
identified the mono-arylated pyrimidine species in addition to the mono- and bis-
aminated pyrimidine species. It is postulated that in the 4,6-dichioropyrimidine species 
arylation at the 4-position of the pyrimidine ring increases the PKa of the N-3 pyrimidyl 
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nitrogen compared to the pKa of the N-I pyrimidyl nitrogen. However, in the 2,4-
dichioropyrimidine series, it is postulated that N-3 is less basic than N-I owing to two a-
chioro groups. It is postulated that in the 2,4-dichloropyrimidine species, arylation at the 
4-position increases the basicity of at N-3 rendering it similar in character to the N-I 
pyrimidyl nitrogen. Furthermore, it is postulated that in the 4-aryl-2-chloropyrimidine 
system, 441, the acid catalysed nucleophilic displacement reaction is easier than the 
analogous 4-aryl-6-chloropyrimidine system, 442, as both sites available for protonation 
are adjacent to the chioro group to be displaced. 
N C1 	 N C1 
441 442 
4.3.2 2-Amino-4-aryl-6-anilino pyrimidines 
Upon reviewing the crystal structure of the pyrimidine 363 bound to CDK2, it was 
considered worthwhile to investigate whether a small substituent at the 2-position of the 
pyrimidine ring would lead to enhanced affinity of the pyrimidine as a result of 
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The commercially available 2-amino-4,6-dichloropyrimidine was an ideal building block 
that could be used to address this question as it was envisaged that 2-amino-4-ary!-6-
anilino-pyrimidines, illustrated by 443, could be synthesized using identical chemistry to 
that being used in the 4-aryl-6-ani!ino-pyrimidine series. Consequently, work was 
initiated to synthesize several pyrimidines based around template 443, although this was 
met with similar problems as to those experienced in the 4,6-d i substituted series. Those 
pyrimidines that were successfully synthesized are presented in Table 4.5. 
I —R 
H2N N N 
R 
443 
R1 R2 X %Yield 
444 3,5-CH3  4-OH C 39 
445 3,5-CH3  4-Cl C 38 
446 3-NHCOCH3  3,5-OCH3  C 19 
447 3-NHCOCH3  3-NO2 C 15 
448 3-NO2 3-OH C 16 
449 3-01-1 3-NO2 C 5 
450 3-OH 3-OH C 22 
451 2,5-CH3  3-NO2 C 7 
452 2,5-CH3  3-01-1 C 10 
453 2,5-F 3,5-NO2 C 23 
454 2,5-F H N 20 
455 2,5-F 3,5-OCH3 C 32 
Table 4.5: Synthesis of 2-amino-4-aryl-6-anilino-pyrimidines 
Assay data obtained for the 2-amino pyrimidines submitted for screening is presented in 
Table 4.15 and discussed in Section 4.4. Analysis of the data presented in Table 4.16 
revealed that 2-amino-substituted pyrimidines were less active than their unsubstituted 
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analogues and consequently further work on the 2-amino substituted series was 
abandoned. 
4.3.3 Further investigation into the Suzuki cross-coupling reaction 
Initially, it was hypothesized that 4,6-dichloropyrimidine may have been decomposing 
under Suzuki conditions, as TLC analysis of the reaction mixtures after the two step 
synthetic sequence showed that the 4,6-dichioropyrimidine species had been consumed. 
To examine this hypothesis, three reactions were set up in series, each containing a 
solution of 4,6-dichioropyrimidine, Pd(OA02 (0.05 eq.) and Cs2CO3 (1.5 eq.) in 10:1 
acetonitrile: water (2.2 mL) in the absence of a boronic acid. Each reaction mixture was 
irradiated in the microwave for 15 minutes at either 90 °C, 110 °C or 130 °C. TLC 
analysis of the reaction mixtures after microwave irradiation showed no evidence of 
decomposition of the dichioropyrimidine. 
Subsequently, it was postulated that the poor recovery of ligand from the two-step 
synthesis was attributable to formation of the bis-arylated species in the Suzuki cross-
coupling reaction. Consequently, a short study was undertaken focussing on the 
optimization of the cross-coupling reaction between 4,6-dichioropyrimidine and phenyl 
boronic acid. The various conditions examined are presented in Table 4.6 together with 
the isolated yields of both the 4-phenyl-6-chloropyrimidine species, 456, and 4,6-




456 	 457 
146 
11 (lwpji -! 	 R'I 









1 Cl (10%) SI BI (1.2 eq.) 25 110 30 5 
2 C2(10%) SI B1(1.2eq.) 25 110 30 5 
3 C3(10%) SI BI (1.2 eq.) 25 110 3 47 
4 C4(1%) Si BI(1.2eq.) 25 110 3 16 
5 C1(10%) S2 BI(1.2eq.) 25 110 3 5 
6 C1(10%) S3 B1(1.2eq.) 25 110 3 5 
7 C1(10%) S4 B1(1.2eq.) 25 110 15 5 
8 Cl (10%) S5 B1(1.2eq.) 25 110 18 5 
9 Cl (10%) S4 132(1.2eq.) 25 110 3 - 
10 C1(10%) S4 133(1.2eq.) 25 110 3 1 	3 
11 Cl (10%) S4 134(1.2eq.) 25 110 9 3 
12 Cl (10%) S4 135 (1.2 eq.) 25 110 - 3 
13 Cl (10%) S4 134(1.2eq.) 25 50 27 3 
14 Cl (10%) S4 134 (1.2 eq.) 25 90 24 3 
15 C1(l0%) S4 134(1.2eq.) 25 110 21 - 
16 Cl (10%) S4 134(1.2eq.) 25 140 24 3 
17 Cl (10%) S4 134(1.2eq.) 5 50 3 - 
18 CI (10%) S4 134(1.2eq.) 10 50 3 3 
19 Cl (10%) S4 B4 (1.2 eq.) 15 50 9 3 
20 Cl (10%) S4 134 (1.2 eq.) 20 50 9 3 
21 C1(1%) S4 134(1.2eq.) 10 50 3 3 
22 Cl (5%) S4 134 (1.2 eq.) 10 50 12 3 
23 Cl (5%) S4 134 (2.0 eq.) 10 50 12 6 
24 Cl (5%) S4 134 (3.0 eq.) 10 50 15 3 
Table 4.6: Reagents and standard conditions: 4,6-dichioropyrimidine (0.17 mmole, 1.0 
eq.), phenylboronic acid (1.0 eq.), catalyst Cl - Pd(dppf)2, C2 — Pd(PPh3)4, C3 — 
Pd2(dba)3, C4 — POPd; solvent (1 mL reaction volume) Si - MeCN, S2 — EtOH, S3 — 
I120, S4 — Dioxane, S5 - THF; base B  - Cs2CO3, 132 - Na2CO3, 133 — K2CO3, 134 — 
KOtBu, 135 — TBAB, K2CO3;  H20 (0.1 mL) added to each reaction to solubilize the 
base, [twave. 
147 
er  ChqpjI  	 RuIi.c\Dfcuvs!vnJI 
It was hoped that conditions could be found to maximize the formation of species 456 
and minimize the formation of species 457 but, unfortunately, no strong conclusions can 
be drawn from the results presented in Table 4.6. The conditions examined in Table 4.6 
are by no means exhaustive, adopting a single point optimization strategy. Entries 1-4 
shows that the chosen catalyst can have a significant affect on the products formed 
during the Suzuki coupling, with Pd2(dba)3 enhancing the formation of 457 over 456. 
Pd(dppf)2 was shown to be as affective as the catalyst Pd(PPh3)4 in the synthesis of the 
mono-arylated species 456 and consequently was selected for further studies over 
Pd(PPh3)4 which had been shown to form triphenylphosphine oxide in the Suzuki cross-
coupling reaction. Entries 1 and 5 - 8 examine the effect of solvent on the cross-
coupling reaction and show that a non-polar solvent affords a greater yield of 456 in 
comparison with a polar solvent. Entries 8 —12 examine the effect of various bases and 
show that the strong base KOtBu  could be used in the Suzuki reaction. It has been 
postulated that the halogen ligand on organopalladium(II) halide can be readily 
displaced by an alkoxy anion to provide a reactive alkoxopalladium(lI) intermediate that 
is involved in the transmetallation process.199 Entries 13 - 16 show that the reaction 
temperature does not have a significant influence on the outcome of the Suzuki 
coupling, with comparable results obtained at both 50 °C and 140 °C. However, direct 
comparison of entries 11 and 15 suggest there is some variability in the ratio of 456 and 
457 obtained under identical conditions. If time had allowed, it would have been prudent 
to repeat the experiments listed in Table 4.6 to obtain average yields of 456 and 457 for 
each set of conditions. Entries 17 - 20 show that a reaction time in excess of 10 mm 
increases the quantity of 456 isolated in the reaction. Entries 21 - 24 show that the use 
of 3 equivalents of base and 5% catalyst affords a greater ratio of 456:457 in the 
reaction. It should be noted that unreacted 4,6-dichloropyrimidine was present in all 
samples listed in Table 4.6 following the Suzuki coupling, which, unfortunately, could 
not be isolated as it was found to undergo sublimation upon solvent evaporation. 
Clearly, no conditions were found that gave significant yields of 456 and minimal 
formation of 457, although, in the majority of conditions examined in the study, and 
illustrated in Table 4.6, species 457 was not isolated in significant quantity. 
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4.3.4 Isolation of 4-aryl-6-chloro-pyrimidines 
To ease purification of the 6-anilino-4-aryl-pyrimidine it was decided to isolate the 4-
aryl-6-chloro-pyrimidine intermediate following the Suzuki coupling. Although in doing 
so this would considerably lengthen the synthetic procedure, it would provide some 
indication of how well the Suzuki couplings were proceeding and possibly explain the 
low isolated yields of 6-anilino-4-aryl-pyrimidine ligands. 5 Suzuki couplings were 
performed using the boronic acids shown in Table 4.7. It was decided to use the electron 
rich 3-methoxy-, 4-methoxy- and 3,4-methoxyphenylboronic acids as building blocks as 
it was envisaged that the 4-aryl-6-chloropyrim i dines generated would be more reactive 
to the subsequent acid catalysed nucleophilic substitution reaction. After microwave 
irradiation of the sample, each sample was divided in 3 aliquots and injected onto the 
F1exTM HPLC (Method A). Following identification of the 4-aryl-6-chloropyrimidine by 
ESI-MS, appropriate fractions were combined and concentrated in vacuo. Isolated yields 
for the Suzuki couplings were 66 - 93%, considerably higher than those yields reported 
in Table 4.6 for the cross-coupling between 4,6-dichloropyrimidine and phenylboronic 
acid, although a direct comparison of conditions cannot be made. Each intermediate was 
used directly in the anilino couplings shown in Table 4.7, without further 
characterization. For the synthesis of ligands 458, 459, 463, 464 and 468, KOtBu was 
used for the nucleophilic aromatic substitution reaction between the 4-aryl-6-chloro-
pyrimidine species and the aniline. 
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383 	 458 - 470 
No. X Y R' Rh % Yield 
458 N C 4-OCH3 H - 
459 N N 4-OCH3 1-1 - 
460 1  C C I 4-OCH3 3-NO2  33 
461 C C 4-OCH3 4-OH 33 
462 C C 4-OCH3 3-OH 13 
463 N C 3-OCH3 H 42 
464 N N 3-OCH3 H - 
465 C C 3-OCH3 3-NO2 - 
466 C C 3-OCH3 4-OH 42 
467 C C 3-OCH3 3-OH 36 
468 N C 3,4-OCH3  H - 
C C 3,4-OCH3  4-OH 14 
L
469 
I470 C I  C  3,4-OCH3  3-OH 38 
Table 4.7: Reagents and conditions: a) Cs2CO3 (3.0 eq.), Pd(OA02 (5%), PPh3 (10%), 
R'-substituted phenyl boronic acid (1.0 eq.), dioxane/H20 (10:1, 3.3 mL), twave, 130 
°C, 20 mm. b) R2-substituted aniline (1.0 - 1.6 eq.), HC1 (4.0 eq.), dioxane (1 mL), 
jiwave, 130 °C, 20 mm. 
The results presented in Table 4.7 were generally an improvement over those obtained 
from previous syntheses of 4-aryl-6-anilino-pyrimidine ligands reported in this chapter. 
It is postulated that this is attributable to two factors, namely the use of electron rich 
phenyl boronic acids in the Suzuki cross-coupling reaction and electron rich anilines in 
the nucleophilic aromatic substitution of the 4-aryl-6-chloropyrimidine intermediate. 
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Nucleophilic aromatic substitution reactions involving either 2-aminopyrimidine, 
illustrated by 459 and 464, or 2-aminopyridine, illustrated by 458 and 468, were largely 
unsuccessful, presumably owing to the poor nucleophilicity of these species. 
4.3.5 Isolation of 6-anilino-4-chloropyrimidines 
It was now apparent that the Suzuki cross-coupling reaction was deactivating the 
pyrimidine system to subsequent nucleophilic aromatic substitution. However, initial 
studies reported for the synthesis of ligands 387 - 389 in which the anilino coupling 
reaction had been performed prior to the Suzuki cross-coupling reaction had also been 
unsatisfactory in terms of isolated yields of desired ligands, with evidence of the bis-
anilino pyrimidine species being identified in the ES1-MS of the intermediates 385 and 
386. Consequently, a short study was performed investigating the nucleophilic 
substitution reaction under both acidic and basic conditions. 3-Fluoroaniline (0.13 
mmole, 1.0 eq.) was added to a solution of 4,6-dichloropyrimidine (1.0 eq.) in 
acetonitrile in the presence of 2 equivalents of acid or base (Table 4.8). Each sample was 
subjected to microwave irradiation for 5 minutes at 100 °C. TLC analysis of each sample 
indicated the presence of 4,6-dichioropyrimidine and consequently, each sample was 
irradiated for a further 10 minutes at 100 °C. ESI-MS analysis of each sample indicated 
the presence of the 6-anilino-4-chloro-pyrimidine, 471, in all cases and subsequently 
each sample was purified by HPLC. Significantly, no evidence of di-substituted 
pyrimidine was found in each case. Unfortunately, owing to mechanical failure of the 
Christ RVC during solvent evaporation, only two samples were recovered. Although the 
study was not repeated, it had shown that Cs2CO3 could be used to effect the 
nucleophilic substitution reaction. However, when Cs2CO3 was employed to effect the 
nucleophilic substitution reaction between a selection of anilines and 4-aryl-6-chloro-
pyrimidines it was found to be unsuccessful, again providing evidence of the 
deactivating effect of a 4-aryl group on the pyrimidine species to the nucleophilic 
aromatic substitution reaction. 
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N' Na F 
471 
Acid/Base (2.0 eq.) 
p -Toluenesulfonic acid 
HCI (2M) 
Triethylamine 
N ,N -diisopropylethylamine 
Cesium carbonate 
Table 4.8: Acids and bases used to effect the nucleophilic aromatic substitution reaction 
between 3-fluoroaniline and 4,6-dichioropyrimidine. 
Given that no evidence of bis-anilino substitution had been found in the reaction 
between 3-fluoroaniline and 4,6-dichioropyrimidine, it was decided to undertake the 
nucleophilic substitution reaction prior to the Suzuki coupling step. Indeed, this 
approach had been reported by Schultz et al. in the development of a combinatorial 
scaffold approach toward kinase-directed heterocycle libraries. 200 The first step of the 
synthesis was the reductive amination of 4-formyl-3,5-dimethoxyphenoxymethyl resin 
472 with a primary alkyl- or benzyl- amine 473 to afford a resin supported secondary 
amine 474. Significantly, subsequent nucleophilic aromatic substitution of 474 with 4,6-
dichloropyrimidine in butanol using NN-diisopropylethylamine at 90 °C afforded the 
solid-supported pyrimidine 475 that was coupled with an aryl boronic acid, 477, under 
Suzuki conditions (Scheme 4.9) to afford the 6-anilino-4-aryl-pyrimidine, 477 in 
excellent yield (>85%) and purity. 
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478 	 476 
Scheme 4.9: Reagents and conditions: a) NaBH(OAc)3, HOAc (1%), THE b) 4,6-
dichioropyrimidine, NN-diisopropylethylamine, butanol, 90 °C, 24 h. c) boronic acid 
(5.0 eq.), Pd2(dba)3 (7%), carbene ligand (14%), Cs2CO3 (6.0 eq.), 1,4-dioxane, 90 °C, 
12 h. d) DCM:TFA:Me2S:H20 (45:45:5:5).200 
Furthermore, during the period of our investigation into the 6-anilino-4-aryl-pyrimidine 
scaffold, a method was published by Wade et al., adopting a similar solid-supported 
approach to that reported by Schultz et al., that specifically focussed on the 4,6-
dichloropyrimidine system. (Scheme 4.10).'0' The 4,6-disubstituted pyrimidines 
synthesized and reported therein were isolated in moderate yields (25 - 48%) although 
in excellent purity. 
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477 	 475 
Scheme 4.10: Reagents and conditions: a) 473 (5.0 eq.), NaBH(OA03 (3.0 eq.), HOAc 
(10.0 eq), THF, room temperature, 15 h. b) 4,6-dichioropyrimidine (4.5 eq.), N,N-
diisopropylethylamine (4.5 eq.), DMF, 50 °C, 18 h. c) R2-substituted boronic acid (4.0 
eq.), Pd2(dba)3 (10 %), P(tBu)3  (20%), spray dried KF (10.0 eq.), 1,4-dioxane, 50 °C, 18 
- 22 h. d) DCM:TFA (4:1).201 
Initially it was thought that the use of an excess of 4,6-dichioropyrimidine to react with 
the resin supported secondary amine, 474, was minimizing the formation of bis-
aminated pyrimidine. However, further investigation of the literature revealed a report 
by Luo et al. that showed 4,6-dichioropyrimidine could be reacted with benzylamine, 
utilizing solution phase microwave assisted organic synthesis, to afford the mono-
aminated product, 478, in excellent yield. Furthermore, it was reported that the first 
addition of benzylamine was substantially easier than the addition of a second amino 
group.202 The Suzuki cross-coupling reaction between 478 and phenylboronic acid to 
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Scheme 4.11: Reagents and conditions: a) benzylamine (0.9 eq.), 2-propanol, N,N-
diisopropylethylamine (2.0 eq.), J.twave, 130 °C, 20 mi b) phenylboronic acid (1.4 
eq.), Pd(PPh3)4 (4%), K2CO3  (2.0 M in water), toluene/ethanol (4:1, 0.13 M), Jiwave, 
140 °C, 10 mm.202 
A series of 6 two-step reactions were undertaken as illustrated in Table 4.9. Following 
the two nucleophilic aromatic substitution reactions between 4,6-dichloropyrimidine and 
either 3-hydroxy- or 3-nitroaniline, which were isolated in 28% and 31% yield 
respectively, the Suzuki cross-coupling reaction was performed using a modification of 
the protocol reported by Luo et al.202  K2CO3  (4.0 eq.) was used as the base, dissolved in 
the minimum amount of water. The reactions were performed in a solution of 4:1 
toluene: EtOH (1 mL), each sample being irradiated in the microwave at 140 °C for 15 
minutes. Pyrimidines 480, 462 and 460 were isolated in low yields, primarily as a 
consequence of incomplete conversion of the pyrimidine to the 6-anilino-4-chloro-
pyrimidine species. 
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No. R' % Yield 
480 3-OCH3 3-OH 12 
481 3-OCH3 3-NO2 - 
462 4-OCH3  3-OH 23 
460 4-OCH3 3-NO2 10 
482 3,4-OCH3  3-OH - 
483 3,4-OCH3 3-NO2 - 
Table 4.9: Reagents and conditions: a) R2-substituted aniline (1.0 eq.), HCI (4.0 eq.), 
1,4-dioxane, j.iwave, 130 °C, 30 mm. b) R'-substituted phenylboronic acid (1.4 eq.), 
Pd(PPh3)4 (4%), K2CO3 (4.0 eq.), toluene/ethanol (4:1), H20 (0.1 mL), jtwave, 140 °C, 
15 mm. 
Adopting the method reported by Luo et al.,202 a number of pyrimidines were 
synthesized, as illustrated by Table 4.10. It was found that it was necessary to reduce the 
reaction temperature from 130 °C, reported for the substitution reaction between 
benzylamine and 4,6-dichioropyrimidine, to 120 °C in order to prevent the safety 
pressure limited of 300 psi being exceeded on the microwave reactor. Consequently, the 
reaction time was increased from 20 minutes to 30 minutes. For synthesis of the 6-
anilino-4-aryl-pyrimidines shown in Table 4.10, the mono-aminated pyrimidine species 
was isolated following HPLC purification before subsequent Suzuki coupling with a 
substituted phenyl boronic acid, its presence being confirmed by ESI-MS. 
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No. X Y R' R  % Yield 
484 C C 3-OCH3 3-NO2 - 
480 C C 3-OCH3  3-OH 15 
462 C C 4-OCH3  3-OH 20 
470 C C 3,4-OCH3 3-OH 19 
485 C I 	C 3-OCH3  3,4-OCH3 72 
486 C C 4-OCH3  3,4-OC II3  29 
487 C C 3,4-OCH3  3,4-OCH3  40 
466 C C 3-OCH3  4-OH 55 
461 C C 4-OCH3 4-OH 9 
488 N N 3-OCH3 H - 
463 N C 3-OCH3 H 5 
489 C C 3-OCH3 F 6 
469 C C 3,4-OCH3 4-OH 25 
490 C C 2,5-CH3 3-OH 51 
491 C C H 3-OH 49 
492 C C 3-OH 4-OH 1 
493 C C 2,5-CH3 4-OH 16 
494 C C 4-OCH3 3-F - 
495 C C 4-OCH3 3-NO2 - 
467 C C 3-OCH3 H 20 
496 C C 4-OCH3 H 40 
497 C C 2,5-CH3 3,4-OCH3 32 
498 C C 3-OH 3,4-OCH3 51 
Table 4.10: Reagents and conditions: a) R2-substituted aniline (1.0 eq.), 2-propanol, 
N,N-diisopropylethylamine, (2.0 eq.), twave, 120 °C, 30 mm. b) R'-Substituted 
phenylboronic acid (1.4 eq.), Pd(PPh3)4 (4%), K2CO3 (4.0 eq.), toluene/ethanol (4:1, 1 
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The results from this library were encouraging as not only were the isolated yields of 
each ligand generally higher than those obtained when performing the Suzuki coupling 
first, the recovery rate of ligand had increased with 19 novel ligands being isolated from 
23 two-step reactions. Pyrimidines 484 and 495 could not be isolated owing to the small 
scale of the Suzuki coupling, with the nucleophilic aromatic substitution reaction 
between 4,6-dichloropyrimidine and the electron poor 3-nitroaniline proceeding in very 
poor yield (3%). Similarly, the nucleophilic substitution reactions between 4,6-
dichloropyrimidine and either 3-fluoroaniline or 2-aminopyrimidine resulted in poor 
recovery of mono-aminated species. 
To investigate whether both the anilino and Suzuki couplings could be performed in a 
two-step, one-pot manner, pyrimidines 499 - 518 were synthesized using the synthetic 
protocol adopted for the synthesis of pyrimidines shown in Table 4.10. Propan-2-ol was 
used as the reaction solvent for both the nucleophilic substitution reaction and the 
Suzuki cross-coupling. Following each anilino coupling, the crude reaction mixture was 
apportioned into four equal aliquots, each aliquot transferred to a microwave tube and 
the reagents for the Suzuki coupling added. The library, together with isolated yields for 
each two-step reaction, is shown in Table 4.11. 
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H H 
383 	 499-518 
No. R' R2 % Yield 
499 3-OCH3  4-F, 3-CH3  57 
500 3-OCH3 4-OH, 2-NO2 - 
501 3-OCH3  3-CN - 
502 3-OCH3  3-OH, 4-OCH3  67 
503 3-OCH3  3,5-OCH3  24 
504 4-OCH3  4-F, 3-CH3  66 
505 4-OCH3  4-OH, 2-NO2 30 
506 4-OCH3 3-CN - 
507 4-OCH3  3-OH, 4-OCH3  37 
508 4-OCH3  3,5-OCH3  14 
509 2,5-CH3  4-F, 3-CH3  54 
510 2,5-CH3  4-OH, 2-NO2 - 
511 2,5-CH3  3-CN - 
512 2,5-CH3  3-OH, 4-OCH3  21 
513 2,5-CH3  3,5-OCH3  20 
514 3-OH 4-F, 3-CH3 45 
515 3-01-1 4-OH, 2-NO2 - 
516 3-01-1 3-CN 3 
517 3-01-1 3-OH, 4-OCH3 6 
518 3-01-1 3,5-OCH3  8 
Table 4.11: Reagents and conditions: a) R2-substituted aniline (1.0 eq.), 2-propanol, 
N,N-diisopropylethylamine, (2.0 eq.), twave, 120 °C, 30 mm. b) R'-substituted 
phenylboronic acid (1.4 eq.), Pd(PPh3)4 (4%), K2CO3 (4.0 eq.), H2O (0.1 mL), twave, 
140'C, 15 mm. 
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Table 4.11 shows that 14 novel ligands were isolated from 20 reactions and 
demonstrates that a two-step, one-pot strategy can be adopted in favour of a two-step 
reaction sequence, with purification of the 6-anilino-4-chloropyrimidine intermediate, 
with no apparent drop in yields. Failures from this library featured electron deficient 
anilines containing either 3-cyano- or 4-hydroxy-2-nitro- substitution patterns. Ligands 
500 and 510 were identified by ESI-MS but were not isolated in sufficient purity for 
screening. 
4.4 	Summary of biological results and conclusions 
Summaries of primary biological results received for pyrimidines submitted to Cyclacel 
Ltd. for screening are shown in Tables 4.12 - 4.16. These results are discussed in the 
light of the crystal structure of the CDK2/ligand 363 complex [PDB Code IPXO], 
shown again in Figure 4.3, that was solved during the period of the research discussed in 
this chapter. It must be stressed that the results presented in Tables 4.12 - 4.16 are from 
a primary screen, and, as such, have an associated error that renders them open to 
interpretation. The main purpose of the primary screen is to reduce the numbers of 




Figure 4.3: The X-ray crystal structure of the inhibitor CYC4223, 363, bound to CDK2 
(PDB Code 1 PXO). 
Table 4.12 shows that greatest inhibition of the CDK2/E complex of those ligands listed 
in the table is with 3,5-dimethyl- aryl and 3,5-bis-trifluoromethyl- anilino substitution 
patterns. However, comparison of the primary screening data of pyrimidines 403 with 
402; 407 with 406; 405 with 404; and 415 with 408; show that pyrimidines with a 4-
trifluoromethyl- anilino substitution pattern are generally more potent than their 3,5-bis-
trifluoromethyl- analogues. It is postulated that the steric bulk of the 3,5-bis-
trifluoromethyl-anilino moiety is not well tolerated in the ATP binding pocket owing to 
the proximity of the residues G1n131, Asp86 and Lys89. Indeed, this trend is also 
apparent for ligands 428, 412, 413 and 410 listed in Table 4.13. Focussing on the 4-aryl 
substituent, the 3,5-dimethyl- substitution pattern affords ligands with reasonably 
potency, exemplified by pyrimidines 409 and 417. This result is surprising as it appears 
from the crystal structure of the CDK2/ligand 363 complex that a hydrophobic group at 
the 3- or 5-position of the aromatic ring would be directed towards the residues Asp145 
161 
or Asn 132 of CDK2. However, it is possible that a favourable hydrophobic interaction 









I R 2 R 
409 3,5-CH, 3,5-CF 81.2 17.8 
416 2-Br 4-CF, 67.1 16.2 
417 3,5-CH, 4-CF. 64.8 -2.0 
420 4-01-I 4-CF, 62.7 15.9 
403 2,5-F 4-CF, 57.9 13.9 
405 2-OCH1, 5-F 4-CF 46.8 25.0 
407 3-CF, 4-CF, 41.1 -8.7 
388 Fl 4-Cft 38.4 59.7 
402 2,5-F 3,5-CF 36.0 19.7 
406 3-CF, 3,5-CF, 35.8 16.9 
418 4-CF, 4-CF, 27.0 7.2 
404 2-OCI-l3. 5-F 3,5-CF 17.5 6.8 
411 2-NO2 3,5-CF 12.8 20.5 
389 H 3,5-CF, 8.6 19.3 
419 2-NO, 4-CF, 7.6 23.2 
415 4-F 4-CF 7.2 0.6 
423 2-thienyl-5-carbaldehyde 4-CF 6.8 16.9 
395 3-NO, 4-CH, 5.2 32.5 
396 3-NO2 4-CF, -1.3 21.9 
408 4-F 3,5-CF -7.9 20.4 
Table 4.12: Primary screening data of a number of 4-aryl-6-anilino-pyrimidines, 
tabulated in descending order of CDK2/cyclin E inhibitory activity. % I = percentage 
inhibition at the ligand concentration shown in the table. Entries highlighted in blue are 
discussed in the text. 
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Table 4.13 shows that the introduction of a hydrogen bond donor at the 3-position of the 
4-aryl moiety, afforded ligands with good potency against CDK2/E at 25 M. It is 
envisaged that a hydrogen bond donor at the 3-position of the 4-aryl moiety can interact 
favourably with the carbonyl of Asp 145 or the carbonyl of Asn132, in an analogous 
manner to the primary amino group of the inhibitor 363. Furthermore, a 3-hydroxy 
substituent off the anilino moiety also appears to afford ligands with reasonable potency, 
exemplified by 429 and 428. Again, it is postulated that a hydrogen bond donor at the 3-
position of the anilino moiety would be well placed to interact with the backbone 
carbonyl ofGlnl3l. 
CDK2/E K9/T1 GSK3 - 
N 
1 R 2 R 






429 80.8 58.5 
414 3-NH2 3.5-CF3 68.0 7.2 94.1 
422 3-NH1 4-CF3 60.6 35.2 94.6 
428 3-NO2  3-OH 52.6 28.0 66.2 
440 2,5-Cft 3-F 47.7 -25.8 32.3 
427 3-NHA 3,5-OCT-I3  33.8 16.9 29.7 
452 2,5-CH3  3-01-1 26.7 4.9 2.5 
421 4-OCH3 4-CF3  24.8 16.1 34.4 
412 4-01-1 3,5-CF3  21.8 20.8 45.5 
413 4-OCT-I3  3,5-CF3  16.8 20.1 71.9 
410 4-CF3  3,5-CF3  1 	-3.0 15.0 19.4 
Table 4.13: Primary screening data of a number of 4-aryl-6-anilino-pyrimidines, 
tabulated in descending order of CDK2/cyclin E inhibitory activity. % I = percentage 
inhibition at the ligand concentration shown in the table. Entries highlighted in blue are 


















461 j 4-OCI13 4-OH 8.8 	74.9 30.6 	64.7 17.0 
490 2,5-0113 3-OH -9.2 63.7 13.4 57.4 -0.3 
491 H 3-OH -2.8 	60.3 25.7 	64.1 5.3 
463 3-0C113 2-Aminopyridinc -2.8 58.3 59.9 87.5 18.2 
496 4-00 13 H -5.4 	52.6 23.6 	56.1 21.7 
507 4-OCI-13 3-OH, 4-OCH3 13.0 52.4 1  22.3 69.7 5.7 
469 3,4-OCH 4-OH -7.9 	49.9 10.5 	25.9 14.5 
504 4-OCH3 4-F, 3-CH3 9.2 48.3 14.6 33.3 2.0 
502 3-OCI-13 3-OH, 4-OCH3 10.5 	47.5 16.6 	50.0 1.0 
514 3-OH 4-F, 3-CH3 4.1 45.0 20.4 59.8 13.8 
498 3-OH 3,4-OCH3 -6.7 	40.8 1 22.5 	55.7 8.8 
512 2,5-CH3 3-OH, 4-OCH3 13.7 38.9 20.5 52.6 -11.2 
509 2,5-CH, 4-F, 3-CH3 10.2 	35.5 12.3 	34.5 -12.7 
467 3-OCH3 H 6.9 33.8 26.7 45.6 -4.9 
497 2,5-CH, 3,4-OCH3 14.2 	30.1 19.8 	37.2 19.9 
466 3-OCH3 4-OH 13.6 29.7 19.7 50.7 -17.9 
489 3-OCH3 3-F 0.5 	28.6 13.5 	49.5 -4.1 
480 3-OCH3 3-OH 11.7 28.4 21.9 58.5 7.7 
505 4-OCH 4-OH, 2-NO2 -2.3 	27.5 9.5 	-2.0 4.3 
516 3-OH 3-CN 9.7 27.1 26.0 68.7 16.5 
513 2,5-CH3 3,5-OCH3 -10.7 	26.8 12.4 	33.9 2.2 
503 3-OCH3 3,5-OCH3  8.0 20.6 5.7 20.4 -10.9 
485 3-OCI13 3.4-OCH3 6.9 	16.9 9.7 	30.0 -3.5 
493 2,5-Cl-I3 4-OH 8.3 12.3 15.1 54.7 0.4 
462 4-0013 3-OH 6.7 	10.5 23.8 	39.4 3.8 
518 3-01-I 3.5-00-13 28.1 1.6 25.0 58.6 4.3 
499 3-OCH3 4-F, 3-CH3 
1 
12.0 	-1.5 17.7 	30.4 1.2 
517 3-OH 3-OH, 4-OCH3 14.5 -15.5 27.1 64.3 1 	1.8 
Table 4.14: Primary screening data of a number of 4-aryl-6-anilino-pyrimidines, 
tabulated in descending order of CDK2/cyclin E inhibitory activity at a ligand 
concentration of 10 jiM. % I = percentage inhibition at the ligand concentration shown 
in the table. Entries highlighted in blue are discussed in the text. 
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It is difficult to draw any conclusions from the primary screening data presented in 
Table 4.14 as there appears to be no correlation between various 4-aryl and 6-anilino 
substituents and the potency of the ligand against CDK2 at 10 tM. Furthermore, at a 
ligand concentration of 0.5 jtM, the ligands presented in Table 4.14 show neglible 
inhibition of CDK2. Table 4.14 shows that ligand 461 inhibits CDK2/cylin E and 
CDK9/T1 with modest potency. Replacement of its 4-hydroxy substituent on the anilino 
ring with a 3-hydroxy group, as exemplified by ligand 462, destroys activity. However, 
several ligands are shown to have activity against CDK2ICycIin E and CDK9/T1 that 
contain a 3-hydroxy substituted aniline, illustrated by ligands 490 and 491. 
Table 4.15 shows the primary screening data received for several 2-amino-4-aryl-6-
anilino-pyrimidines. A direct comparison is made between this data and data obtained 
from analogous ligands not containing a 2-amino substituent in Table 4.16. 
K-s'- 	 R2 H2N N N> 
H 
CDK2/E CDK9/T1 GSK3 - 







448 3-NO2 3-OH 44.8 22.3 22.9 
449 3-OH 3-NO2 38.7 24.4 15.9 
451 2,5-CH3  3-NO2 37.6 18.8 11.5 
450 3-01-1 3-OH 36.9 19.7 7.1 
447 3-NHAc 3-NO2  28.6 9.1 0.6 
446 3-NHAc 3,5OCH3  14.4 19.9 6.3 
Table 4.15: Primary screening data of a number of 2-amino-4-aryl-6-anilino-
pyrimidines. % I = percentage inhibition at the ligand concentration shown in the table. 
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429 3-OH 3-OH 80.8 55.6 58.5 
450 3-OH 3-OH 36.9 19.7 7.1 
428 3-NO2  3-OH 52.6 28.0 66.2 
448 3-NO, 3-OH 44.8 22.3 22.9 
427 3-NHAc  3,5-OCH3  33.8 16.9 29.7 
446 3-NHAc 3,5-OCH31  14.4 1 	19.9 1 	6.3 
Table 4.16: Direct comparison of primary screening data of a number of 4-aryl-6-
anilino-pyrimidines (blue) and 2-amino-4-aryl-6-anilino-pyrimidines. % I = percentage 
inhibition at the ligand concentration shown in the table. 
Table 4.16 shows that the introduction of a 2-amino group to the 4-aryl-6-anilino-
pyrimidine scaffold results in a reduction in ligand potency against the CDK2/E, 
CDK9/T1 and GSK3. It was envisaged that the 2-amino group could potentially 
hydrogen bond with the backbone carbonyl of Glu8 1, in an analogous manner to that 
observed in the CDK2/ATP complex (PDB Code 1HCK) and CDK2/ligand 321 
complex (PDB Code IPXJ). Analysis of the crystal structure of ligand 363 bound to 
CDK2 revealed that the size of the pocket that would accommodate the 2-amino group is 
small. It is therefore postulated that the introduction of a 2-amino group off the central 
pyrimidine ring disrupts the donor-acceptor pair interactions between the N-i of the 
pyrimidine ring and the backbone NH of Leu83, and the anilino-NH of the ligand and 
the backbone carbonyl of Leu83. 
Those ligands that exhibited 50% or greater inhibition of CDK2/E in the primary screen 
were put forward for a secondary screen and their IC50 values against CDK2/E were 
determined. The secondary screen consisted of a full 10 point 1050 determination, 
performed twice, using 2 independent dilution series. The IC50 values of compounds 
submitted for screening against CDK2/Cyclin E that have been received are shown in 
Table 4.17. The dilution series for the IC50 determination of ligands 413, 414 and 422 
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had a highest ligand concentration of 12.5 tM. These three ligands failed to give 50% 






413 >12.5 >12.5 
414 >12.5 >12.5 
422 >12.5 >12.5 
428 18.313 23.953 
429 8.051 20.645 
424 10.690 - 
Table 4.17: Secondary screening data for 4,6-disubstituted pyrimidines tested. 
What is evident from the data presented in Tables 4.12 - 4.17 is that 4-aryl-6-aniliino-
pyrimidines are modest inhibitors of CDK2/E, CDK9/T1 and GSK3. Eight direct 
comparisons of results obtained from the cDK2/cyclin E assay for both the 4,6- and 
2,4-disubstituted pyrimidine series are shown in Table 4.18. These comparisons show 
that in most cases the 4,6-disubstituted-pyrimidine analogue is less potent an inhibitor of 
CDK2/E than its 2,4-disubstituted-pyrimidine analogue. 
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ASCII-202/1 3-OCH 3-F 67.5 - 
489  28.6 - 
ASC11-191 3-OH 3,5-OCH3  13.7 - 
518  1.6 - 
ASC11-85 4-OCI-I 3-01-1 98.3 0.0015 
462  10.5 - 
ASC1-174A 3-NO2 4-01-1 - 3.300 
424  - 10.690 
ASCII-16 2,5-CH, 3-OH 91.8 3.654 
452  2(,7 - 
ASC11-17 2,5-Cl-I1  3-F 8().- >12.5 
440  47.7 - 
ASCII-19 3-01-1 3-OH 97.0 0.491 
429  80.8 8.051 
ASC11-22 3-NO2 3-01-1 93.8  1.396 
428  6 18.313 
ASC1I-36 3-NI-L&c 3,5-OCH3  90.4 5.427 
427  
ASC11-45 3,4-OCI-11  4-OH 8.7 - 
469  49.9 - 
Table 4.18: Comparison of assay results obtained from the CDK2/E assay. Figures in 
red represent % inhibition at 25 1iM; figures in blue represent % inhibition at 10 p.M. 
The comparison of three sets of pyrimidines is worthy of further discussion. Pyrimidine 
ASCII-85 was shown to be an extremely potent inhibitor of CDK2/E with an 1050 of 1.5 
nM. Disappointingly, this activity was not reflected in the analogous 4,6-disubstituted 
pyrimidine series, with ligand 462 exhibiting neglible inhibition of CDK2/E at 10 p.M. 
Furthermore, the poor activity of ligand 462 is difficult to justify when compared with 
the potency of ligand 461 shown in Table 4.14. Repetition of the primary screen of 
ligand 462 is therefore desirable. Pyrimidine 429, exhibiting a meta-hydroxy group on 
both the 4-aryl and 6-an ilino aromatic rings, was shown to be very potent against the 
CDK2/cyclin E complex at 25 p.M and compared favourably with the percentage 
inhibition of CDK2/cyclin E complex measured for the 2,4-di substituted pyrimidine 
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analogue. However, secondary screening data received for pyrimidine 429 revealed it 
was 20-fold less potent than the pyrimidine ASCII-19, again highlighting the danger in 
overinterpretation of data from the primary screen. Intriguingly, the ligand 469 was 
shown to be more potent than the corresponding 2,4-d i substituted analogue, ASCII -45, 
although its activity in the primary screen was below the threshold for full 1050 
determination. 
In the absence of crystal structures of a ligand from both the 4-aryl-6-anilino- and 2-
anilino-4-aryl- pyrimidine series bound to CDK2 it is difficult to justify the significant 
difference in potency shown in Table 4.17 of these two series of ligands. However, it is 
likely that the 6-anilino ring system is unable to adopt a similar conformation to those 
ring systems in the analogous 2-anilino substituted series owing to unfavourable steric 
interactions between the pyrimidyl C-S proton and a proton at the ortho-position on the 
anilino ring, as illustrated in Figure 4.4. This issue could be investigated further by either 
the synthesis of a series of 2,4-disubstituted triazines, or by replacement of the 6-anilino 
moiety in the 4,6-di substituted pyrimidine series with either a functionalised 2-amino 
pyridine or 2-amino-pyrimidine. Indeed, primary screening data presented in Table 4.16 
for ligands 463 and 467 shows that replacement of the 6-anilino moiety with 2-
aminopyridine resulted in an increase in inhibition of CDK2/E and CDK9/T1 at a ligand 
concentration of 25 jiM. Clearly, however, replacement of the anilino moiety requires 
further investigation before firm conclusions can be drawn. It is also worthy of note that 
the co-planarity of the anilino and pyrimidyl ring systems feature in the majority of 
crystal structures reported of 2-anilino-4-(thiazol-5-yl)-pyrimidines bound to CDK2 
(PDB Codes 1PXL, 1PXM, 1PXP), with the crystal structure of the CDK2/ligand 363 









Y= N, X = C, N 
Figure 4.4: Possible explanation for decrease in ligand potency against CDK2 when 
moving from 2-anilino-4-aryl- to 6-anilino-4-aryl- substituted pyrimidines. 
4.5 	Future work 
Unfortunately, time constraints did not allow further work on the 4-aryl-6-anilino-
pyrimidine series. However, given that the synthetic route to these ligands has now been 
established, it would be desirable to prepare further analogues of the 2-anilino-4-aryl-
pyrimidine series that have been shown to be potent inhibitors of the CDK2/cyclin E 
complex, namely containing either a 3-nitro-, 3-hydroxy-, 3-hydroxymethyl- or 4-
hydroxy- substituent on the anilino-ring system and either a 3-hydroxy- or 3-nitro-
substituent on the aryl ring. Furthermore, the resolution of crystal structures of ligands 
from both these series bound to CDK2 should provide an explanation of the marked 
difference in inhibitory activity seen between them. 
It would also be worthwhile to investigate other ring systems that could replace the 
central pyrimidine scaffold whilst retaining activity. The synthesis of a series of 2-
anilino-4-aryl-pyridine analogues would be worthy of merit, as it is expected that the 
hydrogen bond donor-acceptor pair between Leu83 and the anilino nitrogen and N-i of 
the pyridyl ring would be conserved. Furthermore, if the decrease in potency of the 4,6-
disubstituted series compared to the 2,4-disubstituted pyrimidine series is attributable to 
the inability of the ligand to bind in the ATP-binding pocket in a co-planar 
conformation, this could be addressed by the synthesis of a series of 2-anilino-4-aryl-
triazines. It is envisaged that 2,4-dichloro-1,3,5-triazine 521, which can be synthesised 
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from N-cyanochloroformamidine 519 and the chioromethyleniminium salt 520, 
generated in situ from the reaction between phosphoryl chloride and N,N-
dimethylformamide, following protocol reported by Harris (Scheme 4.1 2),203  could 








N NH2 	 I Ci 	 N CI 
69% 
	
519 	 520 	 521 
Scheme 4.12: Reagents and conditions: a) DCM, room temperature, 18 h. 
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5 	Experimental procedures 
5.1 	General techniques 
5.1.1 Instrumentation and basis of characterization of compounds 
All microwave irradiation experiments were carried out using the Discover and Explorer 
systems from CEM Corporation, Buckingham, UK including Chemdriver software 
(versions 2.22 - 3.6). The reactions were performed in heavy-walled Pyrex tubes (10 ml, 
length = 150 mm) sealed with a septum utilizing the standard absorbance level (300 W 
maximum power). 'H and '3C NMR spectra were recorded on Brüker ARX250, DPX-
360, ARX-500, Varian Inova-300 or Varian Gemini-200 instruments. The following 
abbreviations are used: 6, chemical shift; d, doublet; dd, doublet of doublets; dt, doublet 
of triplets; dq, doublet of quartets; J, coupling constant; m, multiplet; q, quartet; s, 
singlet; t, triplet. Chemical shifts (6) are reported in parts per million (ppm) and 
coupling constants (J) in Hz. Residual protic solvent, CHCI3 (6H  7.27, s), CH30H (6H 
3.3 5, s) or (CH3)2S0 (6,-, 2.52, m), was used as the internal standard in 'H NMR spectra, 
and 13C NMR shifts at either 63 or 75 MHz were referenced using CHC13 (6c  77.0, t), 
CH30H (6c  49.0, m) or (CI-13)2S0 (6c 39.7, m) with broad band decoupling. 
Electrospray (ES) nominal mass spectra were recorded using a Micromass Platform II 
mass spectrometer. Fast Atom Bombardment (FAB) high resolution mass spectra were 
recorded on a Kratos MS50TC instrument. Infra-red absorption spectroscopy was 
performed on a Jasco FT-IR 450 plus spectrometer, and Vmax values are quoted in cm-1 . 
All experiments detailed in this chapter were undertaken using a combinatorial, high-
throughput approach with the aim of providing novel ligands for biological screening. 
The adoption this approach, and time constraints imposed, rendered it imprudent to 
obtain full characterization of all compounds and, therefore, where possible, a 
representative proportion of each library has been fully characterized (in excess of 10%). 
172 
Chapter 5 	 - 	 Ex-perunenia! Procedures 
5.1.2 Chromatography 
Analytical TLC was carried out on Merck aluminium-backed plates coated with silica 
gel 60 F254, 0.25 mm. Components were visualised using quenching of ultra-violet 
fluorescence (254 nm), and ammonium molybdate or permanganate dips. Flash 
chromatography was carried out using silica gel 60H (Merck 9385, 0.04-0.063 mm, 230-
400 mesh). 
All HPLC purifications were performed on the Parallex F1exTM purification system 
manufactured by Biotage. This system detects at 254 and 280 nm. The column used was 
a Supercosil ABZ+Plus reverse-phase column, of dimension 25cm x 21.2 mm, particle 
size12 xM. The flow rate used for each method was 20 ml min', unless otherwise 
specified. Methods used are shown in Tables 5.1 - 5.17, with solvents A and B being 
water and acetonitrile respectively. 
Starting A% Ending A % Starting B% Ending B% Duration /min  
90 90 10 10 2 
90 90 10 10 0.5 
90 90 10 10 2 
90 30 10 70 15 
30 5 70 95 2 
5 5 95 95 3 
5 90 95 10 2 
Table 5.1: HPLC Method A 
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Starting A% Ending A % Starting B% Ending B% Duration /min  
90 90 10 10 2 
90 90 10 10 0.5 
90 90 10 10 2 
90 10 10 90 20 
10 5 90 95 1 
5 5 95 95 3 
5 90 95 10 2 
Table 5.2: HPLC Method B 
Starting A% Ending A % Starting B% Ending B% Duration /min  
65 65 35 35 2 
65 65 35 35 0.5 
65 65 35 35 2 
65 35 35 65 20 
35 5 65 95 2 
5 5 95 95 3 
5 65 95 35 2 
Table 5.3: HPLC Method C 
Starting A% Ending A % Starting B% Ending B% Duration /min  
90 90 10 10 2 
90 90 10 10 0.5 
90 90 10 10 2 
90 45 10 55 18 
45 5 55 95 2 
5 5 95 95 3 
5 90 95 10 2 
Table 5.4: HPLC Method D 
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Starting A% Ending A % Starting B% Ending B% Duration /min  
90 90 10 10 2 
90 90 10 10 0.5 
90 90 10 10 2 
90 45 10 55 24 
45 5 55 95 2 
5 5 95 95 3 
5 90 95 10 2 
Table 5.5: HPLC Method E 
Starting A% Ending A % Starting B% Ending B% Duration /min  
90 90 10 10 2 
90 90 10 10 0.5 
90 90 10 10 2 
90 20 10 80 20 
20 5 80 95 2 
5 5 95 95 3 
5 90 95 10 2 
Table 5.6: HPLC Method F 
Starting A% Ending A % Starting B% Ending B% Duration /min  
85 85 15 15 2 
85 85 15 15 0.5 
85 85 15 15 2 
85 35 15 65 27 
35 5 65 95 2 
5 5 95 95 3 
5 85 95 15 2 
Table 5.7: HPLC Method G 
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Starting A% Ending A % Starting B% Ending B% Duration /min  
85 85 15 15 4 
85 85 15 15 1 
85 85 15 15 4 
85 35 15 65 40 
35 5 65 95 4 
5 5 95 95 6 
5 85 95 15 4 
Table 5.8: HPLC Method H, Flow rate 10 ml min- . 
Starting A% Ending A % Starting B% Ending B% Duration /min  
85 85 15 15 2 
85 85 15 15 0.5 
85 85 15 15 2 
85 35 15 65 17 
35 5 65 95 2 
5 5 95 95 3 
5 85 95 15 2 
Table 5.9: HPLC Method I 
Starting A% Ending A % Starting B% Ending B% Duration /min  
65 65 35 35 2 
65 65 35 35 0.5 
65 65 35 35 2 
65 35 35 65 15 
35 5 65 95 2 
5 5 95 95 3 
5 65 95 35 2 
Table 5.10: HPLC Method J 
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Starting A% Ending A % Starting B% Ending B% Duration /min  
65 65 35 35 2 
65 65 35 35 0.5 
65 65 35 35 2 
65 35 35 65 15 
35 5 65 95 2 
5 5 95 95 3 
5 65 95 35 2 
Table 5.11: HPLC Method K 
Starting A% Ending A % Starting B% Ending B% Duration /min  
65 65 35 35 2 
65 65 35 35 0.5 
65 65 35 35 2 
65 35 35 65 15 
35 5 65 95 2 
5 5 95 95 3 
5 65 95 35 2 
Table 5.12: HPLC Method L 
Starting A% Ending A % Starting B% Ending B% Duration /min  
95 95 5 5 2 
95 95 5 5 0.5 
95 95 5 5 2 
95 65 5 35 27 
65 5 35 95 2 
5 5 95 95 3 
5 95 95 5 2 
Table 5.13: HPLC Method M 
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Starting A% Ending A % Starting B% Ending B% Duration /min  
95 95 5 5 4 
95 95 5 5 1 
95 95 5 5 4 
95 35 5 65 40 
35 5 65 95 4 
5 5 95 95 6 
5 95 95 5 4 
Table 5.14: HPLC Method N, Flow rate 10 ml min 1 . 
Starting A% Ending A % Starting B% Ending B% Duration /min  
70 70 30 30 2 
70 70 30 30 0.5 
70 70 30 30 2 
70 10 30 90 15 
10 5 90 95 1 
5 5 95 95 3 
5 90 95 10 2 
Table 5.15: HPLC Method P 
Starting A% Ending A % Starting B% Ending B% Duration /min  
70 70 30 30 2 
70 70 30 30 0.5 
70 40 30 60 15 
40 5 60 95 15 
98 5 2 95 2 
5 70 95 30 2 
Table 5.16: HPLC Method Q 
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Starting A% Ending A % Starting B% Ending B% Duration /min  
95 95 5 5 2 
95 95 5 5 0.5 
95 5 5 95 10 
5 5 95 95 3 
5 95 95 5 1 
95 95 5 5 I 
Table 5.17: HPLC Method R 
Starting A% Ending A % Starting B% Ending B% Duration /min  
90 90 10 10 2 
90 90 10 10 0.5 
90 75 10 25 1 
75 65 25 35 15 
65 5 35 95 2 
5 5 95 95 3 
5 90 95 10 2 
Table 5.18: HPLC Method S 
5.1.3 Solvents and reagents 
All reagents and solvents were standard laboratory grade and were used as supplied 
unless otherwise stated. DMF refers to peptide synthesis grade. 
5.2 	Assay protocol 
5.2.1 Fluorescence polarisation assay 1 
A fluorescence polarisation competitive binding assay was carried out by Cyclacel Ltd. 
using a 96-well microtiter plate (Costar) format. Recombinant Hdm2 (1.5 tg per well) in 
TBS-BSA buffer (50 mM Tris pH 7.4, 150 mM NaCl, and 0.1 % BSA) was incubated 
for 5 minutes at room temperature in the presence of serially diluted test compound (in 
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TBS-BSA buffer with a final concentration of 5 % DMSO). Fluorescently labelled 12/I-
peptide (fluoresceinMetProArgPhe-Met-Asp-Tyr-Trp-GlU-GlY-LeUA5n-NH2, 0.2 
tM) was added to each well and the plate was incubated at room temperature for 45 
minutes. The fluorescence polarisation (excitation 485 nm, emission 520 nm) of the 
peptide was measured. IC50  values were calculated from dose-response curves. 
5.2.2 Fluorescence polarisation assay 2 
The protocol as detailed for Fluoresence Polarisation Assay I was followed, although 
the quantity of Hdm2 used per reaction was reduced from 1.5 jg to 20 ng. 
5.2.3 CDK2/Cyclin E Assay 
The CDK2/E kinase assay was performed by Cyclace! Ltd. with a 96-well plate format 
with recombinant CDKIcyclin complexes (His6-tagged recombinant human 
CDK2/cyclin E was expressed in sf9 cells with a baculovirus expression system, 
proteins were purified by metal chelate affinity chromatography to> 90% homogeneity). 
The assay buffers consisted of 25 mM f3-glycerophosphate, 20 mM MOPS, 5 mM 
EGTA, 1 mM DTT, and 1 mM Na3 V03  (pH 7.4) into which were added 2-4 ig of active 
enzyme with purified histone HI. Inhibitors were made up in 10% aq. DMSO, and 10 
pL of the solutions was added to the wells. Final reaction volume was 50 pL. The 
reaction was initiated by addition of Mg/ATP mix (15 mM MgC12, plus 100 PM ATP 
with 30-50 kBq per well of [y-32P]-ATP), and the mixtures were incubated for 10 min at 
30 °C. Reactions were stopped on ice, and then the mixtures were filtered through p81 
filterplates. After washing three times with 75 mM aq. orthophosphoric acid, plates were 
dried, scintillant (Microscint 40) was added, and incorporated radioactivity was 
measured with a scintillation counter (TopCount; Packard Instruments, Pangbourne, 
Berks., UK). Data was analysed with curve fitting software (GraphPad Prism version 
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3.00 for Windows; GraphPad Software, San Diego, CA) to determine 1050 values 
(concentration of test compound that inhibits kinase activity by 50%). 
5.2.4 CDK9/T1 and GSK3I3 assays 
The CDK9/Ti kinase assay was performed by Cyclacel Ltd. Peptide substrate (biotiny!-
Ahx-(Tyr-Ser-Pro-Thr-Ser-Pro-Ser)4-NH2; I - 2 mg/mL) and recombinant human 
CDK9/cyclin Ti (0.5 - 2 pjg) were incubated at 45 min at 30 °C in the presence of 
varying amounts of test compound in 20 mM MOPS pH 7.2, 25 mM - 
glycerophosphate, 5 mM EGTA, 1 mM DTT, 1 mM Na3VO3, 15 mM MgCl2, and 100 
j.tM ATP (containing a trace amount of [y-32P]-ATP in a total volume of 25 tL in a 96-
well microtitre plate. The reaction was stopped by placing the plate on ice for 2 mm. 
Avidin (50 jtg) was added to each well, and the plate was incubated at room temperature 
for 30 mm. The samples were transferred to a 96-well p81 filterplate and washed (4x 
200 tL per well) with 75 mM phosphoric acid. Microscint 40 scintillation liquid (50 tL) 
was added to each well, and the amount of 32P incorporation for each sample was 
measured using a Packard TopCount microplate scintillation counter. 1050 values were 
calculated from dose response curves (GraphPad Prism curve-fitting software). The 
GSK3I3 assay was carried out by Upstate Discovery, Dundee, UK, essentially as 
described .204  The ATP concentration used in the GSK3I3 assay was 10 tM. 
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5.3 General methods 
5.3.1 General procedure Si 
To a stirring solution of tributyiphosphine (1.5 eq.), the alcohol (1.0 eq.) and the 
sulfonamide (1.5 eq.) in anhydrous benzene (3 mL), at 0°C, TMAD (1.5 eq.) was added. 
The reaction was performed under an atmosphere of nitrogen. After 10 minutes the 
reaction mixture was allowed to warm to room temperature and stirred for a further 24 
hours before being filtered and washed with hexane. The organic filtrate was 
concentrated in vacuo to afford a residue which was columned on silica (hexane: ethyl 
acetate 4:1). Appropriate fractions were combined and concentrated in vacuo to afford 
the title sulfonamide. 
5.3.2 General procedure S2 
To a stirring solution of the sulfonamide (1.0 eq.) in acetone (3.0 mL) was added the 
alkyl halide (5.0 eq.) followed by triethylamine (excess). The reaction mixture was 
irradiated in the DiscoverTM at 70 °C for 10 minutes, with active cooling of the sample. 
The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (2 
x 20 mL). The combined organics were washed with water (2 x 20 mL) before being 
concentrated in vacuo to afford a residue that was columned on silica. Appropriate 
fractions were combined and concentrated in vacuo to afford the title sulfonamide. 
5.3.3 General procedure Al 
To a solution of the aniline (1.0 eq.) in DCM (2.0 mL) was added the acid chloride (1.1 
eq.). The reaction mixture was irradiated in the Discover 
TM  at 110 °C for 5 minutes, with 
active cooling of the sample. The reaction mixture was concentrated in vacuo, and the 
residue diluted with ethyl acetate (10 mL) and washed with water (2 x 10 mL). The 
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organics were dried over anhydrous Na2SO4, filtered and concentrated in vacuo to afford 
the title amide that required no further purification. 
5.3.4 General procedure A2 
The acid chloride (1.2 eq.), amine (1.0 eq.) and morpholinomethyl-polystyrene resin 
(0.200 g, 3.7 mmole g') in anhydrous DCM (2.0 mL) were stirred at room temperature 
for 48 hours before the addition of tris(aminoethyl)amine polystyrene resin (0.400 g, 4.4 
mmole g 1). The reaction mixture was allowed to stir at room temperature for a further 5 
hours before being filtered and the resin washed with DCM (2 x 5.0 mL). The filtrate 
was concentrated in vacuo to afford the title amide that required no further purification. 
5.3.5 General procedure P1 
To a solution of 4,6-dichioropyrimidine (0.600 g, 4.00 mmole, 1.0 eq.) in acetonitrile (3 
mL) was added 3-nitrophenyl boronic acid (0.673 g, 4.00 mmole, 1.0 eq.), Cs2CO3  
(3.940 g, 12.00 mmole, 3.0 eq.), Pd(OAc)2 (0.045 g, 0.20 mmole, 0.05 eq.) and 
triphenylphosphine (0.106 g, 0.40 mmole, 0.10 eq.). Water (0.3 mL) was added to 
solubilize the Cs2CO3. The reaction mixture was irradiated in the DiscoverTM  at 110 °C 
for 15 minutes, with active cooling of the sample, before being divided into aliquots (3 x 
I mL). To one aliquot containing the Suzuki intermediate (1 mL, 1.30 mmole, 1.0 eq.) 
was added the aniline (1.30 mmole, 1.0 eq.) and HC1 (2M, 2.6 mL, 4.0 eq.). The sample 
was irradiated on the Discover TM  at 110 °C for 5 minutes, with active cooing. An aliquot 
(1 mL) of the reaction mixture was injected directly onto the Biotage Parallex FIexTM 
HPLC. Appropriate fractions were combined and concentrated in vacuo to afford the 
title pyrimidine. 
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5.3.6 General procedure P2 
To a solution of 4,6-dichloropyrimidine (0.100 g, 0.67 mmole, 1.0 eq.) in acetonitrile (3 
mL) was added the boronic acid (0.67 mmole, 1.0 eq.), Cs2CO3 (0.328 g, 1.00 mmole, 
1.5 eq.), Pd(OAc)2 (0.008 g, 0.05 eq.) and triphenylphosphine (0.018 g, 0.07 mmole, 
0.10 eq.). Water (0.5 mL) was added to solubilize the Cs2CO3. The reaction mixture was 
irradiated in the Discover TM  at 130 °C for 15 minutes, with active cooling of the sample, 
before the addition of the aniline (0.67 mmole, 1.0 eq.) and HC1 (2M, 1.3 mL, 4.0 eq.). 
The reaction mixture was irradiated on the Discover TM  at 110 °C for 5 minutes, with 
active cooling of the sample. Subsequently, an aliquot (1 mL) of the organic solvent was 
injected directly into the Biotage Parallex Flex  TM HPLC. Appropriate fractions were 
combined and concentrated in vacuo to afford the title compound. 
5.3.7 General procedure P3 
To a solution of 4,6-dichloropyrimidine (0.100 g, 0.67 mmole, 1.0 eq.) in acetonitrile 
(3.0 mL) was added the boronic acid (0.67 mmole, 1.0 eq.), Cs2CO3 (0.328 g, 1.00 
mmole, 1.5 eq.), Pd(OAc)2 (0.008 g, 0.03 mmole, 0.05 eq.) and triphenyiphosphine 
(0.018 g, 0.07 mmole, 0.10 eq.). Water (0.3 mL) was added to the reaction mixture to 
solubilise the Cs2CO3. The reaction mixture was irradiated in the DiscoverTM  at 130 °C 
for 15 minutes, with active cooling of the sample, before the addition of the aniline (0.67 
mmole, 1.0 eq.) and HC1 (2M, 1.3 mL, 4.0 eq.). The reaction mixture was irradiated in 
the DiscoverTM  at 110 °C for 5 minutes, with active cooling of the sample. Subsequently, 
the reaction mixture was divided into aliquots (3 x I mL) and injected directly into the 
Biotage Parallex Flex TM  HPLC. Appropriate fractions were combined and concentrated 
in vacuo to afford the title compound. 
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5.3.8 General procedure P4 
To a solution of the 4,6-dichloropyrimidine (0.50 mmole, 1.0 eq.) in THF (3.0 mL) was 
added the boronic acid (0.50 mmole, 1.0 eq.), Cs2CO3 (0.197 g, 0.60 mmole, 1.2 eq.), 
triphenylphosphine (0.013 g, 0.05 mmole, 0.1 eq.) and Pd(OAc)2  (0.06 g, 0.05 mmole, 
0.05 eq.). Water (0.3 mL) was added to the reaction mixture to dissolve the Cs2CO3. The 
reaction mixture was irradiated in the DiscoverTM at 110 °C for 25 minutes, with active 
cooling of the sample. The reaction mixture was separated into aliquots (3 x I mL) and 
to one aliquot was added the aniline (0.17 mmole, 1.0 eq.) and HCI (4M, 85 j.xL, 2.0 eq.). 
The reaction mixture was irradiated in the Discover 1M at 110 °C for a further 25 minutes, 
with active cooling of the sample, before being injected directly onto the Biotage 
Parallex Flex TM HPLC. Appropriate fractions were combined and concentrated in vacuo 
to afford the title compound. 
5.3.9 General procedure P5 
To a solution of the 4,6-dichloropyrimidine (1.68 mmole, 1.0 eq.) in THF (5 mL) was 
added Cs2CO3 (0.660 g, 2.50 mmole, 1.5 eq.), Pd(OAc)2 (0.020 g, 0.08 mmole, 0.05 
eq.), triphenylphosphine (0.044 g, 0.17 mmole, 0.10 eq.) and the boronic acid (1.68 
mmole, 1.0 eq.). The reaction mixture was irradiated in the DiscoverTM at 110 °C for 25 
minutes, with active cooling of the sample, before being apportioned into aliquots (10 x 
0.5 mL). To one aliquot containing the Suzuki intermediate (0.5 mL, 0.17 mmole, 1.0 
eq.) was added the aniline (0.17 mmole, 1.0 eq.), HC1 (4M, 163 iL, 4.0 eq.) and THF 
(0.5 mL). The reaction mixture was irradiated in the Discover TM at 110 °C for 25 
minutes, with active cooling of the sample, before being injected directly onto the 
Biotage Parallex Flex TM.  Appropriate fractions were combined and concentrated in 
vacuo to afford the title compound. 
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5.3.10 General procedure Li 
Reagent No. Moles Volume Solvent 
Dispensed Dispensed 
(mmol) (mL) 
Aniline 0.162 1.00 Pyridine 











Experimental conditions for library Li 
Stock solutions with concentration 0.162 M of each of the six anilines were 
prepared and loaded onto the reagent rack of the Bodhan Neptune 
TM MB 
Automated Workstation. 
Stock solutions with concentration 0.147 M of each of the two sulfonyl chlorides 
were prepared and loaded onto the reagent rack of the Neptune. 
Each sulfonyl chloride solution (1.0 mL) was dispensed to a horizontal line of 6 
reaction tubes on a single MiniB lockTM. 
Each aniline solution (1.0 mL) was dispensed to a vertical line of 2 reaction tubes 
on a MiniBlockTM, each tube containing either of the sulfonyl chlorides dispensed 
in Step 3. 
The MiniBlockTM  was covered and shaken on the MiniBlockTM  High Capacity 
Shaking and Washing Station overnight. 
6. 	The MiniBlockTM  was transferred to the A11
exTM Liquid/Liquid Extractor and each 
reaction mixture transferred to a boiling tube. 
The AllexTm  was used to dispense HCI (IM, 3 mL) into each boiling tube, 
followed by a mixture of ethyl acetate/ diethyl ether (1:1, 3 mL). The contents of 
each boiling tube were aspirated, and each organic layer extracted and transferred 
to a second boiling tube. 
The AllexTM was used to dispense a saturated solution of brine (3 mL) to each 
boiling tube, and, after washing, the organics were transferred to a 48-well 
microtitre plate. 
The 48-well plate containing the 12 samples were concentrated under reduced 
pressure using the Christ ALPHA-2-4 Freeze Dryer, BETA-RVC Ceramic 
Vacuum Measurement System (3 h, 25 °C, 20 mbar). 
Samples 46 and 47 were used as test samples for mass directed purification on the 
ZMD 4000. Unfortunately, the molecular ions of the sulfonamides 46 and 47 were 
not detected and consequently, despite further attempts to identify 46 and 47 by 
electrospray mass spectrometry, it was decided to undertake further purifications 
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5.3.11 General procedure L2 
Reagent No. Moles Volume Solvent 
Dispensed Dispensed 
(mmol) (mL) 
Aniline 0.220 1.00 Pyridine 






















Stock solutions with concentration 0.220 M of each of the 8 anilines were prepared 
and loaded onto the reagent rack of the Bodhan Neptune TM MB Automated 
Workstation. 
Stock solutions with concentration 0.200 M of each of the 6 sulfonyl chlorides 
were prepared and loaded onto the reagent rack of the Neptune. 
Each sulfonyl chloride solution (1.0 mL) was dispensed to a horizontal line of 8 
reaction tubes on a single MiniBlockTM. 
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Each aniline solution (1.0 mL) was dispensed to a vertical line of 6 reaction tubes 
on a MiniBlockTM, each tube containing one of the sulfonyl chlorides dispensed in 
Step 3. 
The MiniBlockTM was covered and shaken on the MiniBlockTM  High Capacity 
Shaking and Washing Station overnight. 
The MiniBlocklM  was transferred to the A11exTM  Liquid/Liquid Extractor and each 
reaction mixture transferred to a boiling tube. 
The AIIexTM  was used to dispense HC1 (1 M, 3mL) into each boiling tube, followed 
by a mixture of ethyl acetate/ diethyl ether (1:1, 3 mL). The contents of each 
boiling tube were aspirated, and each organic layer extracted and transferred to a 
second boiling tube. 
The A1IexTM  was used to dispense a saturated solution of brine (3 mL) to each 
boiling tube, and, after washing, the organics were transferred to a 48-well 
microtitre plate. 
The 48 samples were concentrated in vacuo using the Christ ALPHA-2-4 Freeze 
Dryer, BETA-RVC Ceramic Vacuum Measurement System (3 h, 25 °C, 20 mbar). 
Samples 90 - 105 were used as test samples for mass directed purification on the 
ZMD 4000. Unfortunately, the molecular ions of the sulfonamides 90 - 105 were 
not detected and the majority of the samples were transferred to waste. Where 
some crude mixture had been recovered, and for subsequent samples 58 - 89, the 
sample was dissolved in methanol (1 mL) and injected directly onto the Biotage 
Parallex FlexTM  14PLC (Method R). 
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5.3.12 General procedure L2b 
Reagent No. Moles Volume Solvent 
Dispensed Dispensed 
(mmol) (mL) 
Aniline 0.220 1.00 Pyridine 














Experimental conditions for sulfonamide library L2b 
The General procedure outlined for Sulfonamide Library L2 was followed. 
Prior to transferring the crude reaction mixtures to the AllexTM,  the contents of the 
MiniBlockTM were drained into a 48-well microtitre plate and concentrated in 
vacuo on the Christ ALPHA-2-4 Freeze Dryer, BETA-RVC Ceramic Vacuum 
Measurement System (3 h, 25 °C, 20 mbar), in order to remove the excess pyridine 
from the crude mixtures. 
Using the A11exTM, each sample contained in the 48-well plate was diluted with 
ethyl acetate (3 mL) and transferred to a boiling tube. 
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The A11exTM was used to dispense HC1 (IM, 3mL) into each boiling tube, the 
contents of each boiling tube aspirated, and each organic layer extracted and 
transferred to a second boiling tube. 
The A1IexTM was used to dispense a saturated solution of brine (2 mL) to each 
boiling tube, and, after washing, the organics were transferred to a 48-well 
microtitre plate. 
The 16 samples were concentrated in vacuo using the Christ ALPHA-2-4 Freeze 
Dryer, BETA-RVC Ceramic Vacuum Measurement System (3 h, 25 °C, 20 mbar). 
Each sample was purified on silica (hexane: ethyl acetate, 1:1) and appropriate 
fractions combined and concentrated in vacuo to afford the sulfonamide. 
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5.3.13 General procedure L3 
Reagent No. Moles Volume Solvent 
Dispensed Dispensed 
(mmol) (mL) 
Aniline 0.220 1.00 Pyridine 
Sulfonyl Chloride 0.200 .00 Pyridine 
Aniline 











Experimental conditions for library L3 
The General procedure outlined for the resynthesis of Sulfonamide Library L2 was 
followed. 
Each sample was purified on silica (hexane: ethyl acetate, 1:1) and appropriate 
fractions combined and concentrated in vacuo to afford the title sulfonamide. 
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5.3.14 General procedure L4 







Aniline 0.440 1.00 DCM 
Sulfonyl Chloride 0.400 1.00 DCM 




(1 R)- 1 -(4-Chloropheny!)ethanamine 




















Experimental conditions for library L4 
1. 	Stock solutions with concentration 0.440 M of each of the 8 anilines were prepared 
and loaded onto the reagent rack of the Bodhan Neptune 
TM  MB Automated 
Workstation. 
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Stock solutions with concentration 0.400 M of each of the 6 sulfonyl chlorides 
were prepared and loaded onto the reagent rack of the Neptune. 
Stock solutions (2 x 14 mL) with concentration 0.400 M of pyridine were prepared 
and loaded onto the reagent rack of the Neptune. 
Each sulfonyl chloride solution (1 mL) was dispensed to a horizontal line of 8 
reaction tubes on a single MiniBlockTM. 
Each aniline solution (1 mL) was dispensed to a vertical line of 6 reaction tubes on 
a MiniBlockTM, each tube containing one of the sulfonyl chlorides dispensed in 
Step 3. 
Pyridine (0.400 M, 1 mL) was dispensed to each of the 48 reaction tubes on a 
MiniblockTM.  
The MiniBlockTM was covered and shaken on the MiniBlockTM High Capacity 
Shaking and Washing Station overnight. 
The MiniBlockTM was transferred to the AllexTM Liquid/Liquid Extractor and each 
reaction mixture transferred to a boiling tube. 
The AllexTM  was used to dispense HC1 (1M, 3 mL) into each boiling tube, 
followed by a mixture of ethyl acetate/ diethyl ether (1:1, 3 mL). The contents of 
each boiling tube were aspirated, and each organic layer extracted and transferred 
to a second boiling tube. 
The AllexTm  was used to dispense a saturated solution of brine (3 mL) to each 
boiling tube, and, after washing, the organics were transferred to a 48-well 
microtitre plate. 
The 48 samples were concentrated in vacuo using the Christ ALPHA-2-4 Freeze 
Dryer, BETA-RVC Ceramic Vacuum Measurement System (3 h, 25 °C, 20 mbar). 
Each sample was purified on silica (hexane: ethyl acetate, 2:1) and appropriate 
fractions combined and concentrated in vacuo to afford the title sulfonamide. 
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5.4 Experimental for Chapter 2 
N-Phenylthiophene-2-sulfonamide (26)205 







To a solution of aniline (5.36 mL, 58.9 mmole, 2.15 eq.) in methanol (45 mL), 
thiophene-2-sulfonyl chloride (5.0 g, 27.3 mmole, 1.00 eq.) was added and the reaction 
mixture allowed to stir overnight at room temperature, before being concentrated in 
vacuo to afford a brown residue which was washed with NaOH (40%) and extracted 
with ethyl acetate. The combined organic extracts were dried over anhydrous potassium 
carbonate and concentrated in vacuo. The residue was columned on silica (hexane: ethyl 
acetate 4:1, Rf  0.15) to afford sulfonamide 26 as a cream solid (4.907 g, 75%); LRMS 
EI1 m/z 239 (M); HRMS E[1 m/z 239.00747 (M) (calculated for C10H9NO2S2, 
239.00747 (Dev - 0.02 ppm)); Vmax (film)/cm' 3204 (N-H), 3104 (thiophene C-H), 3090 
(aryl C-H), 1596 (aryl C=C), 1332 (SO2), 1150 (SO2); 6H  (250 MHz, CDC13): 6.48 - 
6.55 (m, 1H, H9), 6.84— 6.98 (m, 5H, An]), 7.21 (d, 1H, J = 3.5 Hz, H8), 7.45 (d, IH, J 
= 4.9 Hz, H10), 8c (63 MHz, (CD3)2SO): 117.6 (CHAr), 121.7 (2 X CHAr), 127.0 (CHAr), 
127.9 (CHAr), 128.2 (CHAr), 128.8 (2 x CH Ar), 150.5 (C&r), 151.4 (CAr); Mpt. 99.5-100.0 
°C (Lit. 100°C). 
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NMethylNphenylthiophene-2-SUlfOflamide (27)206 
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General procedure Si was followed using tributylphosphine (0.18 mL, 0.72 mmole, 1.5 
eq.), methanol (19.4 jiL, 0.48 mmole, 1.0 eq.), N-phenylthiophene-2-sulfonamide (0.172 
g, 0.72 mmole, 1.5 eq.) and TMAD (0.124 g, 0.72 mmole, 1.5 eq.). Sulfonamide 27 was 
isolated as a white solid (0.036 g, 30%, Rf  0.20 (hexane: ethyl acetate, 4:1)); LRMS EI 
m/z 253 (M); HRMS EI m/z 253.02359 (M) (calculated for C11H11NO2S2, 253.023 12 
(Dev. 1.83 PPM)); Vmax (film)/cm-1  3105 (thiophene C-H), 3096 (aryl C-H), 2926 (C-H), 
1593 (aryl C=C), 1352 (SO2), 1152 (SO2); oH (200 MHz, CDCI3): 3.28 (s, 3H, H7), 7.09 
- 7.19 (m, 3H, ArH), 7.28 - 7.40 (m, 4H, ArH), 7.60 (d, 1H, J = 5.0 Hz, HI I); Oc  (63 
MHz, CDC13): 38.7 (0), 127.1 (2 X CHAr), 127.7 (CHAr), 128.0 (CHAr), 129.4 (2 X 
CHAr), 132.5 (CHAr), 133.1 (CHAr), 137.1 (CA,  141.6 (CAr); Mpt. 96.1 -96.9 °C. 
NEthylN-phenylthiophene-2-SU1fOflamide (28) 







General procedure Si was followed using tributyiphosphine (0.19 mL, 0.74 mmole, 1.5 
eq.), ethanol (28.9 L, 0.49 mmole, 1.0 eq.), N-phenylthiophene-2-sulfonamide (0.178 
g, 0.74 mmole, 1.5 eq.) and TMAD (0.128 g, 0.74 mmole, 1.5 eq.). Sulfonamide 28 was 
isolated as a white solid (0.018 g, 14%, Rf  0.23 (hexane: ethyl acetate, 4:1)); LRMS EI 
m/z 267 (M); HRMS EI m/z 267.03848 (M)+  (calculated for C12H13NO2S2, 267.03877 
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(Dev. - 1. 11 ppm)); Vmax (film)Icm' 3096 (thiophene C-H), 3086 (aryl C-H), 2965 (C-
H), 1599 (aryl C=C), 1344 (SO2), 1154 (SO2); 6H (200 MHz, CDC13): 1.17 (t, 3H, J = 
7.0 Hz, H8), 3.73 (q, 2H, J = 7.0 Hz, H7), 7.04 - 7.20 (m, 2H, H10, Hi 1), 7.23 - 7.39 
(m, 5H, Ark!), 7.63 (d, 1H, J = 5.1 Hz, H12); Mpt. 98.6— 99.7 °C. 
NButylNphenylthiophene-2-SUhfOflam1t1e (29) 
General procedure Si was followed using tributyiphosphine (0.18 mL, 0.72 mmole, 1.5 
eq.), butanol (43.5 tL, 0.48 mmole, 1.0 eq.), N-phenylthiophene-2-sulfonamide (0.171 
g, 0.72 mmole, 1.5 eq.) and TMAD (0.124 g, 0.72 mmole, 1.5 eq.). The reaction was 
carried out at room temperature. Sulfonamide 29 was isolated as a white solid (0.030 g, 
21%, Rf  0.23 (hexane: ethyl acetate, 4:1)); LRMS EI m/z 295 (M); HRMS EI m/z 
295.06978 (M) (calculated for C14H17N0252, 295.07007 (Dev. - 0.98 ppm)); Vmax 
(film)/cm- 1  3096 (thiophene C-H), 3065 (aryl C-H), 2932 (C-H), 1594 (aryl C=C), 1350 
(SO2), 1156 (SO2); on (200 MHz, CDCI3): 0.79 (t, 3H,J= 7.0 Hz, H10) 1.10-1.37 (m, 
4H, H8, H9), 3.51 (t, 2H, J = 6.6 Hz, 117), 6.97 - 7.03 (m, 2H, H12, H13), 7.18 - 7.26 
(m, 5H, Ark!), 7.49 (d, IH, J = 4.8 Hz, H14); Mpt. 71.4-71.6 °C. 
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N-Benzyl-N-phenylthiophene-2-sulfonamide (30) 











General procedure Si was followed using tributylphosphine (0.18 mL, 0.72 mmole, 1.5 
eq.), benzyl alcohol (49.7 IAL, 0.48 mmole, 1.0 eq.), N-phenylthiophene-2-sulfonamide 
(0.171 g, 0.72 mmole, 1.5 eq.) and TMAD (0.124 g, 0.72 mmole, 1.5 eq.). Sulfonamide 
30 was isolated as a white solid (0.056 g, 35%, Rf 0.33 (hexane: ethyl acetate, 4:1)); 
LRMS EI m/z 329 (M); 8H  (200 MHz, CDC13): 4.61 (s, 2H, 117), 6.88 - 7.44 (m, 13H, 
An]). 
N-AIIyl-N-phenylthiophene-2-sulfonamide (31) 
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General procedure Si was followed using tributylphosphine (0.20 mL, 0.79 mmole, 1.5 
eq.), allyl alcohol (36.0 tL, 0.53 mmole, 1.0 eq.), N-phenylthiophene-2-sulfonamide 
(0.190 g, 0.79 mmole, 1.5 eq.) and TMAD (0.137 g, 0.79 mmole, 1.5 eq.). The reaction 
was carried out at room temperature. Sulfonamide 31 was isolated as a white solid 
(0.097 g, 66%, Rf 0.31 (hexane: ethyl acetate, 4:1)); LRMS E[ m/z 279 (M); HRMS 
Ef m/z 279.03886 (M) (calculated for C13H13NO2S2, 279.03877 (Dev. 0.29 ppm)); Vmax 
(film)/cm- 1 3098 (thiophene C-H), 3088 (aryl C-H), 2924 (C-H), 1644 (C=C), 1595 (aryl 
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C=C), 1355 (SO2), 1160 (SO2); 6H  (200 MHz, CDC13): 4.30 (d, 2H, J = 6.3 Hz, 117), 
5.13 (dd, 1H, J = 1.2, 3.5 Hz, H9 1 ), 5.20 (dd, 1H, J = 1.2, 10.5 Hz, H9trans), 5.74 — 5.94 
(m, IH, H8), 7.12-7.21 (m, 2H, HI 1, H12), 7.33-7.44 (m, 5H, ArH), 7.66 (d, 1H, J = 
4.7 Hz, H13); 8c (75 MHz, (CD3)2S0): 54.0 (0), 119.3 (C9), 127.6 (CHAr), 128.4 
(CHAr), 129.0 (2 X CH1 ), 129.3 (2 X CHAr), 132.3 (C8), 132.8 (CAr), 132.9 (CHAr), 
139.0 (CAr); Mpt. 90.7-91.3 °C. 
5-Chloro-N-(4-methoxyphenyl)thiophene-2-sulfonamide (37)206 
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To a solution of p-anisidine (0.98 g, 8.0 mmole, 1.1 eq.) in THF (10 ml), 5-
chlorothiophene-2-sulfonyl chloride (1.50 g, 7.3 mmole, 1.0 eq.) and DIPEA (1.27 mL) 
was added. The reaction mixture was allowed to stir overnight at room temperature 
before being concentrated in vacuo to afford a brown residue that was neutralized with 
HC1 (conc.) and extracted into EtOAc. The organics were combined and concentrated in 
vacuo to afford sulfonamide 37 as a beige solid that required no further purification 
(2.24g, 99%); LRMS EJ m/z 303 (M); HRMS EI m/z 302.97925 (M) (calculated for 
C11 H1035C1NO3S2, 302.97907 (Dev. 0.61 PPM)); Vmax (KBr)/cm 1 3278 (N-H), 3117 
(thiophene C-H), 3056 (aryl C-H), 1331 (SO2), 1155 (SO2); 8H  (250 MHz, CDC13): 3.78 
(s, 3H, 117), 6.58 (bs, IH, NH), 6.80 (d, 2H, J = 9.1 Hz, 112, H6), 6.82 (d, 1H, J = 4.0 
Hz, H10), 7.04 (d, 2H, J = 9.1 Hz, H3, H5), 7.17 (d, 1H, J = 4.0 Hz, H9); 6c  (63 MHz, 
CDC13): 55.4 (C7),114.5 (2 x CHAr), 125.7 (2 x CHAr), 126.6 (CHAr), 127.9 (CA'), 129.2 
(CHAr), 137.1 (CM), 137.6 (CAr), 158.4 (CAr). 
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N-AlIyl-5-chloro-N-(4-methoxyphenyl)thiophefle-2-sulfonamide (39) 
13 	12 	5 
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General procedure Si was followed using tributyiphosphine (829 tL, 3.30 mmole, 1.5 
eq.), allyl alcohol (300 [tL, 6.60 mmole, 2.0 eq.), 5-chloro-N-(4-
methoxyphenyl)thiophene-2-sulfonamide (1.009 g, 3.30 mmole, 1.5 eq.) in anhydrous 
benzene (15 mL), and TMAD (0.572 g, 3.30 mmole, 1.5 eq.). The reaction mixture left 
to stir at room temperature for 4 days. Sulfonamide 39 was isolated as a yellow solid 
(1.056 g, 92%, Rf 0.37 (hexane: ethyl acetate, 4:1)); LRMS EF m/z 343 (M); HRMS 
EI m/z 343.01089 (M) (calculated for C141-11435C1NO3S2, 343.0 1037 (Dev. 1.53 ppm)); 
Vmax (film)/cm-1 3098 (thiophene C-H), 3082 (aryl C-H), 3001 (C-H), 2962 (C-H), 2937 
(C-H), 1646 (C=C), 1355 (SO2), 1155 (SO2); si-i (360 MHz, CDCI3): 3.81 (s, 3H, 117), 
4.20 (dt, 2H, J = 6.3, 1.3 Hz, H8), 5.10 (dd, IH, .J = 10.0, 1.4 Hz, Hl 0 15), 5.13 (dd, IH, 
J = 18.4, 1.4 Hz, HI 0,,,,,), 5.59- 5.75 (m, IH, H9), 6.86 (d, 2H, J = 6.8 Hz, 112, H6), 
6.93 (d, IH, J = 4.0 Hz, H12), 7.04 (d, 2H, J = 6.8 Hz, 113, H5), 7.16 (d, IH, J = 4.0 Hz, 
H13); & (63 MHz, (CD3)2S0): 53.8 (C8), 56.0 (0), 114.9 (2 x CHAr), 119.8 (C I O), 
129.1 (CHAr), 130.6 (2 X CHAr), 131.2 (C), 133.4 (CA ), 133.6 (CA ), 136.2 (CA,), 136.9 
(CA,), 159.5 (CA,); Mpt. 88.7 -90.2 °C. 
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5-Chloro-N- [(5-chloro-2-thienyDsulfoflYl] -N- [4-(trifluoromethyl)phenYl] thiophene- 
2-sulfonamide (43) 









 14 C1 
 
To a solution of 4-(trifluoromethy!)aniline (2.88 g, 23.0 mmole, 1.1 eq.) in THF (25 ml), 
5-chlorothiophene-2-sulfOflYl chloride (4.53 g, 20.8 mmole, 1.0 eq.) and DIPEA (3.63 
mL) was added. The reaction mixture was allowed to stir overnight at room temperature 
before being concentrated in vacuo to afford a brown residue that was neutralized with 
HCI (cone.) and extracted into EtOAc. The organics were combined and concentrated in 
vacuo to afford a residue that was columned on silica (hexane: ethyl acetate, 4:1). 
Appropriate fractions were combined and concentrated in vacuo to afford a white solid 
(1.62 g, 23%); LRMS E1 m/z 520 (M)+; HRMS Ef m/z 520.86684 (M) ((calculated for 
C15H835C12F3NO4S4, 520.86653 (Dev. 0.60 ppm)); Vmax (film)Icm' 3111 (thiophene C-
H), 3086 (aryl C-H), 1318 (SO2), 1132 (SO2); 6H (250 MHz, CDC13): 7.00 (d, 2H, J = 
4.0 Hz, H9, H13), 7.28 (d, 2H, J = 8.2 Hz, H2, H6), 7.56 (d, 2H, J = 4.0 Hz, H8, H12), 
7.69 (d, 2H, J = 8.2 Hz, H3, H5); 8c  (63 MHz, CDCI3): 123.6 (q, JCF = 273 Hz, CF3), 
126.8 (q, JCF = 4 Hz, C3, CS), 127.0 (2 x CHAr), 131.6 (2 X CHAr), 135.5 (2 X CHAr), 




4,5-Dibromo-N- I4(trifluoromethy1)phenYI1 thiophene-2-sulfonamide (46) 
Br9 
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General procedure L4 was followed. Sulfonamide 46 was isolated as a white solid 
(0.071 g, 38%, Rf 0.53 (hexane: ethyl acetate, 2:1)); LRMS FAB m/z 466 (MH); 
HRMS FAB m/z 465.82124 (MH) (calculated for C11 H779Br81BrF3NO2S2, 465.82179 
(Dev. —1.18 PPM)); Vmax (film)Icm1  3260 (N-H), 3106 (thiophene C-H), 3054 (aryl C-
H), 1337 (SO2), 1156 (SO2); 8H (250 MHz, CDCI3): 7.20 (d, 2H, J = 8.4 Hz, H2, H6), 





Br 10  
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General procedure L4 was followed. Sulfonamide 48 was isolated as a yellow solid 
(0.009 g, 5%, Rf  0.53 (hexane: ethyl acetate, 2:1)); LRMS FAB m/z 432 (MH); HRMS 
FAB m/z 431.79633 (MH) (calculated for C10H779Br81Br35C1NO2S2, 431.79543 (Dev. 
2.08 ppm)); oH (250 MHz, CDCI3): 6.91 (s, 1H, NH), 7.04 (d, 2H, J = 6.7 Hz, 112, H6), 
7.23 (s, 1H, 118), 7.24 (d, 2H, J = 6.7 Hz, 113, H5). 
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4,5DibromoN(3,5dichIorophenyl)thiOphefle-2-SUlfOflamide (49) 




I, ..  
General procedure Li was followed. Sulfonamide 49 was isolated as a cream solid 
(0.001 g, 1 %, HPLC Method R, tp 8.21 mm); LRMS ES m/z 463.9 (M-H). 









General procedure L4 was followed. Sulfonamide 50 was isolated as a white solid 
(0.003 g, 1%, Rf 0.58 (hexane: ethyl acetate, 2:1)); LRMS FAB m/z 534 (MH); HRMS 
FAB m/z 533.80129 (MH) (calculated for C1214679Br81BrF6NO2S2, 533.80917 (Dev. 
2.1 PPM)); 8H (250 MHz, CDC13): 7.21 (s, 1H, NH), 7.34 (s, IH, H8), 7.55 (s, 2H, 112, 
H6), 7.64 (s, 1H, H4). 
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4,5Dibromo-N-(2,4,5-trichlorophenyl)thiophene-2-sulfOflamide (51) 
Br 	 CI 
Br —?1 rLr 
CI 
General procedure Li was followed. Sulfonamide 51 was isolated as a white solid 
(0.001 g, 1%, HPLC Method R, tR 8.49 mm). LRMS ES m/z 497.9 (M-H)- assigned to 
C 10H379Br81 Br35C13NO2S2. 
5-Chloro-N- (4-(trifluoromethyl)phenyl] thiophene-2-sulfonamide (5 
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To a stirring solution of 4-(trifluoromethyl)aniline (0.498 g, 3.1 mmole, 1.1 eq.) in 
anhydrous pyridine (4 mL), a solution of 5-chlorothiophene-2-sulfonyl chloride (0.610 
g, 2.8 mmole, 1.0 eq.) in anhydrous pyridine (2 mL) was added. The reaction mixture 
was allowed to stir at room temperature overnight before being washed with HCl (IM, 
25 mL) and extracted into ethyl acetate (3 x 25 mL). The combined organics were 
washed with brine (2 x 25 mL) and dried over anhydrous magnesium sulfate before 
being concentrated in vacuo to afford a brown oil. The oil was purified on silica 
(hexane: ethyl acetate: DCM, 3:2:1). Appropriate fractions were combined and 
concentrated in vacuo to afford sulfonamide 52 as a white solid (0.682g, 71%, Rf  
0.61(hexane: ethyl acetate: DCM, 3:2:1)); LRMS FAB 342 (MIH)+; HRMS FAB m/z 
341.96464 (MII-I) ((calculated for C11H835C1F3NO2S2, 341.96371 (Dev. 2.72 ppm)); Vmax 
(film)/cm' 3261 (N-H), 3107 (thiophene C-H), 3011 (aryl C-H), 1342 (SO2), 1162 
(SO2); 61-1  (250 MHz, CDCI3): 6.87 (d, 1H, J = 4.1 Hz, H9), 7.23 (bs, 1H, NH), 7.25 (d, 
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2H, .1 = 9.2 Hz, 112, H6), 7.36 (d, 1H, J = 4.1 Hz, H8),7.55 (d, 2H, J = 9.2 Hz, 113, H5); 
c (63 MHz, CDCI3): 120.7 (2 X CHAr), 124.2 (q, JCF = 272 Hz, CF3), 127.3 (CHAr), 
127.4 (2 X CHAr), 127.5 (q, JCF = 35 Hz, C4), 133.3 (CHAr), 137.1 (CA,), 139.1 (CA,), 
139.5 (CA,); Mpt. 97.5 —97.7 °C. 
5-Chloro-N-(4-chlorophenyl)thiophene-2-sulfonamide (54)206 
General procedure Li was followed. Sulfonamide 54 was isolated as a white solid 
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General procedure Li was followed. Sulfonamide 55 was isolated as a white solid 
(0.00 1 g, 1%, HPLC Method R, tR = 8.09 mm); LRMS ES m/z 340.0 (M-H) assigned to 
C 10H535C13NO2S2. 
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NI3,5,Bis(trifluoromethyl)pheflyl1 -5-chlorothiophene-2-sulfOflamide (56) 
9 	8 	
6 
CF3  ';1 'I 1 4 
NCF3 
2 
To a stirring solution of 3,5-bis(trifluoromethyl)aniline (396 .iL, 2.50 mmole, 1.1 eq.) in 
pyridine (4 mL) a solution of 5-chlorothiophene-2-sulfonyl chloride (0.500 g, 2.30 
mmole, 1.0 eq.) in pyridine (4 mL) was added. The reaction mixture was allowed to stir 
at room temperature for 24 hours before being concentrated in vacuo to afford a brown 
residue. The residue was dissolved in ethyl acetate (50 mL) and washed with HC1 (IM, 2 
x 50 mL); brine (50 mL) and concentrated in vacuo to afford a residue that was 
columned on silica (hexane: ethyl acetate) to afford sulfonamide 56 as a white solid 
(0.631 g, 67%, Rf  0.56 (hexane: ethyl acetate, 2:1)); LRMS ES m/z 408.0 (M-H); 
(250MHz, CDC13): 6.85 (d, IH,J 4.1 Hz,H9), 7.31 (s, 1H,NII), 7.34 (d, IH,J 4.1 
Hz, H8), 7.54 (s, 2H, 112, H6), 7.60 (s, 1H, H4). 
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Genera! procedure L2 was followed. Sulfonamide 58 was isolated as a white solid 
(0.003 g, 4%, HPLC Method R, tR 8.52 mm); LRMS ES m/z 362.0 (M-H)-. 
5[2(Methylthio)pyrimidifl-5-Yl1 -N- I4(trifluoromethyDphenY1] thiophene-2-
sulfonamide (59) 
N 
General procedure L2 was followed. Sulfonamide 59 was isolated as a white solid 
(0.002 g, 2%, HPLC Method R, tR 11.01 mm); LRMS ES m/z 430.1 (M-H); Vmax 
(film)/cm- 1 3265 (N-H), 3056 (aryl C-H), 2929 (C-H), 1585 (aryl C=C), 1325 (SO2), 
1158 (SO2). 
N-(4-Chlorophenyl)-5- [2(methy1thio)pyrimidifl-5-YI1I thiophene-2-sulfonamide (60) 
General procedure L2 was followed. Sulfonamide 60 was isolated as a white solid 
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N-(4-Methylphenyl)-5- (2-(methylthio)pyrimidin-5-ylJ thiophene-2-sulfonamide (61) 
Genera! procedure L2 was followed. Sulfonamide 61 was isolated as a cream solid 
(0.00 I g, 1%, HPLC Method R, tR 9.38 mm); LRMS ES m/z 376.1 (M-1-I) . 
N-(3,5-Dichorophenyl)-5- [2-(methy!thio)py rim idin-5-ylI thiophene-2-su Ifonamide 
(62) 
CI 
\S4- 	'0 \,D/ 
N LCI 
Genera! procedure L2 was followed. Sulfonamide 62 was isolated as a white solid 
(0.001 g, 1%, HPLC Method R, tR 9.01 mm); LRMS ES m/z 429.9 (M-H)- assigned to 
C15H1035C12N302S3. 
N(4FIuoropheny1)-5-2-(methyIthio)pyrimidifl-5-Yl1 thiophene-2-sulfonamide (63) 
F 
General procedure L2 was followed. Sulfonamide 63 was isolated as a white solid 
(0.001 g, 1%, HPLC Method R, tR 9.17 mm); LRMS ES m/z 380.1 (M-H). 
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General procedure L2 was followed. Sulfonamide 64 was isolated as a cream solid 
(0.002 g, 2%, HPLC Method R, tR 8.31 mm); LRMS ES m/z 498.0 (M-H). 
N-(2,4-Dichloro-phenyl)-5- 12-(methylthio)pyrimidin-5-y11 thiophene-2-sulfonamide 
(65) 
N 	
S & N qCI 
CI 
General procedure L2 was followed. Sulfonamide 65 was isolated as a white solid 
(0.001 g, 1%, HPLC Method R, tR 8.34 mm); LRMS ES- m/z 429.9 (M-H) assigned to 
C15H1035C12N3S302. 





General procedure L2 was followed. Sulfonamide 67 was isolated as a white solid 
(0.007 g, 0%, HPLC Method R, tR 9.02 mm); LRMS ES m/z 367.1 (M-H. 
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N-(4-Chlorophenyl)-4-(1 ,3-oxazol-2-yl)benzenesulfonamide (68) 




General procedure L2 was followed. Sulfonamide 68 was isolated as a white solid 
(0.007 g, 10%, HPLC Method R, tR 8.13 mm); LRMS ES m/z 333.1 (M-H). 
N-(4-Methylphenyl)-4-(1 ,3-oxazol-2-yl)benzenesulfonamide (69) 
General procedure L2 was followed. Sulfonamide 69 was isolated as a white solid 
(0.001 g, 1%, HPLC Method R, tR 8.48 mm); LRMS ES m/z 313.2 (M-H). 
N-(3,5-Dichlorophenyl)-4-(1 ,3-oxazol-2-yI)benzenesulfonamide (70) 
CI 
o /p  
tNb"CI 
H 
General procedure L2 was followed. Sulfonamide 70 was isolated as a white solid 
(0.001 g, 1%, HPLC Method R, tR 9.04 mm); LRMS ES m/z 367.0 (M-H)- assigned to 
C 15H935C12N2O3S. 
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N-(4-Fhiorophenyl)-4-(1 ,3-oxazol-2-yl)benzenesulfOflamide (71) 
General procedure L2 was followed. Sulfonamide 71 was isolated as a white solid 
(0.001 g, 2%, HPLC Method R, tR 7.59 mm); LRMS ES m/z 317.1 (M-H). 
N- I3,5Bis(trifluoromethy1)phe11y11 -4-(1 ,3-oxazol-2-yl)benzenesulfOflamide (72) 
(N 	
CF3 
o) fcLp (c 
H 
General procedure Library L2 was followed. Sulfonamide 72 was isolated as a white 
solid (0.001 g, 1%, HPLC Method R, tR 9.13 mm); LRMS E5 m/z 435.1 (M-H). 
(74) 
Br 
C,— ~~ J~ P C 
General procedure L2 was followed. Sulfonamide 74 was isolated as a yellow solid 




4-Bromo-5-chloro-N- I4(trifluoromethy1)phenYIJthioPhene2sf0m11k (75) 
Br 
S 1CF3  
0 H 
General procedure L2 was followed. Sulfonamide 75 was isolated as a yellow solid 
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General procedure L2 was followed. Sulfonamide 76 was isolated as a yellow solid 




ci-i Nc S 
General procedure L2 was followed. Sulfonamide 77 was isolated as a yellow solid 
(0.001 g, 2%, HPLC Method R, tR 8.52 mm); LRMS ES m/z 363.8 (M-H) assigned to 
C1 1 H879Br35C1NO2S2. 
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N- [3,5-Bis(trifluoromethyl)phenyl] -4-bromo-5-chlorothiophene-2-sulfonamide (80) 
Br 	 CF3 
ci—  i,p 1I' 
S 'N CF3 
General procedure L2 was followed. Sulfonamide 80 was isolated as a yellow solid 






General procedure L2 was followed. Sulfonamide 81 was isolated as a yellow solid 





General procedure L2 was followed. Sulfonamide 82 was isolated as a yellow solid 
(0.002 g, 3%, HPLC Method R, tR 8.58 mm); LRMS ES m/z 315.9 (M-H) assigned to 
C10H879BrNO2S2. 





General procedure L2 was followed. Sulfonamide 83 was isolated as a yellow solid 
(0.001 g, 1%, HPLC Method R, tR 8.28 mm); LRMS ES m/z 385.9 (M-H) assigned to 
C 10H681BrF3NO2S2. 
Also prepared by an alternative method: 
To a stirring solution of 5-bromothiophene-2-sulfonyl chloride (0.800 g, 3.06 mmole, 
1.0 eq.) in DCM (10 mL) was added 4-(trifluoromethyl)aniline (420 [tL, 3.37 mmole, 
1.1 eq.) and pyridine (247 jxL, 3.06 mmole, 1.0 eq.). The reaction mixture was allowed 
to stir at room temperature for 24 hours before being concentrated in vacuo to afford a 
brown residue. The residue was dissolved in ethyl acetate (50 mL) and washed with HC1 
(1M, 2 x 50 mL); brine (50 mL) and concentrated in vacuo to afford a pale yellow solid 
that was columned on silica (hexane: ethyl acetate, 2: 1) to afford sulfonamide 83 (1.055 
g, 89%, Rf 0.51 (hexane: ethyl acetate, 2:1), ES m/z 386.0 (M-H)) which was used 
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directly for the synthesis of sulfonamides 193, 199, 205, 212 and 219 without further 
characterization. 
5-Bromo- N-(4-chlorophenyl)thiophene-2-sulfonamide (84) 
Br-) 'p 
'N 
General procedure L2 was followed. Sulfonamide 84 isolated as a yellow solid (0.001 g, 




General procedure L2 was followed. Sulfonamide 85 was isolated as a yellow solid 
(0.001 g, 1%, HPLC Method R, tR 9.24 mm); LRMS ES m/z 329.9 (M-H)- assigned to 
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General procedure L2 was followed. Sulfonamide 86 was isolated as a yellow solid 
(0.001 g, 1%, Method R, 8.49 mm); LRMS ES m/z 385.8 (M-H) assigned to 
C10H68 1Br35C12NO2S2 . 
N[3,5Bis(trifluoromethyl)phenylJ-5-brOfflOthiOPhefle-2-SU Ifonamide (88) 
CF3  
Br(i 'p r 
S SN.-L-LCF 
General procedure L2 was followed. Sulfonamide 88 was isolated as a yellow solid 
(0.001 g, 1%, Method R, 8.07 mm); LRMS ES m/z 453.9 (M-H)-. 
Also prepared by an alternative method: 
To a stirring solution of 5-bromothiophene-2-sulfonyl chloride (0.800 g, 3.06 mmole, 
1.0 eq.) in DCM (10 mL) was added 3,5-bis(trifluoromethyl)aniline (476pL, 3.37 
mmole, 1.1 eq.) and pyridine (247 jtL, 3.06 mmole, 1.0 eq.). The reaction mixture was 
allowed to stir at room temperature for 24 hours before being concentrated in vacuo to 
afford a brown residue. The residue was dissolved in ethyl acetate (50 mL) and washed 
with HC1 (1M, 2 x 50 mL); brine (50 mL) and concentrated in vacuo to afford a pale 
yellow solid that was columned on silica (hexane: ethyl acetate, 2: 1) to afford 
sulfonamide 88 (0.994 g, 72%, Rf 0.53 (hexane: ethyl acetate, 2:1), ES m/z 453.8 (M- 
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H)) which was used directly for the synthesis of sulfonamides 191, 197, 204, 211 and 





General procedure L2 was followed. Sulfonamide 89 was isolated as a yellow solid 
(0.001 g, 1%, Method R, tp 8.27 mm); LRMS ES m/z 383.8 (M-H) calculated for 
C 1 0H779Br35C12NO2S2. 
3-Nitro-N-phenylbenzenesulfonamide (90)209 
9 






General procedure L2b was followed. Sulfonamide 90 was isolated as a white solid 
(0.016 g, 28%); LRMS ES m/z 277.0 (M-H); 61-1  (250 M1-lz, CDCI 3 ): 6.77 (s, 1H, NH), 
7.00-7.22 (m, 5H, An]), 7.62 (t, IH, J = 7.8 Hz, H9), 8.08 (ddd, 1H, J = 7.8, 1.9, 1.0 
Hz, H10), 8.37 (ddd, 1H, J = 7.8, 2.2, 1.1 Hz, H8), 8.67 (t, 1H, J = 2.2 Hz, H12). 
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To a stirring solution of 3-nitrobenzenesulfonyl chloride (0.600 g, 2.71 mmole, 1.0 eq.) 
in DCM (10 mL), 4-(trifluoromethyl)aniline (374 jtL, 2.98 mmole, 1.10 eq.) and 
pyridine (218 lLL, 2.71 mmole, 1.0 eq.) were added. The reaction mixture was allowed to 
stir at room temperature for 24 hours before being concentrated in vacuo. The crude 
residue was columned on silica (Hexane: Ethyl acetate, 2:1) to afford sulfonamide 91 as 
a pink solid (0.562 g, 60%); LRMS ES m/z 345.0 (M-H); HRMS FAB m/z (MH) 
347.03 189 (calculated for C13H10F3N204, 347.03 134 (Dev. 1.58 ppm)); Vmax (film)/cm-1  
3271 (N-H), 3093 (thiophene C-H), 1618 (aryl C=C), 1534 (NO2), 1354 (NO2), 1334 
(SO2), 1168 (SO2); 6H  (250 MHz, CDC13): 7.18 (d, 2H, J = 8.4 Hz, 112, H6), 7.47 (d, 
2H, J = 8.4 Hz, H3, H5), 7.58 (s, 1H, NH), 7.65 (t, 1H, J = 8.1 Hz, H9), 8.08 (ddd, lH, 
J = 8.1, 1.9, 1.0 Hz, H10), 8.37 (ddd, lH, J = 8.1, 2. 1, 1.0 Hz, H8), 8.67 (dd, IH, J = 
2.1, 1.9 Hz, H12); 6c (63 MHz, CDC13): 120.8 (2 X CHAr), 122.8 (CHAr), 124.1 (q, JCF = 
272 Hz, CF3), 127.4 (2 X CHAr), 128.0 (q, JCF = 33 Hz, C4), 128.4 (CIO), 131.2 (CHAr), 





General procedure L2b was followed. Sulfonamide 92 was isolated as a brown solid 
(0.017 g, 30%); LRMS E5 m/z 311.0 (M-H)-. 
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N-(4-methylphenyl)-3-n itrobenzenesulfonamide (93)211 
02N 
General procedure L2b was followed. Sulfonamide 93 was isolated as a yellow solid 
(0.017 g, 29%); LRMS ES m/z 291.0 (M-H)-. 
N-(3,5-Dichlorophenyl)-3-nitrobenzenesulfonam ide (94) 
9 	 CI 
1O-8 	5 




General procedure L2b was followed. Sulfonamide 94 was isolated as a yellow solid 
(0.021 g, 30%); LRMS ES m/z 345.0 (M-H)- assigned to C12H7 35C12N204S; 6H  (250 
MHz, CDC13): 6.84 (s, IH, NH), 6.98 (d, 2H, J = 1.8 Hz, 112, H6), 7.09 (t, IH, J = 1.8 
Hz, H4), 7.65 (t, IH, J = 8.0 Hz, H9), 8.05 (ddd, 1H, J = 8.0, 1.8, 1.1 Hz, H10), 8.37 
(ddd, IH, J = 8.0, 1.8, 1.1 Hz, H8), 8.67 (t, 1H, J = 1.8 Hz, H12). 
N-(4-Fluorophenyl)-3-nitrobenzenesulfonamide (95) 
02N 	 c F  
General procedure Library L2b was followed. Sulfonamide 95 was isolated as a yellow 
solid (0.0 17 g, 29%); LRMS ES m/z 295.1 (M-H). 
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N- [3,5-Bis(trifluoromethyl)phenyl] -3-nitrobenzenesu Ifonamide (96) 
9 	 CF3  




To a stirring solution of 3-nitrobenzenesulfonyl chloride (0.600 g, 2.71 mmole, 1.0 eq.) 
in DCM (10 mL), 3,5-bis(trifluoromethyl)aniline (463 tL, 2.98 mmole, 1.10 eq.) and 
pyridine (218 tL, 2.71 mmole, 1.0 eq.) were added. The reaction mixture was allowed to 
stir at room temperature for 24 hours before being concentrated in vacuo. The crude 
residue was columned on silica (Hexane: Ethyl acetate, 2:1) to afford sulfonamide 96 as 
a white solid (0.836 g, 77%); LRMS ES m/z 413.0 (M-H; HRMS FAB m/z 415.11893 
(MI-1) (calculated for C14H9F6N204S, 415.01872 (Dev. 0.51 PPM)); Vmax (film)/cm' 
3268 (N-H), 3102 (aryl C-H), 1608 (aryl C=C), 1537 (NO2), 1377 (NO2), 1354 (SO2), 
1132 (SO2); 8H (250 MHz, CDC13): 7.60 (s, 2H, 112, H6), 7.66 (s, IH, NI]), 7.67 (s, IH, 
H4), 7.77 (t, IH, J = 8.1 Hz, H9), 8.15 (dt, 1H, J = 8.1, 2.1 Hz, H10), 8.48 (dd, IH, J = 
8.1, 2.1 Hz, H8), 8.73 (t, 1H, J = 2.1 Hz, H12); öc (63 MHz, CDCI3): 119.1 (CHAr), 
120.4 (2 X CHAr), 122.4 (CH), 122.4 (q, JCF = 273 Hz, CF3), 128.2 (CHAr), 130.8 
(CHAr), 132.3 (CHAr), 133.1 (q, JCF = 34 Hz, C3, C5), 137.3 (CA,), 140.3 (CA,),  148.4 
(CA,); Mpt. 133.8— 134.2 °C. 
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General procedure L2b was followed. Sulfonamide 97 was isolated as a yellow solid 
(0.004 g, 6%); LRMS ES m/z 344.8 (M-H)- assigned to C12H735C12N202S. 
NPhenyl-5-(pheny1sulfonyl)thiophene-2-SUIfOflamide (98) 
a~--ay~O S ,IS N 0 
General procedure as set out for the resynthesis of Library L2 was followed. 
Sulfonamide 98 was isolated as a beige solid (0.012 g, 16%); LRMS ES m/z 378.0 (M- 





General procedure L2b was followed. Sulfonamide 99 was isolated as a yellow solid 
(0.005 g, 6%); LRMS ES m/z 446.0 (M-H). 
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N(4ChIorophenyl)-5-(phenylsulfonyl)thiOPhefle-2-SU Ifonamide (100) 
Genera! procedure L2b was followed. Sulfonamide 100 was isolated as a yellow solid 
(0.006 g, 6%); LRMS ES m/z 411.9 (M-H). 
N(4MethyIphenyl)-5-(phenylsulfonyl)thiOphefle-2-SUlfOnamide (101) 
14 13010 9 	5 7 
15Q /p6(<  12 0 	NI 	3 
S+s 
16 17 	 0 H 2 
General procedure L2b was followed. Sulfonamide 101 was isolated as a yellow solid 
(0.0 10 g, 13%); LRMS ES m/z 392.0 (M-H); 6H  (250 MHz, CDC13): 2.26 (s, 3H, 117), 
6.40 (s, IH, NJ]), 6.90 (d, 2H, J = 8.4 Hz, 112, H6), 7.03 (d, 2H, J= 8.4 Hz, H3, H5), 
7.23 (d, 1H, J= 4.0 Hz, thiophene 1]), 7.44 (d, 1H, J = 4.0 Hz, thiophene 1]), 7.46 - 7.55 




General procedure L2b was followed. Sulfonamide 102 was isolated as a brown solid 









14 	11 11los 	SN_3 
15 16 	C H 2 
General procedure L2b was followed. Sulfonamide 103 was isolated as a yellow solid 
(0.015 g, 19%); LRMS ES 396.1 (M-H); 6H  (250 MHz, CDCI3): 6.53 (s, IH, NH), 6.89 
—7.05 (m, 4H, ArH), 7.22 (d, 1H, J = 4.0 Hz, thiophene fl), 7.45 (d, IH, J = 4.0 Hz, 
thiophene H), 7.47 - 7.59 (m, 31-1, ArH), 7.84 - 7.90 (m, 2H, ArH). 




General procedure L2b was followed. Sulfonamide 104 was isolated as a yellow solid 
(0.003 g, 3%); LRMS ES m/z 514.2 (M-H). 
N(2,4DichEorophenyl)5(phenylSulfOflYl)thiOPheflC-2.SU1f011amide (105) 
0 	 C1 
0 S 'Nq 
CI 
General procedure L2b was followed. Sulfonamide 105 was isolated as a brown solid 
(0.002 g, 3%); LRMS ES m/z 446.0 (M-H). 
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5Chloro-N-(3-chloropheny1)thiophene-2-SU1fOflafflide (108) 
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Genera! procedure L3 was followed. Sulfonamide 108 was isolated as a cream solid 
(0.008 g, 13%); LRMS ES m/z 305.9 (M-H). 
5-Chloro-N- [3-(trifluoromethyl)phenytl thiophene-2-sulfonamide (109) 







0 H2 3  
General procedure L3 was followed. Sulfonamide 109 was isolated as a cream solid 
(0.026 g, 38%); LRMS ES m/z 340.0 (M-H); 6i-i  (250 MHz, CDCI3): 6.87 (bs, IH, NI]), 
6.88 (d, IH, J = 4.0 Hz, H9), 7.32 (d, IH, J = 4.0 Hz, H8), 7.33 - 7.37 (m, lH, An]), 
7.40 (s, 1H, ff2), 7.45 - 7.47 (m, 2H, ArII). 




General procedure L3 was followed. Sulfonamide 110 was isolated as a white solid 
(0.005 g, 7%); LRMS ES- m/z 339.8 (M-H)- assigned to C10H535C13NO2S2. 
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4,5-Dibromo-N- I3(trifluoromethyl)pheny11thiophene-2-suLfonamide (112) 
Br9 
8 	 5 
Br 
O~j 
 N: 	CF3 
°H 2 
General procedure L3 was followed. Sulfonamide 112 as a cream solid (0.011 g, 12%); 
LRMS ES m/z 463.8 (M-H) assigned to C11 H579Br81BrF3NO2S2; Vmax (film)Icm 1 3250 
(N-H), 3107 (thiophene C-H), 2916 (C-H), 1328 (SO2), 1156 (SO2); 6H (250 MHz, 
CDC13): 6.69 (s, IH, NJ]), 7.26 (s, IH, H8), 7.27 - 7.31 (m, 1H, ArE), 7.33 (s, IH, H2), 





General procedure L3 was followed. Sulfonamide 113 was isolated as a biege solid 








9 	 CF3  
O2N12 ,SN 1 	CF3 
General procedure L3 was followed. Sulfonamide 114 was isolated as a white solid 
(0.010 g, 11%); LRMS ES m/z 447.0 (M-H); Vmax (film)/cm' 3293 (N-H), 3083 (aryl 
C-H), 1534 (NO2), 1375 (NO2), 1355 (SO2), 1162 (SO2); 6H (250 MHz, CDCI3): 7.24 (s, 
IH, NH), 7.60 (s, 2H, H2, H6), 7.70 (s, IH, H4), 7.73 (d, IH, J = 8.5 Hz, H9), 7.92 (dd, 
1H, J = 2.3 Hz, 8.5Hz, H8), 8.35 (d, 1H, J = 2.3 Hz, H12); Mpt. 167.5 - 168.9 °C. 
4-Ch loro-N-(3-chlorophenyl)-3-nitrobenzeneSulfOflamide (115) 
CI 
I H a 
02N 	
N 	CI 
General procedure L3 was followed. Sulfonamide 115 was isolated as a cream solid 
(0.004 g, 5%); LRMS ES m/z 345.0 (M-H; 









To a stirring solution of 4-chloro-3-nitrobenzenesulfonyl chloride (1.000 g, 3.9 mmole, 
1.0 eq.) in DCM (10 mL), 3-(trifluoromethyl)aniline (575 j.tL, 4.3 mmole, 1.1 eq.) and 
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pyridine (315 ixL,  4.3 mmole, 1.0 eq.) were added. The reaction mixture was allowed to 
stir at room temperature overnight before being washed with HC1 (1 M, 2 x 10 mL); H20 
(10 mL) and brine (10 mL) and concentrated in vacuo to afford a residue that was 
columned on silica (hexane: ethyl acetate, 1:1) to afford 116 as a pink solid (1.338 g, 
90%); LRMS FAB m/z 380 (M); HRMS FAB m/z 379.98582 (M) (calculated for 
C13H835C1F3N204S, 379.98454 (Dev. 3.38 ppm)); Vmax (film)/cm' 3272 (N-H), 3098 
(aryl C-H), 1540 (NO2), 1337 (NO2), 1327 (SO2), 1172 (SO2); 6H  (250 MHz, (CD3)2S0): 
7.43-7.57 (m, 4H, ArE), 8.02 (s, 2H, ArE), 8.48 (s, IH, H12), 11.07 (s, IH, Nil); & 
(63 MHz, (CD3)2SO): 116.4 (CHAr), 121.1 (CHAr), 123.4 (q, JCF = 273 Hz, CF3), 123.9 
(CHAr), 124.0 (CHAr), 129.8 (q, JCF 	32 Hz, C3), 130.1 (CAf), 130.7 (CA,), 131.0 




General procedure L3 was followed. Sulfonamide 117 was isolated as a white solid 
(0.003 g, 4%); LRMS ES m/z 380.9 (M-H) assigned to C12H637C135C12N204S. 
N- [3,5-Bis(trifluoromethyl)phenylj benzamide (118) 
CF3  
e H NCF3 
General procedure L3 was followed. Amide 118 was isolated as a white solid (0.010 g, 
15%); LRMS ES m/z 334.1 (MH). 
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N-(3-Chlorophenyl)benzamide (119)212 
5 
o 6,-4  
(5-18 
	
ii 	II 	1 3 
7 C1 10 
11 3 
12 
Genera! procedure L3 was followed. Amide 119 was isolated as a white solid (0.015 g, 
3 1%); LRMS ES m/z 229.9 (M-H); 6H  (250 MHz, CDC13): 7.14 (d, 1H, J = 7.9 Hz, 




Genera! procedure L3 was followed. Amide 120 was isolated as a white solid (0.019 g, 





General procedure L3 was followed. Amide 121 was isolated as a white solid (0.013 g, 
24%); LRMS ES m/z 264.0 (M-H). 
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5-Chloro-N-(4-chlorophenyl)-3-methyl-1-benZOth iophene-2-sulfonamide (122) 
General procedure L4 was followed. Sulfonamide 122 was isolated as a yellow solid 
(0.015 g, 10%, Rf 0.53 (hexane: ethyl acetate 2:1); LRMS FAB m/z 371 (M); HRMS 
FAB m/z 370.961 16 (M) (calculated for C15H1135C12NO2S2, 370.96083 (Dev. 0.89 
ppm)); ö (250 MHz, CDCI3): 2,35 (s, 3H, CH3), 6.89 (s, IH, NH), 7.00 (d, 2H, J = 8.9 
Hz, Arff), 7.15 (d, 2H, ArH), 7.38 (dd, IH, J = 8.7, 1.9 Hz, benzothiophene H), 7.63 - 
7.66 (m, 2H, benzothiophene H). 
5-Chloro-N- [(1R)-1-(4-chlorophenyl)ethylj-3-m ethyl- 1 -benzothiophene-2-
sulfonamide (124) 
c TIII:'  
S 
General procedure as set out for Library L4 was followed. Sulfonamide 124 was isolated 
as a yellow solid (0.008 g, 5%, Rf 0.55 (hexane: ethyl acetate, 2:1)); LRMS FAB m/z 
399 (M); HRMS FAB m/z 398.99133 (M) (calculated for C17H1535C12NO2S2, 
398.99213 (Dcv. - 2.01 PPM)); 6H (250 MHz, CDC13): 1.39 (d, 3H, J = 6.9 Hz, 
CH(CH3)), 1.52 (s, 3H, CH3), 4.52 (dq, 1H, J = 6.9 Hz, CH(CH3)), 5.00 (d, 1H, J = 6.9 
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Hz, NH), 6.99 (s, 4H, AnT), 7.36 (dd, 1H, J = 8.6, 2.1 Hz, benzothiophene II), 7.61 - 





' p (H 
S 	
N CF3 
General procedure L4 was followed. Sulfonamide 126 was isolated as a white solid 
(0.014 g, 7%, Rf 0.62 (hexane: ethyl acetate, 2:1)); LRMS FAB m/z 474 (MH); HRMS 
FAB m/z 472.974 12 (MH) (calculated for C17H1035C1F6NO2S2, 472.97457 (Dev. - 0.83 
ppm)); E (250 MHz, CDCI3): 2.51 (s, 3H, CH3), 7.40 (dd, IH, J = 8.7, 2.0 Hz, 
benzothiophene II'), 7.51 (s, lH, NH), 7.54-7.56 (m, 3H, benzothiophene H, An]), 7.67 









General procedure Library L4 was followed. Sulfonamide 127 was isolated as a white 
solid (0.065 g, 33%, Rf  0.58 (hexane: ethyl acetate, 2:1)); LRMS FAB m/z 488 (MH); 
HRMS FAB m/z 486.99120 (MH) (calculated for C18H12 5C1F6NO2S2, 486.99022 
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(Dcv. 2.01 ppm)); oH (250 MHz, CDC13): 2.55 (s, 3H, CH3), 4.36 (d, 2H, .J = 6.4 Hz, 
CH2NH), 5.30 (t, 1H, .J = 6.4 Hz, NH), 7.40 (dd, 1H, J = 8.6, 2.0 Hz, benzothiophene 
II), 7.62 - 7.69 (m, 5H, ArH). 
5ChIoro3.methy1-N-[4-(trifluoromethYl)PheflYl1 -1-benzothiophene-2-sulfonamide 
(128) 
\ CF3  
General procedure L4 was followed. Sulfonamide 128 was isolated as a white solid 
(0.013 g, 8%, Rf O.51 (hexane: ethyl acetate, 2:1)); LRMS FAB m/z 406 (MH); HRMS 
FAB m/z 405.99450 (MH) (calculated for C16H1235C1F3NO2S2, 405.99501 (Dcv. - 1.25 
PPM)); 8H (250 MHz, CDC13): 2.46 (s, 3H, CH3), 7.19 (d, 2H, J = 9.0 Hz, An]), 7.38 
(dd, 1H, J = 8.6, 2.0 Hz, benzothiophene H), 7.46 (d, 2H, J = 9.0 Hz, An]), 7.63 - 7.68 
(m, 2H, benzothiophene I]). 
N-(4-Chlorophenyl)-1 -benzoth iophene-2-suifonamide (130) 
S -N'Cr I, 
General procedure Library L4 was followed. Sulfonamide 130 was isolated as a white 
solid (0.022 g, 17%, Rf  0.49 (hexane: ethyl acetate, 2:1)); LRMS FAB m/z 324 (MH); 
HRMS FAB m/z 323.99185 (MH) (calculated for C14H1135C1NO2S2, 323.99198 (Dcv. 
- 0.39 ppm)); 0H  (250 MHz, CDC13): 6.89 (d, 2H, J = 8.9 Hz, ArE), 7.08 (d, 2H, J = 8.9 
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Hz, ArH), 7.09 (s, 1H, NH), 7.37 - 7.41 (m, 2H, benzothiophene II), 7.77 - 7.82 (m, 1H, 
benzothiophene H), 8.07 - 8.11 (m, 2H, benzothiophene H). 
N-(4-Chlorobenzyl)-1 -benzothiophene-2-sulfonamide (131) 
General procedure L4 was followed. Sulfonamide 131 was isolated as a white solid 
(0.016 g, 12%, Rf 0.45 (hexane: ethyl acetate, 2:1)); LRMS FAB+ m/z 338 (MH); 
HRMS FAB m/z 338.00778 (MH) (calculated for C15H1335C1NO2S2, 338.00763 (Dev. 
0.44 ppm)); oH (250 MHz, CDC13): 4.06 (d, 2H, J = 6.2 Hz, CH2NH), 5.20 (t, I H, J = 
6.2 Hz, NH), 6.96 (d, 2H, J = 8.6 Hz, ArE), 7.07 (d, 2H, J= 8.6 Hz, An]), 7.37 - 7.47 
(m, 2H, benzothiophene 1]), 7.82— 8.86 (m, IH, benzothiophene H), 8.07-8.13 (m, 2H, 
benzothiophene H). 
N- I(1R)-1 -(4-chlorophenyl)ethyl] -1-benzothiophene-2-sulfonamide (132) 
N ° H 
General procedure L4 was followed. Sulfonamide 132 was isolated as a white solid 
(0.014 g, 10%, Rf 0.49 (hexane: ethyl acetate, 2:1)); LRMS FAB m/z 352 (MH); 
HRMS FAB m/z 352.02293 (MH) (calculated for C16H1535C1NO2S2, 352.02328 (Dev. 
- 0.99 PPM)); 0H (250 MHz, CDC13): 1.31 (d, 3H, J = 6.9 Hz, CH(CH3)), 4.44 (dq, I H, J 
= 6.9 Hz, CH(CH3)), 5.14 (d, 1H, J = 6.9 Hz, NH), 6.80 (d, 2H, J = 8.5 Hz, ArE), 6.88 
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(d, 2H, J = 8.5 Hz, Ark!), 7.36 - 7.40 (m, 2H, benzothiophene 1-]), 7.75 - 7.79 (m, IH, 
benzothiophene B), 7.90 (s, 1H, benzothiophene B), 8.00 —8.04 (m, IH, benzothiophene 
B). 
N- [(15)-i -(4-chlorophenyl)ethyl] -1 -benzothiophene-2-su Ifonamide (133) 
Q~I // 0 
I, 
o cI 
General procedure L4 was followed. Sulfonamide 133 was isolated as a white solid 
(0.004 g, 3%, Rf 0.51 (hexane: ethyl acetate, 2:1)); LRMS FAB m/z 352 (MH); HRMS 
FAB m/z 352.02254 (MH) (calculated for C16H1535C1N0252, 352.02328 (Dev. - 2.10 
PPM)); 6H (250 MHz, CDC13): 1.32 (d, 3H, J = 6.9 Hz, CH(CH3)), 4.45 (dq, IH, J = 6.9 
Hz, CH(CH3)), 4.89 (d, 1H, J = 6.9 Hz, NB), 6.80 (d, 2H, J = 8.4 Hz, Ark!), 6.89 (d, 
21-1, J = 8.4 Hz, ArB), 7.37 - 7.42 (m, 2H, benzothiophene H), 7.76 - 7.79 (m, IH, 
benzothiophene II), 7.89 (s, 1H, benzothiophene if), 7.98 - 8.02 (m, 1H, benzothiophene 
B). 





General procedure L4 was followed. Sulfonamide 134 was isolated as a white solid 
(0.050 g, 29%, Rf 0.58 (hexane: ethyl acetate, 2:1)); LRMS FAB m/z 426 (MH); 
HRMS FAB m/z 426.00487 (MH) (calculated for C16H10F6NO2S2, (Dev. - 1.98 ppm)); 
61-1 (250 MHz, CDC13): 7.27 (s, 1H, NB), 7.39 - 7.46 (m, 5H, benzothiophene H, Ark!), 
233 
7.82 - 7.84 (m, 1H, ArH), 8.04 - 8.07 (m, IH, benzothiophene I-f), 8.24 (s, IH, 
benzothiophene I]). 





General procedure L4 was followed. Sulfonamide 135 was isolated as a white solid 
(0.053g, 30%, Rf 0.53 (hexane: ethyl acetate, 2:1)); LRMS FAB m/z 440 (MH); 
HRMS FAB m/z 440.02203 (MH) (calculated for C17H12F6N0252, 440.02137 (Dev. 
1.51 PPM)); 6H (250 MHz, CDC13): 4.26 (d, 2H, J = 6.4 Hz, CH2NH), 5.28 (t, 1H, J = 
6.4 Hz, NR); 7.40 - 7.45 (m, 2H, benzothiophene II), 7.49 (s, 2H, ArH), 7.60 (s, 1H, 




Nc S S 'I, 
General procedure L4 was followed. Sulfonamide 136 was isolated as a white solid 
(0.026 g, 18%, Rf 0.48 (hexane: ethyl acetate, 2:1)); LRMS FAB m/z 358 (MH); 
HRMS FAB m/z 358.0 1782 (MH) (calculated for C15H11F3N0252, 358.01833 (Dev. - 
1.42 ppm)); 6H (250 MHz, CDC13): 7.09 (d, 2H, J = 8.3 Hz, ArH), 7.22 (s, IH, Nil), 
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7.37 - 7.44 (m, 4H, ArH, benzothiophene 11), 7.80 - 7.84 (m, IH, benzothiophene I]), 




General procedure L4 was followed. Sulfonamide 137 was isolated as a white solid 
(0.0 14 g, 9%, Rf 0.44 (hexane: ethyl acetate, 2:1)); LRMS FAB m/z 372 (MH); HRMS 
FAB m/z 372.03359 (MH) (calculated for C16H13F3NO2S2, 372.03398 (Dev.- 1.06 
PPM)); 6H (250 MHz, CDC 13): 4.17 (d, 2H,J= 6.3 Hz, CH2NH), 5.09 (t, 1H,J= 6.3 Hz, 
NH), 7.15 (d, 2H, J = 8.0 Hz, Ark!), 7.34 (d, 2H, J = 8.0 Hz, ArH), 7.40 - 7.44 (m, 2H, 
benzothiophene H), 7.81 - 7.85 (m, 1H, benzothiophene H), 8.06 - 8.10 (m, IH, 
benzothiophene H), 8.14 (s, 1H, benzothiophene H). 




General procedure L4 was followed. Sulfonamide 146 was isolated as a yellow solid 
(0.005 g, 4%, Rf 0.40 (hexane: ethyl acetate, 2:1)); LRMS FAB m/z 326 (MH); HRMS 
FAB m/z 325.98212 (MH) (calculated for C12H935C1N302S2, 325.98247 (Dev. - 1.08 
PPM)); 6H(250 MHz, CDC13): 6.83 (s, 1H, NH), 7.00 (m, 2H, ArH), 7.16 (m, 2H, ArH), 
7.79 (dd, 1H, J = 1.8Hz, 9.2 Hz, benzothiadiazole H), 8.03 (dd, IH, J = 0.7 Hz, 9.2 Hz, 
benzothiadiazole H), 8.46 (dd, IH, J = 0.7 Hz, 1.8 Hz, benzothiadiazole H). 
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N-(4-Chlorobenzyl)-2,1 ,3-benzothiadiazole-5-sulfonamide (147) 
I 	I 	o 
' 
N 
0 H Ii I 
Genera! procedure L4 was followed. Sulfonamide 147 was isolated as a pale yellow 
solid (0.009 g, 7%, Rf  0.42 (hexane: ethyl acetate, 2:1)); LRMS FAB m/z 340 (MH); 
HRMS FAB m/z 339.99880 (MH) (calculated for C13H11 35C1N302S2, 339.998 12 (Dev. 
1.99 PPM)); 6H (250 MHz, CDC13): 4.15 (d, 2H, J = 6.2 Hz, CH2NH), 5.00 (t, IH, J = 
6.2 Hz, NH), 7.06 (d, 2H, J = 10.4 Hz, Arfl), 7.12 (d, 2H, J = 10.4 Hz, Ark!), 7.86 (dd, 
IH, J = 9.2, 0.8 Hz, benzothiadiazole H), 8.06 (dd, IH, J = 9.2, 1.7 Hz, 
benzothiadiazole II), 8.48 (dd, IH, J = 1.7, 0.8 Hz, benzothiadiazole H). 




General procedure L4 was followed. Sulfonamide 148 was isolated as pale yellow solid 
(0.007 g, 5%, Rf 0.38 (hexane: ethyl acetate, 2:1)); LRMS FAB m/z 354 (MH); 
HRMS FAB m/z 354.0 1406 (M1-T) (calculated for C14H1335C1N302S2, 354.0 1377 (Dev. 
0.79 ppm)); 8H  (250 MHz, CDC13): 1.39 (d, 3H, J = 6.9 Hz, CH(CH3)), 4.53 (dq, 1H, J 
= 6.9 Hz, CH(CH3)), 5.00 (d, 1H, J = 6.9 Hz, NH), 6.93 (s, 4H, ArE), 7.72 (dd, 1H, J = 
9.2, 1.8 Hz, benzothiadiazole H), 7.94 (dd, IH, J = 9.2, 0.8 Hz, benzothiadiazole II), 
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N- 1(15)-i -(4-Chlorophenyl)ethylJ-2,1 ,3-benzoth iadiazole-5-sulfonamide (149) 
SQ 
General procedure L4 was followed. Sulfonamide 149 was isolated as a yellow solid 
(0.018 g, 13%, Rf 0.38 (hexane: ethyl acetate, 2:1)); LRMS FAB m/z 354 (MH)*; 
HRMS FA}3 m/z 354.0 1447 (MH) (calculated for C14H1335C1N302S2, 354.0 1377 (Dev. 
1.96 ppm)); oH  (250 MHz, CDC13): 1.38 (d, 3H, J = 6.9 Hz, CH(CH3)), 4.53 (dq, 1H, J 
= 6.9 Hz, CH(CH3)), 5.33 (d, 1H, J = 6.9 Hz, NH), 6.88 - 6.96 (m, H, ArH), 7.73 (dd, 
IH, J = 9.2, 1.8 Hz, benzothiadiazole H), 7.94 (dd, IH, J = 9.2, 0.7 Hz, 
benzothiadiazole II), 8.25 (dd, I H, J = 1.8, 0.7 Hz, benzothiadiazole H). 






General procedure L4 was followed. Sulfonamide 150 was isolated as a yellow solid 
(0.048 g, 28%, Rf 0.49, (hexane: ethyl acetate, 2:1)); LRMS FAB m/z 428 (MH); 
HRMS FAB m/z 427.9960 (MH) (calculated for C14H8F6N302S2, 427.99622 (Dev. - 
0.44 ppm)); 8H  (250 MHz, CDC13): 7.43 (s, 1H, NH), 7.58 (s, 2H, ArH), 7.84 (s, 1H, 
ArH), 8.09 (dd, IH, J = 9.2, 1.8 Hz, benzothiadiazole H), 8.03 (dd, 1H, J= 9.2, 0.7 Hz, 
benzothiadiazole H), 8.57 (dd, IH, J = 1.8, 0.7 Hz, benzothiadiazole II). 
237 
fvpc'ri;iici'iiui !iIur 
N- 13,5-Bis(trifluoromethyl)benzyll -2,1,3-benzothiadiazole-5-sulfon amide (151) 
S 0 
'N 	 1CF3 N  
CF3 
General procedure Library L4 was followed. Sulfonamide 151 was isolated as a yellow 
solid (0.077 g, 44%, Rf 0.47 (hexane: ethyl acetate, 2:1)); LRMS FAB m/z 442 (MH); 
HRMS FAB m/z 442.01195 (MH) (calculated for C15H10 F6N302S2, 442.01187 (Dev. 
0.20 ppm)); 6H  (250 MHz, CDCI3): 4.34 (d, 2H, J = 6.3 Hz, CH2NH), 5.33 (t, 1 H, J = 
6.3 Hz, CH2NII), 7.60 (s, 2H, An]), 7.63 (s, IH, An]), 7.86 (dd, 1H, J = 9.2, 1.8 Hz, 
benzothiadiazole H), 8.07 (dd, J = 9.2, 0.8 Hz, benzothiadiazole 1]), 8.50 (dd, 1 H, J = 
1.8, 0.8 Hz, benzothiadiazole I]). 




General procedure L4 was followed. Sulfonamide 152 was isolated as a yellow solid 
(0.012 g, 8%, Rf 0.40 (hexane: ethyl acetate, 2:1)); LRMS FAB m/z 360 (MH)+; HRMS 
FAB m/z 360.00804 (MH) (calculated for C13H9F3N302S2, 360.00883 (Dev. —2.19 
PPM)); 8H (250 MHz, CDC13): 7.19 (d, 2H, ArH), 7.41 - 7.45 (m, 3H, ArH, NI]), 7.87 
(dd, 1H, J = 9.2, 1.8 Hz, benzothiadiazole H), 8.06 (dd, 1H, J = 9.2, 0.7 Hz, 
benzothiadiazole H), 8.58 (dd, 1H, J = 1.8, 0.7 Hz, benzothiadiazole II). 
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General procedure L4 was followed. Sulfonamide 153 was isolated as a white solid 
(0.048 g, 32%, Rf 0.36 (hexane: ethyl acetate, 2:1)); LRMS FAB m/z 374 (MH); 
HRMS FAB m/z 374.02405 (MH) (calculated for C14H1 1 F3N302S2, 374.02448 (Dev. - 
1.15 PPM));  6 (250 MHz, CDC13): 4.25 (d, 2H, J = 6.2 Hz, CH2NH), 5.07 (t, IH, J = 
6.2 Hz, CH2NH), 7.28 (d, 2H, J = 8.1 Hz, ArH), 7.42 (d, 2H, J = 8.1 Hz, An]), 7.88 
(dd, 1H, J = 9.2, 1.8 Hz, benzothiadiazole II), 8.07 (dd, IH, J = 9.2, 0.7 Hz, 
benzothiadiazole 1]), 8.50 (dd, 1H, J = 1.8, 0.7 Hz, benzothiadiazole I]). 
N-(4-Chlorophenyl)-5-pyridin-2-ylthiophene-2-sulfonamide (154) 
General procedure L4 was followed. Sulfonamide 154 was isolated as a yellow solid 
(0.041 g, 29%, Rf 0.25 (hexane: ethyl acetate, 2:1)); LRMS FAB m/z 351 (MH); 
HRMS FAB m/z 351.00241 (MH) (calculated for C15H1235C1N202S2, 351.00288 (Dev. 
—1.34 ppm)); 6H  (250MHz, CDC13): 7.03 (d, 2H,J= 8.9 Hz, ArH), 7.16-7.21 (m, 4H, 
pyridyl H, ArH, NH), 7.33 (d, 2H, J = 4.0 Hz, thiophene H), 7.38 (d, 1H, J = 4.0 Hz, 






General procedure L4 was followed. Sulfonamide 155 was isolated as a yellow solid 
(0.003 g, 2%, Rf 0.25 (hexane: ethyl acetate, 2:1)); LRMS FAB m/z 365 (MH); HRMS 
FAB m/z 365.0 1790 (MH) (calculated for C16H1435C1N202S2, 365.01853 (Dev. - 1.72 
PPM)); 6H (250 MHz, CDCI3): 4.17 (d, 2H,J= 6.2 Hz, CH2NH), 4.88 (t, IH,J= 6.2 Hz, 
CH2NII), 7.13 - 7.24 (m, 5H, ArH, pyridyl II), 7.42 (d, IH, J = 4.0 Hz, thiophene H), 
7.53 (d, 1H, J = 4.0 Hz, thiophene II), 7.61 - 7.74 (m, 2H, pyridyl H), 8.53 - 8.55 (m, 
IH, pyridyl H). 





General procedure L4 was followed. Sulfonamide 156 was isolated as a yellow solid 
(0.012 g, 8%, Rf 0.29 (hexane: ethyl acetate, 2:1)); LRMS FAB m/z 379 (MH); HRMS 
FAB m/z 379.03451 (MH) (calculated for C17H1635C1N202S2, 379.03418 (Dev. 0.88 
PPM)); oH (250 MHz, CDC13): 1.40 (d, 3H, J = 6.9 Hz, CH(CH3)), 4.52 (dq, IH, J = 6.9 
Hz, CH(CH3)), 4.95 (d, 1H, J = 6.9 Hz, NH), 7.06 - 7.22 (m, 5H, An]), 7.30 (d, 1 H, J = 
4.0 Hz, thiophene H), 7.32 (d, 1H, J = 4.0 Hz, thiophene H), 7.57 - 7.71 (m, 2H, pyridyl 
H), 8.51 -8.54 (m, 1H, pyridyl H). 
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N- [(IS)-1 -(4-Chlorophenyl)ethyl] -5-py rid in-2-ylth iophene-2-sulfon a mide (157) 
General procedure L4 was followed. Sulfonamide 157 was isolated as a yellow solid 
(0.005 g, 3%, Rf 0.27 (hexane: ethyl acetate, 2:1)); LRMS FAB m/z 379 (MH); HRMS 
FAB m/z 379.03367 (MH) (calculated for C17H1635C1N202S2, 379.03418 (Dev. - 1.32 
PPM)); & (250 MHz, CDC13): 1.40 (d, 3H, J = 6.9 Hz, CH(CH3)), 4.52 (dq, I H, J = 6.9 
Hz, CH(CH3)), 4.87 (d, 11-I, J = 6.9 Hz, NB), 7.06 - 7.22 (m, 5H, ArII), 7.30 (d, I H, J 
= 3.9 Hz, thiophene II), 7.32 (d, IH, J = 3.9 Hz, thiophene 1]), 7.58 - 7.72 (m, 2H, 





General procedure L4 was followed. Sulfonamide 158 was isolated as a white solid 
(0.053 g, 29%, Rf 0.47 (hexane: ethyl acetate, 2:1)); LRMS FAB m/z 453 (MH); 
HRMS FAB m/z 453.01639 (MH) (calculated for C17H11 F6N202, 453.01662 (Dev - 
0.50 ppm)); 6H (250 MHz, CDC13): 7.20 - 7.22 (m, IH, pyridyl H), 7.40 (d, 1H, J = 4.0 
Hz, thiophene B), 7.52 - 7.54 (m, 3H, ArH), 7.55 (d, 1H, J= 4.0 Hz, thiophene H), 7.58 
- 7.62 (m, 1H, pyridyl B), 7.68 (m, IH, pyridyl B), 7.80 (s, IH, NB), 8.51 (m, 1H, 
pyridyl B). 
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General procedure L4 was followed. Sulfonamide 159 was isolated as a yellow solid 
(0.061 g, 33%, Rf 0.33 (hexane: ethyl acetate, 2:1)); LRMS FAB m/z 467 (MH); 
HRMS FAB m/z 467.03259 (MH) (calculated for C18H13 F6N202S2, 467.03227 (Dev. 
0.69 ppm)); 6H  (250 MHz, CDCI3): 4.34 (d, 2H, J = 6.5 Hz, CH2NH), 5.19 (t, IH, J = 
6.5 Hz, NH), 7.20- 7.24 (m, IH, pyridyl H), 7.40 (d, 1H, J = 4.0 Hz, thiophene H), 7.52 
(d, 1H, J = 4.0 Hz, thiophene H), 7.60 - 7.74 (m, 5H, pyridyl H, ArE), 8.51 - 8.53 (m, 
IH, pyridyl H). 




General procedure L4 was followed. Sulfonamide 160 was isolated as a pale yellow 
solid (0.012 g, 8%, Rf 0.27 (hexane: ethyl acetate, 2:1)); LRMS FAB m/z 385 (MH); 
HRMS FAB m/z 385.02921 (MH) (calculated for C16H12F3N202S2, 385.02923 (Dev. - 
0.05 ppm)); 6H  (250 MHz, CDC13): 7.18 - 7.22 (m, 4H, ArH, pyridyl H), 7.36 (d, IH, J 
= 4.0 Hz, thiophene H), 7.45 - 7.52 (m, 3H, ArE), 7.55 - 7.70 (m, 2H, ArE), 8.50 - 
8.52 (m, IH, pyridyl H); Mpt. 219.4 -219.8 °C. 
5-Pyridin-2-yI-N- 14-(trifluoromethyl)benzyl] thiophene-2-sulfonamide (161) 
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Genera! procedure L4 was followed. Sulfonamide 161 was isolated as a yellow solid 
(0.031 g, 19%, Rf 0.24 (hexane: ethyl acetate, 2:1)); LRMS FAB m/z 399 (MH); 
HRMS FAB m/z 399.04554 (MH) (calculated for C17H14 F3N202S2, 399.04488 (Dev. 
1.65 PPM)); 6H (250 MHz, CDC13): 4.26 (d, 2H, J = 6.4 Hz, CH2NH), 5.06 (t, 1H, J = 
6.4 Hz, NI]), 7.17 - 7.24 (m, 1 H, pyridy! H), 7.34 (d, 2H, J = 8.1 Hz, ArH), 7.40 (d, 1 H, 
J = 4.0 Hz, thiophene H), 7.49 (d, 2H, J = 8.1 Hz, ArH), 7.51 (d, IH, J = 4.0 Hz, 
thiophene H), 7.60 - 7.74 (m, 2H, pyridy! H), 8.51 - 8.54 (m, I H, pyridyl H). 
4,5-Dibromo-N-(4-chlorobenzyl)thiophene-2-sulfonamide (162) 
Br 
Br- i 'P S 
Genera! procedure L4 was followed. Sulfonamide 162 was isolated as a white solid 
(0.028 g, 16%, Rf 0.51(hexane: ethyl acetate, 2:1)); LRMS FAB m/z 446 (MH); 
HRMS FAB m/z 445.81207 (MH) (calculated for C11 H979Br81Br35C1NO2S2, 445.81108 
(Dev. 2.22 ppm)); 6H  (250 MHz, CDC13): 4.15 (d, 2H, J = 6.2 Hz, CH2NH), 4.89 (t, 1H, 
= 6.2 Hz, NH), 7.13 (d, 2H, J = 8.7 Hz, ArH), 7.24 (d, 2H, J = 6.2 Hz, ArH), 7.27 (s, 
IH, thiophene I-I). 
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Genera! procedure L4 was followed. Sulfonamide 163 was isolated as a white solid 
(0.015 g, 8%, Rf 0.49 (hexane: ethyl acetate, 2:1)); LRMS FAB m/z 460 (MH); HRMS 
FAB m/z 459.82693 (MH) (calculated for C12H11 79Br81Br35C1NO2S2, 459.82673 (Dev. 
0.42 PPM)); 5H (250 MHz, CDCI3): 1.48 (d, 3H, J = 6.9 Hz, CH(CH3)), 4.56 (dq, IH, J 
= 6.9 Hz, CH(CH3)), 4.98 (d, 1H, J = 6.9 Hz, NI]), 7.04 (s, IH, thiophene 1]), 7.10 (d, 
2H, J = 8.4 Hz, AnT), 7.26 (d, 2H, J = 8.4 Hz, ArT]). 
N-[3,5-Bis(trifluoromethyl)benzyfl-4,5-dibro moth iophene-2-sulfonamide (165) 
Br 
Br-i 0 
"EN 	CF3 0H9'  
CF3 
General procedure L4 was followed. Sulfonamide 165 was isolated to afford 165 as a 
white solid (0.071 g, 33%, Rf 0.58 (hexane: ethyl acetate, 2:1)); LRMS FAB m/z 548 
(M1-I)+; HRMS FAB m/z 547.82464 (N4H) (calculated for C13H879Br81BrF6NO2S2, 
547.82482 (Dev. - 0.34 ppm)); 6H  (250 MHz, CDC13): 4.40 (d, 2H, J = 6.4 Hz, CH2NH), 
5.30 (t, IH, J = 6.4 Hz, NR), 7.33 (s, 1H, thiophene II), 7.74 (s, 2H, An]), 7.83 (s, 1H, 
An]). 
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4,5-Dibromo-N- 14-(trifluoromethyl)benzyll thiophene-2-sulfonamide (166) 
Br 
Br-  b 'p 
S S N 
° H 
CF3  
General procedure L4 was followed. Sulfonamide 166 was isolated as a white solid 
(0.024 g, 13%, Rf 0.51 (hexane: ethyl acetate, 2:1)); LRMS FAB m/z 480 (MH); 
HRMS FAB m/z 479.83798 (MH) (calculated for C12H979Br81 BrF3NO2S2, 479.83744 
(Dev. 1.12 PPM)); 8H(250 MHz, CDCI3): 4.31 (d, 2H,J= 6.3 Hz, CH2NH), 5.17 (t, IH, 
J = 6.3 Hz, NB), 7.34 (s, IH, thiophene II), 7.40 (d, 2H, J = 8.0 Hz, An]), 7.60 (d, 2H, 
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A solution of benzenesulfonyl chloride (54 1iL, 0.42 mmole, 2.10 eq.) in DCM (1.5 mL, 
anhydrous) was added to PS-DMAP (570 mg, 0.20 mmole, 1.0 eq.) and allowed to stir 
for 2 hours at room temperature before the resin was washed five times with DCM. A 
solution of the 4-fluoroaniline (14 .tL, 0.14 mmole, 0.70 eq.) in DCM (1.5 mL, 
anhydrous) was added to the resin and allowed to stir at room temperature for 72 hours. 
The resin was washed with DCM and the filtrate collected and concentrated in vacuo to 
a residue that was columned on silica (hexane: ethyl acetate, 1:1). Sulfonamide 172 was 
isolated as a white solid (0.008 g, 23 %, Rf 0.46 (hexane: ethyl acetate, 1:1)); LRMS ES 
m/z 250.0 (M-H; 6H (250 MHz, CDC13): 6.78 (bs, IH, NH), 6.82 - 6.89 (m, 2H, 112, 
H6), 6.94 —7.00 (m, 2H, 113, H5), 7.33-7.42 (m, 2H, H9, HI 1), 7.45 —7.52 (m, IH, 
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To a stirring solution of 4-chloro-3-nitrobenzenesulfonyl chloride (0.500 g, 1.95 mmole, 
1.0 eq.), in DCM (5 mL) was added 3,5-dichloroaniline (0.348 g, 2.15 mmole, 1.1 eq.) 
and pyridine (158 jiL, 1.95 mmole, 1.0 eq.). The reaction mixture was allowed to stir at 
room temperature for 24 hours before being concentrated in vacuo to afford a brown 
residue. The residue was dissolved in ethyl acetate (50 mL) and washed with HCI (1 M, 2 
x 50 mL); brine (50 mL) and concentrated in vacuo to afford a residue that was 
columned on silica (hexane: ethyl acetate, 2:1) to afford sulfonamide 174 as a white 






To a stirring solution 4-chloro-3-nitrobenzenesulfonyl chloride (0.500 g, 1.95 mmole, 
1.0 eq.), in DCM (5 mL) was added 4-fluoroaniline (207 .iL, 2.15 mmole, 1.1 eq.) and 
pyridine (158 1.iL, 1.95 mmole, 1.0 eq.). The reaction mixture was allowed to stir at 
room temperature for 24 hours before being concentrated in vacuo to afford a brown 
residue. The residue was dissolved in ethyl acetate (50 mL) and washed with HC1 (1M, 2 
x 50 mL); brine (50 mL) and concentrated in vacuo to afford a residue that was 
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columned on silica (hexane: ethyl acetate, 2:1) to afford sulfonamide 175 as a pink solid 
(0.555 g, 86%); LRMS ES m/z 329.0 (M-H)-. 
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To a stirring solution of N-[3,5-bis(trifluoromethyl)phenyl]-5-chlorothiophene-2-
sulfonamide (0.080 g, 0.19 mmole, 1.0 eq.) in acetone (3 mL), methyl iodide (61 jtL, 
0.98 mmole, 5.0 eq.) and triethylamine (27 tL, 0.19 mmole, 1.0 eq.) were added. The 
reaction mixture was allowed to stir at room temperature for 24 hours before being 
diluted with water (20 mL) and extracted into ethyl acetate (2 x 20 mL). The combined 
organics were washed with water (2 x 20 mL), dried over anhydrous MgSO4, and 
concentrated in vacuo to afford a residue that was purified on silica (hexane: ethyl 
acetate 15:1). Appropriate fractions were combined and concentrated in vacuo to afford 
sulfonamide 192 as a white solid (0.010 g, 12%); 8H  (250 MHz, CDC13): 3.23 (s, 3H, 
117), 6.90 (d, IH, J = 4.0 Hz, H9), 7.09 (d, 1H, J = 4.0 Hz, H10), 7.57 (s, 2H, H2, H6), 
7.75 (s, 2H, H4). 
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N-AIlyl-N- [3,5-bis(trifluoromethyl)phenyl] -5-chlorothiophene-2-sulfonamide (205) 
CF3 12 	11 
' 1
C1 —3"S 10 s 
~64 
CF3 0 	2 
7 H8 
9 
General procedure S2 was followed using N-[3 ,5 -bis(trifluoromethyl)phenyl]-5-
ch!orothiophene-2-sulfonamide (0.091 g, 0.22 mmole, 1.0 eq.), allyl bromide (96 pL, 
1.10 mmole, 5.0 eq.) and triethylamine (300 j.tL, excess). The reaction mixture was 
irradiated in the Discover TM at 80 °C for 10 minutes. The crude reaction mixture was 
columned on silica (hexane: ethyl acetate 15:1) to afford sulfonamide 205 as a white 
solid (0.045 g, 45%); 8H (250 MHz, CDCI3): 4.19 (dt, 2H, J = 6.4, 1.3 Hz, H7), 5.07 (dd, 
1H, J = 9.5, 1.3 Hz, H9 15), 5.12 (dd, IH, J = 16.3, 1.3 Hz, H9trans), 5.58 - 5.72 (m, IH, 
H8), 6.89 (d, IH, J = 4.0 Hz, Hi 1), 7.10 (d, IH, J = 4.0 Hz, H12), 7.50 (s, 2H, 112, H6), 
7.76 (s, 1H, H4). 
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General procedure S2 was followed using 4,5-dibromo-N-[4-(trifluoromethyl)-
phenyl]thiophene-2-sulfonamide (0.104 g, 0.23 mmole, 1.0 eq.), methyl iodide (61 lit, 
0.98 mmole, 4.4 eq.) and triethylamine (200 tL, excess). The reaction mixture was 
irradiated in the DiscoverTM at 150 °C for 5 minutes. The crude reaction mixture was 
columned on silica (hexane: ethyl acetate 15:1) to afford sulfonamide 196 as a white 
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solid (0.022 g, 20%); LRMS EI m/z 479 (M) calculated for C12H879Br2F3NO2S2; oH 
(250 MHz, CDCI3): 3.21 (s, 3H, 117), 7.11 (s, 1H, H9), 7.27 (d, 2H, J = 7.5 Hz, 112, H6), 
7.57 (d, 2H, J = 7.5 Hz, 113, H5). 
N-Benzyl-N- 13,5-bis(trifluoromethyl)phenylj -5-bromothiophene-2-sulfonamide 
(197) 
CF 3  16 	15 	5 
Bri 1 S 14




General procedure S2 was followed using N-[3 ,5 -bis(trifluoromethyl)phenyl ]-5 - 
bromothiophene-2-sulfonamide (0.100 g, 0.22 mmole, 1.0 eq.), benzyl bromide (131 .tL, 
1.10 mmole, 5.0 eq.) and triethylamine (300 j.iL, excess). The reaction mixture was 
irradiated in the DiscoverTM  at 60 °C for 10 minutes. The crude reaction mixture was 
purified on silica (hexane: ethyl acetate 15:1) to afford sulfonamide 197 as a white solid 
(0.046 g, 38%, Rf 0.29 (hexane: ethyl acetate 15:1)); LRMS ES m/z 566.0 (M + Na) 
calculated for C19H1279BrF6NO2S2; Vm (film)/cm' 3094 (thiophene C-H), 3034 (aryl C-
H), 2922 (C-H), 1368 (SO2), 1164 (SO2); 8H  (250 MHz, CDC13): 4.72 (s, 2H, 117), 7.05 
(d, 1H, J = 4.0 Hz, H15), 7.10 (d, 1H, J = 4.0 Hz, H16), 7.14 - 7.20 (m, 5H, H9, H10, 
Hi 1, H12, H13), 7.41 (s, 2H, 112, H6), 7.67 (s, 1H, H4); Mpt. 109.4— 110. 2 °C. 
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General procedure S2 was followed using N-[3,5-bis(trifluoromethyl)phenyl]-5-
chlorothiophene-2-sulfonamide (0.091 g, 0.22 mmole, 1.0 eq.), benzyl bromide (131 l.iL, 
1.10 mmole, 5.0 eq.) and triethylamine (300 tL, excess). The reaction mixture was 
irradiated in the Discover TM at 60 °C for 10 minutes. The crude reaction mixture was 
columned on silica (hexane: ethyl acetate 15:1) to afford sulfonamide 198 as a white 
solid (0.052 g, 47%,, R f 0.25 (hexane: ethyl acetate 15:1)); LRMS ES m/z 522.0 (M + 
Na); HRMS ET m/z 498.98972 (M) (calculated for C19H1235C1F6NO2S2, 498.99022 
(Dev. - 1.01 PPM)); 6H (250 MHz, CDCI3): 4.73 (s, 2H, 117), 6.92 (d, 1H, J = 4.0 Hz, 
H16), 7.13 —7.21 (m, 6H, H9, H10, HI 1, H12, H13, HIS), 7.41 (s, 2H, 112, H6), 7.67 (s, 
1H, H4). 
N-Benzyl-5-bromo-N-[4-(trifluoromethyl)phenyl] thiophene-2-sulfonamide (199) 
16 	15 	5 





General procedure per S2 was followed using 5-bromo-N- [4-(trifluoromethyl)phenyl] - 
thiophene-2-sulfonamide (0.085 g, 0.22 mmole, 1.0 eq.), benzyl bromide (131 ttL, 1.10 
mmole, 5.0 eq.) and triethylamine (300 j.iL, excess). The reaction mixture was irradiated 
in the Discover  TM at 60 °C for 10 minutes. The crude reaction mixture was purified on 
silica (hexane: ethyl acetate 15:1) to afford sulfonamide 199 as a white solid (0.067 g, 
64%, Rf 0.20 (hexane: ethyl acetate 15:1)); LRMS ES m/z 498.0 (M + Na); Vmax 
(film)/cm-1 3094 (thiophene C-H), 3069 (aryl C-H), 2924 (C-H), 1325 (SO2), 1164 
(SO2); 61-1  (250 MHz, CDC13): 4.72 (s, 2H, 117), 7.02 (d, IH, J = 4.0 Hz, H15), 7.08 (d, 
2H, J = 4.0 Hz, H16), 7.11 —7.20 (m, 7H, 112, H6, H9, H10, HI I, H12, H13), 7.45 (d, 
2H, J = 8.3 Hz, H3, H5); öc (63 MHz, CDC13): 54.6 (C7), 120.5 (CA,), 123.5 (q, JCF = 
272 Hz, CF3), 126.1 (2 x CHAr), 128.0 (CHAr), 128.3 (2 x CHAr), 128.5 (2 X CHAr), 128.8 
(2 x CHM), 130.0 (q, JCF = 33 Hz, C4), 130.5 (CHAr), 133.0 (CHAs), 134.6 (CA,), 139.1 
(CA,), 141.5 (CA,); Mpt.103.2 —103.5 °C. 
N-Benzyl-5-ch!oro-N- [4-(trifluoromethyl)phenylj thiophene-2-sulfonamide (200) 





General procedure S2 was followed using 5-ch!oro-N-[4-(trifluoromethyl)phenyl]-
thiophene-2-sulfonamide (0.075 g, 0.22 mmole, 1.0 eq.), benzyl bromide (131 itL,  0.98 
mmole, 5.0 eq.) and triethylamine (300 jit, excess). The reaction mixture was irradiated 
in the DiscoverTM  at 60 °C for 10 minutes. The crude reaction mixture was columned on 
silica (hexane: ethyl acetate 15:1) to afford sulfonamide 200 as a pale yellow solid 
(0.083 g, 87%); LRMS ES m/z 454.1 (M + Na); Vmax (film)/cm-1 3106 (thiophene C-
H), 3094 (aryl C-H), 2923 (C-H), 1334 (SO2), 1163 (SO2); 6H  (250 MHz, CDC13): 4.73 
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(s, 2H, 117), 6.89 (d, IH, J = 4.0 Hz, H15), 7.13 (d, 2H, J = 4.0 Hz, H16), 7.16— 7.19 
(m, 7H, 112, H6, H9, H10, HI 1, H12, H13), 7.47 (d, 2H, J = 8.4 Hz, H3, H5); Mpt. 
112.9-113.3°C. 
N-Benzyl-N- 13,5-bis(trifluorom ethyl) phenyl] -4,5-dibromothiophene-2-sulfonamide 
(201) 
Br 16 	 CF3 15  





General procedure S2 was followed using N-[3 ,5 -bis(trifluoromethyl)phenyl] -4,5-
dibromothiophene-2-sulfonamide (0.103 g, 0.19 mmole, 1.0 eq.), benzyl bromide (131 
j.iL, 1.10 mmole, 5.0 eq.) and triethylamine (300 tL, excess). The reaction mixture was 
irradiated in the Discover TM at 60 °C for 10 minutes. The crude reaction mixture was 
columned on silica (hexane: ethyl acetate) to afford sulfonamide 201 as a cream solid 
(0.090 g, 75%); LRMS ES m/z 578.0 (M + Na) calculated C191-11279Br81 BrF6NO2S2; 
Vmax (film)/cm-1 3082 (thiophene C-H), 3037 (aryl C-H), 2929 (C-H), 1358 (SO2), 1134 
(SO2); 6H(2SO  MHz, CDCI3): 4.72 (s, 2H, 117), 7.13 —7.22 (m, 6H, H9, H10, H11, H12, 
H13, HIS), 7.43 (s, 2H, H2, H6), 7.71 (s, 1H, H4); Mpt. 137.7— 138.4 °C. 
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General procedure S2 was followed using 4,5-dibromo-N-[4-(trifluoromethyl)phenyl] - 
thiophene-2-sulfonamide (0.075 g, 0.22 mmole, 1.0 eq.), benzyl bromide (131 iL, 1.10 
mmole, 5.0 eq.) and triethylamine (300 IlL, excess). The reaction mixture was irradiated 
in the Discover TM at 60 °C for 10 minutes. The crude reaction mixture was columned on 
silica (hexane: ethyl acetate 15:1) to afford sulfonamide 202 as a white solid (0.114 g, 
81%); LRMS ES m/z 646.1 (M + Na) calculated for C18H1279Br81BrF3NO2S2; 8H (250 
MHz, CDCI3): 4.73 (s, 2H, 117), 7.14-7.20 (m, IH, J = 4.0 Hz, HIS), 7.13 (d, 21-1, J = 
4.0 Hz, H16), 7.16-7.19 (m, 8H, 112, H6, H9, H10, HI I, H12, H13, H15), 7.49 (d, 2H, 
J= 8.3 Hz, H3,H5). 
N-Benzyl-N- [3,5-bis(trifluoromethyl)phenyl] -5- [2-(methylthio)pyrimidin-5-ylJ - 
thiophene-2-sulfonamide (203) 
19 16 15 	5 
CF3 
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General procedure S2 was followed using N-[3 ,5 -bis(trifluoromethyl)phenyl]-5 -[2-
(methylthio)pyrimidin-5-yl]-thiophene-2-sulfonamide (0.110 g, 0.22 mmole, 1.0 eq.), 
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benzyl bromide (131 jtL, 1.10 mmole, 5.0 eq.) and triethylamine (300 iL, excess). The 
reaction mixture was irradiated in the Discover TM  at 60 °C for 10 minutes. The crude 
reaction mixture was columned on silica (hexane: ethyl acetate 15:1) to afford 
sulfonamide 203 as a yellow solid (0.074 g, 57%); LRMS ES m/z 612.3 (M + Na); 
Vmax (film)/cm-1 3093 (aryl C-H), 2930 (C-H), 1355 (SO2), 1137 (SO2); 8H (250 MHz, 
CDCI3): 2.59 (s, 3H, 1122), 4.83 (s, 2H, 117), 7.20 - 7.27 (m, 6H, H9, H10, HI 1, H12, 
HI 3, HI 9), 7.45 (d, I H, J = 4.0 Hz, HI 5), 7.57 (s, 2H, 112, H6), 7.73 (d, 1 H, J = 4.0 Hz, 
H16), 7.81 (s, IH, H4), 8.65 (d, 1H, J = 5.2 Hz, 1121); Mpt. 141.8— 142.3. 
N-Allyl-N- [3,5-bis(trifluoromethyl)phenyl] -5-bromothiophene-2-sulfonamide (204) 
12 11 	CF3 
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General procedure S2 was followed using N-[3,5-bis(trifluoromethyl)phenyl]-5-
bromothiophene-2-sulfonamide (0.100 g, 0.22 mmole, 1.0 eq.), allyl bromide (96 tL, 
1.10 mmole, 5.0 eq.) and triethylamine (300 j.tL, excess). The reaction mixture was 
irradiated in the Discover TM at 60 °C for 10 minutes. The crude reaction mixture was 
columned on silica (heptane: hexane: ethyl acetate, 8:2:1) to afford sulfonamide 204 as a 
pale yellow solid (0.052 g, 48%, Rf 0.26 (heptane: hexane: ethyl acetate 8:2:1)); 6H  (250 
MHz, CDC13): 4.19 (dt, 2H, J = 6.4, 1.3 Hz, 117), 5.08 (dd, 1H, J = 9.5, 1.3 Hz, 
5.10 (dd, IH, J = 17.6, 1.3 Hz, fl9trans),  5.58 - 5.74 (m, 1H, 118), 7.03 (d, 1H, J = 4.0 
Hz, H12), 7.06 (d, 1H, J = 4.0 Hz, Hi 1), 7.50 (s, 2H, 112, H6), 7.76 (s, 1H, H4). 
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N-Allyl-5-bromo-N- 14-(trifluoromethyl)phenyll thiophene-2-sulfona mide (206) 
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General procedure S2 was followed using 5-bromo-N- [4-(tri fi uoromethyl)phenyl]-
thiophene-2-sulfonamide (0.085 g, 0.22 mmole, 1.0 eq.), allyl bromide (96 [tL, 1.10 
mmole, 5.0 eq.) and triethylamine (300 tL, excess). The reaction mixture was irradiated 
in the Discover TM at 60 °C for 10 minutes. The crude reaction mixture was columned on 
silica (heptane: hexane: ethyl acetate, 8:2:1) to afford sulfonamide 206 as a white solid 
(0.054 g, 57%, Rf 0.14 (heptane: hexane: ethyl acetate, 8:2:1)); 6H (250 MHz, CDCI3): 
4.18 (dt, 2H, J = 9.3, 1.3 Hz, 117), 5.04 (dd, lH, J = 9.3, 1.3 Hz, H9 15), 5.07 (dd, 1H, J 
= 16.6, 1.3 Hz, H9trans), 5.59— 5.75 (m, IH, H8), 7.00 (d, 1H, J = 4.0 Hz, H12), 7.05 (d, 
1H, J = 4.0 Hz, Hi 1), 7.20 (d, 2H, J = 8.9 Hz, 112, H6), 7.55 (d, 2H, J = 8.9 Hz, 113, 
H5). 
N-AlIyl-5-chloro-N- 14-(trifluoromethyl)phenyll thiophene-2-sulfonamide (207) 
12 	11 	5 
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To a stirring solution of 5 -chloro-N-[4-(trifluoromethyl)phenyl]thiophene-2-sulfonamide 
(0.118 g, 0.22 mmole, 1.0 eq.) in acetone (3.0 mL) was added allyl bromide (96 iL, 1.10 
mmole, 5.0 eq.) followed by triethylamine (300 tL, excess). The reaction mixture was 
255 
Chapter . 	 Lvpr ii,tiiul Procedurcs  
irradiated in the DiscoverTM at 70 °C for 10 minutes, with active cooling of the sample. 
The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (2 
x 20 mL). The combined organics were washed with water (2 x 20 mL) before being 
concentrated in vacuo to afford a residue that was columned on silica (heptane: hexane: 
ethyl acetate, 8:2:1). Appropriate fractions were combined and concentrated in vacuo to 
afford sulfonamide 207 as a cream solid (0.074 g, 84%, Rf 0. 16, (heptane: hexane: ethyl 
acetate, 8:2:1)); LRMS El m/z 381 (M); HRMS EI m/z 380.98640 (M) (calculated 
for C14H1135C1F3NO2S2, 380.987 19 (Dev. —2.05 ppm)); 8H  (250 MHz, CDC13): 4.18 (dt, 
2H, J = 6.3, 1.3 Hz, 117), 5.06 (dd, 1H, J = 9.8, 1.3 Hz, 	5.08 (dd, IH, J = 17.6, 
1.3 Hz, H9irans), 5.59-5.75 (m, 11-1, H8), 6.86 (d, IH, J = 4.0 Hz, HI 1), 7.09 (d, Il-I, J = 
4.0 Hz, H12), 7.20 (d, 2H, J = 8.4 Hz, 112, H6), 7.55 (d, 2H, J = 8.4 Hz, H3, H4); 6 (63 
MHz, CDC13): 53.4 (C7), 119.8 (C9), 123.5 (q, JCF = 272 Hz, CF3), 126.1 (2 x CHAr), 
126.8 (CHAr), 128.7 (2 X CHAr), 131.0 (q, JCF = 33 Hz, C4), 131.6 (C8), 132.2 (CHAr), 
136.1 (CAr), 137.8 (CA,),  141.6 (CAr). 
N-All yI-N- 13,5-bis(trifluoromethyl)phenyll -4,5-dibromothiophene-2-sulfonamide 
(208) 
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General procedure S2 was followed using N-[3,5-bis(trifluoromethyl)phenyl]-4,5-
dibromothiophene-2-sulfonamide (0.103 g, 0.19 mmole, 1.0 eq.), allyl bromide (96 jit, 
1.10 mmole, 5.7 eq.) and triethylamine (300 lLL, excess). The reaction mixture was 
irradiated in the Discover TM  at 70 °C for 10 minutes. The crude reaction mixture was 
columned on silica (heptane: hexane: ethyl acetate, 8:2:1) to afford sulfonamide 208 as a 
white solid (0.040 g, 36%); 6H (250 MHz, CDC13): 4.19 (dt, 2H, J = 6.4, 1.3 Hz, 117), 
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5.08 (dd, 1 H, J = 9.3, 1.3 Hz, H9), 5.13 (dd, 1 H, J = 16.6, 1.3 Hz, H9tran ), 5.61 - 5.71 
(m, 1H, H8), 7.12 (s, 1H, HI 1), 7.51 (s, 2H, 112, H6), 7.79 (s, 1H, H4). 
N-Allyl-4,5-dibromo-N- 14-(trifluoromethyl)phenyll thiophene-2-sulfonamide (209) 
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General procedure S2 was followed using 4, 5-dibromo-N-[4-(tri fluoromethyl)phenyl] - 
thiophene-2-sulfonamide (0.104 g, 0.22 mmole, 1.0 eq.), allyl bromide (96 [tL, 1.10 
mmole, 5.0 eq.) and triethylamine (300 jtL, excess). The reaction mixture was irradiated 
in the DiscoverTM  at 70 °C for 10 minutes. The crude reaction mixture was columned on 
silica (heptane: hexane: ethyl acetate 8:2:1) to afford sulfonamide 209 as a white solid 
(0.043 g, 39%, Rf 0.30 (heptane: hexane: ethyl acetate 8:2:1)); Vmax (film)/cm' 3116 
(thiophene C-H), 3089 (aryl C-H), 2927 (C-H), 1327 (SO2), 1170 (SO2); 6H  (250 MHz, 
CDCI3): 4.18 (dt, 2H, J = 6.3, 1.3 Hz, 117), 5.06 (dd, IH, J = 9.1, 1.3 Hz, H9 1 ), 5.11 
(dd, 1H, .J = 16.6, 1.3 Hz, H9trans), 5.61 - 5.72 (m, 1H, H8), 7.14 (s, IH, HI 1), 7.22 (d, 
2H, J = 8.9 Hz, 112, H6), 7.57 (d, 2H, J = 8.9 Hz, H3, H5); Mpt. 85.2 - 85.7 °C. 
257 
Lxrri,iint;/ 
N- [3,5-Bis(trifluoromethyl)phenyl] -5-bromo-N-ethylthiophene-2-sulfonamide (211) 
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General procedure S2 was followed using N-[3,5-bis(trifluoromethyl)phenyl]-5-
bromothiophene-2-sulfonamide (0.100 g, 0.22 mmole, 1.0 eq.), ethyl iodide (88 [LL, 1.10 
mmole, 5.0 eq.) and triethylamine (300 jiL, excess). The reaction mixture was irradiated 
in the Discover TM  at 70 °C for 10 minutes. The crude reaction mixture was columned on 
silica (heptane: hexane: ethyl acetate 8:2:1) to afford sulfonamide 211 as a white solid 
(0.037 g, 35%); 6H(25O  MHz, CDCI3): 1.16 (t, 3H,J= 7.2 Hz, H8), 3.71 (q, 2H,J= 7.2 
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General procedure S2 was followed using N-[3 ,5-bis(trifluoromethyl)pheny!] -5-
chlorothiophene-2-sulfonamide (0.091 g, 0.22 mmole, 1.0 eq.), ethyl iodide (88 i.tL,  1.10 
mmole, 5.0 eq.) and triethylamine (300 j.iL, excess). The reaction mixture was irradiated 
in the Discover TM at 70 °C for 10 minutes. The crude reaction mixture was columned on 
silica (heptane: hexane: ethyl acetate, 8:2:1) to afford sulfonamide 212 as a white solid 
(0.044 g, 46%, Rf 0.25 (heptane: hexane: ethyl acetate, 8:2:1)); 6H (250 MHz, CDC13): 
1.15 (t, 3H, J = 7.2 Hz, H8), 3.71 (q, 2H, J = 7.2 Hz, H7), 6.96 (d, 1H, J = 4.0 Hz, 
HI 1), 7.15 (d, 1H, .1 = 4.0 Hz, H10), 7.58 (s, 2H, 112, H6), 7.87 (s, 1H, H4); 8c (63 
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MHz, CDC13): 13.9 (C8), 43.8 (0), 121.9 (C4), 122.5 (q, JCF = 273 Hz, CF3), 126.9 
(CHAr), 128.8 (2 X CHAr), 132.4 (CHAr), 132.6 (q, JCF = 32 Hz, C3, CS), 135.3 (CA,), 
138.3 (CA,), 135.3 (CA,), 140.2 (CAr). 
5-Bromo-N-ethyl-N- [4-(trifluoromethyl)phenyl] thiophene-2-sulfonamide (213) 
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General procedure S2 was followed using 5-bromo-N-[4-(trifl uoromethyl)phenyl] - 
thiophene-2-sulfonamide (0.08 g, 0.22 mmole, 1.0 eq.), ethyl iodide (88 jL, 1.10 
mmole, 5.0 eq.) and triethylamine (300 gxL, excess). The reaction mixture was irradiated 
in the DiscoverTM at 70 °C for 10 minutes. The crude reaction mixture was columned on 
silica (hexane: ethyl acetate 8:1) to afford sulfonamide 213 as a white solid (0.046 g, 
51%, Rf 0.19 (hexane: ethyl acetate 8:1)); 5H (250 MHz, CDC13): 1.12 (t, 3H,J= 7.1 Hz, 
H8), 3.69 (q, 2H, J = 7.1 Hz, 117), 7.06 (d, IH, J = 4.0 Hz, Hi 1), 7.10 (d, 1H, J = 4.0 
Hz, H10), 7.28 (d, 2H, J = 8.3 Hz, 112, H6), 7.63 (d, 2H, J = 8.3 Hz, H3, H5); 6c (63 
MHz, CDC13): 13.9 (C8), 45.7 (C7), 120.1 (CAr), 123.1 (q, JCF = 272 Hz, CF3), 126.3 (2 
x CIIAr), 128.8 (2 x CHAr), 130.1 (q, JCF = 30 Hz, C4), 130.4 (CHAr), 132.7 (CHAr), 
139.0 (CA,), 141.5 (CA,). 
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General procedure S2 was followed using 5 -chloro-N-[4-(trifluoromethyl)phenyl]-
thiophene-2-sulfonamide (0.075 g, 0.22 mmole, 1.0 eq.), ethyl iodide (81 j.tL, 1.10 
mmole, 5.0 eq.) and triethylamine (300 jiL, excess). The reaction mixture was irradiated 
in the DiscoverTM  at 70 °C for 10 minutes. The crude reaction mixture was columned on 
silica (hexane: ethyl acetate, 8:1) to afford sulfonamide 214 as a white solid (0.031 g, 
38%); 6H(2SO  MHz, CDC13): 1.13 (t, 3H, J = 7.1 Hz, H8), 3.69 (q, 2H, J = 7.1 Hz, 117), 
6.73 (d, 1H, J = 4.0 Hz, HI 1), 7.14 (d, 1H, J = 4.0 Hz, HI 0), 7.29 (d, 2H, J = 8.3 Hz, 
112, H6), 7.63 (d, 2H, J = 8.3 Hz, H3, H5). 
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General procedure S2 was followed using N-[3 ,5 -bis(trifluoromethyl)phenyl]-4,5-. 
dibromothiophene-2-sulfonamide (0.103 g, 0.19 mmole, 1.0 eq.), ethyl iodide (88 iL, 
1.10 mmole, 5.8 eq.) and triethylamine (300 jtL, excess). The reaction mixture was 
irradiated in the DiscoverlM  at 70 °C for 10 minutes. The crude reaction mixture was 
columned on silica (hexane: ethyl acetate, 8:1) to afford a white solid (0.028 g, 26%); 6H 
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(250 MHz, CDC13): 1.16 (t, 3H,J= 7.2 Hz, 118), 3.71 (q, 2H,J= 7.2 Hz, 117), 7.18 (s, 
IH, HI 0), 7.60 (s, 2H, 112, H6), 7.90 (s, IH, H4). 
4,5-Dibromo-N-ethyl-N- 14-(trifluoromethyDphenyll thiophene-2-sulfonamide (216) 
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General procedure S2 was followed using 4,5-dibromo-N-[4-(trifl uoromethyl)phenyl] - 
thiophene-2-sulfonamide (0.118 g, 0.25 mmole, 1.0 eq.), ethyl iodide (88 pL, 1.10 
mmole, 4.4 eq.) and triethylamine (300 ltL, excess). The reaction mixture was irradiated 
in the Discover TM  at 70 °C for 10 minutes. The crude reaction mixture was columned on 
silica (hexane: ethyl acetate 8:1) to afford sulfonamide 216 as a white solid (0.044 g, 
35%); Vmax (film)/cm-1 3117 (thiophene C-H), 3087 (aryl CH), 2979 (C-H), 1332 (SO2), 
1169 (SO2); 6H(250  MHz, CDC13): 1.14 (t, 3H,J= 7.1 Hz, H8), 3.70 (q, 2H,J= 7.1 Hz, 
117), 7.19 (s, IH, H10), 7.30 (d, 2H, J = 8.8 Hz, 112, 116), 7.67 (d, 2H, J = 8.8 Hz, 113, 
H5); Mpt. 140.4-141.7°C. 
5-Chloro-N-isobutyl-N- [4-(trifluoromethyl)phenyl]thiophene-2-sulfonamide (221) 
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General procedure S2 was followed using 5-chloro-N-[4-(trifluoromethyl)phenyl]-
thiophene-2-sulfonamide (0.075 g, 0.22 mmole, 1.0 eq.), 1-iodo-2-methylpropane (131 
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j.tL, 1.10 mmole, 5.0 eq.) and triethylamine (300 ptL, excess). The reaction mixture was 
irradiated in the DiscoverTM  at 70 °C for 10 minutes. The crude reaction mixture was 
columned on silica (heptane: hexane: ethyl acetate 8:2:1) to afford sulfonamide 221 as a 
white solid (0.007 g, 8%); 6H  (250 MHz, CDCI3): 0.85 (d, 6H, J = 6.7 Hz, H9, H10), 
1.44— 1.61 (m, IH, H8), 3.32 (d, 2H, J = 7.4, 117), 6.85 (d, IH, J = 4.0 Hz, H13), 7.03 













General procedure S2 was followed using N-[3 ,5 -bis(trifluoromethyl)phenyl]-4,5-
dibromothiophene-2-sulfonamide (0.103 g, 0.19 mmole, 1.0 eq.), 1-iodo-2-
methylpropane (131 .xL, 0.98 mmole, 5.8 eq.) and triethylamine (300 IL, excess). The 
reaction mixture was irradiated in the DiscoverTM  at 70 °C for 10 minutes. The crude 
reaction mixture was columned on silica (heptane: hexane: ethyl acetate, 8:2:1) to afford 
sulfonamide 222 as a white solid (0.003 g, 3%); 6H  (250 MHz, CDC13): 0.88 (d, 6H, J = 
6.6 Hz, H9, H10), 1.44— 1.61 (m, 1H, 118), 3.33 (d, 2H, J = 7.4 Hz, 117), 7.05 (s, IH, 
H12), 7.52 (s, 2H, 112, H6), 7.81(s, 1H, H4). 
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4,5-Dibromo-N-isobutyl-N- [4-(trifluoromethyl)phenyl] thiophene-2-sulfonamide 
(223) 
	








Genera! procedure S2 was followed using 4,5-dibromo-N-[4-(trifluoromethyl)phenyl] - 
thiophene-2-su!fonamide (0.118 g, 0.25 mmole, 1.0 eq.), 1-iodo-2-methylpropane (131 
j.iL, 1.10 mmole, 4.4 eq.) and triethylamine (300 1.tL, excess). The reaction mixture was 
irradiated in the Discover TM  at 70 °C for 10 minutes. The crude reaction mixture was 
columned on silica (heptane: hexane: ethyl acetate 8:2:1) to afford sulfonamide 223 as a 
white solid (0.008 g, 6%); oH (250 MHz, CDC13): 0.86 (d, 6H, J = 6.7 Hz, H9, H10), 
1.45— 1.62 (m, 1H, H8), 3.33 (d, 2H, J = 7.4, 117), 7.08 (s, 1H, H12), 7.24 (d, 2H, J = 
8.3 Hz, 112, H6), 7.59 (d, 2H, J = 8.3 Hz, H3, H5). 
N- 13,5-Bis(trifluoromethyl)phenyll -4-chloro-3-nitrobenzamide (225) 
CF3 
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Genera! procedure Al was followed using 3,5-(trifluoromethyl)aniline (141 iL, 0.91 
mmole, 1.0 eq.) and 4-chloro-3-nitrobenzoyl chloride (0.220 g, 1.0 mmole, 1.1 eq.). 
Amide 225 was isolated as a white solid (0.298 g, 79%); LRMS FAB m/z 413 (MH); 
HRMS FAB m/z 413.01316 (MH) (calculated for C15H835C1F6N203, 413.01276 (Dev. 
0.97 ppm)); 6H  (250 MHz, (CD3)2S0): 7.87 (s, lI-I, H4), 8.03 (d, 1H, J = 8.5 Hz, H12), 
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8.30 (dd, IH, J = 8.5, 2.1 Hz, H13), 8.49 (s, 2H, 112, H6), 8.70 (d, IH, J = 2.1 Hz, H9), 
11.10 (s, 1H, Nil); 8c (63 MHz, (CD3)2S0): 116.8 (CHAr), 119.8 (C2, C6), 123.0 (q, JCF 
= 273 Hz, CF3), 124.7 (CHAr), 128.6 (CA,), 130.5 (q, JCF = 33 Hz, C3, CS), 132.0 
(CHAr), 132.7 (CHAr), 133.6 (CA,), 140.3 (CA,), 147.1 (CA,), 162.9 (0). 
4-Chloro-N-(3-chlorophenyl)-3-nitrobenzamide (226) 
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General procedure Al was followed using 3-chioroaniline (96 j.tL, 0.91 mmole, 1.0 eq.) 
and 4-chloro-3-nitrobenzoyl chloride (0.220 g, 1.0 mmole, 1.1 eq.). Amide 226 was 
isolated as a pale yellow solid (0.259 g, 92 %); LRMS EI m/z 310 (M); HRMS E1 m/z 
309.99179 (M) (calculated for C13H835C12N203, 309.99120 (Dev. 1.92 ppm)); Vmax 
(KBr)/cm' 3310 (N-H), 3045 (aryl C-H), 1646 (C=O), 1530 (NO2), 1350 (NO2); 5H(2SO 
MHz, (CD3)2S0): 7.23 (ddd, 1H, J = 8.0, 1.2, 0.9 Hz, H4), 7.43 (t, IH, J = 8.0 Hz, H5), 
7.71 (ddd, 1H, J = 8.0, 1.2, 0.9 Hz, H6), 7.95 (t, IH, J = 0.9 Hz, 112), 8.00 (d, IH, J = 
8.4 Hz, H12), 8.28 (dd, IH, J = 8.4, 2.1 Hz, H13), 8.65 (d, 1H, J = 2.1 Hz, H9), 10.73 
(s, 1H, NH); 6c(63  MHz, (CD3)2S0): 118.6 (CHAr), 119.7 (CHAr), 123.7 (CHAr), 124.7 
(CHAr), 128.1 	130.3 (CHAr), 131.8 (MA,),  132.7 (CHAr), 132.8 (CA,), 134.3 (CA,), 
139.8 (CA,), 147.1 (CA,), 162.5 (C7); Mpt. 159.5 - 160.0 T. 
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General procedure Al was followed using 3,4-dichloroaniline (0.147 LI, 0.91 mmole, 
1.0 eq.) and 4-chloro-3-nitrobenzoyl chloride (0.220 g, 1.0 mmole, 1.1 eq.). Amide 227 
was isolated as a pale brown solid (0.224 g, 71 %); LRMS EI+ m/z 344 (M); HRMS E1 
m/z 343.95161 (M) (calculated for C13H735C13N203, 343.95223 (Dev. - 1.79 ppm)); 
Vmax (KBr)/cm 1 3281 (N-H), 3096 (aryl C-H), 1655 (C0), 1534 (NO2), 1340 (NO2); oH 
(250 MHz, (CD3)2S0): 7.65 (d, 1H, J = 8.8 Hz, H5), 7.74 (dd, IH, J = 8.8, 2.4 Hz, H6), 
7.99 (d, 1H, J = 8.4 Hz, H12), 8.12 (d, 1H, J =2.4 Hz, H2), 8.26 (dd, IH, J = 8.4, 2.1 
Hz, H13), 8.64 (d, 1H, J = 2.1 Hz, H9), 10.80 (s, IH, Nil); 0c (63 MHz, (CD3)2S0): 
120.2 (CHAr), 121.4 (CHAr), 124.7 (CHAr), 125.5 (CA,), 128.3 (CA,),  130.5 (CHAr), 130.7 
(CA,), 131.9 (CHAr), 132.7 (CHAr), 134.0 	138.5 (CA,), 147.1 (CA,  162.5 (C7). 









General procedure Al was followed using 4-(trifluoromethyl)aniline (114 [tL, 0.91 
mmole, 1.0 eq.) and 4-chloro-3-nitrobenzoyl chloride (0.220 g, 1.0 mmole, 1.1 eq.). 
Amide 228 was isolated as a cream solid (0.206 g, 66 %); LRMS Ef m/z 344 (M); 
HRMS Ef m/z 344.01720 (M) (calculated for C14H83 C1F3N203, 344.01755 (Dev. - 
1.02 ppm)); Vm (KBr)Icm' 3293 (N-H), 3084 (aryl C-H), 1654 (C=O), 1529 (NO2), 
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1341 (NO2); oH (250 MHz, (CD3)2S0): 7.78 (d, 2H, J = 8.8 Hz, H3, H5), 8.02 (d, 2H, J 
= 8.8 Hz, 112, H6), 8.02 (d, 1H, J = 8.4 Hz, H12), 8.30 (dd, IH, J = 8.4, 2.1 Hz, H13), 
8.68 (d, 1H, J = 2.1 Hz, H9), 10.88 (s, IH, NH); 0c (63 MHz, (CD3)2S0): 120.1 (2 x 
CHAr), 123.9 (q, JCF 32 Hz, C4), 124.1 (q, JCF = 271 Hz, CF3), 124.8 (CHAr), 125.9 (2 
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General procedure Al was followed using 4-chloroaniline (0.116 g, 0.91 mmole, 1.0 
eq.) and 4-chloro-3-nitrobenzoyl chloride (0.220 g, 1.0 mmo!e, 1.1 eq.). Amide 229 was 
isolated as a pale yellow solid (0.234 g, 83%); LRMS FAB m/z 311 (MH); HRMS 
FAB m/z 310.99868 (MH) (calculated for C13H935C!2N203, 310.99902 (Dev. —1.11 
PPM)); Vmax (film)/cm-' 3285 (N-H), 3060 (aryl C-H), 2930 (C-H), 1648 (C0), 1534 
(NO2), 1341 (NO2); 0H (250 MHz, (CD3)2S0): 7.46 (d, 2H, J = 8.8 Hz, H3, H5), 7.82 (d, 
2H, J = 8.8 Hz, 112, H6), 8.00 (d, 1H, J = 8.4 Hz, H12), 8.28 (dd, 1H, J = 8.4, 2.1 Hz, 
H13), 8.65 (d, 1H,J= 2.1 Hz, H9), 10.71 (s, IH,N11); 6c(63 MHz, (CD3)2S0): 121.8(2 
X CHAr), 124.7 (CHAr), 127.6 (CA,), 128.0 (CA,), 128.4 (2 X CHAr), 131.8 (CHAr), 132.6 
(CHAr), 134.4 (C), 137.3 (CA,), 147.1 (C), 162.3 (C7); Mpt. 187.8— 188.2 °C. 
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4-Ch loro-N-(4-fluorophenyl)-3-nitrobenzamide (230) 
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General procedure Al was followed using 4-fluoroaniline (87 pL, 0.91 mmole, 1.0 eq.) 
and 4-chloro-3-nitrobenzoyl chloride (0.220 g, 1.0 mmole, 1.1 eq.). Amide 230 was 
isolated as a grey solid (0.079 g, 30 %); LRMS EI m/z 294 (M); HRMS EI m/z 
294.0 1993 (M) (calculated for C13H835C1FN203, 294.02075 (Dev.- 2.79 ppm)); Vmax 
(KBr)Icm1 3286 (N-H), 3075 (aryl C-H), 1651 (C0), 1538 (NO2),1321 (NO2); 6H (250 
MHz, (CD3)2S0): 7.24 (t, 2H, J = 8.9 Hz, JHF 8.9 Hz, H3, H5), 7.79 (dd, 2H, .1 = 8.9 
Hz, JHF 5.0 Hz, 112, Ho), 7.99 (d, IH, J = 8.4 Hz, H12), 8.27 (dd, 1H, J = 8.4, 2.1 Hz, 
H13), 8.64 (d, 1H, J - 2.1 Hz, H9), 10.62 (s, 1H, Nil); öc (63 MHz, (CD3)2S0): 115.2 
(d, JCF = 22 Hz, C3, C5), 122.2 (d, JCF = 8Hz, C2, C6), 124.6 (CHAr), 127.9 (CA,), 131.8 
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General procedure Al was followed using 3,4-difluoroaniline (87 tL, 0.91 mmole, 1.0 
eq.) and 4-chloro-3-nitrobenzoyl chloride (0.220 g, 1.0 mmole, 1.1 eq.). Amide 231 was 
isolated as a white solid (0.041 g, 14 %); LRMS EI1 m/z 312 (M); HRMS EI m/z 
312.02421 (M) (calculated for C13H73 ClF2N203, 312.01133 (Dev. 3.59 ppm)); Vmax 
267 
1. 
(KBr)/cm 1 3291 (N-H), 3029 (aryl C-H), 1653 (C0), 1518 (NO2), 1336 (NO2); 6H(2SO 
MHz, (CD3)2S0): 7.42 - 7.59 (m, 2H, H2, H5), 7.93 (ddd, IH, J = 7.7, 2.3 Hz, .JHF = 
13.1 Hz, H6), 8.01 (d, IH, J = 8.6 Hz, H12), 8.27 (dd, IH, J = 8.6, 2.1 Hz, H13), 8.64 
(d, 1H, J =2.1 Hz, H9), 10.76 (s, 1H, Nil); 6c (63 MHz, (CD3)2S0): 109.3 (d, .'CF = 22 
Hz, CHAr), 116.6 (CHAr), 117.3 (d, JCF = 18 Hz, CHAr), 124.7 (CHAr), 128.2 (CAr), 131.8 
(CHAr), 132.6 (CHAr), 134.1 (CA,), 135.3 (d, JCF = 6 Hz, Cl), 145.7 (dd, JCF = 243, 13 










General procedure Al was followed using 3-fluoroaniline (87 p.L, 0.91 mmole, 1.0 eq.) 
and 4-chloro-3-nitrobenzoyl chloride (0.220 g, 1.0 mmole, 1.1 eq.). Amide 232 was 
isolated as a white solid (0.176 g, 66 %); LRMS El rn/z 294 (M); HRMS EI m/z 
294.02074 (M) (calculated for C13H8C1FN203, 294.02075 (Dev. - 0.02 ppm)); Vmax 
(KBr)1cm 1 3278 (N-H), 3085 (aryl C-H), 1650 (C=O), 1539 (NO2), 1358 (NO2); 6H(250 
MHz, (CD3)2S0): 6.96 - 7.04 (m, 1H, H4), 7.44 (dt, I H, JHF = 6.7 Hz, J = 8.0 Hz, H5), 
7.56 (ddd, 1H, J = 8.0, 2.3, 1.0 Hz, H6), 7.75 (dt, IH, JHF = 11.7 Hz, J = 2.3 Hz, 112), 
8.00 (d, 1H, J = 8.4 Hz, H12), 8.28 (dd, 1H, J = 8.4, 2.1 Hz, H13), 8.65 (d, 1H, J = 2.1 
Hz, H9), 10.74 (s, 1H, NI]); 6c (63 MHz, (CD3)2S0): 107.0 (d, JCF = 26 Hz, CHAr), 
110.5 (d, JCF = 21 Hz, CHir), 116.0 (CHAr), 124.7 (CHA ), 128.1 (C r), 130.2 (d, JCF = 9 
Hz, C5), 131.8 (CHAr), 132.7 (CHi ), 134.3 (CA,), 140.1 (d, JCF = 11 Hz, C), 147.1 
(CA,), 161.8 (d, JCF = 242 Hz, C3), 162.5 (0). 
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4-Ch loro-N-(2,4-dichlorophenyl)-3-nitrobenzamide (233) 
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General procedure Al was followed using 2,4-dichioroaniline (0.147 g, 0.91 mmole, 1.0 
eq.) and 4-chloro-3-nitrobenzoyl chloride (0.220 g, 1.0 mmole, 1.1 eq.). Amide 233 was 
isolated as a white solid (0.290 g, 92 %); LRMS EI+ m/z 344 (M); HR-MS EI m/z 
343.95204 (M) (calculated for C13H735C13N203, 343.95223 (Dev. - 0.55 ppm)); Vmax 
(KBr)Icm' 3406 (N-H), 3081 (aryl C-H), 1686 (C0), 1537 (NO2), 1357 (NO2); H(250  
MHz, (CD3)2S0): 7.52 (dd, 1H, J = 8.6, 2.3 Hz, H5), 7.63 (d, 1H, J = 8.6 Hz, H6), 7.77 
(d, IH, J = 2.3 Hz, H3), 8.00 (d, 1H, J = 8.4 Hz, H12), 8.28 (dd, Il-I, J = 8.4 , 2.1 Hz, 
H13), 8.66 (d, IH, J = 2.1 Hz, H9), 10.57 (s, 1H, Nil); 6C (63 MHz, (CD3)2S0): 124.8 
(CHAr), 127.6 (CHAr), 128.4 (CA,), 129.0 (CHAr), 129.6 (CHAr), 130.4 (CA,  131.1 (CA,), 
132.0 (CH Ar), 132.6 (CHAr), 133.4 (CA,), 133.8 (CA,), 147.2 (CA,), 162.5 (C7); Mpt. 












General procedure Al was followed using 3,5-dichloroaniline (147 El, 0.91 mmole, 1.0 
eq.) and 4-chloro-3-nitrobenzoyl chloride (0.220 g, 1.0 mmole, 1.1 eq.). Amide 234 was 
isolated as a cream solid (0.291 g, 93 %); LRMS EI m/z 344 (M); HRMS EI m/z 
343.95139 (M) (calculated for C13H735C13N203, 343.95223 (Dev. -2.43 ppm)); Vmax 
,Is 
L VI) I//11/?I(/! l>!7)C( 
(KBr)/cm' 3283 (N-H), 3079 (aryl C-H), 1667 (C=O), 1532 (NO2), 1340 (NO2); 6E1(250 
MHz, (CD3)2S0): 7.39 (t, 1H, J = 1.8 Hz, H4), 7.88 (d, 2H, J = 1.8 Hz, H2, H6), 8.01 
(d, 1H, J = 8.4 Hz, H12), 8.26 (dd, IH, J = 8.4, 2.1 Hz, H13), 8.65 (d, IH, J = 2.1 Hz, 
H9), 10.82 (s, IH, Nil); 5C  (63 MHz, (CD3)2S0): 118.2 (C2, C6), 123.2 (CHAr), 124.7 
(CHAr), 128.4 (CAr), 131.9 (CHAr), 132.7 (CHAr), 133.8 (3 X CAr), 140.7 (CA,), 147.1 
(CA,), 162.7 (C7); Mpt. 207.4-207.8 T. 
4-Ch Ioro-3-nitro-N-(2,4,5-trichlorophenyl)benzamide (235) 
CI 
o 6 1 -L-ci 
O2N 7N 	3 
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General procedure Al was followed using 2,4,5-trichloroaniline (0.179 g, 0.91 mmole, 
1.0 eq.) and 4-chloro-3-nitrobenzoyl chloride (0.220 g, 1.0 mmole, 1.1 eq.). Amide 235 
was isolated as a grey solid (0.215 g, 62 %); LRMS EI m/z 378 (M); HRMS E1 m/z 
377.91319 (M) (calculated for C13H635C14N203, 377.91325 (Dev. - 0.17 ppm)); Vmax 
(KBr)Icm' 3413 (N-H), 3113 (aryl C-H), 3082 (aryl C-H), 1697 (C=O), 1536 (NO2), 
1354 (NO2); 6H  (250 MHz, (CD3)2S0): 8.01 (s, 1H, 113), 8.03 (d, 1H, J = 8.0 Hz, H12), 
8.04 (s, 1H, H6), 8.28 (dd, 1H, J = 8.0, 2.1 Hz, H13), 8.66 (d, 1H, J = 2.1 Hz, H9), 
10.67 (s, 1H, Nil); 6C (63 MHz, (CD3)2S0): 124.9 (CHAr), 128.5 (CA,), 128.8 (CA,), 
129.1 (CFTAr), 129.3 (C), 129.7 (CA,), 130.6 (CHAs), 132.0 (CHs.,), 132.7 (CHAr), 133.8 
(CA,), 134.5 (CA,), 147.1 (C), 162.7 (C7). 
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Genera! procedure Al was followed using 1-[4-(trifluoromethy!)pheny!]methanamine 
(130 iL, 0.91 mmole, 1.0 eq.) and 4-ch!oro-3-nitro-benzoy!ch!oride (0.220 g, 1.0 
mmole, 1.1 eq.). Amide 236 was isolated as a cream solid (0.306 g, 94 %); LRMS EI 
m/z 358 (M); HRMS EI m/z 358.03389 (M) (calculated for C15H1035C1F3N203, 
35 8.03320 (Dev. 1.93 ppm)); Vmax (KBr)/cm' 3274 (N-H), 3073 (aryl C-H), 2940 (C-H), 
2878 (C-H), 1640 (C=O), 1536 (NO2), 1329 (NO2); 6H (250 MHz, (CD3)2S0): 4.60 (d, 
2H, J = 5.7 Hz, 117), 7.58 (d, 2H, J = 8.0 Hz, H2, H6), 7.72 (d, 2H, J = 8.0 Hz, 113, H5), 
7.95 (d, 1H, J = 6.3 Hz, H13), 8.22 (dd, 1H, J = 6.3, 2.1 Hz, H14), 8.59 (d, 1H, J = 2.1 
Hz, H10), 9.54 (t, IH, J = 5.7 Hz, NI]); 5c (63 MHz, (CD3)2S0): 42.4 (0), 124.1 (q, J 
= 272 Hz, CF3), 124.4 (CHAr), 125.0 (d, JCF = 4 Hz, C3, CS), 127.4 (q, JCF 32 Hz, C4), 
127.7 (C2, C6), 127.8 (CA'), 131.8 (CHAr), 132.2 (CHAr), 133.8 (CA,), 143.7 (CM), 147.1 
(CAT), 163.2 (C8); 
N- 13,5-Bis(trifluoromethy!)benzyll -4-chloro-3-nitrobenzamide (237) 
0 
7 	6 




General procedure Al was followed was using 1 -[3,5-bis(trifiuoromethy!)pheny!]-
methanamine (0.221 g, 0.91 mmole, 1.0 eq.) and 4-ch!oro-3-nitrobenzoyl chloride 
(0.220 g, 1.0 mmole, 1.1 eq.). Amide 237 was isolated as a cream solid (0.226 g, 58 %); 
LRMS EI m/z 426 (M); HRMS EI m/z 426.02084 (M) (calculated for 
271 
C16H935C1F6N203, 426.02059 (Dev. 0.59 ppm)); 6H  (250 MHz, CD30D): 4.78 (s, 2H, 
H7), 7.87 (d, 1H, J = 8.7 Hz, H13), 8.14 (s, 1H, H4), 8.18 (dd, IH, J = 2.1, 8.7 Hz, 
H14), 8.20 (s, 2H, H2, H6), 8.51 (d, 1H,J= 2.1 Hz, H10). 
4-Chloro-N-(4-chlorobenzyl)-3-nitrobenzamide (238) 
CI &1 8 N a4 1214 	2 	CI 13 	 3 
General procedure Al was followed using 1-[(4-chlorophenyl)phenyl]methanamine (111 
tL, 0.91 mmole, 1.0 eq.) and 4-chloro-3-nitrobenzoyl chloride (0.220 g, 1.0 mmole, 1.1 
eq.). Amide 238 was isolated as a white solid (0.217 g, 74 %); LRMS EI m/z 324 (M); 
HRMS EI m/z 324.007 12 (M) (calculated for C14H1035C12N203, 324.00685 (Dev. 0.85 
PPM)); Vmax (KBr)/cm' 3270 (N-H), 3071 (aryl C-H), 1635 (C0), 1538 (NO2), 1362 
(NO2); 6H  (250 MHz, (CD3)2S0): 4.50 (d, 2H, J = 5.8 Hz, 117), 7.37 (d, 2H, J = 8.8 Hz, 
112, H6), 7.41 (d, 2H, J = 8.8 Hz, 113, H5), 7.93 (d, IH, J = 8. 4 Hz, H13), 8.20 (dd, 1H, 
J = 8.4, 2.1 Hz, H14), 8.57 (d, 1H, J = 2.1 Hz, H10), 9.46 (t, IH, J = 5.8 Hz, Nil); öc 
(63 MHz, (CD3)2S0): 42.1 (0), 124.3 (CHAr), 127.8 (CA,), 128.1 (2 X CHAr), 129.0 (2 X 
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General procedure A2 was followed using 3,5-dinitrobenzoyl chloride (0.139 g, 0.60 
mmole 1.2 eq.) and 3,5-bis(trifluoromethyl)aniline (78 tL, 0.50 mmole, 1.0 eq.). Amide 
239 was isolated as a cream solid (0.049 g, 23%); LRMS FAB m/z 424 (MH); HRMS 
FAB m/z 424.03658 (MH) (calculated for C151-18176N305, 424.03682 (Dev. - 0.54 
PPM)); Vmax (KBr)/cm' 3293 (N-H), 3099 (aryl C-H), 1657 (C0), 1544 (NO2), 1348 
(NO2); 6H(25O  MHz, (CD3)2S0): 7.93 (s, 1H, H4), 8.51 (s, 2H, 112, H6), 9.05 (t, li-I, J 
= 1.9 Hz, HI 1), 9.21 (d, 2H, J = 1.9 Hz, H9, H13), 11.37 (s, IH, NIT); 6c  (63 MHz, 
(CD3)2S0): 117.2 (CA,), 120.2 (C2, C6), 120.2 (Cl 1), 123.0 (q, JCF = 273 Hz, CF3), 
127.9 (C9, C13), 130.6 (q, JCF = 33.0 Hz, C3, CS), 136.2 (CA,),  140.1 (CA,),  148.0 (CIO, 










General procedure A2 was followed using 3,5-dinitrobenzoyl chloride (0.139 g, 0.60 
mmole, 1.2 eq.) and 4-chloroaniline (0.064 g, 0.50 mmole, 1.0 eq.) Amide 240 was 
isolated as a cream solid (0.042 g, 26 %); LRMS FAB m/z 322 (MH); HRMS FAB 
m/z 322.02362 (MH) (calculated for C13H935C1N305, 322.023 07 (Dev. 1.70 ppm)); Vm 
273 
1\7)(uffI1f1f(/( /'H 
(film)/cm-1 3292 (N-H), 3092 (aryl C-H), 2928 (C-H), 1653 (C=O), 1535 (NO2), 1340 
(NO2); 6H  (250 MHz, (CD3)2S0): 7.48 (d, 2H, J = 8. 8 Hz, H3, H5), 7.84 (d, 2H, J = 8.9 
Hz, 112, H6), 9.02 (t, IH, J = 2.0 Hz, HI 1), 9.17 (d, 2H, J = 2.0 Hz, H9, H13), 10.97 (s, 
1H, NH); 8C (63 MHz, (CD3)2S0): 121.0 (Cl 1), 122.0 (2 x CHAr), 127.8 (C9, C13), 
128.0 (CAr), 128.5 (2 X CHAr), 136.9 (CAr), 137.0 (CAr), 147.9 (C I O, C12), 161.2 (0); 
Mpt. 241.6-242.2 °C. 
N-[3,5-Bis(trifluoromethyl)phenyl] -4-methyl-3-nitrobenzamide (241) 
CF3 
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Genera! procedure A2 was followed using 4-methyl-3-nitrobenzoyl chloride (76 !.IL, 
0.60 mmole 1.2 eq.) and 3,5-bis(trifluoromethyl)aniline (0.064 g, 0.50 mmole, 1.0 eq.). 
Amide 241 was isolated as a white solid (0.078 g, 40%); LRMS FAB m/z 393 (MH); 
HRMS FAB m/z 393.06681 (MH) (calculated for C16H 11 F6N203, 393.06739 (Dev. - 
1.46 ppm)); Vmax (film)/cm1  3316 (N-H), 3081 (aryl C-H), 2934 (C-H), 1644 (C0), 
1530 (NO2), 1326 (NO2); 61-1 (250 MHz, CD30D): 2.70 (s, 3H, H14), 7.68 (d, IH, J = 
8.0 Hz, H12), 7.77 (s, 1H, H4), 8.23 (dd, IH, J = 1.9, 8.0 Hz, H13), 8.48 (s, 2H, 112, 
H6), 8.65 (d, 1H, J = 1.9 Hz, H9); öc (63 MHz, CD30D): 19.5 (04), 116.6 (CHAr), 
119.9 (2 X CHAr), 123.0 (q, JCF = 273 Hz, CF3), 123.5 (CHAr), 130.5 (q, JCF = 33 Hz, C3, 













General procedure A2 was followed using 4-methyl-3-nitrobenzoyl chloride (76 jiL, 
0.60 mmole, 1.2 eq.) and 3-chloroaniline (53 tL, 0.50 mmole, 1.0 eq.). Amide 242 was 
isolated as a pale cream solid (0.117 g, 8 1%); LRMS FAB m/z 291 (MH); HRMS 
FAB m/z 291.05364 (MH) (calculated for C14H1235C1N203, 291.05365 (Dev. - 0.03 
PPM)); Vmax (film)/cm' 3297 (N-H), 3081 (aryl C-H), 1654 (C0), 1530 (NO2), 1346 
(NO2); 6H  (250 MHz, (CD3)2S0): 2.62 (s, 3H, H14), 7.21 (ddd, I H, J = 8.2, 1.2, 1.1 Hz, 
H4), 7.43 (t, 11-I, J = 8.2 Hz, H5), 7.69 - 7.75 (m, 2H, H6, H12), 7.97 (d, 1H, J = 1.1 
Hz, 112), 8.22 (dd, IH,J= 8.0, 0.9 Hz, H13), 8.59 (d, IH,J= 0.9 Hz, H9), 10.63 (s, 1H, 
NI!); 8c (63 MHz, (CD3)2SO): 19.4 (04), 118.6 (CHAr), 119.7 (CHAr), 123.4 (CHAr), 
123.5 (CHAr), 130.2 (CHAr), 132.0 (CHAr), 132.8 (CA,.), 132.9 (CHAr), 133.0 (CA,),  133.1 
(CA,), 136.4 (CA,),  148.5 (CA,), 163.2 (0); Mpt. 161.0- 161.3 T. 









General procedure A2 was followed using 4-methyl-3-nitrobenzoyl chloride (76 tL, 
0.60 mmole, 1.2 eq.) and 3 -(trifluoromethyl)ani line (63 .tL, 0.50 mmole, 1.0 eq.). Amide 
243 was isolated as a pale yellow solid (0.096 g, 59%); LRMS FAB m/z 325 (MH); 
HRMS FAB m/z 325.07967 (MH) (calculated for C35H12N203F3, 325.08000 (Dev. - 
275 
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1.02 PPM)); 6H (250 MHz, (CD3)2S0): 2.62 (s, 3H, H14), 7.50 (d, 1H, J = 8.0 Hz, H4), 
7.64 (t, 1H, J = 8.0 Hz, H5), 7.72 (d, 1H, J = 8.2 Hz, H12), 8.09 (d, IH, J = 8.0 Hz, 
H6), 8.22-8.27 (m, 2H, H2, H13), 8.63 (d, 1H, J = 1.8 Hz, H9), 10.77 (s, IH, Nil); 6c  
(63 MHz, (CD3)2S0): 19.40 (C14), 116.34 (d, JCF = 4.0 Hz, CHAr), 120.1 (CHAr), 123.4 
(CH Ar), 123.7 (CHAr), 123.9 (q, JCF = 272 Hz, CF3), 129.4 (q, JCF = 32 Hz, C3), 129.7 
(CHAr), 132.0 (CHAr), 133.0 (CHAr), 133.0 (CA,  136.5 (CA,), 139.3 (CA,), 148.6 (CA,), 
163.3 (0). 











General procedure A2 was followed using 4-methyl-3-nitrobenzoyl chloride (76[IL, 
0.60 mmole, 1.2 eq.) and 4-(trifluoromethyl)aniline (63 jL, 0.50 mmole, 1.0 eq.). Amide 
244 was isolated as a white solid (0.095 g, 59%); LRMS FAB m/z 325 (MH)4 ; HRMS 
FAB m/z 325.07980 (MH) (calculated for C 15H11N203F3, 325.08000 (Dev. - 0.63 
ppm)); 8H (250 MHz, (CD3)2S0): 2.62 (s, 3H, H14), 7.72 (d, IH,J= 8.0 Hz, H12), 7.77 
(d, 2H, J = 8.8 Hz, 113, H5), 8.04 (d, 2H, J = 8.8 Hz, 112, H6), 8.25 (dd, I H, J = 8.0, 1.8 
Hz, H13), 8.62 (d, 1H, J = 1.8 Hz, H9), 10.80 (s, IH, NH); 6c (63 MHz, (CD3)2S0): 
19.4 (C14), 120.1 (2 X CHAr), 123.5 (CH), 123.8 (q, JCF = 31 Hz, C4), 124.1 (q, JCF = 
271 Hz, CF3), 126.0 (2 X CHM), 132.1 (CHAr), 133.0 (CA,), 133.1 (CA,), 136.5 (CA,), 
142.2 (CA,), 148.5 (CAr), 163.5 (0). 
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General procedure A2 was followed using 4-methyl-3-nitrobenzoyl chloride (76 jiL, 
0.60 mmole 1.2 eq.) and 4-chloroaniline (0.064 g, 0.50 mmole, 1.0 eq.). Amide 245 was 
isolated as a white solid (0.088 g, 61%); LRMS FAB m/z 291 (MH); HRMS FAB m/z 
291.05355 (MH) (calculated for C14H1235C1N203, 291.05365 (Dev. - 0.32 ppm)); 8H 
(250 MHz, (CD3)2S0): 2.61 (s, 3H, H14), 7.45 (d, 2H,J= 8.8 Hz, H3, H5), 7.70 (d, IH, 
J= 8.1 Hz, H12), 7.83 (d, 2H,J= 8.8 Hz, H2, H6), 8.22 (dd, IH,J= 8.1, 1.8 Hz, H13), 
8.58 (d, IH, J = 1.8 Hz, H9), 10.61 (s, IH, Nil); öc (63 MHz, (CD3)2S0): 19.4 (04), 
121.8 (2 X CHJ%J), 123.4 (CHAr), 127.5 (CAr), 128.4 (2 X CHAr), 132.0 (CHAr), 132.9 
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General procedure A2 was followed using 4-methyl-3-nitrobenzoyl chloride (76 .IL, 
0.60 mmole, 1.2 eq.) and 4-fluoroaniline (48 tL, 0.50 mmole, 1.0 eq.). Amide 246 was 
isolated as a yellow solid (0.072 g, 53%); LRMS FAB m/z 275 (MH); HRMS FAB 
m/z 275.08359 (MH) (calculated for C14H12FN203, 275.08320 (Dev. 1.42 ppm)); 6H 
(250 MHz, (CD3)2S0): 2.63 (s, 3H, H14), 7.25 (d, 2H, J = 8.8 Hz, JHF = 8.8 Hz, H3, 
H5), 7.70 (d, 1H, J = 8.1 Hz, H12), 7.95 (dd, 2H, J = 8.8 Hz, JHF = 5.1 Hz, ifl, H6), 
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8.24 (dd, 1H, J = 8.0, 1.9 Hz, H13), 8.60 (d, 1H, J = 1.9 Hz, H9), 10.55 (s, IH, NI]); 8c 
(63 MHz, (CD3)2S0): 19.4 (04), 115.1 (d, JCF = 14 Hz, C3, C5), 122.2 (d, JCF = 9 Hz, 
C2, C6), 123.3 (CHAr), 131.9 (CHAr), 132.9 (CHAr), 133.4 (CA,), 134.9 (d, JCF = 3 Hz, 










General procedure A2 was followed using 4-methyl-3-nitrobenzoyl chloride (76 1.tL, 
0.60 mmole, 1.2 eq.) and 3,4-difluoroaniline (50 !.tL, 0.50 mmole, 1.0 eq.). Amide 247 
was isolated as a white solid (0.089 g, 61%); LRMS FAB m/z 293 (MH); HRMS 
FAB m/z 293.07302 (MIH) (calculated for C14H11 F2N203, 293.07377 (Dev. - 2.57 
PPM)); 61-I (250 MHz, (CD3)2S0): 2.62 (s, 3H, H14), 7.41 - 7.59 (m, 2H, An]), 7.72 (d, 
1H, J = 8.1 Hz, H12), 7.95 (ddd, IH, J = 13.2, 7.5. 2.3 Hz, An]), 8.22 (dd, 1H, J = 8.0, 
1.9 Hz, H13),8.59 (d, 1H, J = 1.9 Hz, H9), 10.67 (s, 1H, NI]); 6C (63 MHz, (CD3)2S0): 
19.4 (04), 109.3 (d, JCF = 22 Hz, CHAr), 116.6 (d, JCF = 5.9 Hz, CHAr), 117.2 (d, 'CF = 
18 Hz, CHAr), 123.4 (CHAr), 131.9 (CHAr), 133.0 (CHAr), 133.0 (CAr), 135.5 (d, JCF = 6 
Hz, Cl), 136.4 (CA,), 145.5 (dd, JCF  242, 13 Hz, CA,), 148.5 (CA,), 148.6 (dd, JCF = 
243,13 Hz, C), 163.1 (0). 
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General procedure A2 was followed using 4-methyl-3-nitrobenzoyl chloride (76 tL, 
0.60 mmole, 1.2 eq.) and 3,5-dichloroaniline (0.081 g, 0.50 mmole, 1.0 eq.). Amide 248 
was isolated as a white solid (0.055 g, 34%); LRMS FAB m/z 325 (MH); HRMS 
FAB m/z 325.01465 (MH) (calculated for C14H11 35C12N203, 425.01467 (Dev. - 0.09 
PPM)); 6H (250 MHz, (CD3)2S0): 2.61 (s, 3H, H14), 7.36 (t, IH, J = 1.8 Hz, H4), 7.71 
(d, IH, J = 8.1 Hz, H12), 7.89 (d, 2H, J = 1.8 Hz, 112, H6), 8.20 (dd, IH, J = 8.1, 1.8 
Hz, H13), 8.58 (d, IH, J = 1.8 Hz, H9), 10.71 (s, IH, NH); 8c  (63 MHz, (CD3)2S0): 
19.4 (C14), 118.2 (C2, C6), 123.0 (CHAr), 123.4 (CHAr), 132.0 (CHAr), 132.7 (CA,), 
133.0 (CHAr), 133.8 (C3, C5), 136.7 (CA,), 140.9 (CA,), 148.5 (CA,  163.4 (0). 
4-Methyl-3-nitro-N- [4-(trifluoromethyl)benzyl] benzamide (249) 
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General procedure A2 was followed using 4-methyl-3-nitrobenzoyl chloride (76 jiL, 
0.60 mmole, 1.2 eq.) and I-[4-(trifluoromethyl)phenyl]methanamine (71 p.L, 0.50 
0 mmole, 1.0 eq.). Amide 249 was isolated as a white solid (0.129 g, 76/o); LRMS FAB+  
m/z 339 (MH); HRMS FAB m/z 339.09599 (MH) (calculated for C16H13F3N203, 
339.09565 (Dev. 1.00 PPM)); 6H (250 MHz, (CD3)2S0): 2.59 (s, 3H, HI 5), 4.59 (d, J = 
5.6 Hz, 2H, 117), 7.56 (d, 2H, J = 8. 2 Hz, 112, Ho), 7.66 (d, IH, J = 8.0 Hz, H13), 7.72 
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(d, 2H, J = 8.2 Hz, 113, H5), 8.15 (dd, JH, J = 8.0, 1.4 Hz, H14), 8.53 (d, IH, J = 1.4 
Hz, H10), 9.44 (t, 1H, J = 5.6 Hz, NH); 8C (63 MHz, (CD3)2S0): 19.4 (C15), 42.3 (0), 
123.0 (CHAr), 124.1 (q, JCF = 272 Hz, C173), 125.0 (d, JCF  4 Hz, C3, C5), 127.4 (q, JCF 
= 32 HZ, C4), 127.8 (C2, C6), 131.5 (CHAr), 132.8 (CA,), 13 3. 0 (CHAr), 136.0 (CA, 
143.9 (CAr), 148.6 (CAr), 164.0 (C8); Mpt. 136.8— 137.5 °C. 
N-[3,5-Bis(trifluoromethyl)benzyll -4-methyl-3-nitrobenzamide (250) 
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General procedure A2 was followed using 4-methyl-3-nitrobenzoyl chloride (76 j.iL, 
0.60 mmole, 1.2 eq.) and 1-[3,5-bis(trifluoromethyl)phenyl]methanamine (0.122 g, 0.50 
mmole, 1.0 eq.). Amide 250 was isolated as a white solid (0.149 g, 73%); LRMS FAB 
m/z 407 (MH); HRMS FAB m/z 407.08266 (MH) (calculated for C17H13F6N203, 
407.08304 (Dev. - 0.92 ppm)); 6H  (250 MHz, (CD3)2S0): 2.58 (s, 3H, HIS), 4.69 (d, 
1H, J = 5.8 Hz, 117), 7.66 (d, 1H, J = 8.0 Hz, H13), 8.02 (s, 1H, H4), 8.05 (s, 2H, 112, 
Ho), 8.15 (dd, 1H,.J= 8.0, 1.8 Hz, H14), 8.51 (d, IH,J= 1.8 Hz, H10), 9.48 (t, IH,J= 
5.8 Hz, NH); 8c (63 MHz, (CD3)2S0): 19.4 (C15), 42.0 (0), 120.6 (CHAr), 123.0 
(CHAr), 123.1 (q, JCF = 273 Hz, CF3 ), 128.1 (C2, C6), 130.0 (q, JCF = 33 Hz, C3, CS), 
131.6 (CHAr), 132.5 (CA,), 133.0 (CHAr), 136.1 (CA,), 142.6 (CA,), 164.2 (C8). 
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N-(4-Chlorobenzyl)-4-methyl-3-nitrobenzamide (251) 
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Genera! procedure A2 was followed using 4-methyl-3-nitrobenzoy! chloride (76 L, 
0.60 mmo!e, 1.2 eq.) and 1-(4-chlorophenyl)methanamine (61 jtL, 0.50 mmo!e, 1.0 eq.) 
Amide 251 was isolated as a white solid (0.118 g, 78 %); LRMS FAB m/z 305 (MH); 
HRMS FAB m/z 305.06879 (MH) (calculated for C15H1435C!N203, 305.06930 (Dev. - 
1.64 ppm)); Vmax (KBr)Icm 3294 (N-H), 3066 (aryl C-H), 2866 (C-H), 1639 (C=O), 
1525 (NO2), 1353 (NO2); 8H  (250 MHz, (CD3)2S0): 2.59 (s, 3H, H15), 4.50 (d, 2H, J = 
5.8 Hz, 117), 7.37 (d, 2H, J = 8.7 Hz, 112, H6), 7.42 (d, 2H, J = 8.7 Hz, H3, H5), 7.65 (d, 
1H, J = 8.0 Hz, H13), 8.14 (dd, IH, J = 8.0, 1.0 Hz, H14), 8.52 (d, 1H, J = 1.0 Hz, 
H10), 9.37 (t, 1H, J = 5.8 Hz, Nil); 6c  (63 MHz, (CD3)2S0): 19.4 (C15), 42.0 (C7), 
123.0 (CHAr), 128.1 (2 X CHAr), 129.0 (2 X CHAr), 131.3 (CA,), 131.5 (CHAr), 132.9 
(CHAr), 132.9 (CAr), 135.9 (CA,), 138.1 (CA,), 148.5 (C), 163.9 (C8); Mpt. 156.7 - 
157.2 °C. 
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General procedure A2 was followed using 4-methyl-3-nitrobenzoy! chloride (76 L, 
0.60 mmo!e, 1.2 eq.) and (1R)-1-(4-ch!orophenyl)ethanamine (70 IL, 0.50 mmo!e, 1.0 
eq.). Amide 252 was isolated as a white solid (0.097 g, 61%); LRMS FAB m/z 319 
(MH); HRMS FAB m/z 319.08501 (MH) (calculated for C16H1635C!N203, 319.08495 
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(Dev. 0.21 ppm)); Vmax (KBr)/cm' 3261 (N-H), 3056 (aryl C-H), 2977 (C-H), 2931 (C-
H), 2871 (C-H), 1635 (C=O), 1523 (NO2), 1340 (NO2); 6H  (250 MHz, (CD3)2S0): 1.49 
(d, 3H, J = 7.1 Hz, H8), 2.58 (s, 3H, H16), 5.17 (quintet, J = 7.1 Hz, H7), 7.32— 7.45 
(m, 4H, H2, 113, H5, H6), 7.63 (d, IH, J = 8.1 Hz, H14), 8.14 (dd, 1H, J = 8.1, 1.8 Hz, 
HIS), 8.52 (d, IH, J = 1.8 Hz, H11), 9.12 (d, 1H, J = 7.1 Hz, Nil); 6c  (63 MHz, 
(CD3)2S0): 19.3 (C16), 21.7 (C8), 48.1 (C7), 123.0 (CHAr), 127.8 (2 X CHAr), 128.0(2 X 
CHAr), 131.0 (CAr), 131.7 (CHAr), 132.8 (CH Ar), 133.0 (CAr), 135.8 (CAr), 143.4 (CAr), 
148.5 (CAr), 163.1 (C9). 
N-[(1S)-1 -(4-Ch Lorophenyl)ethyl] -4-methyl-3-n itrobenzamide (253) 
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General procedure A2 was followed using 4-methyl-3-nitrobenzoyl chloride (76 jtL, 
0.60 mmole, 1.2 eq.) and (1S)-1-(4-chloropheny!)ethanamine (70 tL, 0.50 mmole, 1.0 
eq.). Amide 253 was isolated as a pale yellow solid (0.096 g, 60%); LRMS FAB m/z 
319 (MH); HRMS FAB m/z 319.08465 (MH) (calculated for C16H1635C1N203, 
319.08495 (Dev. - 0.94 ppm)); Vmax (KBr)/cm' 3298 (N-H), 3073 (aryl C-H), 2978 (C-
H), 2932 (C-H), 2874 (C-H), 1632 (C0), 1524 (NO2), 1344 (NO2); 5H  (250 MHz, 
(CD3)2S0): 1.49 (d, 3H, .J = 7.1 Hz, H8), 2.57 (s, 3H, H16), 5.17 (quintet, J = 7.1 Hz, 
H7), 7.32 - 7.45 (m, 4H, 112, 113, H5, H6), 7.63 (d, IH, J = 8.1 Hz, H14), 8.14 (dd, IH, 
J= 8.1, 1.8 Hz, HI 5), 8.52 (d, 1H,J= 1.8 Hz, H11), 9.11 (d, 1H,J= 7.1 Hz, Nil); 6C  
(63 MHz, (CD3)2S0): 19.3 (06), 21.7 (C8), 48.1 (C7), 123.0 (CH), 127.8 (2 x CHAr), 
128.0 (2 X CHAr), 131.0 (CA,), 131.7 (CHAs), 132.8 (CHAJ), 133.0 (CA,), 135.8 (CAd), 
143.4 (CA,), 148.5 (CA,), 163.1 (C9). 
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Genera! procedure A2 was followed using 5-ch!oro-4-nitrothiophene-2-carbony! 
chloride (0.680 g, 3.00 mmole, 1.2 eq.), 3,5-bis(trifluoromethyl)aniline (389 j.tL, 2.50 
mmole, 1.0 eq.), morpho!inomethyl-polystyrene resin (1.000 g, 3.7 mmole g) and tris-
(2-aminoethyl)-po!ystyrene resin (2.000 g, 4.4 mmole g'). Amide 254 was isolated as a 
yellow solid (0.176 g, 17%); LRMS ES m/z 416.9 (M-H) assigned to 
C13H435C1F6N203S; HRMS FAB m/z 418.9546992 (MH) (calculated for 
C13H635C1F6N203S, 416.95408 (Dev. 1.77 ppm)); Vmax (film)/cm' 3305 (N-H), 3112 
(thiophene C-H), 3105 (aryl C-H), 1652 (C=O), 1536 (NO2), 1332 (NO2); oH (250 MHz, 
CD30D): 7.77 (s, 1H, H4), 8.41 (s, 2H, H2, H6), 8.55 (s, IH, H9); Oc (75 MHz, 
(CD3)2S0): 117.3 (CHAr), 119.9 (2 X CHAr), 123.5 (q, JCF = 272 Hz, C173), 124.6 (CHAr), 
132.2 (q, JCF = 33 Hz, C3, CS), 135.4 (CA,), 137.1 (CA,), 140.2 (CA,), 143.3 (CAr), 158.9 
(0); Mpt. 218.2 —218.9 °C. 
5-Chloro-4-nitro-N- 14-(trifluoromethyl)pheny!1 thiophene-2-carboxamide (255) 
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Genera! procedure A2 was followed using 5-ch!oro-4-nitrothiophene-2-carbonyl 
chloride (0.136 g, 0.60 mmole, 1.2 eq.) and 4-(trifluoromethy!)aniline (63 jL, 0.50 
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mmole, 1.0 eq.). Amide 255 was isolated as a white solid (0.048 g, 27%); LRMS ES 
m/z 349.0 (M-H); 6H  (250 MHz, (CD3)2S0): 7.78 (d, 2H, J = 8.9 Hz, H3, H5), 7.96 (d, 





General procedure A2 was followed using 5-chloro-4-nitrothiophene-2-carbonyl 
chloride (0.680 g, 3.00 mmole, 1.2 eq.), 4-chloroaniline (0.319 g, 2.50 mmole, 1.0 eq.), 
morphol inomethyl -polystyrene resin (1.000 g, 3.7 mmole g) and tris-(2-aminoethyl)-
polystyrene resin (2.000 g, 4.4 mmole g'). Amide 256 was isolated as a yellow solid 
(0.238 g, 30%; LRMS ES m/z 314.8 (M-H); HRMS FAB m/z 316.95613 (MH) 
(calculated for C11H735C12N203S, 316.95544 (Dev. 2.18 ppm)); Vmax (film)/cm- 1 3294 
(N-H), 3120 (thiophene C-H), 2928 (C-H), 1644 (C=O), 1548 (NO2), 1335 (NO2); 6H 
(250 MHz, (CD3)2S0): 7.64 (d, 2H, J = 8.9 Hz, ArE), 7.94 (d, 2H, J = 8.9 Hz, ArH), 
8.88 (s, 1H, thiophene 11), 10.92 (s, IH, NI]); 6c(75  MHz, (CD3)2S0): 122.5 (2 x CHAr), 
125.3 (CHAr), 128.9 (CA'), 120.5 (2 X GHAJ), 136.5 (CM), 136.8 (CA,), 137.6 (CA'), 143.4 
(CA,), 158.3 (CO); Mpt. 264.4 -264.6 °C. 
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General procedure A2 was followed using 5-chloro-4-nitrothiophene-2-carbonyl 
chloride (0.136 g, 0.60 mmole, 1.2 eq.) and 4-fluoroaniline (48 p.L, 0.50 mmole, 1.0 
eq.). Amide 257 was isolated as a white solid (0.032 g, 21%); LRMS ES m/z 416.9 (M-
H). 





General procedure A2 was followed using 5-chloro-4-nitrothiophene-2-carbonyl 
chloride (0.136 g, 0.60 mmole, 1.2 eq.) and 1-[4-(trifluoromethyl)phenyl]methanamine 
(71 [tL, 0.50 mmole, 1.0 eq.). Amide 258 was isolated as a white solid (0.088 g, 48%); 
LRMS ES m/z 363.0 (M-H). 
5-Chloro-N-(4-chlorobenzyl)-4-nitrothiophene-2-carboxamide (259) 
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General procedure A2 was followed using 5-chloro-4-nitrothiophene-2-carbonyl 
chloride (0.136 g, 0.60 mmole, 1.2 eq.) and 1-(4-chlorophenyl)methanamine (61 jtL, 
0.50 mmole, 1.0 eq.). Amide 259 was isolated as a white solid (0.097 g, 58%); LRMS 
ES m/z 328.9 (M-H); oH (250 MHz, (CD3)2S0): 4.47 (d, 2H, J = 5.8 Hz, 117), 7.36 (d, 
2H, J = 8.4 Hz, 112, H6), 7.43 (d, 2H, J = 8.4 Hz, H3, H5), 8.48 (s, 1H, H10), 9.54 (t, 
IH,J= 5.8 Hz, NI]). 
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General procedure A2 was followed using 1 -benzothiophene-2-carbonyl chloride (0.118 
g, 0.60 mmole, 1.2 eq.) and 3,5-bis(trifluoromethyl)aniline (78 [tL, 0.50 mmole, 1.0 eq.). 
Amide 260 was isolated as a pale yellow solid (0.116 g, 60%); LRMS FAB m/z 390 
(MH); HRMS FAB m/z 390.03772 (MH) (calculated for C17H10 F6N0S, 390.03873 
(Dev. —2.59 ppm)); 3H  (250 MHz, (CD3)2S0): 7.44 - 7.57 (m, 2H, H12, H13), 7.85 (s, 
1H, H4), 8.02-8.13 (m, 2H, HI 1, H14), 8.42 (s, 1H, H9), 8.50 (s, 2H, 112, H6), 11.09 
(s, 1H, Nil); Oc  (63 MHz, (CD3)2S0): 118.7 (q, JCF = 272 Hz, CF3), 119.4 (CH), 122.7 
(CHAr), 125.0 (2 X CHAr), 125.5 (2 X CHAr), 126.7 (2 x CUM), 130.5 (q, JCF = 33 Hz, C3, 
C5),138.5 (CA,), 138.7 (CA,), 140.4 (CA,), 140.6 (C), 160.9 (0). 
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General procedure A2 was followed using l-benzothiophene-2-carbonyl chloride (0.118 
g, 0.60 mmole, 1.2 eq.) and 3-(trifluoromethyl)aniline (63 tL, 0.50 mmole, 1.0 eq.). 
Amide 261 was isolated as a yellow solid (0.156 g, 97%); LRMS FAB m/z 322 (MH); 
HRMS FAB m/z 322.05108 (MH) (calculated for C16H11 F3N0S, 322.05135 (Dev. - 
0.84 ppm)); 6H  (250 MHz, (CD3)2S0): 7.46 - 7.54 (m, 3H, ArH), 7.65 (t, 1H, J = 7.9 
Hz, H3), 8.04 - 8.13 (m, 3H, ArE), 8.26 (s, IH, H6), 8.42 (s, IH, H9), 10.85 (s, 1H, 
NH); 6c(63  MHz, (CD3)2S0): 116.1 (CHAr), 120.0 (CHAr), 121.7 (q, JCF = 272 Hz, C173), 
122.7 (CHAr), 123.5 (CHAr), 124.9 (CHAr), 125.3 (CHAr), 126.2 (CHAr), 126.5 (CHAr), 
129.3 (q, JCF = 32 Hz, CS), 129.8 (CHAr), 138.8 (CAr), 139.1 (CAr), 139.2 (CAr), 140.4 
(CAr), 160.5 (C7); Mpt. 141.1 - 141.9 T. 









General procedure A2 was followed using 1 -benzothiophene-2-carbonyl chloride (0.118 
g, 0.60 mmole, 1.2 eq.) and 4-(trifluoromethyl)aniline (63 tL, 0.50 mmole, 1.0 eq.). 
Amide 262 was isolated as an off-white solid (0.055 g, 34%); LRMS FAB m/z 322 
(MH)+; HRMS FAB m/z 322.05161 (MH) (calculated for C16H11 F3N0S, 322.05135 
287 
(Dev. 0.81 PPM)); 6H(2SO MHz, (CD3)2S0): 7.42- 7.57 (m, 2H, aromatic), 7.77 (d, 2H, 
J = 8.8 Hz, H2, H6), 8.02- 8.11 (m, 4H, aromatic), 8.44 (s, 11-I, H9), 10.87 (s, IH, NI]); 
6c (63 MHz, (CD3)2S0): 119.9 (2 X CHAr), 122.0 (q, JCF = 273 Hz, CF3), 122.7 (CHAr), 
123.6 (q, JCF = 32 Hz, C4), 124.9 (CHAr), 125.4 (CH Ar), 125.9 (2 X CHAr), 126.3 (CHAr), 
126.5 (CHAr), 138.8 (CA,), 139.2 (CA,), 140.5 (CA,), 142.1 (CA,), 160.6 (0). 
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General procedure A2 was followed using I -benzothiophene-2-carbonyl chloride (0.118 
g, 0.60 mmole, 1.2 eq.) and 4-chloroaniline (0.064 g, 0.50 mmole, 1.0 eq.). Amide 263 
was isolated as a cream solid (0.073 g, 51%); LRMS FAB m/z 288 (MH); HRMS 
FAB 	m/z 288.02503 (MH) (calculated for CIA,  35C1N0S, 288.02499 (Dev. 0.13 
PPM)); Vmax (KBr)Icm' 3362 (N-H), 3054 (aryl C-H), 1646 (C=O); 6H  (250 MHz, 
(CD3)2S0): 7.48 (d, 2H, J = 8.9 Hz, 113, H5), 7.50 - 7.58 (m, 2H, H12, H13), 7.86 (d, 
2H, J = 8.9 Hz, 112, H6), 8.04- 8.14 (m, 2H, HI 1, H14), 8.41 (s, IH, H9), 10.70 (s, IH, 
Nil); 6c  (63 MHz, (CD3)2S0): 121.6 (2 X CHAr), 122.7 (CHAr), 124.9 (CHAr), 125.3 
(CF1Ar), 125.8 (CHAr), 126.4 (CHAr), 127.4 (CAr), 128.5 (2 X CHAr), 137.4 (CA,), 138.8 









General procedure A2 was followed using I -benzothiophene-2-carbonyl chloride (0.118 
g, 0.60 mmole, 1.2 eq.) and 4-fluoroaniline (48 L, 0.50 mmole, 1.0 eq.). Amide 264 
was isolated as a cream solid (0.079 g, 55%); LRMS FAB m/z 272 (MH); HRMS 
FAB m/z 272.05459 (MH) (calculated for C15H11 FNOS, 272.05454 (Dcv 0.20 ppm)); 
Vm (KBr)Icm' 3393 (N-H), 3067 (aryl C-H), 1642 (C=O); 6H  (250 MHz, (CD3)2S0): 
7.25 (t, 2H, J = 8.9 Hz, JHF = 8.9 Hz, H3, H5), 7.46-7.56 (m, 2H, H12, H13), 7.82 (dd, 
2H, J = 9.1 Hz, JHF = 5.0 Hz, 5.7 Hz, 1-12, H6), 8.02-8.12 (m, 2H, HI 1, H14), 8.37 (s, 
IH, H9), 10.62 (s, 1H, NI]); öc (63 MHz, (CD3)2S0): 115.2 (d, JCF = 22 Hz, C3, CS), 
122.0 (d, JCF = 8 Hz, C2, C6), 122.7 (CHAr), 124.9 (CHAr), 125.2 (CHAr), 125.6 (CHAr), 
126.3 (CHAr), 134.7 (d, JCF = 2 Hz, Cl), 138.9 (CA,), 139.6 (CA,), 140.3 (CA,), 158.2 (d, 
JCF = 241 Hz, C4), 160.0 (C7). 
N-(3,4-Difluorophenyl)- 1-benzothiophene-2-carboxamide (265) 
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General procedure A2 was followed using I -benzothiophene-2-carbonyl chloride (0.118 
g, 0.60 mmole, 1.2 eq.) and 3,4-difluoroaniline (50 jtL, 0.50 mmole, 1.0 eq.). Amide 265 
was isolated as a beige solid (0.075 g, 52%); LRMS FAB m/z 290 (MH); HRMS FAB 
RUS 
m/z 290.04555 (MH) (calculated for C15H10F2N0S, 290.045 12 (Dev. 1.48 ppm)); 6H 
(250 MHz, (CD3)2S0): 7.45 - 7.57 (m, 4H, aromatic), 7.91 - 8.12 (m, 3H, aromatic), 
8.38 (s, IH, H9), 10.75 (s, IH, NI]); 6c  (63 MHz, (CD3)2S0): 109.1 (d, JCF = 22 Hz, 
CHAr), 116.4 (CHAr), 117.3 (d, JCF = 18 Hz, CHAr), 122.7 (CHAr), 124.9 (CHAr), 125.3 
(CHAr), 126.0 (CHAr), 126.5 (CHAr), 135.5 (CAr), 138.8 (CAr), 139.1 (CAr), 140.4 (CAr), 
145.5 (dd, JCF = 242, 13 Hz, C4), 148.8 (dd, JCF  243, 13 Hz, C5), 160.3 (0). 
N- 14-(Trifluoromethyl)ben1yI1 -1-benzothiophene-2-carboxamide (266) 
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General procedure A2 was followed using I -benzothiophene-2-carbonyl chloride (0.11 8 
g, 0.60 mmole, 1.2 eq.) and 1-[4-(trifluoromethyl)phenyl]methanamine (71 jiL, 0.50 
mmole, 1.0 eq.). Amide 266 was isolated as a white solid (0.121 g, 72%); LRMS FAB 
m/z 336 (MH); HRMS FAB m/z 336.06738 (MH) (calculated for C17H13F3N0S, 
336.06700 (Dev 1.14 ppm)); Vmax (KBr)/cm' 3296 (N-H), 3077 (aryl C-H), 2917 (C-H), 
1628 (C=O); 6H (250 MHz, (CD3)2S0): 4.61 (d, 2H, J = 5.9 Hz, 117), 7.43 - 7.53 (m, 
2H, H13, H14), 7.59 (d, 2H, J = 8.1 Hz, 112, H6), 7.75 (d, 2H, J = 8.1 Hz, 113, H5), 7.95 
-8.07 (m, 2H, H12, HI 5), 8.18 (s, 1H, H10), 9.48 (t, IH, J = 5.9 Hz, NI]); 6C(63  MHz, 
(CD3)2S0): 42.1 2 (C7), 122.6 (CHAr), 124.1 (q, JCF 272 Hz, CF3), 125.0 (3 x CHAr), 
125.1 (2 X CHAr), 126.1 (CHAr), 127.1 (q, JCF = 32 Hz, C4), 127.6 (2 X CHAr), 138.9 
(CAr), 139.3 (CAr), 140.0 (CAr), 143.9 (C), 161.5 (C8); Mpt. 192.0- 193.2 T. 
290 
Chanter .) 
N-(4-Chlorobenzyl)-1 -benzothiophene-2-carboxamide (267) 
13 	12 
14 	10 	6 	4 CI ( 
sy 
ifl( 




Genera! procedure A2 was followed using I -benzothiophene-2-carbonyl chloride (0.118 
g, 0.60 mmole, 1.2 eq.) and 1-(4-chlorophenyl)methanamine (61 tL, 0.50 mmole, 1.0 
eq.). Amide 267 was isolated as a pale yellow solid (0.070 g, 46%); LRMS FAB m/z 
302 (MH); HRMS FAB m/z 302.04094 (MH) (calculated for C16H 13 35C1NOS, 
302.04064 (Dev. 1.01 ppm)); Vm (KBr)/cm' 3291 (N-H), 3083 (aryl C-H), 2922 (C-H), 
1628 (C=O); 8H  (250 MHz, (CD3)2S0): 4.59 (d, 2H, J = 5.9 Hz, R7), 7.35 - 7.53 (m, 
6H, Ar!]), 7.92- 8.09 (m, 2H, ArE), 8.17 (s, 1H, 1-110), 9.41 (t, IH, I = 5.9 Hz, NI]); & 
(63 MHz, (CD3)2S0): 41.8 (0), 122.6 (CHM), 124.7 (2 x CHAr), 125.0 (CHAr), 126.0 
(CHAr), 128.1 (2 X CHAr), 129.0 (2 X CHAr), 131.3 (CA,  138.8  (CA,),  138.9 (CM), 139.4 
(CA, 140.0 (CAr), 161.4(C8); Mpt. 223.6-224.0 °C. 
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General procedure A2 was followed using 5-(4-chlorophenyl)-2-methyl-3-furoyl 
chloride (0.153 g, 0.60 mmole, 1.2 eq.) and 3,5-bis(trifluoromethyl)aniline (78 PtL, 0.50 
mmole, 1.0 eq.). Amide 268 was isolated as a cream solid (0.166 g, 74%); LRMS FAB 
m/z 448 (MH); HRMS FAB m/z 448.05331 (MH) (calculated for C20H13 35C1F6NO2 , 
291 
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448.05390 (Dcv. —1.33 PPM)); 8H(2SO MHz, (CD3)2S0): 2.67 (s, 3H, HI 2), 7.51 (s, 1H, 
H9), 7.56 (d, 2H, J = 8.5 Hz, H15, H17), 7.70 (d, 2H, .J = 8.5 Hz, H14, H18), 7.82 (s, 
IH, H4), 8.49 (s, 2H, 112, H6), 10.44 (s, 1H, NI]); 3c (63 MHz, (CD3)2S0): 13.4 (C12), 
105.1 (CHAr), 116.4 (CHAr), 117.3 (CAr), 119.3, (2 X CHAr), 121.9 (q, JCF = 272 Hz, 
CF3), 124.7 (2 X CHAr), 128.0 (CA,), 129.0 (2 X CHAr), 130.4 (q, JCF = 32 Hz, C3, CS), 
132.1 (CA,), 140.7 (CA, 149.4 (CA,), 157.9 (CA,), 161.9 (0). 
5-(4-Chlorophenyl)-2-methyl-N- 14-(trifluoromethyl)phenyl] -3-furamide (269) 
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General procedure A2 was followed using 5-(4-chlorophenyl)-2-methyl-3-furoyl 
chloride (0.153 g, 0.60 mmole, 1.2 eq.) and 4-(trifluoromethyl)aniline (63 tL, 0.50 
mmole, 1.0 eq.). Amide 269 was isolated as a white solid (0.133 g, 70%); LRMS FAB 
m/z 380 (MH); HRMS FAB m/z 380.06648 (MH) (calculated for C19H1435C1F3NO2, 
380.06652 (Dcv. —0.09 ppm)); Vmax (KBr)/cm 1 3286 (N-H), 3114 (Furan C-H), 3029 
(aryl C-H), 2925 (C-H), 1649 (C=0); 6H(2SO MHz, (CD3)2S0): 2.65 (s, 3H, H13), 7.53 
(s, IH, H10), 7.55 (d, 211, J = 8.5 Hz, H16, H18), 7.70 (d, 2H, J = 8.5 Hz, HI 5, H19), 
7.84 (d, 2H, .1 = 8.3 Hz, H2, H6), 8.00 (d, 2H, J = 8.3 Hz, H3, H5), 10.18 (s, 1H, NI]); 
8c (63 MHz, (CD3)2S0): 13.3 (C13), 105.4 (CHAr), 117.8 (CAr), 122.0 (q, JCF = 273 Hz, 
C7), 119.6 (2 X CHAr), 123.5 (q, JCF = 32 Hz, C4), 124.7 (2 x CHAr), 125.7 (2 X CHAr), 
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General procedure A2 was followed using 5 -(4-chlorophenyl)-2-methyl-3 -furoyl 
chloride (0.153 g, 0.60 mmole, 1.2 eq.) and 4-chioroaniline (0.064 g, 0.50 mmole, 1.0 
eq.). Amide 270 was isolated as a white crystalline solid (0.114 g, 66%); LRMS FAB 
m/z 346 (MH); HRMS FAB m/z 346.04010 (MH) (calculated for C18H1435C12NO2, 
346.04016 (Dev. - 0.17 ppm)); Vmax (KBr)/cm 1 3272 (N-H), 3031 (aryl C-H), 1643 
(C0); 6H (250 MHz, (CD3)2S0): 2.63 (s, 3H, H12), 7.42 (d, 2H, J = 8.8 Hz, H3, H5), 
7.49 (s, 1H, H9), 7.54 (d, 2H, J = 8.5 Hz, HIS, H17), 7.68 (d, 2H, J = 8.5 Hz, H14, 
H18), 7.79 (d, 2H, J = 8.8 Hz, H2, H6), 9.98 (s, 1H, Nil); 6C(63 MHz, (CD3)2S0): 13.3 
(C12), 105.5 (CHA ), 117.9 (CA,), 121.4 (2 X CHAr), 124.6 (2 X CHAr), 126.9 (CAr), 128.2 
(CA,), 128.3 (2 X CHjs r), 128.9 (2 X CHAr), 131.9 (CA'), 137.7 (CA, 149.1 (CA, 157.0 
(CA,), 161.3 (0). 
5-(4-Chlorophenyl)-N-(4-fluorophenyl)-2-methyl-3-ftl ram ide (271) 
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General procedure A2 was followed using 5-(4-ch!orophenyl)-2-methyl-3-furoyl 
chloride (0.153 g, 0.60 mmole, 1.2 eq.) and 4-fluoroaniline (48 tL, 0.50 mmole, 1.0 
eq.). Amide 271 was isolated as a pale brown solid (0.136 g, 83%); LRMS FAB m/z 
330 (MH); FIRMS FAB m/z 330.07038 (MH) (calculated for C18H1435C1FN02, 
293 
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330.06971 (Dev. 1.73 ppm)); Vmax (KBr)Icm' 3288 (N-H), 3142 (Furan C-H), 3056 (aryl 
C-H), 2925 (C-H), 1639 (C=O); 6H (250 MHz, (CD3)2S0): 2.64 (s, 3H, H12), 7.21 (t, 
2H, J = 8.8 Hz, JHF = 8.8 Hz, H3, H5), 7.49 (s, 1H, H9), 7.55 (d, 2H, J = 8.5 Hz, HI 5, 
H17), 7.70 (d, 2H, J = 8.5 Hz, H14, H18), 7.77 (dd, 2H, J = 8.8 Hz, JHF 5.0 Hz, H2, 
H6), 9.98 (s, IH, NH); 5c (63 MHz, (CD3)2S0): 13.3 (C12), 105.5 (CHAr), 115.0 (d, JCF 
= 22 Hz, C3, C5), 118.0 (CAr), 121.8 (d, JCF 8 Hz, C2, C6), 124.6 (2 X CHAr), 128.3 
(CAr), 128.9 (2 X CHAr), 131.9 (CAr), 135.1 (d, JCF = 2 Hz, Cl), 149.1 (CAr), 156.7 (CAr), 
158.0 (d, JCF 240 Hz, C4), 161.1 (C7); Mpt. 183.9— 185.4 T. 
5-(4-C h lorophenyl)-2- methyl-N- 14-(trifluoromethyl)benzyll -3-fu ram ide (272) 
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General procedure A2 was followed using 5-(4-ch!orophenyl)-2-methyl-3 -furoyl 
chloride (0.153 g, 0.60 mmole, 1.2 eq.) and 1-[4-(trifluoromethyl)phenyl]methanamine 
(71 j.iL, 0.50 mmole, 1.0 eq.). Amide 272 was isolated as a white solid (0.138 g, 70%); 
LRMS FAB m/z 394 (MH); HRMS FAB m/z 394.08259 (ME) (calculated for 
C20H1635C1F3NO2, 394.082 17 (Dev. 1.07 ppm)); Vmax (KBr)Icm' 3302 (N-H), 3064 (aryl 
C-H), 2961 (C-H), 2925 (C-H), 1643 (C=O); 8H (250 MHz, (CD3)2S0): 2.53 (s, 3H, 
H13), 4.54 (d, 2H, J = 5.8 Hz, 117), 7.37 (s, 1H, H10), 7.54 (d, 2H, J = 8.4 Hz, 112, H6), 
7.57 (d, 2H, J = 8.5 Hz, H16, H18), 7.66 (d, 2H, J = 8.4 Hz, H3, H5), 7.74 (d, 2H, J = 
8.5 Hz, H15, H19), 8.78 (t, J = 5.8 Hz, NH); 6c (63 MHz, (CD3)2S0): 13.1 (C13), 41.5 
(C7), 105.2 (CHjsr), 117.5 (CAr), 122.0 (q, JCF = 272 Hz, CF3), 124.6 (2 x CHAr), 125.0 
(2 X CHAr), 127.0 (q, JCF = 32 Hz, C4), 127.7 (2 x CHAr), 128.3 (CAr), 128.9 (2 X CHAr), 
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N-(4-Chlorobenzyl)-5-(4-chlorophenyl)-2-methyi-3-fu ram ide (273) 
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General procedure A2 was followed using 5-(4-chlorophenyl)-2-methyl-3-furoyl 
chloride (0.153 g, 0.60 mmole, 1.2 eq.) and 1-(4-chlorophenyl)methanamine (61 jiL, 
0.50 mmole, 1.0 eq.). Amide 273 was isolated as a white solid (0.149 g, 83%); LRMS 
FAB m/z 360 (MH); HRMS FAB m/z 360.05603 (MH) (calculated for 
C19H1635C12NO2, 360.05581 (Dev. 0.60 PPM)); Vmax (KBr)1cm 1 3262 (N-H), 3048 (aryl 
C-H), 2918 (C-H), 2873 (C-H), 1632 (C=O); 8H  (250 MHz, (CD3)2S0): 2.60 (s, 3H, 
H13), 4.42 (d, 2H, J = 6.0 Hz, H7), 7.35 (d, 2H, J = 8.5 Hz, 112, H6), 7.43 (s, 1H, H10), 
7.41 (d, 2H, J = 8.5 Hz, H3, H5), 7.52 (d, 2H, J = 8.6 Hz, H16, H18), 7.63 (d, 2H, .J = 
8.6 Hz, H15, H19), 8.68 (t, J = 6.0 Hz, NI]); 8c  (63 MHz, (CD3)2S0): 13.1 (C13), 41.2 
(C7), 105.2 (CHAr), 117.5 (CA,),  124.6(2 X CHAr), 128.0(2 X CHAr), 128.3 (CA,), 128.9 
(4 X CHAr), 131.1 (CAr), 131.8 (CM), 138.5 (CM), 149.0 (CA,), 156.0 (CA,), 162.4 (C8). 
N- [3,5-Bis(trifluoromethyl)phenyll -5-nitrothiophene-2-carboxamide (278) 
10 
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General procedure A2 was followed using 5-nitrothiophene-2-carbonyl chloride (0.115 
g, 0.60 mmole, 1.2 eq.) and 3,5-bis(trifluoromethyl)aniline (78 jiL, 0.50 mmole, 1.0 eq.). 
Amide 278 was isolated as a green solid (0.035 g, 18%); LRMS ES m/z 384 (M); 6H 
295 
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(250 MHz, (CD3)2S0): 7.87 (s, IH, H4), 7.97 (s, IH, Ni]), 8.05 (d, 1H, J = 4.4 Hz, H9), 
8.25 (d, IH, J = 4.4 Hz, H10), 8.43 (s, 2H, H2, H6). 
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General procedure A2 was followed using 5-nitrothiophene-2-carbonyl chloride (0.115 
g, 0.60 mmole, 1.2 eq.) and 3-chloroaniline (53 1iL, 0.50 mmole, 1.0 eq.). Amide 279 
0 was isolated as a brown solid (0.083 g, 59/a); LRMS El
+  m/z 282 (M)+; Vmax (KBr)/cm-I  
3399 (N-H), 3107 (thiophene C-H), 3055 (aryl C-H), 1677 (C0), 1541 (NO2), 1351 
(NO2); 8H  (250 MHz, (CD3)2S0): 7.27 (ddd, IH, J = 8.0, 2.0, 0.9 Hz, H4), 7.46 (t, 1H, J 
= 8.0 Hz, 113), 7.72 (ddd, 1H, J = 8.0, 2.0, 0.9 Hz, 112), 7.94 (t, 1H, J = 2.0 Hz, H6), 
8.13 (d, IH, J = 4.4 Hz, H9), 8.25 (d, JH, J = 4.4 Hz, H10), 10.86 (s, IH, Nil); 6c  (91 
MHz, CD30D): 118.1 (CHAr), 119.8 (CHAr), 123.9 (CHAr), 126.9 (CHAr), 127.9 (CHAr), 
129.4 (CHAr), 133.6 (CA,), 138.7 (CA,), 144.9 (CA,), 154.0 (CA,), 158.7 (0). 
5-Nitro-N- 13-(trifluoromethyl)phenyll thiophene-2-carboxamide (280) 
10 




General procedure A2 was followed using 5-nitrothiophene-2-carbonyl chloride (0.115 
g, 0.60 mmole, 1.2 eq.) and 3-(trifluoromethyl)aniline (63 j.tL, 0.50 mmole, 1.0 eq.). 
Amide 280 was isolated as a yellow solid (0.075 g, 48%); LRMS EI m/z 316 (M); 6H 
296 
(250 MHz, (CD3)2S0): 7.81 (d, 1H, J = 8.0 Hz, H4), 8.07 (t, IH, J = 8.0 Hz, H3), 8.49 
(d, IH, J = 8.0 Hz, H2), 8.52 (d, IH, J = 4.4 Hz, H9), 8.66 (d, 1H, J = 4.4 Hz, H10), 
11.36 (s, IH,NJI). 
5-Nitro-N- [4-(trifluoromethyl)phenyl] thiophene-2-carboxamide (281) 
2 
O2N(,H 7 N 8 
II ::ICF30 10 
General procedure A2 was followed using 5-nitrothiophene-2-carbonyl chloride (0.115 
g, 0.60 mmole, 1.2 eq.) and 4-(trifluoromethyl)aniline (63 iL, 0.50 mmole, 1.0 eq.). 
Amide 281 was isolated as a brown solid (0.071 g, 45%); LRMS EV m/z 316 (M); 
HRMS EI m/z 316.01348 (M) (calculated for C12H7173N203S, 316.01295 (Dev. 1.68 
PPM)); Vmax (KBr)/cm 1 3329 (N-H), 3122 (thiophene C-H), 3056 (aryl C-H), 1655 
(C=O), 1538 (NO2), 1328 (NO2); oH  (250 MHz, (CD3)2S0): 7.58 (d, 2H, J = 8.9 Hz, H8, 
H10), 7.79 (d, 2H, J = 8.9 Hz, 117, Hi 1), 7.93 (d, 1H, J = 4.5 Hz, H3), 8.05 (d, IH, J = 
4.5 Hz, 112), 10.77 (s, 1H, Nil); 0c  (63 MHz, (CD3)2S0): 121.2(2 x CHAr), 121.9 (q, JCF 
= 272 Hz, CF3), 124.2 (q, JCF = 33 Hz, C9), 125.9 (2 x CHA ), 128.7 (CHAr), 129.9 
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General procedure A2 was followed using 5-nitrothiophene-2-carbonyl chloride (0.115 
g, 0.60 mmole, 1.2 eq.) and 4-chloroaniline (0.064 g, 0.50 mmole, 1.0 eq.). Amide 282 
297 
________ 
was isolated as a brown solid (0.044 g, 3 1%); LRMS EI m/z 292 (M); 6H (250 MHz, 
(CD3)2S0): 7.28 (d, 2H, .1 = 6.9 Hz, H8, H10), 7.60 (d, 2H, J = 6.9 Hz, 117, HI 1) 7.88 
(d, 1H, J = 4.4 Hz, H3), 8.03 (d, IH, J = 4.4 Hz, H2), 10.61 (s, lH, NH); 6c  (63 MHz, 
(CD3)2S0): 121.9 (2 X CHI%), 128.2 (CA,), 128.4 (CHAr), 128.7 (2 X CHAr), 130.0 
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General procedure A2 was followed using 5-nitrothiophene-2-carbonyl chloride (0.115 
g, 0.60 mmole, 1.2 eq.) and 4-fluoroaniline (48 tL, 0.50 mmole, 1.0 eq.). Amide 283 
was isolated as a yellow solid (0.079 g, 59%); LRMS EL m/z 266 (M); HRMS EI m/z 
266.01634 (M) (calculated for C11H7FN203S 266.01614, Dev. 0.75 ppm); Vmax 
(film)/cm- 1 3292 (N-H), 3107 (thiophene C-H), 2928 (C-H), 1646 (C=O), 1540 (NO2), 
1338 (NO2); 3H  (250 MHz, (CD3)2S0): 7.43 - 7.52 (m, 2H, H8, H10), 7.97 - 8.02 (m, 
2H, 117, HI 1), 8.30 (d, 1H, J = 4.4 Hz, H3), 8.44 (d, 1H, J = 4.4 Hz, 112), 10.97 (s, 1H, 
NI]); 6c (63 MHz, (CD3)2S0): 115.3 (d, JCF = 22 Hz, C8, C I O), 122.3 (d, JCF = 8 Hz, 
C7, Cl 1), 128.1 (CHAr), 129.9 (CHjsj), 134.0 (C4), 146.0 (CA,), 153.1 (CA,), 156.7 (d, 
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General procedure A2 was followed using 5-nitrothiophene-2-carbonyl chloride (0.115 
g, 0.60 mmole, 1.2 eq.) and 3,4-difluoroaniline (50 jit, 0.50 mmole, 1.0 eq.). Amide 284 
was isolated as a yellow solid (0.072 g, 5 1%); LRMS E1 m/z 284 (M); Vmax (KBr)1cm 1  
3377 (N-H), 3112 (thiophene C-H), 3047 (aryl C-H), 1668 (C0), 1552 (NO2), 1340 
(NO2); oH (250 MHz, (CD3)2S0): 7.46 - 7.54 (m, 2H, H2, H6), 7.84 - 7.97 (m, I H, H3), 
8.06 (d, IH, J = 4.4 Hz, H9), 8.23 (d, 1H, J = 4.4 Hz, HI 0), 10.86 (s, IH, NH). 
N-(3,5-Dichlorophenyl)-5-nitrothiophene-2-carboxamide (285) 
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General procedure A2 was followed using 5-nitrothiophene-2-carbonyl chloride (0.115 
g, 0.60 mmole, 1.2 eq.) and 3,5-dichloroaniline (0.081 LI, 0.50 mmole, 1.0 eq.). Amide 
285 was isolated as a brown solid (0.068 g, 43%); LRMS ES m/z 316 (M); HRMS 
FAB m/z 316.95445 (MT-I) (calculated for C11 H735C12N203S, 315.95544 (Dev. - 3.12 
ppm)); Vmax (KBr)/cm' 3370 (N-H), 3102 (thiophene C-H), 3089 (aryl C-H), 1666 
(C=O), 1541 (NO2), 1337 (NO2); 0H  (250 MHz, (CD3)2S0): 7.49 (s, IH, H4), 7.84 (s, 
2H, 112, H6), 8.07 (d, IH, J = 4.3 Hz, H9), 8.22 (d, 1H, J =4.3 Hz, H10), 10.91 (s, 1H, 
NH); 8c  (63 MHz, (CD3)2S0): 118.3 (C2, C6), 123.5 (CHAr), 128.8 (CHAr), 130.0 
WE 
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(CHAr), 133.8 (C3, C5), 140.1 (CA,), 144.9 (CA,), 153.6 (CA,), 158.5 (0); Mpt. 217.6-
218.3 °C. 
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General procedure A2 was followed using 5-nitrothiophene-2-carbonyl chloride (0.115 
g, 0.60 mmole, 1.2 eq.) and 1-[3,5-bis(trifluoromethyl)phenyl]methanamine (0.122 g, 
0.50 mmole, 1.0 eq.). Amide 286 was isolated as a green solid (0.151 g, 76%); LRMS 
Ef m/z 398 (M); 6H  (250 MHz, (CD3)2S0): 4.70 (d, 2H, J = 5.8 Hz, 117), 4.28 (d, I H, 
J= 4.4 Hz, H10), 8.04 (s, IH, H4), 8.10 (s, 2H, H2, H6), 8.17 (d, IH, J = 4.4 Hz, HI 1), 
9.71 (t, 1H, J = 5.8 Hz, NH); öc (63 MHz, (CD3)2S0): 41.9 (0), 120.7 (CHAr), 123.1 
(q, JCF = 273 Hz, CF3), 127.6 (CHAr), 128.2 (C2, C6), 129.9 (CHAr), 130.1 (q, JCF = 33 
Hz, C3, C5), 142.0 (CA,), 145.3 	152.9 (CA,), 159.7 (C8). 
N-(4-Chlorobenzyl)-5-nitrothiophene-2-carboxamide (287) 
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General procedure A2 was followed using 5-nitrothiophene-2-carbonyl chloride (0.115 
g, 0.60 mmole, 1.2 eq.) and 1-(4-chlorophenyl)methanamine (61 tL, 0.50 mmole, 1.0 
eq.). Amide 287 was isolated as a brown solid (0.035 g, 47%); LRMS EI m/z 296 (M); 
61-I (250 MHz, (CD3)2S0): 4.49 (d, 2H, J = 5.9 Hz, 117), 7.36 (d, 2H, J = 8.4 Hz, H2, 
H6), 7.43 (d, 2H, J = 8.4 Hz, 113, H5), 7.86 (d, IH, J = 4.4 Hz, H10), 8.16 (d, IH, J 
300 
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=4.4 Hz, Hi 1), 9.59 (t, 1H, J = 5.9 Hz, Nil); 3c  (63 MHz, (CD3)2S0): 42.0 (0), 127.3 
(CHAr), 128.2 (2 X CH Ar), 129.1 (2 X CHAr), 130.0 (CHA1), 131.5 (CA,  137.5 (CA,), 
145.8 (CA,), 152.8 (CA,), 159.39 (C8). 
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General procedure A2 was followed using 5-nitrothiophene-2-carbonyl chloride (0.115 
g, 0.60 mmole, 1.2 eq.) and (1R)-1-(4-chlorophenyl)ethanamine (70 iL, 0.50 mmole, 1.0 
0 eq.). Amide 288 was isolated as a biege solid (0.116 g, 74/o); LRMS El
+  m/z 310 (M)+  
8H(250 MHz, CD30D): 1.61 (d, 3H,J= 7.1 Hz, H8), 5.23 (q, 1H,J=r 7.1 Hz, 117), 7.38 
(d, 2H, J = 8.9 Hz, 112, H6), 7.43 (d, 2H, J = 8.9 Hz, H3, H5), 7.79 (d, IH, J = 4.4 Hz, 
HI 1), 8.01 (d, 1H, .J = 4.4 Hz, H12); Mpt. 162.0- 162.6 °C. 
N-[(1S)-(4-Ch Iorophenyl)ethylJ -5-nitrothiophene-2-carboxamide (289) 
8 
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General procedure A2 was followed using 5-nitrothiophene-2-carbonyl chloride (0.115 
g, 0.60 mmole, 1.2 eq.) and (15)-1-(4-chlorophenyl)ethanamine (70 j.tL, 0.50 mmole, 1.0 
eq.). Amide 289 was isolated as a beige solid (0.107 g, 69%); LRMS EI m/z 310 (M); 
HRMS FAB m/z 311.75645 (MH) (calculated for C13H1235C1N2O3S, 311.02598 (Dev. 
0.87 ppm)); Vm (film)/cm-' 3297 (N-H), 3105 (thiophene C-H), 3086 (aryl C-H), 2978 
301 
(C-H), 2932 (C-H), 1628 (C=O), 1546 (NO2), 1341 (NO2); 6F1  (250 MHz, (CD3)2S0): 
1.50 (d, 3H, J = 7.0 Hz, H8), 5.13 (quintet, 2H, J = 7.0 Hz, 117), 7.42 (s, 4H, H2, H3, 
H5, H6), 7.97 (d, 1H, J= 4.4 Hz, HI 1), 8.17 (d, IH,J = 4.4 Hz, H12), 9.36 (d, IH,J= 
7.0 Hz, Nil); 5c  (63 MHz, (CD3)2S0): 21.5 (C8), 48.3 (C7), 127.4 (CHAr), 127.8 (2 X 
CHAr), 128.1 (2 X CHAJ), 129.9 (CHAr), 131.3 (CA,), 142.7 (CA,  146.0 (CA,), 152.8 
(CA,), 158.6 (C9); Mpt. 154.7— 155.2 °C. 
5-Chloro-4-nitrothiophene-2-carboxylic acid (291)215 
To a stirring suspension of 5-chlorothiophene-2-carboxylic acid (8.13 g, 50 mmole) in 
acetic anhydride (15 mL) a mixture of fuming nitric acid (16 mL) in glacial acetic acid 
(25 mL) was added over a period of 1 hour whilst maintaining the temperature of the 
reaction mixture below 30 °C. The reaction mixture was then stirred at room temperature 
for 2 hours before the dropwise addition of acetic acid (75 mL) over a period of 30 
minutes, again whilst maintaining the temperature of the reaction mixture below 30 °C. 
The reaction mixture was then stirred at room temperature for 19 hours before being 
neutralised with NaOH pellets. The reaction mixture was diluted with H20 (200 mL) 
and extracted into Et20 (200 mL). The organic layer was washed with H20 (2 x 100 mL) 
and brine (2 x 100 mL) before being dried over anhydrous MgSO4 and concentrated in 
vacuo to afford a pale yellow solid (3.08 g, 30 %); LRMS ES m/z 205.8 (M-H); HRMS 
FAB m/z 207.94756 (MH) (calculated for C5H335C1N04S, 207.94713 (Dev. 2.07 
PPM)); 6H (500 MHz, (CD3)2SO): 8.52 (s, 1H, thiophene II), 10.92 (bs, 1H, 01]); Mpt 
156.0-157.6°C. 
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5-Ch loro-4-nitrothiophene-2-carbonyl chloride (292) 
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To a stirring suspension of 5-ch!oro-4-nitrothiophene-2-carboxylic acid (1.21 g, 5.8 
mmole, 1.0 eq.) in DCM (15 mL, anhydrous) was added oxalyl chloride (610 mL, 7.0 
mmole, 1.2 eq.) followed by two drops of DMF. The reaction mixture was left to stir at 
room temperature for 24 hours before being concentrated in vacuo to afford a brown 
residue that was used directly for the synthesis of amides 254 - 259. 




To a stirring suspension of silver oxide, produced in situ from the addition of NaOH 
pellets (4.00 g) to AgNO3 (10.30 g) in water (200 mL), a solution of 5-nitrothiophene-2-
carbaldehyde (4.52 g, 28.8 mmole) in ethanol (50 mL) was added. The free silver was 
removed by filtration, washed with water (2 x 50 mL) and the filtrate was acidified with 
HC1. The white precipitate was filtered and dried in air to afford carboxylic acid 294 as a 
white solid (1.57g, 26 %, LRMS ES m/z 171.5 (M-H)) which was converted to 5-
nitrothiophene-2-carbonyl chloride, using standard procedure reported for compound 
292, and used for the synthesis of amides 278 - 289. 
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4-Nitro-N- [4-(trifluoromethyl)phenyl] benzamide (296)210 
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To a sample of 4-nitrobenzoic acid (0.200 g, 1.2 mmole, 1.0 eq.) was added 4-
trifluoromethylan i line (211 i.tL, 1.8 mmole, 1.5 eq.). Under solvent free conditions, the 
reaction mixture was irradiated in the DiscoverTM  at 160 °C for 15 minutes, with active 
cooling of the sample. The reaction mixture was diluted with EtOAc (30 mL), washed 
with HC1 (1M, 20 mL) and neutralized with NaHCO3 (saturated) before being dried over 
anhydrous Na2SO4, filtered and concentrated in vacuo to afford a pale yellow solid 
(0.053 g, 15 %) which required no further purification; LRMS m/z 311.1 (MH); HRMS 
FAB m/z 311.06472 (MH) (calculated for C14H10F3N203, 311.06435 (Dev. 1.19 ppm)); 
Vmax (KBr)Icm' 3413 (N-H), 3113 (thiophene C-H), 3078 (aryl C-H), 1685 (C=O), 1536 
(NO2), 1320 (NO2); 8H  (250 MHz, (CD3)2S0): 7.56 (d, 2H, J = 8.5 Hz, H3, H5), 7.82 (d, 
2H, J = 8.5 Hz, 112, H6), 8.01 (d, 2H, J = 8.5 Hz, H9, H13), 8.19 (d, 2H, J = 8.5 Hz, 
H10, H12), 10.66 (s, 1H, Nil); Sc (75 MII-Iz, (CD3)2S0): 120.4 (2 x CHAr), 121.0 (2 X 
CHAr), 124.3 (2 X CHAr), 125.6 (q, JCF = 272 Hz, CF3), 130.1 (2 X CHAr), 131.4 (CA,), 
140.8 (CA,), 143.1 (CA,), 150.1 (CA,), 165.1 (C7);Mpt.228.9-231.2 °C. 
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5.5 Experimental for Chapter 4 
N-(4-methylphenyl)-6-phenylpyrimidin-4-am me (388) 
To a solution of 4,6-dichloropyrimidine (0.200 g, 1.34 mmole, 1.0 eq.) in NaOH (2M, 
2.6 mL, 4.0 eq.), 4-methylaniline (0.144 g, 1.34 mmole, 1.0 eq.) was added. The reaction 
mixture was irradiated in the DiscoverTM  at 110 °C for 5 minutes during which time a 
grey precipitate formed. The precipitate was filtered and washed with water and dried in 
air to afford 6-chloro-N-(4-methylphenyl)pyrimidin-4-amine (0.217 g, 85%); LRMS 
ES m/z 219.8 (MH). 
To a solution of 6-chloro-N-(4-methylphenyl)pyrimidin-4-amine (0.217 g, 0.99 mmole, 
1.0 eq.) in THF (3 mL) was added phenylboronic acid (0.120 g, 0.99 mmole, 1.0 eq.), 
Cs2CO3 (0.964 g, 2.97 mmole, 3.0 eq.), Pd(OA02 (0.011 g, 0.05 mmole, 0.05 eq.) and 
triphenylphosphine (0.026 g, 0.10 mmole, 0.10 eq.). Water (0.3 mL) was added to 
solubilize the Cs2CO3. The reaction mixture was irradiated in the Discover 
TM  at 110 °C 
for 15 minutes. An aliquot (1 mL) of the reaction mixture was injected directly onto the 
Biotage Parallex F1exTM  HPLC (Method C, tR = 7.35 mm.). Appropriate fractions were 
combined and concentrated in vacuo to afford pyrimidine 388 as a white solid (0.001 g, 
1 %); LRMS ES m/z 261.9 (MH). 
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N- 13,5-Bis(trifluoromethyl)phenyll -6-phenylpyrimidin-4-am me (389) 
LLJ 	CF3 
NCF3 
To a stirring solution of 4,6-dichloropyrimidine (0.200 g, 1.34 mmole, 1.0 eq.) in NaOH 
(2M, 2.6 mL, 4.0 eq.), 3,5-bis(trifluoromethyl)aniline (209 PL, 1.34 mmole, 1.0 eq.) was 
added. The reaction mixture was irradiated in the DiscoverTM  at 110 °C for 5 minutes 
during which time a precipitate formed. The precipitate was filtered and washed with 
water and dried in air to afford N- [3,5-bis(trifluoromethyl)phenyl]-6-chloropyrimidifl-4-
amine (0.366 g, 80%); LRMS ES m/z 341.9 (MH). 
To a solution of N-[3 ,5-bis(trifluoromethyl)phenyl]-6-chloropyrimidin-4-amine (0.366 g, 
1.10 mmole, 1.0 eq.) in THF (3 mL) was added phenylboronic acid (0.131 g, 1.10 
mmole, 1.0 eq.), Cs2CO3 (1.050 g, 3.30 mmole, 3.0 eq.), Pd(OAc)2 (0.012 g, 0.05 
mmole, 0.05 eq.) and triphenylphosphine (0.028 g, 0.11 mmole, 0.10 eq.). Water (0.3 
mL) was added to solubilize the Cs2CO3. The reaction mixture was irradiated in the 
DiscoverTM at 110 °C for 15 minutes. An aliquot (1 mL) of the reaction mixture was 
injected onto the Biotage Parallex F1exTM  HPLC (Method C, tp. = 18.47 mm.). 
Appropriate fractions were combined and concentrated in vacuo to afford pyrimidine 
389 as a cream solid (0.001 g, 1 %); LRMS ES m/z 384.0 (MH). 
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N- [3,5-Bis(trifluoromethyl)phenyl] -6-(3-nitrophenyl)pyrimidin-4-amine (392) 
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Genera! procedure P1 was followed using 3,5-bis(trifluoromethyl)aniline (203 pL, 1.30 
mmole, 1.0 eq.). Pyrimidine 392 was isolated as a white solid (HPLC Method C, tR = 
19.49 mm., 0.003 g, I %); LRMS ES m/z 429.1 (MH); oH (250 MHz, CD30D): 7.35 
(d, 1H, J = 1.1 Hz, H8), 7.61 (s, IH, H4), 7.82 (t, IH, J = 7.9 Hz, H15), 8.40— 8.44 (m, 
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Genera! procedure P1 was followed using 4-chioroaniline (0.166 g, 1.30 mmole, 1.0 
eq.). Pyrimidine 393 was isolated as yellow solid (HPLC Method C, tR = 15.06 mm., 
0.002 g, 1%); LRMS ES 327.0 (MH); HRMS FAB m/z 327.06499 (M}1) (calculated 
for C16H1235C1N402, 327.06488 (Dev. 0.34 ppm)); Vmax (film)/cm' 3392 (N-H), 3085 
(aryl C-H), 2929 (C-H), 1623 (C=C), 1588 (aryl C=C), 1524 (NO2), 1507 (C=N), 1360 
(NO2); Mpt. 219.8 —220.8 °C. 
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Also synthesized using an alternative procedure: 
To a solution of 4,6-dichloropyrimidine (0.075 g, 0.50 mmole, 1.0 eq.) in THF (3.0 mL) 
was added 3 -nitrophenyl boron ic acid (0.084 g, 0.50 mmole, 1.0 eq.), Cs2CO3 (0.197 g, 
0.60 mmole, 1.2 eq.), Pd(OAc)2 (0.006 g, 0.03 mmole, 0.05 eq.) and triphenyiphosphine 
(0.013 g, 0.05 mmole, 0.10 eq.). Water (0.3 mL) was added to the reaction mixture to 
solubilise the Cs2CO3. The reaction mixture was irradiated in the DiscoverTM  at 110 °C 
for 25 minutes with active cooling of the sample. To an aliquot (1 mL) of the crude 
reaction mixture was added 4-chloroaniline (0.022 g, 0.17 mmole, 1.0 eq.) followed by 
HC1 (4M, 85 j.iL, 2.0 eq.) and the sample was irradiated in the DiscoverTM  at 110 °C for 
a further 25 minutes. The sample was then injected directly onto the Biotage Parallex 
Flex  TM HPLC (Method E, tR 17.32 mm.). Appropriate fractions were combined and 
concentrated in vacuo to afford pyrimidine 393 as a biege solid (0.017 g, 31 %); LRMS 
ES m/z 327.0 (MH) assigned to C16H11 35C1N402; 6H  (250 MHz, (CD3)2S0): 7.40 (s, 
1H, H8),7.43 (d, 2H, J = 8.9 Hz, 112, H6), 7.80 (d, 2H, J = 8.9 Hz, H3, H5), 7.87 (t, IH, 
J = 8.2 Hz, HIS), 8.39 (dd, IH, J = 8.2, 1.7 Hz, H16), 8.48 (d, IH, J = 8.2 Hz, H14), 
8.81 (s, 1H, H10), 8.85 (d, 1H, J = 1.7 Hz, H12), 9.98 (s, IH, Nil). 
N-(4-Methylphenyl)-6-(3-nitrophenyl)-pyrimidin-4-amine (395) 
General procedure P1 was followed using 4-methylaniline (0.139 g, 1.30 mmole, 1.0 
eq.). Pyrimidine 395 was isolated as a yellow solid (HPLC Method C, tp = 11.26 mm, 
0.001 g, I %); LRMS ES m/z 307.0 (MH). 
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6-(3-Nitrophenyl)-N- [4-(trifluoromethyl)phenytJ py rim idin-4-amine (396) 
NL1 	CF3 
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General procedure P1 was followed using 4-(trifiuoromethyl)aniline (0.139 g, 1.30 
mmole, 1.0 eq.). Pyrimidine 396 was isolated as a cream solid (HPLC Method C, tR = 
23.46 mm., 0.002 g, I %); LRMS ES m/z 361.1 (MH). 
6-(2,5-Difluorophenyl)-N-pheuylpy rim idin-4-amine (401) 
To a solution of 4,6-dichioropyrimidine (1.000 g, 6.70 mmole, 1.0 eq.) in acetonitrile (5 
mL) was added 2,5-difluorophenylboronic acid (1.059 g, 6.70 mmole, 1.0 eq.), Cs2CO3  
(3.280 g, 10.00 mmole, 1.5 eq.), Pd(OAc)2 (0.075 g, 0.34 mmole, 0.05 eq.) and 
triphenylphosphine (0.176 g, 0.67 mmole, 0.10 eq.). Water (0.5 mL) was added to 
solubilize the Cs2CO3. The reaction mixture was irradiated in the Discover 
TM  at 130 °C 
for 15 minutes before being divided into aliquots (5 x I mL). To one aliquot containing 
the Suzuki intermediate (1 mL, 1.34 mmole, 1.0 eq.) was added aniline (122 L, 1.34 
mmole, 1.0 eq.) and p-toluenesulfonic acid (0.510 g, 2.68 mmole, 2.0 eq.) and the 
sample was irradiated on the DiscoverlM  at 110 °C for 5 minutes. The reaction mixture 
was injected directly onto the Biotage Parallex FIexTM  HPLC (Method C, tR = 22.13 
309 
mm). Appropriate fractions were combined and concentrated in vacuo to afford 
pyrimidine 401 as a cream solid (0.002 g, I %); LRMS ES m/z 284.0 (MH). 
N-[3,5-Bis(trifluoromethyl)phenyl)-6-(2,5-difluorophenyl)pyrimidin-4-amine (402) 
F 	 CF3 
NCF3 
General procedure P2 was followed using 2,5-difluorophenylboronic acid (0.106 g, 0.67 
mmole, 1.0 eq.) followed by 3,5-bis(trifluoromethyl)aniline (102 L, 0.67 mmole, 1.0 
eq.). Pyrimidine 402 was isolated as a white solid (HPLC Method L, tR = 24.21 mm., 
0.002 g, I %); LRMS ES m/z 420.0 (MH); Vmax (film)/cm' 3307 (N-H), 3116 (aryl C-
H), 1636 (C=C), 1601 (aryl C=C), 1515 (C=N). 





General procedure P2 was followed using 2,5-difluorophenylboronic acid (0.106 g, 0.67 
mmole, 1.0 eq.) followed by 4-(trifluoromethyl)aniline (82 L, 0.67 mmole, 1.0 eq.). 
Pyrimidine 403 was isolated as a cream solid (HPLC Method L, tR = 19.33 mm., 0.005 
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General procedure P2 was followed using 5-fluoro-2-methoxyphenylboronic acid (0.1 14 
g, 0.67 mmole, 1.0 eq.) followed by 3,5-bis(trifluoromethyl)aniline (102 tL, 0.67 
mmole, 1.0 eq.). Pyrimidine 404 was isolated as a white solid (HPLC Method L, tR = 
16.54 mm., 0.003 g, I %); LRMS ES m/z 432.0 (MH)'; Vmax (film)/cm' 3392 (N-H), 
2917 (C-H), 2850 (0-CH3), 1646 (C=C), 1602 (aryl C=C), 1507 (C=N); 6H  (250 MHz, 
CD30D): 3.96 (s, 3H, H17), 7.21 - 7.26 (m, 2H, H14, H15), 7.54 (d, 1H, J = 1.2 Hz, 
H8), 7.61 (s, IH, H4), 7.69 (dd, IH, J = 3.0 Hz, JHF = 9.5 Hz, H12), 8.48 (s, 2H, 112, 
H6),8.85(d, IH,J= 1.2Hz,H10). 
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General procedure P2 was followed using 5-fluoro-2-methoxyphenylboronic acid (0.114 
g, 0.67 mmole, 1.0 eq.) followed by 4-(trifluoromethyl)aniline (82 tL, 0.67 mmole, 1.0 
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eq.). Pyrimidine 405 was isolated as a white solid (HPLC Method L, tR = 11.08 mm., 
0.002 g, I %); LRMS ES m/z 364.0 (MH)t 






General procedure P2 was followed using 3 -(tri fl uoromethyl)phenyl boron i c acid (0.284 
g, 0.67 mmole, 1.0 eq.) followed by 3,5-bis(trifluoromethyl)aniline (102 tL, 0.67 
mmole, 1.0 eq.). Pyrimidine 406 was isolated as a pale yellow solid (HPLC Method L, tR 
= 24.18 mm., 0.003 g, I %); LRMS ES m/z 452.1 (MH). 
6- [3-(Trilluoromethyl)phenylj -N- 14-(trifluoromethyDphenyll py rim idin-4-amine 
(407) 
14 
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General procedure P2 was followed using 3-(trifluoromethyl)phenylboronic acid (0.284 
g, 0.67 mmole, 1.0 eq.) followed by 4-(trifluoromethyl)aniline (82 L, 0.67 mmole, 1.0 
eq.). Pyrimidine 407 was isolated as a pale yellow solid (HPLC Method L, tR = 20.08 
mm., 0.003 g, 1 %); LRMS ES m/z 384.2 (MH)+; Vm (film)/cm' 3308 (N-H), 3116 
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(aryl C-H), 2925 (C-H), 1645 (C=C), 1584 (aryl C=C), 1520 (C=N); SM  (250 MHz, 
CD30D): 7.34 (d, 1H, J = 1.1 Hz, H8), 7.70 (d, 2H, J = 8.6 Hz, 112, H6), 7.80 (t, IH, J 
= 7.9 Hz, HIS), 7.91 (d, IH, J = 7.9 Hz, H14), 8.01 (d, 2H, J = 8.6 Hz, H3, H5), 8.28 
(d, JH,J = 7.9 Hz, H16), 8.36(s, IH,H12), 8.86(d, lH,J= 1.1 Hz, H10);Mpt. 151.2-
152.6 °C. 
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General procedure P3 was followed using 4-fluorophenylboronic acid (0.094 g, 0.67 
mmole, 1.0 eq.) followed by 3,5-bis(trifluoromethyl)aniline (102 [tL, 0.67 mmole, 1.0 
eq.). Pyrimidine 408 was isolated as a cream solid (HPLC Method L, tR = 20.45 mm., 
0.022 g, 8 %); LRMS ES m/z 402.0 (MH); HRMS FAB m/z 402.08447 (MH) 
(calculated for C18H11F7N3, 402.08412 (Dev. 0.87 ppm)); Vmax (film)/cm 3419 (N-H), 
3102 (aryl C-H), 2917 (C-H), 1645 (C=C), 1602 (aryl C=C), 1515 (C=N); 6H  (250 MHz, 
CD30D): 7.28 (d, IH, J = 1.0 Hz, 118), 7.37 (t, 2H, J = 8.7 Hz, JHF = 8.7 Hz, H13, H15), 
7.73 (s, 1H, H4), 8.05 (dd, 2H, J = 8.7 Hz, JHF = 5.2 Hz, H12, H16), 8.45 (s, 2H, H2, 
H6), 8.94 (d, 1H, J = 1.0 Hz, H10); Mpt. 171.6— 173.2 °C. 
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General procedure P3 was followed using 3,5-dimethylphenyl boron ic acid (0.101 g, 
0.67 mmole, 1.0 eq.) followed by 3,5-bis(trifluoromethyl)aniline (102 1iL, 0.67 mmole, 
1.0 eq.). Pyrimidine 409 was isolated as a yellow solid (HPLC Method L, tR = 16.01 
mm., 0.064 g, 23%); LRMS ESm/z 412.0 (MH); 8H(25O  MHz, CD30D): 2.41 (s, 3H, 
H18), 2.43 (s, 3H, H17), 7.09 (d, IH, J = 1.0 Hz, H8), 7.33 (s, IH, H14), 7.34 (s, 2H, 
H12, H16), 7.80 (s, 1H, H4), 8.48 (s, 2H, 112, H6), 9.00 (d, 1H, J = 1.0 Hz, HI 0). 





16 	12 	CF3 1I i 
N 8 
3 CF3  
H 2 
General procedure P3 was followed using 4-(trifluoromethyl)phenylboronic acid (0.128 
g, 0.67 mmole, 1.0 eq.) followed by 3,5-bis(trifluoromethyl)aniline (102 .tL, 0.67 
mmole, 1.0 eq.). Pyrimidine 410 was isolated as a white solid (HPLC Method K, tR = 
23.45 mm., 0.029 g, 10 %); LRMS ES m/z 452.1 (MH); Vmax (film)/cm' 3248 (N-H), 
3108 (aryl C-H), 2927 (C-H), 1637 (C=C), 1592 (aryl C=C), 1519 (C=N); 6H  (250 MHz, 
314 
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CD30D): 7.26 (d, IH, J = 1.1 Hz, H8), 7.60 (s, IH, H4), 7.84 (d, 2H, J = 8.1 Hz, H12, 
H16), 8.19 (d, 2H, J = 8.1 Hz, H13, H15), 8.44 (s, 2H, 112, H6), 8.87 (d, IH, J = 1.1 Hz, 
Hl0); Mpt. 192.0-192.5°C. 
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General procedure P3 was followed using 2-nitrophenylboronic acid (0.112 g, 0.67 
mmole, 1.0 eq.) followed by 3,5-bis(trifluoromethyl)aniline (102 [tL, 0.67 mmole, 1.0 
eq.). Pyrimidine 411 was isolated as a brown oil (HPLC Method L, tR = 21.11 mm., 
0.002 g, 1 %); LRMS ES m/z 429.1 (MH); Vmax (fi!m)Icm' 3371 (N-H), 3108 (aryl C-
H), 2919 (C-H), 1636 (C=C), 1589 (aryl C=C),  1523 (NO2), 1508 (C=N), 1379 (NO2); 
611(250 MHz, CD30D): 7.04 (d, 1H, J = 1.1 Hz, H8), 7.64 (s, IH, H4), 7.73 - 7.79 (m, 
2H, H14, H15), 7.85 (dd, 1H, J =1.4,7.4 Hz, H16), 8.09 (dd, 1H, J = 1.6, 8.0 Hz, H13), 
8.49 (s, 2H, H3, H5), 8.80 (d, 1H, J = 1.1 Hz, HI 0). 
4-(6- { [3,5-Bis(trifluoromethyl)phenyl] amino pyrimidin-4-yl)phenol (412) 
OH 
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General procedure P3 was followed using 4-hydroxyphenylboronic acid (0.093 g, 0.67 
mmole, 1.0 eq.) followed by 3,5-bis(trifluoromethyl)aniline (102 L, 0.67 mmole, 1.0 
eq.). Pyrimidine 412 was isolated as a yellow oil (HPLC Method J, tR = 13.40 mm., 
0.008 g, 3 %); LRMS ES m/z 399.9 (MH); 6H (250 MHz, CD30D): 7.26 (m, 1 H, An]), 
7.45 (d, 1H, J = 0.9 Hz, H8), 7.55 - 7.63 (m, 3H, ArH), 7.94 (s, IH, H4), 8.63 (s, 2H, 
112, H6), 9.12 (d, IH, J= 0.9 Hz, H10). 





l612 	CF3 1I 	i 
3 CF3 
H 2 
General procedure P3 was followed using 4-methoxyphenyl boron ic acid (0.102 g, 0.67 
mmole, 1.0 eq.) followed by 3,5-bis(trifluoromethyl)aniline (102 1iL, 0.67 mmole, 1.0 
eq.). Pyrimidine 413 was isolated as a pale cream solid (HPLC Method K, tR = 15.14 
mm., 0.018 g, 6 %); LRMS ES m/z 413.9 (MH); Vmax (film)1cm 1 3307 (N-H), 2927 
(C-H), 2844 (0-CH3), 3054 (aryl C-H), 1636 (C=C), 1593 (aryl C=C), 1515 (C=N); 6 
(250 MHz, CD30D): 3.94 (s, 3H, H17), 7.20 (d, 2H, J = 9.0 Hz, H13, H15), 7.28 (d, IH, 
J = 0.9 Hz, H8), 7.78 (s, 1H, H4), 7.95 (d, 2H, J = 9.0 Hz, H12, H16), 8.45 (s, 2H, H2, 
H6), 8.94 (d, 1H, J = 0.9 Hz, H10); Mpt. 180.9— 181.7 °C. 
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General procedure P3 was followed using 3-aminophenyl boron ic acid (0.125 g, 0.67 
mmole, 1.0 eq.) followed by 3,5-bis(trifluoromethyl)aniline (102[LL, 0.67 mmole, 1.0 
eq.). Pyrimidine 414 was isolated as a brown oil (HPLC Method J, tR = 10.27 mm., 
0.002 g, I %); LRMS ES m/z 399.1 (MH)t 












General procedure P3 was followed using 4-fluorophenylboronic acid (0.094 g, 0.67 
mmole, 1.0 eq.) followed by 4-(trifluoromethyl)aniline (82 jtL, 0.67 mmole, 1.0 eq.). 
Pyrimidine 415 was isolated as a pale brown solid (HPLC Method L, tR = 14.37 mm., 
0.019 g, 9 %); LRMS ES m/z 334.0 (MH); Vmax (film)/cm' 3250 (N-H), 2995 (C-H), 
1647 (C=C), 1602 (aryl C=C), 1513 (C=N); 6H(2SO  MHz, CD30D): 7.24(d, 1H,J= 1.0 
Hz, H8), 7.34 (t, 2H, J = 8.7 Hz, JHF = 8.7 Hz, H13, H15), 7.70 (d, 2H, J = 9.1 Hz, 112, 
H6), 7.97 (s, 2H, J = 9.1 Hz, 113, H5), 8.03 (dd, 2H, J = 8.7 Hz, .J1 y = 5.2 Hz, H12, 
H16), 8.81 (d, 1H,J= 1.O Hz, H10); Mpt. 202.8-204.0°C. 
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General procedure P3 was followed using 2-bromophenylboronic acid (0.135 g, 0.67 
mmole, 1.0 eq.) followed by 4-(trifluoromethyl)aniline (82 tL, 0.67 mmole, 1.0 eq.). 
Pyrimidine 416 was isolated as a brown oil (F-IPLC Method L, tR = 14.48 mm., 0.019 g, 
7 %); LRMS ES m/z 396.1 (MH) assigned to C18H1081BrF6N3; 8H  (250 MHz, CD30D): 
7.16 (d, IH, J = 0.9 Hz, H8), 7.52-7.66 (m, 3H, H14, H15, H16), 7.77 (d, 2H, J = 8.6 
Hz, H2, H6), 7.88 (dd, IH, J = 0.9, 7.5 Hz, H13), 8.02 (d, 2H, I = 8.6 Hz, H3, H5), 9.95 
(d, IH,J=0.9 Hz, H10). 
6-(3,5-Dimethylphenyl)-N- [4-(trifluoromethyl)phenyll pyrimidin-4-am me (417) 
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General procedure P3 was followed using 3,5-dimethylphenylboronic acid (0.101 g, 
0.67 mmole, 1.0 eq.) followed by 4-(trifluoromethyl)aniline (82 [tL, 0.67 mmole, 1.0 
eq.). Pyrimidine 417 was isolated as a white solid (HPLC Method L, tR = 24.08 mm., 
0.041 g, 18 %); LRMS ES m/z 344.0 (MH); Vmax (film)/cm' 3306 (N-H), 2927 (C-H), 
1646 (C=C), 1586 (aryl C=C), 1508 (C=N); 6j-i(250  MHz, CD30D): 2.41 (s, 3H, H18), 
318 
Chapler  5 
2.43 (s, 3H, H17), 7.04 (s, 1H, H8), 7.32 (s, IH, H14), 7.35 (s, 2H, H12, H16), 7.77 (d, 
2H,J= 8.6 Hz, H2,H6), 8.01 (d,2H,J= 8.6 Hz, H3, H5), 8.91 (s, IH,H10). 
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Genera! procedure P3 was followed using 4-(trifluoromethyl)pheny!boronic acid (0.128 
g, 0.67 mmole, 1.0 eq.) followed by 4-(trifluoromethyl)aniline (82 IL, 0.67 mmole, 1.0 
eq.). Pyrimidine 418 was isolated as a cream solid (HPLC Method L, tR = 21.09 mm., 
0.017 g, 7 %); LRMS ES m/z 384.0 (MH); Vmax (film)Icm' 3237 (N-H), 3052 (aryl C-
H), 2992 (C-H), 1612 (C=C), 1593 (aryl C=C), 1525 (C=N); 6H (250 MHz, CD30D): 
7.27 (d, IH, J = 1.1 Hz, H8), 7.64 (d, 2H, J = 8.4 Hz, 112, H6), 7.84 (d, 2H, J = 8.2 Hz, 
H12, H16), 7.97 (d, 2H, J = 8.4 Hz, H3, H5), 8.19 (d, 2H, J = 8.2 Hz, H13, H15), 8.79 
(d, IH, I = 1.1 Hz, H10); Mpt. 222.2 —222.8 °C. 
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General procedure P3 was followed using 2-nitrophenylboronic acid (0.112 g, 0.67 
mmole, 1.0 eq.), followed by 4-(trifluoromethyl)aniline (82 iL, 0.67 mmole, 1.0 eq.). 
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Pyrimidine 419 was isolated as a brown oil (HPLC Method L, tR = 16.14 mm., 0.005 g, 
2 %); LRMS ES m/z 361.1 (MH)4 . 
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General procedure P3 was followed using 4-hydroxyphenylboronic acid (0.093 g, 0.67 
mmole, 1.0 eq.), followed by 4-(trifluoromethyl)aniline (82 jtL, 0.67 mmole, 1.0 eq.). 
Pyrimidine 420 was isolated as a yellow oil (HPLC Method L, tp. = 11.49 mm., 0.018 g, 
8 %); LRMS ES m/z 332.0 (MH); 6H (250 MHz, CD30D): 6.67 - 6.71 (m, 1H, An]), 
7.24 (d, IH, J = 0.7 Hz, H8), 7.35 - 7.47 (m, 3H, An]), 7.62 (d, 2H, J = 8.4 Hz, 112, 
H6), 7.98 (d, 2H, J = 8.4 Hz, 113, H5), 8.84 (d, IH, J = 0.7 Hz, HI 0). 









General procedure P3 was followed using 4-methoxyphenylboronic acid (0.102 g, 0.67 
mmole, 1.0 eq.) followed by 4-(tnifluoromethyl)aniline (82 L, 0.67 mmole, 1.0 eq.). 
Pyrimidine 421 was isolated as a cream solid (HPLC Method K, tR = 10.16 mm., 0.034 
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g, 15 %); LRMS ES m/z 345.9 (MH); 8H (250 MHz; (CD3)2S0) 3.87 (s, 3H, H17), 
7.15 (d, 2H, J = 8.9 Hz, 112, H6), 7.29 (s, IH, H8), 7.74 (d, 2H, J = 8.7 Hz, H13, H15) 
7.98 (d, 2H, J = 8.7 Hz, H12, H16), 8.03 (d, 2H, J = 8.9 Hz, H3, H5), 8.83 (s, IH, H10), 
10.35 (s, IH,NR). 




General procedure P3 was followed using 3-aminophenylboronic acid (0.125 g, 0.67 
mmole, 1.0 eq.) followed by 4-(trifluoromethyl)aniline (82 p.L, 0.67 mmole, 1.0 eq.). 
Pyrimidine 422 was isolated as a brown oil (HPLC Method K, tR = 6.46 mm., 0.003 g, 1 
%); LRMS ES m/z 331.0 (MH)t 
5-(6-{ [4-(Trifluoromethyl)phenyl] amino) pyrim idmn-4-yl)-thiophene-2-carbaldehyde 
(423) 
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General procedure P3 was followed using 5-formylthiophene-2-boronic acid (0.105 g, 
0.67 mmole, 1.0 eq.) followed by 4-(trifluoromethyl)aniline (82 l.LL, 0.67 mmole, 1.0 
eq.). Pyrimidine 423 was isolated as a yellow solid (HPLC Method L, tR = 22.10 mm., 
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0.005 g, 2 %); LRMS ES m/z 350.0 (MH); 8H  (250 MHz, CD30D): 7.30 (d, IH, J = 
0.9 Hz, H8), 7.67 (d, 2H, J = 8.8 Hz, 112, H6), 7.95 (d, IH, J = 4.2 Hz, H12), 7.98 (d, 
2H, J = 8.8 Hz, H3, H5), 7.01 (d, JH, J = 4.2 Hz, H13), 8.72 (d, IH, J = 0.9 Hz, H10), 
9.99 (s, IH, H16). 









To a solution of 4,6-dichloropyrimidine (0.100 g, 0.67 mmole, 1.0 eq.) in dioxane (3.0 
mL) was added 3-nitrophenylboronic acid (0.112 g, 0.67 mmole, 1.0 eq.), Cs2CO3 
(0.656 g, 1.00 mmole, 3.0 eq.), Pd(OAc)2 (0.008 g, 0.03 mmole, 0.05 eq.) and 
triphenylphosphine (0.018 g, 0.07 mmole, 0.10 eq.). Water (0.3 mL) was added to the 
reaction mixture to solubilise the Cs2CO3. The reaction mixture was irradiated in the 
DiscoverTM at 130 °C for 20 minutes with active cooling of the sample. To an aliquot (1 
mL) of the crude reaction mixture was added 4-aminophenol (0.026 g, 0.24 mmole, 1.0 
eq.) followed by HC1 (4M, 222 jiL, 4.0 eq.) and the sample irradiated in the DiscoverTM 
at 130 °C for a further 20 minutes, with active cooling of the sample, before being 
injected directly onto the Biotage Parallex F1exTM  HPLC (Method E, tR = 16.01 mm.). 
Appropriate fractions were combined and concentrated in vacuo to afford pyrimidine 
424 as a yellow solid (0.011 g, 15 %); LRMS ES m/z 309.0 (MH); HRMS FAB m/z 
309.09932 (M1-J) (calculated for C161-113N403, 309.09877 (Dev. 1.78 ppm)); Vmax 
(film)/cm- 1 3392 (0-H), 3250 (N-H), 2918 (C-H), 1636 (C=C), 1522 (NO2), 1507 
(C=N), 1346 (NO2); 6H  ((CD3)2S0): 6.81 (d, 2H, J = 8.9 Hz, 112, H6), 7.25 (s, I H, H8), 
7.45 (d, 2H, J = 8.9 Hz, H3, H5), 7.86 (t, 1H, J = 8.1 Hz, H15), 8.38 - 8.44 (m, 2H, 
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H14, H16), 8.73 (s, IH, H10), 8.81 (t, IH, J = 1.9 Hz, H12), 9.80 (s, 1H, 011); Mpt. 
188.4— 189.0°C. 











To a solution of 4,6-dichloropyrimidine (0.050 g, 0.34 mmole, 1.0 eq.) in acetonitrile 
(1.0 mL) was added 2-naphthylboronic acid (0.058 g, 0.34 mmole, 1.0 eq.), Cs2CO3  
(0.164 g, 0.50 mmole, 1.5 eq.) and Pd(OAc)2 (0.04 g, 0.02 mmole, 0.05 eq.). Water (0.3 
mL) was added to the reaction mixture to dissolve the Cs2CO3. The reaction mixture was 
irradiated in the DiscoverTM  at 130 °C for 15 minutes, with active cooling of the sample, 
before the addition of 4-hydroxyaniline (0.037 g, 0.34 mmole, 1.0 eq.) and p-
toluenesulfonic acid (0.128 g, 0.67 mmole, 2.0 eq.). The reaction mixture was irradiated 
in the DiscoverTM  at 110 °C for a further 5 minutes before being injected directly onto 
the Biotage Parallex FlexTm  HPLC (Method E tR = 20.17 mm) to afford 425 as a yellow 
solid (0.002 g, 2 %); LRMS ES m/z 313.9 (MH); HRMS FAB m/z 314.12878 (MIH) 
(calculated for C20H16N30, 314.12934 (Dcv. - 1.78 ppm)); Vm (film)/cm- 1 3392 (0-H), 
2921 (C-H), 1636 (C=C), 1576 (aryl C=C), 1507 (C=N); 6H(2SO  MHz, CD30D): 7.55-
7.66 (m, 2H, H16, H17), 7.89 - 8.06 (m, 3H, H12, HI 5, H18), 8.19 (d, 1H, J = 1.1 Hz, 
H8), 8.23 (dd, 1H, J = 1.9, 8.7 Hz, H13), 8.73 (dd, 1H, J = 0. 7, 1.4 Hz, 1120), 9.03 (d, 
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General procedure P4 was followed using 4,6-dichioropyrimidine (0.075 g, 0.50 mmole, 
1.0 eq.) and 2-naphthylboronic acid (0.087 g, 0.50 mmole, 1.0 eq.) followed by 4-nitro-
aniline (0.023 g, 0.17 mmole, 1.0 eq.). Pyrimidine 426 was isolated as a yellow solid 
(HPLC Method E, tR = 18.21 mm., 0.019 g, 33 %); LRMS ES m/z 343.1 (MIH); HRMS 
FAB m/z 343.11989 (MH) (calculated for C20H15N402 343.11950, Dev. 1.15 ppm); 
Vmax (film)/cm- 1  3325 (N-H), 3063 (aryl C-H), 2920 (C-H), 1635 (C=C), 1576 (aryl 
C=C), 1545 (NO2), 1504 (C=N), 1347 (NO2); SH (250 MHz, (CD3)2S0): 7.61 —7.68 (m, 
3H, ArH), 8.00 - 8.04 (m, 1H, ArfT), 8.09— 8.18 (m, 3H, Ark!), 8.10 (d, 2H, J = 9.3 Hz, 
112, H6), 8.27 (d, 2H, J = 9.3 Hz, 113, H5), 8.71 (s, 1H, H10), 8.93 (s, 1H, ArE), 10.83 
(s, IH,NR); 
N-(3- { [6-(3,5-Dimethoxyphenyl)aminol pyrimidin-4-yl phenyl)acetamide (427) 
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General procedure P4 was followed using 4,6-dichioropyrimidine (0.075 g, 0.50 mmole, 
1.0 eq.) and 3-acetamidophenylboronic acid (0.090 g, 0.50 mmole, 1.0 eq.) followed by 
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3,5-dimethoxyaniline (0.019 g, 0.17 mmole, 1.0 eq.). Pyrimidine 427 was isolated as a 
brown solid (HPLC Method E, tR 18.07 mm., 0.004 g, 6%); LRMS ES m/z 365.0 
(MH)+; HRMS FAB m/z 365.16203 (M1H) (calculated for C20H21N403, 365.16137 
(Dev. 1.82 ppm)); Vmax (film)/cm' 3306 (N-H), 2930 (C-H), 2842 (0-CH3), 1636 (C=C), 
1592 (aryl C=C), 1508 (C=N); 6H  (250 MHz, CD30D): 2.38 (s, 3H, H18), 4.02 (s, 6H, 
H19), 6.60 (t, lH, J = 2.2 Hz, H4), 7.09 (d, 2H, J = 2.2 Hz, H2, H6), 7.35 (d, IH, J= 
0.9 Hz, H8), 7.75 - 7.86 (m, 3H, ArE), 8.49 (m, IH, ArR), 8.99 (d, 1H, J = 0.9 Hz, 
H10). 
3-{[6-(3-Nitrophenyl)pyrimidin-4-ytl amino) phenol (428) 
NO 
L NcLOH  
To an aliquot (1 mL) of the crude Suzuki intermediate 424 was added 3-aminophenol 
(0.026 g, 0.24 mmole, 1.0 eq.) followed by HC1 (4M, 222 [tL, 4.0 eq.). The sample was 
irradiated in the Discover TM  at 130 °C for a further 20 minutes before being injected 
directly onto the Biotage Parallex F1exTM  HPLC (Method G, tR = 7.16 mm.). 
Appropriate fractions were combined and concentrated in vacuo to afford pyrimidine 
429 as a yellow oil (0.011 g, 15 %); LRMS ES m/z 309.5 (MIH)t 
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3-16- L(3-Hydroxyphenyl)aminol pyrimidin-4-yl} phenol (429) 
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General procedure P4 was followed using 4,6-dichloropyrimidine (0.075 g, 0.50 mmole, 
1.0 eq.) and 3-hydroxyphenylboronic acid (0.076 g, 0.5 mmole, 1.0 eq.) 3-hydroxy-
aniline (0.019 g, 0.17 mmole, 1.0 eq.). Pyrimidine 429 was isolated as a yellow oil 
(HPLC Method A, tR = 11.36 mm., 0.015 g, 32 %); LRMS ES m/z 280.0 (MH)t 
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General procedure P5 was followed using 4,6-dichloropyrimidine (0.250 g, 1.67 mmole, 
1.0 eq.) and 2,5-difluorophenylboronic acid (0.265 g, 1.67 mmole, 1.0 eq.) followed by 
3-hydroxy-4-methoxyaniline (0.024 g, 0.17 mmole, 1.0 eq.). Pyrimidine 430 was 
isolated as a brown solid (HPLC Method G, tR = 10.48 mm, 0.005 g, 9 %); LRMS ES 
m/z 330.0 (MH); 8H  (250 MHz, CD30D): 3.92 (s, 3H, H17), 7.00 - 7.19 (m, 4H, H2, 
H5, H6, H8), 7.41 - 7.51 (m, 2H, H14, HIS), 7.57 —7.65 (m, 1H, H12), 8.80 (d, 1H, J = 
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General procedure P5 was followed using 4,6-dichloropyrimidine (0.250 g, 1.67 mmole, 
1.0 eq.) and 2,5-difluorophenylboronic acid (0.265 g, 1.67 mmole, 1.0 eq.) followed by 
3,4-dimethoxyaniline (0.026 g, 0.17 mmole, 1.0 eq.). Pyrimidine 431 was isolated as a 
yellow solid (HPLC Method G, tR = 11.16 mm, 0.017 g, 29 %); LRMS ES m/z 344.2 
(MH); Vmax (film)/cm' 3420 (N-H), 3078 (aryl C-H), 2940 (C-H), 1646 (C=C), 1589 
(aryl C=C), 1507 (C=N); 6H  (250 MHz, CD30D): 3.92 (s, 6H, Hi 7, Hi 8), 7.08 (d, I H, .1 
= 8.7 Hz, H6), 7.17 - 7.37 (m, 3H, H2, H5, H8), 7.45 - 7.53 (m, 2H, H14, HI 5), 7.60 - 
7.68 (m, IH, H12), 8.85 (d, IH,J= 0.9 Hz, H10); Mpt. 180.2-180.7°C. 








General procedure P5 was followed using 4,6-dichioropyrimidine (0.250 g, 1.67 mmole, 
1.0 eq.) and 2,5-difluorophenylboronic acid (0.265 g, 1.67 mmole, 1.0 eq.) followed by 
4-aminophenol (0.019 g, 0.17 mmole, 1.0 eq.). Pyrimidine 432 was isolated as a cream 
solid (HPLC Method 0, tR = 10.19 mm, 0.035 g, 63 %); LRMS ES m/z 330.0 (MH); 
Vmax (film)/cm- 1 3392 (0-H), 2917 (C-H), 1636 (C=C), 1508 (C=N); 6H  (250 MHz, 
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CD30D): 6.72(ddd, 1I-I,J= 0.9, 2.4, 8.1 Hz, H6), 7.07-7.13 (ddd, IH,J=r  0.9, 2.4, 8.1 
Hz, H4), 7.21 —7.25 (m, 2H, H2, 1-18), 7.27 (t, 1H, J = 8.1 Hz, H5), 7.41 - 7.47 (m, 2H, 
H14, H15), 7.60-7.68 (m, IH, H12), 8.82 (d, IH, J = 0.9 Hz, HI 0); Mpt. 176.6— 178.5 
OC. 
4-fl6-(2,5-Difluorophenyl)pyrimidin-4-ylj amino) phenol (433) 
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Genera! procedure P5 was followed using 4,6-dichioropyrimidine (0.250 g, 1.67 mmole, 
1.0 eq.) and 2,5-difluorophenylboronic acid (0.265 g, 1.67 mmole, 1.0 eq.) followed by 
4-aminopheno! (0.019 g, 0.17 mmole, 1.0 eq.). Pyrimidine 433 was isolated as a yellow 
solid (HPLC Method G, tR = 10.12 mm, 0.011 g, 22 %); LRMS ES m/z 300.1 
(MH); Vmax (film)/cm' 3392 (0-H), 2918 (C-H), 1636 (C=C), 1508 (C=N); 6i-  (250 
MHz, CD30D); 6.92 (d, 2H, J = 8.9 Hz, 112, H6), 7.11 (d, 1H, J = 0.8 Hz, H8), 7.46 - 
7.53 (m, 4H, H3, H5, H14, H15), 7.58 - 7.67 (m, 1H, H12), 8.79 (d, IH, J = 0.8 Hz, 
H10); Mpt. 213.2-213.8 T. 
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(434) 
General procedure P5 was followed using 4,6-dichioropyrimidine (0.250 g, 1.67 mmole, 
1.0 eq.) and 3-acetamidophenylboronic acid (0.300 g, 1.67 mmole, 1.0 eq.) followed by 
3,5-dimethoxyaniline (0.026 g, 0.17 mmole, 1.0 eq.). Pyrimidine 434 was isolated as a 
brown solid (HPLC Method G, tp. = 10.01 mm, 0.009 g, 16 %); LRMS ES m/z 323.1 
(MH); oH  (250 MHz, CD30D): 3.85 (s, 6H, H17, H18), 6.47 (t, IH, J = 2.2 Hz, H4), 
6.92 (d, 2H, I = 2.2 Hz, 112, H6), 7.19 (d, IH, I = 0.9 Hz, H8), 7.24 (ddd, IH, I = 1. 1, 
2.2, 8.2 Hz, H14), 7.38— 7.41 (m, 2H, H12, H16), 7.52 (t, IH, J = 8.2 Hz, H15), 8.84 (d, 
IH, I = 0.9 Hz, H10). 
(435) 
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General procedure PS was followed using 4,6-dichloropyrimidine (0.250 g, 1.67 mmole, 
1.0 eq.) and 2,5-difluorophenylboronic acid (0.265 g, 1.67 mmole, 1.0 eq.) followed by 
3,5-dimethoxyaniline (0.026 g, 1.67 mmole, 1.0 eq.). Pyrimidine 435 was isolated as a 
biege solid (HPLC Method G, tR = 19.02 mm, 0.012 g, 20 %); LRMS ES m/z 344.1 
(MH); HRMS FAB m/z 344.12198 (ME) (calculated for C18H16F2N302, 344.12106 
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(Dcv. 2.67 ppm)); Vmax (film)/cm' 3250 (N-H), 2928 (C-H), 2840 (O-CH3), 1625 (CC), 
1585 (aryl C=C), 1507 (C=N); 8H  (250 MHz, CD30D): 3.86 (s, 6H, H17, H18), 6.42 (t, 
IH, .1 = 2.2 Hz, H4), 6.94 (d, 2H, J = 2.2 Hz, H2, H6), 7.27 (d, 1H, I = 0.9 Hz, H8), 
7.41 - 7.47 (m. IH, H14), 7.57 - 7.75 (m, 2H, H12, HiS), 8.84 (d, IH, I = 0.9 Hz, 
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To a solution of 4,6-dichloropyrimidine (0.175 g, 1.18 mmole, 1.0 eq.) in acetonitrile 
(3.0 mL) was added 3-hydroxyphenylboronic acid (0.162 g, 1.18 mmole, 1.0 eq.), 
Cs2CO3  (0.462 g, 1.42 mmole, 1.2 eq.), Pd(OAc)2  (0.014 g, 0.06 mmole, 0.05 eq.) and 
tri-o-tolylphosphine (0.036 g, 0.12 mmole, 0.10 eq.). Water (0.5 mL) was added to the 
reaction mixture to solubilise the Cs2CO3. The reaction mixture was irradiated in the 
Discover TM  at 110 °C for 25 minutes, with active cooling of the sample. The sample was 
then divided into aliquots (7 x 0.5 mL, 436a). To one aliquot containing the Suzuki 
intermediate (0.17 mmole, 1.0 eq.) was added aniline (16 iL, 0.17 mmole, 1.0 eq.) 
followed by HC1 (4M, 168 j.tL, 4.0 eq.) and the sample irradiated in the DiscoverTM at 
110 °C for a further 25 minutes. The sample was then injected directly onto the Biotage 
Parallex FIexTM HPLC (Method A, tR 11.07 mm.). Appropriate fractions were combined 
and concentrated in vacuo to afford pyrimidine 436 as a white solid (0.014 g, 31%); 
LRMS ES m/z 262.9 (MH); 5H  (500 MHz, CD30D): 7.12 (s, 1H, H8), 7.28 (d, 1H, I = 
7.9 Hz, H16), 7.31 - 7.34 (m, 2H, ArII), 7.46 (t, 1H, I = 7.9 Hz, HI 5), 7.48 - 7.58 (m, 
5H, ArH), 8.77 (s. IH, H10), 7.57 - 7.75 (m, 2H, H12, H15), 8.84 (d, IH, I = 0.9 Hz, 
HI 0); 
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3-16- L(3-Nitrophenyl)aminol pyrimidin-4-yl} phenol (437) 
OH 
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To one aliquot (0.5 mL) containing the Suzuki intermediate 436a (0.17 mmole, 1.0 eq.) 
was added 3-nitroaniline (0.024 g, 0.17 mmole, 1.0 eq.) followed by HCI (4M, 168 .tL, 
4.0 eq.). The reaction mixture was irradiated in the DiscoverTM at 110 °C for a further 25 
minutes before being injected directly onto the Biotage Parallex FIexTM  HPLC (Method 
A, tR 15.19 mm.). Appropriate fractions were combined and concentrated in vacuo to 
afford pyrimidine 437 as a brown solid (0.008 g, 15%); LRMS ES m/z 309.1 (MH). 
3-16- I(3-Fluorophenyl)aminol pyrimidin-4-yl} phenol (438) 
OH i  
L N O F 
To one aliquot (0.5 mL) containing the Suzuki intermediate 436a (0.17 mmole, 1.0 eq.) 
was added 3-nitroaniline (0.024 g, 0.17 mmole, 1.0 eq.) followed by HC1 (4M, 168 tL, 
4.0 eq.). The reaction mixture was irradiated in the DiscoverTM at 110 °C for a further 25 
minutes before being injected directly onto the Biotage Parallex FlexTM  HPLC (Method 
A, tR 13.48 mm.). Appropriate fractions were combined and concentrated in vacuo to 
afford pyrimidine 438 as a brown solid (0.006 g, 13%); LRMS ES m/z 282.1 (MH). 
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To a solution of 4,6-dichioropyrimidine (0.175 g, 1.18 mmole, 1.0 eq.) in acetonitrile 
(3.0 mL) was added 2,5-dimethylphenylboronic acid (0.176 g, 1.18 mmole, 1.0 eq.), 
Cs2CO3  (0.462 g, 1.42 mmole, 1.2 eq.), Pd(OAc)2  (0.014 g, 0.06 mmole, 0.05 eq.) and 
tri-o-tolylphosphine (0.036 g, 0.12 mmole, 0.10 eq.). Water (0.5 mL) was added to the 
reaction mixture to solubilise the Cs2CO3. The reaction mixture was irradiated in the 
DiscoverTM at 110 °C for 25 minutes, with active cooling of the sample. The sample was 
then divided into aliquots (7 x 0.5 mL). To one aliquot containing the Suzuki 
intermediate (0.17 mmole, 1.0 eq.) was added (3-aminophenyl)methanol (0.024 g, 0.17 
mmole, 1.0 eq.) followed by HCI (4M, 168 tL, 4.0 eq.) and the sample irradiated in the 
Discover TM  at 110 °C for a further 25 minutes. The sample was then injected directly 
onto the Biotage Parallex FlexTM HPLC (Method A, tR 10.54 mm.). Appropriate 
fractions were combined and concentrated in vacuo to afford pyrimidine 439 as a brown 
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To a solution of 4,6-dichloropyrimidine (0.025 g, 0.17 mmole, 1.0 eq.) in toluene (1.0 
mL) was added 2,5-dimethyiphenylboronic acid (0.026 g, 0.17 mmole, 1.0 eq.), Cs2CO3  
(0.082 g, 0.25 mmole, 1.5 eq.), KF (0.015 g, 0.25 mmole, 1.5 eq), Pd(OAc)2 (0.002 g, 
0.01 mmole, 0.05 eq.) and triphenylphosphine (0.005 g, 0.17 mmole, 0.10 eq.). Water 
(0.1 mL) was added to the reaction mixture to solubilise the Cs2CO3. The reaction 
mixture was irradiated in the Discover TM  at 130 °C for 15 minutes, with active cooling of 
the sample before being filtered and injected directly onto the FIexTM HPLC (Method P, 
tR14.28  mm). Appropriate fractions were combined and concentrated in vacuo to afford 
a brown residue (0.011g) that was dissolved in dioxane (1.0 mL) and to which was 
added 3-fluoroaniline (6 jiL, 0.05 mmole, 1.0 eq., calculation based on recovered Suzuki 
intermediate) and HCI (4M, 51 tL, 4.0 eq.). The reaction mixture was irradiated in the 
DiscoverTM  at 110 °C for 25 minutes, with stirring and active cooling of the sample, 
before being injected directly onto the Biotage Parallex F1exTM HPLC (Method A, tp. 
14.50 mm.). Appropriate fractions were combined and concentrated in vacuo to afford 
pyrimidine 440 as a yellow solid (0.004 g, 8 %); LRMS ES m/z 294.2 (MH); 6H  (250 
MHz, CD30D): 6.69 (d, IH, J = 0.8 Hz, H8), 7.28 (s, 1H, H12), 7.29 - 7.36 (m, 2H, 
H14, H15), 7.69- 7.76 (m, IH, Ark!), 7.72 (d, 1H, H6), 8.14 - 8.15 (m, IH, Ark!), 8.17 
-8.21 (m, 1H, Ark!), 9.05 (d, 1H, J = 0.8 Hz, H10). 
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4-1 [2-Amino-6-(3,5-dimethylphenyl)pyrimidin-4-yl1 amino} phenol (444) 




8 6 OH 
H2N1ON N 
H 2 
General procedure P4 was followed using 2-amino-4,6-dichloropyrimidine (0.083 g, 
0.50 mmole, 1.0 eq.) and 3,5-dimethylphenylboronic acid (0.062 g, 0.50 mmole, 1.0 eq.) 
followed by 4-hydroxyaniline (0.019 g, 0.17 mmole, 1.0 eq.). Pyrimidine 444 was 
isolated as a white solid (HPLC Method E, tR = 17.46 mm., 0.020 g, 39%); LRMS ES 
m/z 307.0 (MH); Vmax (film)/cm-1 3307 (0-H), 2928 (C-H), 1636 (C=C), 1616 (aryl 
C=C), 1508 (C=N); 6H (250 MHz, CD30D): 2.39 (s, 3H, H18), 2.41 (s, 3H, H17), 6.19 
(s, 1H, H8), 6.87 (d, 2H, J = 8.8 Hz, H2, H6), 7.27 (s, IH, H14), 7.33 (s, 2H, H12, H16), 
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General procedure P4 was followed using 2-amino-4,6-dich loropyrim i dine (0.083 g, 
0.50 mmole, 1.0 eq.) and 3,5-dimethyiphenylboronic acid (0.062 g, 0.50 mmole, 1.0 eq.) 
followed by 4-chloroaniline (0.022 g, 0.17 mmole, 1.0 eq.). Pyrimidine 445 was isolated 
as a brown solid (HPLC Method E, tR = 22.45 mm., 0.021 g, 38%); LRMS ES m/z 
325.0 (MH); Vm (film)/cm' 3487 (N-H), 3298 (N-H), 3154 (aryl C-H), 2928 (C-H), 
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1636 (C==C), 1605 (aryl C=C), 1506 (C=N); 6H  (250 MHz, CD30D): 2.40 (s, 3H, H18), 
2.42 (s, 3H, H17), 6.08 (s, 1H, H8), 7.30 (s, 1H, H14), 7.34 (s, 2H, H12, H16), 7.44 (d, 
2H, J = 8.9 Hz, 112, H6), 7.83 (d, 2H, J = 8.9 Hz, 113, H5); Mpt. 236.1 —236.7 T. 





General procedure P4 was followed using 2-amino-4,6-dichloropyrimidine (0.083 g, 
0.50 mmole, 1.0 eq.) and 3-acetamidophenylboronic acid (0.090 g, 0.50 mmole, 1.0 eq.) 
followed by 3,5-dimethoxyaniline (0.026 g, 0.17 mmole, 1.0 eq.). Pyrimidine 446 was 
isolated as a yellow solid (HPLC Method E, tR = 15.48 mm., 0.012 g, 19%); LRMS ES 
m/z 379.0 (MH). 
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General procedure P4 was followed using 2-amino-4,6-dichloropyrimidine (0.083 g, 
0.50 mmole, 1.0 eq.) and 3-acetamidophenylboronic acid (0.090 g, 0.50 mmole, 1.0 eq.) 
followed by 3-nitroaniline (0.026 g, 0.17 mmole, 1.0 eq.). Pyrimidine 447 was isolated 
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as a yellow oil (HPLC Method E, tR = 15.30 mm., 0.009 g, 15%); LRMS ES m/z 365.3 
(MH). 
3-1 [2Amino6I3nitrophenyl)pyrimidifl-4-Yl1 amino} phenol (448) 
NL 
aOH H2N N N 
H 
General procedure P4 was followed using 2-amino-4,6-dichloropyrimidine (0.083 g, 
0.50 mmole, 1.0 eq.) and 3-nitrophenylboronic acid (0.084 g, 0.50 mmole, 1.0 eq.) in 
followed by 3 -hydroxyani line (0.019 g, 0.17 mmole, 1.0 eq.)to an aliquot (1.0 mL, 0.17 
mmole, 1.0 eq.). Pyrimidine 448 was isolated as a yellow solid (HPLC Method A, tR = 
13.37 mm., 0.008 g, 16 %); LRMS ES m/z 323.9 (MH); Vmax (film)/cm' 3392 (0-H), 
2928 (C-H), 1636 (C=C), 1527 (NO2),1350 (NO2). 
3-1 [2-Amino-6-(3-nitrophenyl)aminOl pyrimidin-4-yl] -phenol (449) 
OH 
N 
H2N N N 	NO2  
H 
General procedure P4 was followed using 2-amino-4,6-dichloropyrimidine (0.083 g, 
0.50 mmole, 1.0 eq.) and 3-hydroxyphenylboronic acid (0.069 g, 0.50 mmole, 1.0 eq.) 
followed by 3-nitroaniline (0.023 g, 0.17 mmole, 1.0 eq.). Pyrimidine 449 was isolated 
as a cream solid (HPLC Method A, tp. = 15.31 mm., 0.003 g, 5 %); LRMS ES m/z 323.9 
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3-12-Amino-6- [(3-hydroxyphenyl)aminol pyrimidin-4-yl} phenol (450) 
OH 
N 
H2N N N 	OH 
H 
General procedure P4 was followed using 2-amino-4,6-dichloropyrimidine (0.083 g, 
0.50 mmole, 1.0 eq.) and 3-hydroxyphenylboronic acid (0.069 g, 0.50 mmole, 1.0 eq.) 
followed by 3-hydroxyaniline (0.019 g, 0.17 mmole, 1.0 eq.). Pyrimidine 450 was 
isolated as a yellow solid (HPLC Method A, tR = 12.59 mm., 0.011 g, 22 %); LRMS ES 
m/z 294.8 (MH); Vmax (film)/cm' 3392 (0-H), 2928 (C-H), 1636 (C=C), 1585 (aryl 




H2N N N 	NO2  
H 
General procedure P4 was followed using 2-amino-4,6-dichloropyrimidine (0.083 g, 
0.50 mmole, 1.0 eq.) and 2,5-dimethyiphenylboronic acid (0.076 g, 0.50 mmole, 1.0 eq.) 
followed by 3-nitroaniline (0.023 g, 0.17 mmole, 1.0 eq.). Pyrimidine 451 was isolated 
as a white solid (HPLC Method A, tR = 17.06 mm., 0.004 g, 7 %); LRMS ES m/z 336.0 
(MH). 
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30H H2N1ON H 2 
General procedure P4 was followed using 2-amino-4,6-dichloropyrimidine (0.083 g, 
0.50 mmole, 1.0 eq.) and 2,5-dimethyiphenylboronic acid (0.076 g, 0.50 mmole, 1.0 eq.) 
followed by 3-hydroxyaniline (0.023 g, 0.17 mmole, 1.0 eq.). Pyrimidine 452 was 
isolated as a yellow oil (HPLC Method A, tR = 14.43 mm., 0.005 g, 10 %); LRMS ES 
m/z 307.0 (MH); 6H  (250 MHz, CD30D): 2.63 (s, 3H, Hi 8), 2.65 (s, 3H, HI 7), 6.50 (s, 





H 2N N N6NO2 
H 
General procedure P4 was followed using 2-amino-4,6-dichloropyrimidine (0.083 g, 
0.50 mmole, 1.0 eq.) and 2,5-difluorophenylboronic acid (0.079 g, 0.5 mmole, 1.0 eq.) 
followed by 3,5 -dinitroan i line (0.031 g, 0.17 mmole, 1.0 eq.). Pyrimidine 453 was 
isolated as a yellow solid (HPLC Method G, tR = 19.48 mm., 0.015 g, 23%); LRMS ES 
m/z 388.9 (ME) 
3i 
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General procedure P4 was followed using 2-amino-4,6-dichloropyrimidine (0.083 g, 
0.50 mmole, 1.0 eq.) and 2,5 -di fluorophenyl boron ic acid (0.079 g, 0.50 mmole, 1.0 eq.) 
followed by 3-aminopyridine (0.016 g, 0.17 mmole, 1.0 eq.). Pyrimidine 454 was 
isolated as a yellow solid (HPLC Method I, tR = 7.38 mm., 0.010 g, 20 %); LRMS ES 
m/z 299.9 (MH); 6H  (250 MHz, CD30D): 6.70 (s, 1H, 117), 7.48 - 7.54 (m, 2H, H5, 
H13), 7.60 - 7.69 (m, 1H, H14), 7.79 (dd, IH, .JHF = 8.4, 5.2 Hz, Hi 1), 8.53 - 8.59 (m, 














H2N  N N 3O 
H 
General procedure P4 was followed using 2-amino-4,6-dichloropyrimidine (0.083 g, 
0.50 mmole, 1.0 eq.) and 2,5-difluorophenylboronic acid (0.079 g, 0.5 mmole, 1.0 eq.) 
followed by 3,5-dimethoxyaniline (0.026 g, 0.17 mmole, 1.0 eq.). Pyrimidine 455 was 
isolated as a yellow solid (HPLC Method I, tR = 15.12 mm., 0.019 g, 32%); LRMS ES 
m/z 358.9 (MH); HRMS FAB m/z 359.13204 (MH) (calculated for C181417 F2N402 , 
359.13196 (Dev. 0.22 ppm)); Vmax (film)/cm' 3308 (N-H), 2926 (C-H), 2840 (O-CH3), 
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1646 (CC), 1507 (C=N); 6F1  (250 MHz, CD3CN): 3.83 (s, 6H, 117, H8), 6.39 (t, I H, J = 
2.0 Hz, H4), 6.51 (s, 1H, H10), 6.95 (d, 2H, J = 2.0 Hz, 112, H6), 7.33 - 7.39 (m, 2H, 
HIS, H16), 7.50-7.55 (m, IH, H13), 8.92 (s, IH, Nil); Mpt. 203.2— 204.0 °C. 






To a solution of 4,6-dichloropyrimidine (0.025 g, 0.17 mmole, 1.0 eq.) in acetonitrile 
(1.0 mL) was added phenylboronic acid (0.021 g, 0.17 mmole, 1.0 eq.), Cs2CO3 (0.066 
g, 0.20 mmole, 1.2 eq.) and Pd(PPh3)4  (0.020 g, 0.02 mmole, 0.10 eq.). Water (0.1 mL) 
was added to the reaction mixture to solubilise the Cs2CO3. The reaction mixture was 
irradiated in the DiscoverTM  at 110 °C for 25 minutes with active cooling of the sample, 
before being injected directly onto the Biotage Parallex F1exTM  HPLC (Method A, tR = 
18.12 mm). Pyrimidine 456 was isolated as a biege solid (0.010 g, 30%); LRMS ES m/z 
191.1 (MH); 5H  (250 MHz, CDCI3): 7.52 - 7.57 (m, 3H, 117, H8, H9), 7.77 (d, IH, J 
1.1 Hz, 112), 8.07-8.11 (m, 2H, H6,H10), 9.05 (d, 1H,J= 1.1 Hz, H4). 
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4,6-Diphenylpyrimidine (457 - Table 4.6 Entry 2)218 
N- 
N 
Isolated during the synthesis of pyrimidine 457 (HPLC Method A, tR - 20.59 mm,) as a 
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10L N
1  N 	34NO2 
H 2 
To a solution of 4,6-dichloropyrimidine (0.100 g, 0.67 mmole, 1.0 eq.) in dioxane (3 
mL) was added was added 3-nitroaniline (0.093 g, 0.67 mmole, 1.0 eq.) and HCI (4M, 
670 iL, 4.0 eq.). The reaction mixture was irradiated in the DiscoverTM  at 130 °C for 30 
minutes before being injected, in 3 x 1 mL aliquots, onto the Biotage Parallex F1exTM 
HPLC (Method B, tR = 14.26 mm.). Appropriate fractions were combined and 
concentrated in vacuo to afford a residue (460a) that was dissolved in a mixture of 
toluene/ethanol (3 mL, 4:1) and divided into aliquots (3 x 1 mL). To one aliquot 
containing the anilino intermediate (1 mL, 0.17 mmole, 1.0 eq.) was added 4-
methoxyphenyl boronic acid (0.048 g, 0.17 mmole, 1.0 eq.), K2CO3 (0.122 g, 0.68 
mmole, 2.0 eq.) and Pd(PPh3)4 (0.010 g, 0.01 mmole, 0.04 eq.). Water (0.2 mL) was 
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added to solubilize the K2CO3  and the reaction mixture was irradiated in the Discover TM 
at 140 °C for 15 minutes before being injected directly onto the Biotage Parallex FIexTM 
HPLC (Method S, tR = 7.17 mm). Appropriate fractions were combined and 
concentrated in vacuo to afford pyrimidine 460 as a yellow solid (0.007 g, 10%); LRMS 
ES m/z 322.6 (MH); Vmax (film)/cm- 1 3328 (N-H), 3096 (aryl C-H), 2930 (C-H), 2839 
(0-CH3), 1625 (C=C), 1526 (NO2), 1361 (NO2); 6H  (500 MHz, CD30D): 3.92 (s, 3H, 
H17), 7.01 (dd, IH,J = 8.1, 1.5 Hz, H6), 7.03 (s, 1H, H8), 7.16 (d, 2H,J= 8.7 Hz, H13, 
HIS), 7.27 (t, IH, J = 8.1 Hz, H5), 7.44 (dd, IH, J = 8.1, 1.5 Hz, H4), 7.67 (t, 1H, Jr= 
1.5 Hz, 112), 7.84 (d, 2H, J = 8.7 Hz, H12, H16), 8.69 (s, 1H, H10); Mpt. 179.1 - 
180.7 °C. 







lOL I N 	NLJ 3 
H 2 
To a solution of 523 (0.15 mmole, 1.0 eq.) in toluene/ethanol (1 mL, 4:1) was added 4-
methoxyphenylboronic acid (0.032 g, 0.21 mmole, 1.4 eq.), K2CO3 (0.083 g, 0.60 
mmole, 4.0 eq.) and Pd(PPh3)4 (0.07 g, 0.01 mmole, 0.04 eq.). The reaction mixture was 
irradiated in the DiscoverTM at 140 °C for 15 minutes, before being injected directly onto 
the Biotage Parallex F1exTM  HPLC (Method S, tR = 6.44 mm). Appropriate fractions 
were combined and concentrated in vacuo to afford pyrimidine 461 as a yellow solid 
(0.005 g, 11%); LRMS ES m/z 293.6 (MH); FIRMS FAB m/z 294.12453 (MH) 
(calculated for C17H16N302, 294.12425 (Dev. 0.97 ppm)); Vmax (film)/cm 3388 (0-H), 
2928 (C-H), 2834 (O-CH3), 1633 (CC), 1579 (aryl CC), 1505 (CN); 8H  (250 MHz; 
CD30D) 3.95 (s, 3H, H17), 6.92 (d, 2H, .1 = 8.8 Hz, 1-12, H6), 7.01 (s, 1H, H8), 7.20 (d, 
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2H, J = 8.9 Hz, H13, H15), 7.44 (d, 2H, J = 8.8 Hz, H3, H5), 7.84 (d, 2H, J = 8.9 Hz, 
H12, H16), 8.70 (s, 1H, H10); 8c  (75 MHz; CD30D) 56.6 (C17), 111.2 (CHAr), 116.5 (2 
X CHAr), 116.6 (2 X CHAr), 116.7 (2 X CH1 ), 117.4 (CA,), 117.5 (CA,), 124.0 (2 X CHAr), 
130.3 (CA,), 130.5 (CHAr), 133.6 (CA,), 148.0 (CA,), 165.3 (CHAT); Mpt. 227.2 - 
227.8 °C. 
3-I {6-(4-Methoxyphenyl)pyrimidin-4-ylJ amino} phenol (462) 
17 
14 1  
15 	13 
16 	12 




To a solution of 460a (0.23 mmole, 1.0 eq.) in a mixture of toluene/ethanol (1.0 mL, 
4:1) was added 4-methoxyphenylboronic acid (0.048 g, 0.32 mmole, 1.4 eq.), Pd(PPh3)4  
(0.010 g, 0.01 mmole, 0.04 eq.), K2CO3 (0.122 g, 0.91 mmole, 4.0 eq.) and water (0.1 
mL). The reaction mixture was irradiated in the DiscoverTM  at 140 °C for 15 minutes 
before being injected directly onto the Biotage Parallex Flex TM  HPLC (Method S, tR = 
8.12 mm.). Appropriate fractions were combined and concentrated in vacuo to afford 
pyrimidine 462 as a white solid (0.013 g, 20%); LRMS ES m/z 293.6 (MH); Vm 
(film)/cm- 1 3352 (0-H), 2929 (C-H), 2841 (0-CH3 ), 1635 (C=C), 1592 (aryl C=C), 1509 
(C=N); 8H  (250 MHz, CD30D): 4.04 (s, 3H, H17), 6.85 (dd, 1H, J = 8.1, 2.3 Hz, H6), 
7.19 (dd, 1H, J = 8.1, 2.2 Hz, H4), 7.23 (s, 1H, H8), 7.28 (m, 1H, H8), 7.30 (d, 2H, J = 
8.9 Hz, H13, HIS), 7.39 (t, 1H, J = 8.1 Hz, H5), 7.96 (d, 2H, J = 8.9 Hz, H12, H16), 
8.85 (s, 1H, H10); Mpt. 190.4— 192.0 °C. 
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To a solution of 525 (0.015 g, 0.08 mmole, 1.0 eq.) in toluene/ethanol (1 mL, 4:1) was 
added 3-methoxyphenylboronic acid (0.016 g, 0.11 mmole, 1.4 eq.), K2CO3 (0.040 g, 
0.32 mmole, 4.0 eq.) and Pd(PPh3)4 (0.04 g, 0.01 mmole, 0.04 eq.). The reaction mixture 
was irradiated in the Discover TM at 140 °C for 15 minutes, before being injected directly 
onto the Biotage Parallex FIexTM HPLC (Method S, tR = 7.39 mm). Appropriate 
fractions were combined and concentrated in vacuo to afford pyrimidine 463 as a white 
solid (0.009 g, 43%); LRMS ES m/z 278.7 (MH); Vmax (film)Icm' 3258 (N-H), 3028 
(aryl C-H), 2929 (C-H), 2840 (0-CH3), 1658 (C=C), 1602 (aryl C=C), 1496 (C=N); 6 
(250 MHz; CD30D) 3.93 (s, 3H, 1121), 7.20 - 7.23 (m, 1H, H13), 7.42 - 7.59 (m, 3H, 
An]), 7.67-7.70 (m, 1H, An]), 7.70 (s, 1H, Hi 1), 7.77 (s, IH, 117), 8.27-8.34 (m, IH, 
AnII), 8.48-8.51 (m, IH, Ark!), 9.05 (s, 1H, H9); Mpt. 176.0 —177.0 °C. 





OH h~ 8 6.
1ONNL 3 
H 2 
To a solution of 4,6-dichloropyrimidine (0.110 g, 0.74 mmole, 1.1 eq.) in 2-propanol (3 
mL), 4-aminophenol (0.078 g, 0.67 mmole, 1.0 eq.) and NN-diisopropylethylamine (117 
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jiL, 1.34 mmole, 2.0 eq.) were added. The reaction mixture was irradiated in the 
DiscoverTM at 120 °C for 30 minutes, with active cooling of the sample, and then divided 
into 3 x I mL aliquots. To one aliquot containing the Suzuki intermediate (1 mL, 0.23 
mmole, 1.0 eq.) was added 3-methoxy-phenyl boronic acid (0.048 g, 0.32 mmole, 1.4 
eq.), K2CO3 (0.122g, 0.92 mmole, 4.0 eq.) and Pd(PPh3)4 (0.10 g, 0.02 mmole, 0.1 eq.). 
The reaction mixture was irradiated in the DiscoverTM  at 140 °C for 15 minutes, before 
being injected directly onto the Biotage Parallex FlexTM  HPLC (Method S, tR = 6.46 
mm). Appropriate fractions were combined and concentrated in vacuo to afford 
pyrimidine 466 as a yellow solid (0.044 g, 68%); LRMS ES m/z 293.5 (MH); Vmax 
(film)/cm 1  3397 (0-H), 2841 (0-CH3), 2918 (C-H), 1636 (C=C), 1578 (aryl C=C), 1508 
(CN); 8H  (250 MHz, CD30D): 3.93 (s, 3H, H17), 6.91 (d, 2H, J = 8.9 Hz, 112, H6), 
7.07 (s, IH, H8), 7.27 (ddd, IH, J = 8.4, 2.5, 0.8 Hz, H14), 7.39 - 7.48 (m, 4H, H3, H5, 








1OL L NN L 3 
H 2 
To a stirring solution of 526 (0.045 g, 0.22 mmole, 1.0 eq.) in 2-propanol (1.0 mL) was 
added 3-methoxyphenylboronic acid (0.047 g, 0.31 mmole, 1.4 eq.), Pd(PPh3)4 (0.010 g, 
0.01 mmole, 0.04 eq.) and K2CO3  (0.121 g, 0.88 mmole, 4.0 eq.). The reaction mixture 
was irradiated in the DiscoverTM at 140 °C for 15 minutes, with active cooling of the 
sample. The reaction mixture was injected directly onto the Biotage Parallex F1exTM 
(Method S, tR = 12.45 mm.). Appropriate fractions were combined and concentrated in 
vacuo to afford pyrimidine 467 as a yellow solid (0.0 19 g, 3 1%); LRMS ES m/z 277.6 
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(MH); 6H(250  MHz; CD30D) 3.94 (s, 3H, H17), 7.07 (s, 1H, H8), 7.31 —7.35 (m, 2H, 
ArH), 7.42-7.61 (m, 6H, ArH), 7.69-7.73 (m, 2H, ArH), 8.83 (s, IH, H10). 









1OLNN LJ 3 
H 2 
To a solution of 523 (0.046 g, 0.21 mmole, 1.0 eq.) in toluene/ethanol (1 mL, 4:1) was 
added 3,4-dimethoxyphenylboronic acid (0.053 g, 0.29 mmole, 1.4 eq.), K2CO3  (0.116 
g, 0.84 mmole, 4.0 eq.) and Pd(PPh3)4 (0.10 g, 0.01 mmole, 0.04 eq.). The reaction 
mixture was irradiated in the Discover TM  at 140 °C for 15 minutes, before being injected 
directly onto the Biotage Parallex F1exTM  HPLC (Method S, tR = 6.28 mm). Appropriate 
fractions were combined and concentrated in vacuo to afford pyrimidine 469 as a yellow 
solid (0.021 g, 31%); LRMS ES m/z 323.7 (MH); Vmax (film)/cm-1 3391 (0-H), 3253 
(N-H), 2939 (C-H), 2839 (0-CH3), 1636 (CC), 1599 (aryl C=C), 1500 (CN); 6H  (250 
MHz; CD30D) 3.96 (s, 3H, H17), 3.97 (s, 3H, H18), 6.91 (d, 2H, J = 8.9 Hz, 112, H6), 
7.03 (s, 1H, H8), 7.20 (d, 1H, J = 8.4 Hz, HI 5), 7.42 - 7.50 (m, 4H, 113, H5, H12, H16), 
8.70 (s, 1H, H10); Mpt. 223.5 —224.5 °C. 
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To a solution of 460a (0.23 mmole, 1.0 eq.) in a mixture of toluene/ethanol (1.0 mL, 
4:1) was added 3,4-dimethoxyphenylboronic acid (0.058 g, 0.32 mmole, 1.4 eq.), 
Pd(PPh3)4  (0.010 g, 0.01 mmole, 0.04 eq.) and K2CO3 (0.122 g, 0.92 mmole, 4.0 eq.). 
The reaction mixture was irradiated in the Discover TM  at 140 °C for 15 minutes, with 
active cooling of the sample. The reaction mixture was injected directly onto the Biotage 
Parallex Flex TM (Method S, tR = 7.07 mm.). Appropriate fractions were combined and 
concentrated in vacuo to afford pyrimidine 470 as a yellow solid (0.014 g, 19%); LRMS 
ES m/z 323.7 (MH); 6H  (250 MHz, CD30D): 3.97 (s, 3H, H17), 3.98 (s, 3H, H18), 
6.73-6.78 (m, 1H, ArII), 7.10 (ddd, 1H, ArH), 7.16 (s, 1H, H8), 7.21 (t, 1H,J= 2.1 Hz, 
H2), 7.22 (d, IH, J = 8.4 Hz, H15), 7.29 (t, 1H, 8.1 Hz, H5), 7.46 (d, 1H, J = 2.2 Hz, 
H12), 7.52 (dd, 1H, J = 8.4, 2.2 Hz, H16), 8.77 (s, IH, H10). 
6-Chloro-N-(3-fluorophenyl)pyrimidin-4-amine (471) 
CI 




N N  
H 2 
To a solution of 4,6-dichloropyrimidine (0.020 g, 0.13 mmole, 1.0 eq.) was added 3-
fluoroaniline (0.018 g, 0.13 mmole, 1.0 eq.) followed byp-toluenesulfonic acid (0.051 g, 
0.26 mmole, 2.0 eq.). The reaction mixture was irradiated in the Discover 
TM  at 100 °C 
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for 15 minutes before being injected directly onto the Biotage Parallex F1exTM  HPLC 
(Method I, tR = 20.19 mm.). Pyrimidine 471 was isolated as a white solid (0.008 g, 27 
LRMS ES m/z 223.5 (MH); 5H  (250 MHz, CDC13): 6.58 (s, IH, H8), 6.73 - 6.80 
(m, IH, H5), 6.93 (dd, IH, J = 8. 1, 1.1 Hz, H6), 7.04 (dt, IH, JHF = 7.9 Hz, J = 2.2 Hz, 
112), 7.17 -7.25 (m, 2H, H4, NH), 8.35 (s, IH, H10). 
Also prepared following a similar protocol to that described for the synthesis of 
pyrimidine 522 using 3-fluoroaniline (69 [tL, 0.67 mmole, 1.0 eq.). Pyrimidine 471 was 
isolated as a white solid (HPLC Method A, tR = 12.21 mm, 0.030 g, 20%); LRMS ES 
m/z 223.6 (MH). 
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To a solution of 522 (0.23 mmole, 1.0 eq.) in a mixture of toluene/ethanol (LU mL, 4:1) 
was added 3-methoxyphenylboronic acid (0.048 g, 0.32 mmole, 1.4 eq.), Pd(PPh3)4 
(0.010 g, 0.01 mmole, 0.04 eq.) and K2CO3  (0.122 g, 0.92 mmole, 4.0 eq.). The reaction 
mixture was irradiated in the Discover 
TM  at 140 °C for 15 minutes, with active cooling of 
the sample. The reaction mixture was injected directly onto the Biotage Parallex Flex 
TM 
(Method S, tR = 8.20 mm.). Appropriate fractions were combined and concentrated in 
vacuo to afford pyrimidine 480 as a yellow solid (0.010 g, 15%); LRMS ES m/z 293.5 
(MB) Vma., 011m)/cm 1 3307 (0-H), 2918 (C-H), 2840 (0-CH3), 1646 (C=C), 1595 
(aryl C=C), 1508 (C=N); 6H  (250 MHz, CD30D): 4.13 (s, 3H, H17), 6.94 (ddd, 1H, J = 
8.2, 2.3, 0.9 Hz, ArH), 7.27 - 7.32 (m, 1H, ArII), 7.38 (s, 1H, H8), 7.42 - 7.47 (m, 2H, 
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ArfI), 7.48 (t, IH, J = 8.2 Hz, H5), 7.62 - 7.66 (m, 2H, ArH), 7.77 (t, 1H, J = 8.2 Hz, 










To a solution of 524 (0.23 mmole, 1.0 eq.) in a mixture of toluene/ethanol (1.0 mL, 4:1) 
was added 3-methoxyphenylboronic acid (0.048 g, 0.32 mmole, 1.4 eq.), Pd(PPh3)4 
(0.010 g, 0.01 mmole, 0.04 eq.) and K2CO3 (0.122 g, 0.92 mmole, 4.0 eq.). The reaction 
mixture was irradiated in the Discover TM  at 140 °C for 15 minutes, with active cooling of 
the sample. The reaction mixture was injected directly onto the Biotage Parallex Flex 
TM 
(Method S, tR = 7.45 mm.). Appropriate fractions were combined and concentrated in 
vacuo to afford pyrimidine 485 as a yellow oil (0.056 g, 72%); LRMS ES m/z 337.8 
(MH); Vm (film)/cm' 3235 (N-H), 2925 (C-H), 1645 (C=C), 1586 (aryl C=C), 1506 
(C=N); oH  (250 MHz; CDCI3): 3.91 (s, 6H, 117, H8), 3.98 (s, 3H, H19), 7.08 (d, 1H, J = 
8.6 Hz, H5), 7.15 (s, 1H, H10), 7.18 - 7.40 (m, 5H, An]), 7.60 (t, IH, J = 8.4 Hz, H17), 
8.81 (s, 1H,H12). 
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To a solution of 524 (0.23 mmole, 1.0 eq.) in a mixture of toluene/ethanol (1.0 mL, 4:1) 
was added 4-methoxyphenylboronic acid (0.048 g, 0.32 mmole, 1.4 eq.), Pd(PPh3)4 
(0.010 g, 0.01 mmole, 0.04 eq.) and K2CO3  (0.122 g, 0.92 mmole, 4.0 eq.). The reaction 
mixture was irradiated in the Discover TM  at 140 °C for 15 minutes, with active cooling of 
the sample. The reaction mixture was injected directly onto the Biotage Parallex Flex 
TM 
(Method S, tR = 8.34 mm.). Appropriate fractions were combined and concentrated in 
vacuo to afford pyrimidine 486 as a yellow solid (0.022 g, 29%); LRMS ES m/z 337.8 
(MH); oH (250 MHz, CD30D): 3.77 (s, 6H, 2 x CH3), 3.95 (s, 3H, CH3), 7.07 (s, 1H, 
112), 7.08 (d, IH, J = 8.6 Hz, H6), 7.19 - 7.25 (m, 3H, H5, H15, H17), 7.32 (s, 1H, 
H10), 7.85 (d, 2H, J = 8.9 Hz, H14, H18), 8.76 (s, 1H, H12); 
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To a solution of 524 (0.23 mmole, 1.0 eq.) in a mixture of toluene/ethanol (1.0 mL, 4:1) 
was added 4-methoxyphenylboronic acid (0.048 g, 0.32 mmole, 1.4 eq.), Pd(PPh3)4 
(0.010 g, 0.01 mmole, 0.04 eq.) and K2CO3  (0.122 g, 0.92 mmole, 4.0 eq.). The reaction 
mixture was irradiated in the Discover TM  at 140 °C for 15 minutes, with active cooling of 
the sample. The reaction mixture was injected directly onto the Biotage Parallex FIexTM 
(Method S, tR = 7.26 mm.). Appropriate fractions were combined and concentrated in 
vacuo to afford pyrimidine 487 as a yellow solid (0.033 g, 41%); LRMS ES m/z 367.6 
(NM)+; Vmax (film)/cm' 3392 (N-H), 2926 (C-H), 2840 (0-CH3), 1637 (CC), 1585 
(aryl C=C), 1507 (C=N); 8H(SOO MHz; CD30D) 3.89 (s, 6H, 2 x CH3), 6.94 (s, 6H, 2 x 
CH3), 7.04 (s, 1H, H2), 7.07 (d, IH, J = 8.0 Hz, H6), 7.16-7.20 (m, 2H, H5, H17), 7.32 
(s, 1H, H10), 7.44 (s, IH, H14), 7.48 (d, 1H, J = 8.4 Hz, H18), 8.72 (s, IH, H12); Mpt. 
203.2 - 204.2 °C. 
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To a solution of 471 (0.029 g, 0.13 mmole, 1.0 eq.) in toluene/ethanol (1 mL, 4:1) was 
added 3-methoxyphenylboronic acid (0.028 g, 0.18 mmole, 1.4 eq.), K2CO3 (0.072 g, 
0.32 mmole, 4.0 eq.) and Pd(PPh3)4  (0.06 g, 0.01 mmole, 0.04 eq.). The reaction mixture 
was irradiated in the DiscoverTM  at 140 °C for 15 minutes, before being injected directly 
onto the Biotage Parallex F1exTM HPLC (Method S, tR = 14.15 mm). Appropriate 
fractions were combined and concentrated in vacuo to afford pyrimidine 489 as a white 
solid (0.011 g, 29%); LRMS ES m/z 295.6 (MH); 3 (250 MHz; CD30D) 3.89 (s, 3H, 
H17, H18), 6.94 (m, 1H, ArII), 7.19 (s, 1H, H8), 7.19— 7.23 (m, IH, ArII), 7.39 - 7.45 
(m, 4H, ArH), 7.49 —7.52 (m, 1H, Ar!]), 7.70-7.75 (m, 111, An]), 8.90 (s, 1H, H10). 









To a stirring solution of 522 (0.056 g, 0.25 mmole, 1.0 eq.) in 2-propanol (1.0 mL) was 
added 2,5-dimethylphenylboronic acid (0.053 g, 0.35 mmole, 1.4 eq.), Pd(PPh3)4 (0.013 
g, 0.01 mmole, 0.04 eq.) and K2CO3  (0.140 g, 1.00 mmole, 4.0 eq.). The reaction 
mixture was irradiated in the DiscoverTM  at 140 °C for 15 minutes, with active cooling of 
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the sample. The reaction mixture was injected directly onto the Biotage Parallex F1exTM 
(Method S, tR = 11.28 mm.). Appropriate fractions were combined and concentrated in 
vacuo to afford pyrimidine 490 as a yellow solid (0.051 g, 70%); LRMS ES m/z 291.7 
(MH); Vmax (film)Icm' 3410 (0-H), 2926 (C-H), 1646 (C=C), 1586 (aryl C=C), 1504 
(C=N); 6H (250 MHz; CD30D) 2.42 (s, 3H, H17),2.45 (s, 3H, H18), 6.78 (dd, 1H, J = 
8.1, 1.5 Hz, H6), 6.95 (s, 1H, H8), 7.14 (d, IH, J = 7.6 Hz, H4), 7.24 (m, 1H, H2), 7.31 
(t, IH, J = 8.1 Hz, H5), 7.33 (s, 1H, H12), 7.38 -7.43 (m, 2H, H14, H15), 8.85 (s, lH, 
H10); 6c (75 MHz; CD30D) 18.2 (CH3), 19.6 (CH3), 110.0 (CA,), 113.5 (CA,), 120.1 
(CHAr), 120.9 (CA,), 128.6 (CA,), 129.4 (CHAr), 130.0 (CHAr), 131.2 (CA,  131.3 (CHAr), 
132.1 (CHAr), 133.2 (CHAr), 134.7 (CA,), 136.7 (CHAs), 142.0 (CA,), 152.4 (CHAr), 158.4 
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To a stirring solution of 522 (0.053 g, 0.24 mmole, 1.0 eq.) in 2-propanol (1.0 mL) was 
added phenylboronic acid (0.041 g, 0.34 mmole, 1.4 eq.), Pd(PPh3)4 (0.012 g, 0.01 
mmole, 0.04 eq.) and K2CO3  (0.133 g, 0.96 mmole, 4.0 eq.). The reaction mixture was 
irradiated in the DiscoverTM  at 140 °C for 15 minutes, with active cooling of the sample. 
The reaction mixture was injected directly onto the Biotage Parallex F1exTM  (Method S, 
tR = 8.44 mm.). Appropriate fractions were combined and concentrated in vacuo to 
afford pyrimidine 491 as a yellow solid (0.042 g, 67%); LRMS ES m/z 263.7 (MH); 
HRMS FAB m/z 264.11452 (MH)+  (calculated for C16H14N30, 264.11369 (Dcv. 3.14 
ppm)); Vm (film)/cm' 3420 (0-H), 1646 (C=C), 1586 (aryl C=C), 1506 (C=N); 6H(2SO 
MHz; CD30D) 6.74 (dd, 1H, J = 6.5, 1.6 Hz, H6), 7.09 (d, 1H, J = 8.0 Hz, H4), 7.17 (s, 
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IH, H8), 7.19 - 7.20 (m, 11-1, 112), 7.26 (t, 11-1, J = 8.0 Hz, H5), 7.64 - 7.71 (m, 3H, 
H13, H14, HI 5), 7.85 (dd, 2H, J = 6.4, 1.9 Hz, H12, H16), 8.79 (s, 1H, H10); Mpt. 
188.4— 190.0°C. 




To a stirring solution of 523 (0.050 g, 0.23 mmole, 1.0 eq.) in 2-propanol (1.0 mL) was 
added 3-hydroxyphenylboronic acid (0.043 g, 0.32 mmole, 1.4 eq.), Pd(PPh3)4 (0.011 g, 
0.01 mmole, 0.04 eq.) and K2CO3 (0.125 g, 0.92 mmole, 4.0 eq.). The reaction mixture 
was irradiated in the DiscoverTM at 140 °C for 15 minutes, with active cooling of the 
sample. The reaction mixture was injected directly onto the Biotage Parallex FIexTM 
(Method S, tR = 7.55 mm.). Appropriate fractions were combined and concentrated in 
vacuo to afford 492 as a white solid (0.001 g, 2%); LRMS ES m/z 279.6 (MH)t 
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To a stirring solution of 523 (0-050 g, 0.23 mmole, 1.0 eq.) in 2-propanol (1.0 mL) was 
added 2,5-dimethyiphenylboronic acid (0.050 g, 0.32 mmole, 1.4 eq.), Pd(PPh3)4 (0.011 
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g, 0.01 mmole, 0.04 eq.) and K2CO3 (0.125 g, 0.92 mmole, 4.0 eq.). The reaction 
mixture was irradiated in the Discover 
TM  at 140 °C for 15 minutes, with active cooling of 
the sample. The reaction mixture was injected directly onto the Biotage Parallex F1exTM 
(Method S, tR = 10.42 mm.). Appropriate fractions were combined and concentrated in 
vacuo to afford pyrimidine 493 as a yellow solid (0.016 g, 24%); LRMS ES m/z 291.7 
(MI-I); 6H  (250 MHz; CD30D) 2.35 (s, 6H, H17, H18), 6.82 - 6.84 (m, 3H, H8, H14, 
HIS), 7.25 - 7.30 (m, 4H, H2, 113, H5, H6), 7.48 - 7.51 (m, IH, H12), 8.69 (s, IH, 
H10). 
6(4Methoxyphenyl)-N-phenylPYrimidin-4-am me (496) 
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To a stirring solution of 526 (0.045 g, 0.22 mmole, 1.0 eq.) in 2-propanol (1.0 mL) was 
added 4-methoxyphenylboronic acid (0.047 g, 0.31 mmole, 1.4 eq.), Pd(PPh3)4 (0.010 g, 
0.01 mmole, 0.04 eq.) and K2CO3 (0.121 g, 0.88 mmole, 4.0 eq.). The reaction mixture 
was irradiated in the DiscoverTM at 140 °C for 15 minutes, with active cooling of the 
sample. The reaction mixture was injected directly onto the Biotage Parallex Flex 
TM 
(Method S, tR = 12.04 mm.). Appropriate fractions were combined and concentrated in 
vacuo to afford pyrimidine 496 as a white solid (0.038 g, 62%); LRMS ES m/z 277.6 
(N4T-1); HRMS FAB m/z 278.12920 (MH) (calculated for C17H16N30, 278.12934 
(Dev. - 0.50 ppm)); Vmax  (film)/cm-1 3420 (N-H), 2929 (C-H), 2840 (O-CH3), 1645 
(C=C), 1578 (aryl CC), 1506 (C=N); 6H  (250 MHz; CD30D): 3.67 (s, 3H, H17), 7.15 
(s, 1H, H8), 7.22 (d, 2H, J = 8.9 Hz, H13, H15), 7.35 (t, IH, J = 7.5 Hz, H4), 7.52 (t, 
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2H, J = 7.5 Hz, H3, H5), 7.70 (d, 2H, J = 7.5 Hz, H2, H6), 7.87 (d, 2H, J = 8.9 Hz, 
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To a stirring solution of 524 (0.083 g, 0.31 mmole, 1.0 eq.) in 2-propanol (1.0 ml-) was 
added 2,5-dimethyiphenyl boron ic acid (0.066 g, 0.44 mmole, 1.4 eq.), Pd(PPh3)4 (0.015 
g, 0.01 mmole, 0.04 eq.) and K2CO3 (0.173 g, 1.25 mmole, 4.0 eq.). The reaction 
mixture was irradiated in the Discover TM  at 140 °C for 15 minutes, with active cooling of 
the sample. The reaction mixture was injected directly onto the Biotage Parallex F1exTM 
(Method S, tR = 11.26 mm.). Appropriate fractions were combined and concentrated in 
vacuo to afford pyrimidine 497 as a yellow oil (0.039 g, 37%); LRMS ES m/z 335.8 
(N/[H) 	H (250 MHz; CD30D): 2.40 (s, 3H, H20), 2.43 (s, 3H, H19), 3.91 (s, 6H, H7, 
H8), 6.91 (s, IH, H10), 7.08 (d, IH, J = 8.1 Hz, H6), 7.33 - 7.38 (m, 4H, H2, H6, H16, 
H17), 7.49 (s, iT-I, H14), 8.95 (s, IH, H12). 
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To a stirring solution of 524 (0.072 g, 0.27 mmole, 1.0 eq.) in 2-propanol (1.0 mL) was 
added 3-hydroxyphenylboronic acid (0.052 g, 0.38 mmole, 1.4 eq.), Pd(PPh3)4 (0.013 g, 
0.01 mmole, 0.04 eq.) and K2CO3 (0.150 g, 1.25 mmole, 4.0 eq.). The reaction mixture 
was irradiated in the DiscoverTM at 140 °C for 15 minutes, with active cooling of the 
sample. The reaction mixture was injected directly onto the Biotage Parallex Flex 
TM 
(Method S, tp. = 8.03 mm.). Appropriate fractions were combined and concentrated in 
vacuo to afford pyrimidine 498 as a yellow solid (0.052 g, 59%); LRMS ES m/z 323.7 
(MH); Vmax  (film)/cm' 3310 (0-H), 3118 (N-H), 3054 (aryl C-H), 2928 (C-H), 2840 
(0-CH3), 1646 (C=C), 1578 (aryl C=C), 1506 (C=N); 6H  (250 MHz; CD30D) 3.91 (s, 
6H, H8, 1-19), 7.05 - 7.15 (m, 4H, ArE), 7.25 - 7.32 (m, 3H, ArE), 7.49 (t, 1H, J = 8.0 z, 
H17), 8.79 (s, IH, H12); 6c  (63 MHz, (CD3)2S0): 55.5 (2 x Cl-I3), 111.1 (CA,), 112.0 
(CAr), 112.1 (2 X CAr), 113.7 (CHAr), 117.9(2 X CHAr), 119.6 (CHAr), 130.9(2 X CHAr), 
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To a solution of 4,6-dichloropyri mid ine (0.147 g, 1.0 mmole, 1.1 eq.) in 2-propanol (4 
mL), 4-fluoro-3-methylaniline (0.113 g, 0.9 mmole, 1.0 eq.) and N,N-
diisopropylethylamine (172 tL, 1.8 mmole, 2.0 eq.) were added. The reaction mixture 
was irradiated in the DiscoverTM at 120 °C for 30 minutes, with active cooling of the 
sample, and then split into 4 x 1 mL aliquots. To one aliquot was added 3-
methoxyphenyl boron ic acid (0.048 g, 0.32 mmole, 1.4 eq.), potassium carbonate 
(0.122g, 0.9 mmole, 4.0 eq.) and Pd(PPh3)4 (0.10 g, 0.02 mmole, 0.1 eq.). The reaction 
mixture was irradiated in the Discover TM  at 140 °C for 15 minutes, before being injected 
directly onto the Biotage Parallex F1exTM  HPLC (Method S, tR = 14.34 mm) Appropriate 
fractions were combined and concentrated in vacuo to afford pyrimidine 499 as a yellow 
solid (0.040g, 57%); LRMS ES m/z 309.7 (MH); HRMS FAB m/z 310.13642 (M1H) 
(calculated for C18H17FN 30, 310.13556 (Dev. 2.77 ppm)); Vmax (film)/cm' 3299 (N-H), 
2931 (C-H), 2841 (0-CH3), 1646 (C=C), 1586 (aryl C=C), 1506 (C=N); o (250 MHz, 
CD30D): 2.37 (d, 3H, JHF = 2.0 Hz, H7), 3.94 (s, 3H, H18), 7.17 (s, 1H, H9), 7.18 (t, 
IH, J = 9.1 Hz, JHF = 9.1 Hz, H5), 7.30 (ddd, IH, J = 8.2, 2.5, 0.8 Hz, HI 5), 7.42 (d, 
1H,J = 1.7 Hz, H17), 7.44 (dd, 1H,J = 2.5, 0.8 Hz, H13), 7.51 —7.63 (m, 3H, 112, H6, 
HIS), 8.82 (s, 1H, Hi 1); Mpt. 145.6— 145.8 °C. 
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To a solution of 4,6-dichloropyrimidine (0.147 g, 1.0 mmole, 1.1 eq.) in 2-propanol (4 
mL), 3-hydroxy-4-methoxyaniline (0.125 g, 0.9 mmole, 1.0 eq.) and N,N-
diisopropylethylamine (172 tL, 1.8 mmole, 2.0 eq.) were added. The reaction mixture 
was irradiated in the DiscoverTM at 120 °C for 30 minutes, with active cooling of the 
sample, and then split into 4 x 1 mL aliquots. To one aliquot was added 3-
methoxyphenylboronic acid (0.048 g, 0.32 mmole, 1.4 eq.), potassium carbonate 
(0.122g, 0.9 mmole, 4.0 eq.) and Pd(PPh3)4 (0.10 g, 0.02 mmole, 0.1 eq.). The reaction 
mixture was irradiated in the DiscoverTM at 140 °C for 15 minutes, before being injected 
directly onto the Biotage Parallex F1exTM HPLC (Method S, tR = 7.32 mm) Appropriate 
fractions were combined and concentrated in vacuo to afford pyrimidine 502 as a yellow 
solid (0.049 g, 67%); LRMS ES m/z 323.6 (MH); Vmax (film)1cm 1 3392 (0-H), 2938 
(C-H), 2835 (0-CH3), 1646 (C=C), 1582 (aryl C=C), 1510 (C=N); 6H (250 MHz, 
CD30D): 3.92 (s, 3H, H7), 3.94 (s, 3H, H18), 7.05 —7.19 (m, 4H, 112, H5, H6, H9), 7.28 
(ddd, IH, J = 8.1, 2.4, 0.7 Hz, HI 5), 7.39 (d, IH, J = 0.7 Hz, H13), 7.40 (dd, 1H, J = 
8.1, 0.7 Hz, H17), 7.62 (t, 1H, J = 8.1 Hz, H16), 8.77 (d, IH, J = 0.4 Hz, HI 1); Mpt. 
184.7-185.4°C. 
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To a solution of 4,6-dichioropyrimidine (0.147 g, 1.0 mmole, 1.1 eq.) in 2-propanol (4 
mL), 3,5-dimethoxyaniline (0.137 g, 0.9 mmole, 1.0 eq.) and N,N-diisopropylethylamine 
(172 jtL, 1.8 mmole, 2.0 eq.) were added. The reaction mixture was irradiated in the 
DiscoverTM at 120 °C for 30 minutes, with active cooling of the sample, and then split 
into 4 x 1 mL aliquots. To one aliquot was added 3-methoxyphenylboronic acid (0.048 
g, 0.32 mmole, 1.4 eq.), potassium carbonate (0.122g, 0.9 mmole, 4.0 eq.) and Pd(PPh3)4  
(0.10 g, 0.02 mmole, 0.1 eq.). The reaction mixture was irradiated in the DiscoverTM at 
140 °C for 15 minutes, before being injected directly onto the Biotage Parallex FICxTM 
HPLC (Method S, tR = 14.15 mm) Appropriate fractions were combined and 
concentrated in vacuo to afford pyrimidine 503 as a yellow solid (0.018 g, 24%); LRMS 
ES m/z 337.7 (MH); HRMS FAB m/z 338.15089 (MH) (calculated for C19H20N303, 
338.15047 (Dev. 1.24 ppm)); Vmax (film)/cm' 3391 (N-H), 3051 (aryl C-H), 2942 (C-H), 
2840 (0-CH3), 1646 (C=C), 1592 (aryl C=C), 1519 (C=N); 8H  (250 MHz, CD30D): 3.85 
(s, 6H, 117, H8), 3.94 (s, 3H, H19), 6.46 (t, 111, J = 2.2 Hz, H4), 6.93 (d, 2H, J = 2.2 Hz, 
112, H6), 7.20 (d, 1H, J = 0.8 Hz, H10), 7.29 (ddd, IH, J = 8.2, 2.5, 0.9 Hz, H16), 7.43 
(d, IH, J = 2.5 Hz, H14), 7.44 (dd, J = 8.2, 0.9 Hz, H18), 7.58 (t, 1H, J = 8.2 Hz, H17), 
8.84 (d, IH, J = 0.8 Hz, H12); Mpt. 143.2 - 143.8 °C. 
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To a solution of 4,6-dichloropyrimidine (0.147 g, 1.0 mmole, 1.1 eq.) in 2-propanol (4 
mL), 4-fluoro-3-methylaniline (0.113 g, 0.9 mmole, 1.0 eq.) and N,N-
diisopropylethylamine (172 L, 1.8 mmole, 2.0 eq.) were added. The reaction mixture 
was irradiated in the DiscoverTM  at 120 °C for 30 minutes, with active cooling of the 
sample, and then split into 4 x I mL aliquots. To one aliquot was added 4-
methoxyphenylboronic acid (0.048 g, 0.32 mmole, 1.4 eq.), potassium carbonate 
(0.122g, 0.9 mmole, 4.0 eq.) and Pd(PPh3)4  (0.10 g, 0.02 mmole, 0.1 eq.). The reaction 
mixture was irradiated in the DiscoverTM at 140 °C for 15 minutes, before being injected 
directly onto the Biotage Parallex Flex TM HPLC (Method S, tR = 13.58 mm) Appropriate 
fractions were combined and concentrated in vacuo to afford pyrimidine 504 as a yellow 
solid (0.046 g, 66%); LRMS ES m/z 309.7 (MH); FIRMS FAB m/z 310.13589 (MH) 
(calculated for C 8H17FN30, 310.13556 (Dev. 1.09 ppm)); Vmax (film)/cm 1 3306 (N-H), 
3053 (aryl C-H), 2936 (C-H), 2842 (0-CH3), 1646 (C=C), 1592 (aryl C=C), 1516 
(C=N); 6H  (250 MHz, CD30D): 2.35 (d, 314, .JHF = 2.0 Hz, 117), 3.95 (s, 3H, H18), 7.09 
(d, 1H, J = 0.7 Hz, H9), 7.17 (t, IH, J = 8.9 Hz, JHF = 8.9 Hz, H5), 7.21 (d, 2H, J = 8.9 
Hz, H14, H16), 7.48-7.56 (m, 2H, 1-12, H6), 7.86 (d, 211, J = 8.9 Hz, H13, H17), 8.77 
(d, IH, J = 0.7 Hz, H11); 6c (75 MHz; CD30D) 13.5 (C7), 55.1 (C18), 102.3 (CA,), 
111.2 (Cr), 115.1 (2 X CH), 115.2(2 X CHAr), 122.5 (CH1 ), 128.9(2 x CH&r), 132.9 
(CA, 133.0 (C1 ), 140.1 (CM), 152.7 (CHAr), 154.7 (CA,), 162.1 (CA,), 163.7 (CHAr); 
Mpt. 179.9-180.7°C. 
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To a solution of 4,6-dichloropyrimidine (0.147 g, 1.0 mmole, 1.1 eq.) in 2-propanol (4 
mL), 4-hydroxy-2-nitroaniline (0.138 g, 0.9 mmole, 1.0 eq.) and N,N-
diisopropylethylamine (172 jtL, 1.8 mmole, 2.0 eq.) were added. The reaction mixture 
was irradiated in the Discover TM  at 120 °C for 30 minutes, with active cooling of the 
sample, and then split into 4 x I mL aliquots. To one aliquot was added 4-
methoxyphenylboronic acid (0.048 g, 0.32 mmole, 1.4 eq.), potassium carbonate 
(0.122g, 0.9 mmole, 4.0 eq.) and Pd(PPh3)4 (0.10 g, 0.02 mmole, 0.1 eq.). The reaction 
mixture was irradiated in the Discover TM  at 140 °C for 15 minutes, before being injected 
directly onto the Biotage Parallex FlexTM  HPLC (Method S, tR = 8.44 mm) Appropriate 
fractions were combined and concentrated in vacuo to afford pyrimidine 505 as a red oil 
(0.023 g, 30%); LRMS ES m/z 338.7 (MH). 
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To a solution of 4,6-dichloropyrimidine (0.147 g, 1.0 mmole, 1.1 eq.) in 2-propanol (4 
mL), 3-hydroxy-4-methoxyaniline (0.125 g, 0.9 mmole, 1.0 eq.) and N,N-
diisopropylethylamine (172 tL, 1.8 mmole, 2.0 eq.) were added. The reaction mixture 
was irradiated in the Discover TM at 120 °C for 30 minutes, with active cooling of the 
sample, and then split into 4 x I mL aliquots. To one aliquot was added 4-
methoxyphenylboronic acid (0.048 g, 0.32 mmole, 1.4 eq.), potassium carbonate 
(0.122g, 0.9 mmole, 4.0 eq.) and Pd(PPh3)4 (0.10 g, 0.02 mmole, 0.1 eq.). The reaction 
mixture was irradiated in the Discover TM at 140 °C for 15 minutes, before being injected 
directly onto the Biotage Parallex F1exTM HPLC (Method S, tR = 7.26 mm) Appropriate 
fractions were combined and concentrated in vacuo to afford pyrimidine 507 as a yellow 
solid (0.027 g, 37%); LRMS m/z 324.1 (MH); Vmax (film)/cm' 3400 (0-H), 2929 (C-
H), 2842 (0-CH3), 1636 (C=C), 1576 (aryl C=C), 1507 (C=N); oH (250, MHz, CD30D): 
3.92 (s, 3H, 117), 3.93 (s, 3H, H18), 7.03 (m, 3H, 112, H5, H6), 7.14 (s, 1H, H9), 7.18 (d, 
2H, J = 8.8 Hz, H14, H16), 7.82 (d, 2H, J = 8.8 Hz, H13, H17), 8.69 (s, 1H, Hi 1); Mpt. 
226.5 - 227.0 °C. 
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To a solution of 4,6-dichloropyrimidine (0.147 g, 1.0 mmole, 1.1 eq.) in 2-propanol (4 
mL), 3,5-dimethoxyaniline (0.137 g, 0.9 mmole, 1.0 eq.) and N,N-diisopropylethylamine 
(172 L, 1.8 mmole, 2.0 eq.) were added. The reaction mixture was irradiated in the 
Discover TM  at 120 °C for 30 minutes, with active cooling of the sample, and then split 
into 4 x 1 mL aliquots. To one aliquot was added 4-methoxyphenylboronic acid (0.048 
g, 0.32 mmole, 1.4 eq.), potassium carbonate (0.122g. 0.9 mmole, 4.0 eq.) and Pd(PPh3)4 
(0.10 g, 0.02 mmole, 0.1 eq.). The reaction mixture was irradiated in the DiscoverTM  at 
140 °C for 15 minutes, before being injected directly onto the Biotage Parallex Flex TM 
HPLC (Method S, tR = 11.33 mm) Appropriate fractions were combined and 
concentrated in vacuo to afford pyrimidine 508 as a cream solid (0.011 g, 14%); LRMS 
ES m/z 337.8 (MH); Vnax (film)Icm' 3248 (N-H), 3058 (aryl C-H), 2933 (C-H), 1654 
(C=C), 1595 (aryl C=C), 1508 (C=N); 6H  (250 M}Iz, CD30D): 4.04 (s, 6H, H7, H8), 
4.14 (s, 3H, H19), 6.65 (t, IH, J = 2.2 Hz, H4), 7.10 (d, 2H, .1 = 2.2 Hz, 112, H6), 7.34 
(d, 1H, J = 0.9 Hz, H10), 7.40 (d, 2H, J =9.0 Hz, HI 5, H17), 8.98 (d, 1H, J = 0.9 Hz, 
H12); Mpt. 196.7 - 197.2 °C. 
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To a solution of 4,6-dichioropyrimidine (0.147 g, 1.0 mmole, 1.1 eq.) in 2-propanol (4 
mL), 4-fluoro-3-methylaniline (0.113 g, 0.9 mmole, 1.0 eq.) and N,N-
diisopropylethylamine (172 iL, 1.8 mmole, 2.0 eq.) were added. The reaction mixture 
was irradiated in the DiscoverTM at 120 °C for 30 minutes, with active cooling of the 
sample, and then split into 4 x 1 mL aliquots. To one aliquot was added 2,5-
dimethyiphenylboronic acid (0.047 g, 0.32 mmole, 1.4 eq.), potassium carbonate 
(0.122g, 0.9 mmole, 4.0 eq.) and Pd(PPh3)4  (0.10 g, 0.02 mmole, 0.1 eq.). The reaction 
mixture was irradiated in the DiscoverTM at 140 °C for 15 minutes, before being injected 
directly onto the Biotage Parallex F1exTM HPLC (Method S, tR = 13.07 mm) Appropriate 
fractions were combined and concentrated in vacuo to afford pyrimidine 509 as a white 
solid (0.037 g, 54%); LRMS ES m/z 307.4 (MH); HRMS FAB m/z 308.15689 (MH) 
(calculated for C19H19FN3, 308.15630 (Dev. 1.91 ppm)); Vmax (film)/cm-1 3244 (N-H), 
3054 (aryl C-H), 2929 (C-H), 2863 (0-CH3), 1640 (C=C), 1590 (aryl C=C), 1504 
(C=N); 6H  (250 MHz, CD30D): 2.36 (d, 3H, JHF = 2.0 Hz, 117), 2.40 (s, 3H, H19), 2.43 
(s, 31-1, H18), 6.91 (s, 1H, 119), 7.18 (t, 1H, J = 9.0 Hz, JHF = 9.0 Hz, H5), 7.32 (s, 1H, 
H13), 7.36 (d, IH, J = 8.4 Hz, H15), 7.40 (d, IH, J = 8.4 Hz, H16), 7.43 - 7.59 (m, 2H, 
112, H6), 8.83 (s, 1H, HI 1); Mpt. 115.0— 115.4 °C. 
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To a solution of 4,6-dichloropyrimidine (0.147 g, 1.0 mmole, 1.1 eq.) in 2-propanol (4 
mL), 3-hydroxy-4-methoxyaniline (0.125 g, 0.9 mmole, 1.0 eq.) and N,N-
diisopropylethylamine (1172 L, 1.8 mmole, 2.0 eq.) were added. The reaction mixture 
was irradiated in the DiscoverTM at 120 °C for 30 minutes, with active cooling of the 
sample, and then split into 4 x I mL aliquots. To one aliquot was added 2,5-
dimethylphenylboronic acid (0.047 g, 0.32 mmole, 1.4 eq.), potassium carbonate 
(0.122g, 0.9 mmole, 4.0 eq.) and Pd(PPh3)4  (0.10 g, 0.02 mmole, 0.1 eq.). The reaction 
mixture was irradiated in the DiscoverTM at 140 °C for 15 minutes, before being injected 
directly onto the Biotage Parallex FIexTM HPLC (Method S, tp. = 7.10 mm) Appropriate 
fractions were combined and concentrated in vacuo to afford pyrimidine 512 as a yellow 
solid (0.015 g, 21%); LRMS ES m/z 321.7 (MH); 6H  (250 MHz, CD30D): 2.39 (s, 3H, 
H18), 2.43 (s, 3H, H19), 3.93 (s, 3H, 117), 6.86 (s, 1H, 119), 7.02 - 7.11 (m, 3H, H2, H5, 
H6), 7.31 (s, 1H, H13), 7.35 (d, 2H, J = 8.7 Hz, HIS), 7.39 (d, 2H, J = 8.7 Hz, H16), 
8.79 (s, 1H, Hi!). 
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To a solution of 4,6-dichloropyri mid ine (0.147 g, 1.0 mmole, 1.1 eq.) in 2-propanol (4 
mL), 3,5-dimethoxyaniline (0.137 g, 0.9 mmole, 1.0 eq.) and NN-diisopropylethylamine 
(172 jiL, 1.8 mmole, 2.0 eq.) were added. The reaction mixture was irradiated in the 
DiscoverTM at 120 °C for 30 minutes, with active cooling of the sample, and then split 
into 4 x I mL aliquots. To one aliquot was added 2,5-dimethyiphenylboronic acid (0.047 
g, 0.32 mmole, 1.4 eq.), potassium carbonate (0.122 g, 0.9 mmole, 4.0 eq.) and 
Pd(PPh3)4 (0.10 g, 0.02 mmole, 0.1 eq.). The reaction mixture was irradiated in the 
Discover TM at 140 °C for 15 minutes, before being injected directly onto the Biotage 
Parallex FIexTM  HPLC (Method S, tR = 12.58 mm) Appropriate fractions were combined 
and concentrated in vacuo to afford pyrimidine 513 as a white solid (0.015 g, 20%); 
LRMS ES m/z 335.8 (Nil-1); 8H  (250 MHz, CD30D): 2.40 (s, 3H, H19), 2.43 (s, 3H, 
H20), 3.86 (s, 6H, 117, H8), 6.48 (t, 1H, J = 2.2 Hz, H4), 6.93 (d, 2H, J = 2.2 Hz, 112, 
H6), 6.95 (s, lH, J = 0.9 Hz, H10), 7.32 (s, 1H, H14), 7.35 (d, IH, J = 8.5 Hz, H16), 
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To a solution of 4,6-dichioropyrimidine (0.147 g, 1.0 mmole, 1.1 eq.) in 2-propanol (4 
mL), 4-fluoro-3-methylaniline (0.113 g, 0.9 mmole, 1.0 eq.) and N,N-
diisopropylethylamine (172 tL, 1.8 mmole, 2.0 eq.) were added. The reaction mixture 
was irradiated in the DiscoverTM  at 120 °C for 30 minutes, with active cooling of the 
sample, and then split into 4 x I mL aliquots. To one aliquot was added 3-
hydroxyphenylboronic acid (0.044 g, 0.32 mmole, 1.4 eq.), potassium carbonate (0.122 
g, 0.9 mmole, 4.0 eq.) and Pd(PPh3)4 (0.10 g, 0.02 mmole, 0.1 eq.). The reaction mixture 
was irradiated in the DiscoverTM  at 140 °C for 15 minutes, before being injected directly 
onto the Biotage Parallex FlexTM  HPLC (Method S, tR = 10.43 mm) Appropriate 
fractions were combined and concentrated in vacuo to afford pyrimidine 514 as a yellow 
solid (0.030 g, 45%); LRMS ES m/z 295.7 (MH); HRMS FAB m/z 296.12073 (MII-I) 
(calculated for C17H15FN30, 296.11991 (Dev. 2.77 ppm)); Vmax (film)/cm' 3309 (N-H), 
3157 (0-H), 3058 (aryl C-H), 2928 (C-H), 2840 (0-CH3), 1647 (C=C), 1636 (aryl 
C=C), 1507 (C=N); 6H  (250 MHz, CD30D): 2.35 (d, 3H, J = 2.0 Hz, 117), 7.11 (d, 1H, J 
= 0.7 Hz, H9), 7.11 -7.14 (m, 1H, HiS), 7.16 (t, IH, J = 9.1 Hz, JHF = 9.1 Hz, H5), 
7.27 (t, IH, J = 1.9 Hz, H13), 7.29 - 7.34 (m, IH, H17), 7.48 (t, 1H, J = 7.9 Hz, H16), 
7.49 - 7.59 (m, 2H, 112, H6), 8.78 (d, 1H, J = 0.7 Hz, HI 1); 6c (75 MHz; CD30D) 13.7 
(C7), 103.2 (CA,), 112.5 (Co,), 113.7 (CH,,,), 117.9 (CHAr), 119.4 (CHAr), 122.2 (CAr), 
124.6 (CHr), 126.7 (CHAr), 128.9 (CHAr), 130.8 (CHAr), 130.9 (CAr), 132.3 (CJ%), 151.2 
(CA,), 153.1 (CHjr), 155.1 (CA,), 158.7(C);Mpt.237.9-238.4°C. 
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To a solution of 4,6-dichioropyrimidine (0.147 g, 1.0 mmole, 1.1 eq.) in 2-propanol (4 
mL), 3-aminobenzonitrile (0.106 g, 0.9 mmole, 1.0 eq.) and NV-diisopropylethylamine 
(172 jtL, 1.8 mmole, 2.0 eq.) were added. The reaction mixture was irradiated in the 
Discover TM  at 120 °C for 30 minutes, with active cooling of the sample, and then split 
into 4 x I mL aliquots. To one aliquot was added 3-hydroxyphenylboronic acid (0.044 g, 
0.32 mmole, 1.4 eq.), potassium carbonate (0.122 g, 0.9 mmole, 4.0 eq.) and Pd(PPh3)4 
(0.10 g, 0.02 mmole, 0.1 eq.). The reaction mixture was irradiated in the DiscoverTM at 
140 °C for 15 minutes, before being injected directly onto the Biotage Parallex FlexTM 
HPLC (Method S, tR = 10.36 mm) Appropriate fractions were combined and 
concentrated in vacuo to afford pyrimidine 516 a white solid (0.002 g, 3%); LRMS ES 
m/z 288.7 (MH); 6H  (250 MHz, CD30D): 7.30 - 7.34 (ddd, IH, J = 8.0, 2.4, 1.3 Hz, 
H14), 7.45 (d, J = 1.0 Hz, H8), 7.55 (t, IH, J = 1.9 Hz, 112), 7.58 (dd, 1H, J = 8.0, 1.3 
Hz, H16), 7.69 (t, IH, J = 8.0 Hz, HI 5), 7.81 (dt, 1H, J = 1.9 Hz, H6), 7.86 (t, IH, J = 
7.6 Hz, H5), 8.16 (dt, 1H, J = 7.6, 1.9 Hz, H4), 8.54- 8.55 (m, 1H, H12), 9.10 (d, IH, J 
= 1.0 Hz, H10). 
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5-1 I6-(3-Hydroxvpheny1) pyrimidin-4-yll amino -2-methoxyphenol (517) 
To a solution of 4,6-dichioropyrimidine (0.147 g, 1.0 mmole, 1.1 eq.) in 2-propanol (4 
mL), 3-hydroxy-4-methoxyaniline (0.125 g, 0.9 mmole, 1.0 eq.) and N,N-
diisopropylethylamine (172 tL, 1.8 mmole, 2.0 eq.) were added. The reaction mixture 
was irradiated in the DiscoverTM  at 120 °C for 30 minutes, with active cooling of the 
sample, and then split into 4 x 1 mL aliquots. To one aliquot was added 3-hydroxy-
phenyl boronic acid (0.044 g, 0.32 mmole, 1.4 eq.), potassium carbonate (0.122 g, 0.9 
mmole, 4.0 eq.) and Pd(PPh3)4  (0.10 g, 0.02 mmole, 0.1 eq.). The reaction mixture was 
irradiated in the Discover TM  at 140 °C for 15 minutes, before being injected directly onto 
the Biotage Parallex F1CxTM  HPLC (Method S, tR = 6.27 mm) Appropriate fractions were 
combined and concentrated in vacuo to afford pyrimidine 517 as a yellow solid (0.004 g, 
6%); LRMS ES m/z 309.7 (MH); 6H (250 MHz, CD30D): 3.68 (s, 1H, 117), 7.02-7.18 
(m, 5H, 112, H5, H6, H13, HI 5), 7.24 (s, 1H, H9), 7.29 (d, 1H, J = 7.8 Hz, H17), 7.48 (t, 












To a solution of 4,6-dichloropyrimidine (0.147 g, 1.0 mmole, 1.1 eq.) in 2-propanol (4 
mL), 3,5-dimethoxyaniline (0.137 g, 0.9 mmole, 1.0 eq.) and NN-diisopropylethylamine 
(172 1.tL, 1.8 mmole, 2.0 eq.) were added. The reaction mixture was irradiated in the 
DiscoverTM  at 120 °C for 30 minutes, with active cooling of the sample, and then split 
into aliquots (4 x 1 mL). To one aliquot was added 3-hydroxyphenylboronic acid (0.044 
g, 0.32 mmole, 1.4 eq.), potassium carbonate (0.122 g, 0.9 mmole, 4.0 eq.) and 
Pd(PPh3)4  (0.10 g, 0.02 mmole, 0.1 eq.). The reaction mixture was irradiated in the 
DiscoverTM at 140 °C for 15 minutes, before being injected directly onto the Biotage 
Parallex FIexTM  HPLC (Method S, tR = 9.02 mm) Appropriate fractions were combined 
and concentrated in vacuo to afford pyrimidine 518 as a cream solid (0.006 g, 8%); 
LRMS ES m/z 354.6 (MH); oH (250 MHz, CD30D): 3.84 (s, 6H, 117, H8), 6.47 (t, 1H, 
J - 2.1 Hz, H4), 6.91 (bs, 2H, H2, H6), 7.13 (ddd, 1H, .J = 8.3, 2.1, 0.8 Hz, H16), 7.17 
(s, 1H, H10), 7.24 - 7.32 (m, 3H, H14, NH, 011), 7.49 (t, 1H, J = 8.3 Hz, H17), 7.74 (d, 
1H, J = 8.3 Hz, Hi 8), 8.83 (s, 1H, H12). 
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Synthesis of 6-anilino-4-chloropyrimidine intermediates 
[(6-Chloropyrimidin-4-yl)aminol phenol (522) 
NOH 
To a solution of 4,6-dichloropyrimidine (0.110 g, 0.74 mmole, 1.1 eq.) in 2-propanol (3 
mL) was added 3-hydroxyaniline (0.078 g, 0.67 mmole, 1.0 eq.) followed by DIPEA 
(117 tL, 1.34 mmole, 2.0 eq.). The reaction mixture was irradiated in the Discover TM at 
120 °C for 30 minutes before being injected directly, in 3 x I mL aliquots, on the 
Biotage Parallex Flex TM  HPLC (Method A, tR = 14.24 mm.). Pyrimidine 533 was 
isolated as a white solid (0.109 g, 73%); LRMS ES m/z 221.6 (MH). 
I(6-Chloropyrimidin-4-yI)aminol phenol (523) 
The general procedure for pyrimidine 522 was followed using 4-hydroxyaniline (0.078 
g, 0.67 mmole, 1.0 eq.). Pyrimidine 523 was isolated as a white solid (HPLC Method A, 
tR = 12.42 mm, 0. 100 g, 67%); LRMS ES m/z 221.5 (MH). 
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6-Chloro-N-(3,4-dimethoxyphenyl)pyrimidin-4-amine (524) 
The general procedure for pyrimidine 522 was followed using 3,4-dimethoxyaniline 
(0.105 g, 0.67 mmole, 1.0 eq.). Pyrimidine 524 was isolated as a white solid (HPLC 
Method A, tR = 14.09 mm, 0.155 g, 87%); LRMS ES m/z 265.6 (MH). 
6-Chloro-N-pyridin-2-ylpyrimidin-4-amine (525) 
The general procedure for pyrimidine 522 was followed using 2-aminopyridine (0.066 g, 
0.67 mmole, 1.0 eq.). Pyrimidine 525 was isolated as a white solid (HPLC Method A, tp.  
= 8.16 mm, 0.015 g, 11%); LRMS ES m/z 206.4 (MH). 
6-Chloro-N-phenylpyrimidin-4-amine (526)219 
The general procedure for pyrimidine 522 was followed using aniline (0.069 g, 0.67 
mmole, 1.0 eq.). Pyrimidine 526 was isolated as a white solid (HPLC Method A, tR = 
17.16 mm, 0.090 g, 65%); LRMS ES m/z 205.4, 207.4 (MH). 
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